<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37440013</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0065-2598</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>1415</Volume>
            <PubDate>
              <Year>2023</Year>
            </PubDate>
          </JournalIssue>
          <Title>Advances in experimental medicine and biology</Title>
          <ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1Alpha (PGC-1α): A Transcriptional Regulator at the Interface of Aging and Age-Related Macular Degeneration?</ArticleTitle>
        <Pagination>
          <StartPage>49</StartPage>
          <EndPage>53</EndPage>
          <MedlinePgn>49-53</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-031-27681-1_8</ELocationID>
        <Abstract>
          <AbstractText>Human age-related macular degeneration (AMD) is a prevalent age-related disease which causes retinal dysfunction and disability. Genetic and cell culture studies from AMD patients have implicated impaired activity of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α). PGC-1α is a transcriptional co-regulator that acts to control a plethora of metabolic processes relevant to AMD pathophysiology including gluconeogenesis, oxidative phosphorylation, and response to oxidative injury. Perturbation of PGC-1α activity in mice causes AMD-like RPE and retinal pathology. There is potential for therapeutic modulation of the PGC-1α pathway in AMD treatment.</AbstractText>
          <CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mowat</LastName>
            <ForeName>Freya M</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology and Visual Sciences (School of Medicine and Public Health), Department of Surgical Sciences (School of Veterinary Medicine), Medical Sciences Center, University of Wisconsin-Madison, Madison, WI, USA. mowat@wisc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Adv Exp Med Biol</MedlineTA>
        <NlmUniqueID>0121103</NlmUniqueID>
        <ISSNLinking>0065-2598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047495" MajorTopicYN="Y">PPAR gamma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071248" MajorTopicYN="N">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword>
        <Keyword MajorTopicYN="N">Aging</Keyword>
        <Keyword MajorTopicYN="N">Metabolism</Keyword>
        <Keyword MajorTopicYN="N">PGC-1alpha</Keyword>
        <Keyword MajorTopicYN="N">PPARGC-1alpha</Keyword>
        <Keyword MajorTopicYN="N">Retina</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>11</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37440013</ArticleId>
        <ArticleId IdType="doi">10.1007/978-3-031-27681-1_8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Egger A, Samardzija M, Sothilingam V, Tanimoto N, Lange C, Salatino S, et al. PGC-1alpha determines light damage susceptibility of the murine retina. PLoS One. 2012;7(2):e31272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22348062</ArticleId>
            <ArticleId IdType="pmc">3278422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saint-Geniez M, Jiang A, Abend S, Liu L, Sweigard H, Connor KM, et al. PGC-1alpha regulates normal and pathological angiogenesis in the retina. Am J Pathol. 2013;182(1):255&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23141926</ArticleId>
            <ArticleId IdType="pmc">3538026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blasiak J, Pawlowska E, Sobczuk A, Szczepanska J, Kaarniranta K. The aging stress response and its implication for AMD pathogenesis. Int J Mol Sci. 2020;21(22):8840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33266495</ArticleId>
            <ArticleId IdType="pmc">7700335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson R, Prolla T. PGC-1alpha in aging and anti-aging interventions. Biochim Biophys Acta. 2009;1790(10):1059&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19371772</ArticleId>
            <ArticleId IdType="pmc">2743759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kramer AI, Handschin C. How epigenetic modifications drive the expression and mediate the action of PGC-1alpha in the regulation of metabolism. Int J Mol Sci. 2019;20(21):5449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31683747</ArticleId>
            <ArticleId IdType="pmc">6862278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson RM, Barger JL, Edwards MG, Braun KH, O&#x2019;Connor CE, Prolla TA, et al. Dynamic regulation of PGC-1alpha localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response. Aging Cell. 2008;7(1):101&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18031569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunst S, Wolloscheck T, Kelleher DK, Wolfrum U, Sargsyan SA, Iuvone PM, et al. Pgc-1alpha and Nr4a1 are target genes of circadian melatonin and dopamine release in murine retina. Invest Ophthalmol Vis Sci. 2015;56(10):6084&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26393668</ArticleId>
            <ArticleId IdType="pmc">4585341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baba K, Pozdeyev N, Mazzoni F, Contreras-Alcantara S, Liu C, Kasamatsu M, et al. Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor. Proc Natl Acad Sci U S A. 2009;106(35):15043&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19706469</ArticleId>
            <ArticleId IdType="pmc">2736407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ban N, Ozawa Y, Inaba T, Miyake S, Watanabe M, Shinmura K, et al. Light-dark condition regulates sirtuin mRNA levels in the retina. Exp Gerontol. 2013;48(11):1212&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23648587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roggia MF, Ueta T. alphavbeta5 Integrin/FAK/PGC-1alpha pathway confers protective effects on retinal pigment epithelium. PloS One. 2015;10(8):e0134870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26244551</ArticleId>
            <ArticleId IdType="pmc">4526642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell. 2004;119(1):121&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15454086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Kang SU, Zhang S, Karuppagounder S, Xu J, Lee YK, et al. Adult conditional knockout of PGC-1&#x3b1; leads to loss of dopamine neurons. eNeuro. 2016;3(4):ENEURO.0183-16.2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27622213</ArticleId>
            <ArticleId IdType="pmc">5011687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosales MAB, Shu DY, Iacovelli J, Saint-Geniez M. Loss of PGC-1&#x3b1; in RPE induces mesenchymal transition and promotes retinal degeneration. Life Sci Alliance. 2019;2(3):e201800212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31101737</ArticleId>
            <ArticleId IdType="pmc">6526284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felszeghy S, Viiri J, Paterno JJ, Hyttinen JMT, Koskela A, Chen M, et al. Loss of NRF-2 and PGC-1alpha genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration. Redox Biol. 2019;20:1&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30253279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blasiak J, Koskela A, Pawlowska E, Liukkonen M, Ruuth J, Toropainen E, et al. Epithelial-mesenchymal transition and senescence in the retinal pigment epithelium of NFE2L2/PGC-1&#x3b1; double knock-out mice. Int J Mol Sci. 2021;22(4):1684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33567500</ArticleId>
            <ArticleId IdType="pmc">7915526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Chu Y, Mowery J, Konkel B, Galli S, Theos AC, et al. Pgc-1alpha repression and high-fat diet induce age-related macular degeneration-like phenotypes in mice. Dis Model Mech. 2018;11(9):dmm032698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29925537</ArticleId>
            <ArticleId IdType="pmc">6176989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, Dason ES, Zanon-Moreno V, Jiang Q, Nahirnyj A, Chan D, et al. PGC-1alpha signaling coordinates susceptibility to metabolic and oxidative injury in the inner retina. Am J Pathol. 2014;184(4):1017&#x2013;29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24508229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Michan S, Juan AM, Hurst CG, Hatton CJ, Pei DT, et al. Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy. Angiogenesis. 2013;16(4):985&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23912262</ArticleId>
            <ArticleId IdType="pmc">4006695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Austin S, St-Pierre J. PGC1&#x3b1; and mitochondrial metabolism&#x2013;emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012;125(Pt 21):4963&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23277535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R&#xf3;na-V&#xf6;r&#xf6;s K, Weydt P. The role of PGC-1&#x3b1; in the pathogenesis of neurodegenerative disorders. Curr Drug Targets. 2010;11(10):1262&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20840068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan R, Tsaih SW, Petkova SB, Marin de Evsikova C, Xing S, Marion MA, et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell. 2009;8(3):277&#x2013;87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19627267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Gil JL, Watkins-Chow DE, Baxter LL, Elliot G, Harper UL, Wincovitch SM, et al. Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1. Disease models &amp; mechanisms. 2020;13(3):dmm042614.</Citation>
        </Reference>
        <Reference>
          <Citation>Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25104651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global burden of dry age-related macular degeneration: a targeted literature review. Clin Ther. 2021;43(10):1792&#x2013;818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34548176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Swaroop A, Ratnapriya R. Making biological sense of genetic studies of age-related macular degeneration. Adv Exp Med Biol. 2021;1256:201&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33848003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SanGiovanni JP, Chen J, Sapieha P, Aderman CM, Stahl A, Clemons TE, et al. DNA sequence variants in PPARGC1A, a gene encoding a coactivator of the omega-3 LCPUFA sensing PPAR-RXR transcription complex, are associated with NV AMD and AMD-associated loci in genes of complement and VEGF signaling pathways. PLoS One. 2013;8(1):e53155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23335958</ArticleId>
            <ArticleId IdType="pmc">3546058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golestaneh N, Chu Y, Cheng SK, Cao H, Poliakov E, Berinstein DM. Repressed SIRT1/PGC-1alpha pathway and mitochondrial disintegration in iPSC-derived RPE disease model of age-related macular degeneration. J Transl Med. 2016;14(1):344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27998274</ArticleId>
            <ArticleId IdType="pmc">5175395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Jiang N, Chu Y, Postnikova O, Varghese R, Horvath A, et al. Dysregulated metabolic pathways in age-related macular degeneration. Sci Rep. 2020;10(1):2464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32051464</ArticleId>
            <ArticleId IdType="pmc">7016007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrington DA, Ebeling MC, Kapphahn RJ, Terluk MR, Fisher CR, Polanco JR, et al. Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degeneration. Redox Biol. 2017;13:255&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28600982</ArticleId>
            <ArticleId IdType="pmc">5466586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrahan C, Ash JD. The potential use of PGC-1&#x3b1; and PGC-1&#x3b2; to protect the retina by stimulating mitochondrial repair. Adv Exp Med Biol. 2016;854:403&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26427438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iacovelli J, Rowe GC, Khadka A, Diaz-Aguilar D, Spencer C, Arany Z, et al. PGC-1alpha induces human RPE oxidative metabolism and antioxidant capacity. Invest Ophthalmol Vis Sci. 2016;57(3):1038&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26962700</ArticleId>
            <ArticleId IdType="pmc">4788093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong W, MacColl Garfinkel AE, Li Y, Benowitz LI, Cepko CL. NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. J Clin Invest. 2015;125(4):1433&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25798616</ArticleId>
            <ArticleId IdType="pmc">4396467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL. Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet. 2012;21(8):1861&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22246294</ArticleId>
            <ArticleId IdType="pmc">3313800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nashine S, Subramaniam SR, Chwa M, Nesburn A, Kuppermann BD, Federoff H, et al. PU-91 drug rescues human age-related macular degeneration RPE cells; implications for AMD therapeutics. Aging (Albany NY). 2019;11(17):6691&#x2013;713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31477635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang LN, Zhou HY, Fu YY, Li YY, Wu F, Gu M, et al. Novel small-molecule PGC-1alpha transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes. 2013;62(4):1297&#x2013;307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23250358</ArticleId>
            <ArticleId IdType="pmc">3609556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nashine S, Cohen P, Nesburn AB, Kuppermann BD, Kenney MC. Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration. Sci Rep. 2018;8(1):15175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30310092</ArticleId>
            <ArticleId IdType="pmc">6182005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang PM, Cheng KC, Huang JY, Wang SY, Lin YN, Tseng YT, et al. Sulforaphane inhibits blue light-induced inflammation and apoptosis by upregulating the SIRT1/PGC-1&#x3b1;/Nrf2 pathway and autophagy in retinal pigment epithelial cells. Toxicol Appl Pharmacol. 2021;421:115545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33894213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17112576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagiolari G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab. 2011;14(1):80&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21723506</ArticleId>
            <ArticleId IdType="pmc">3130927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010;285(1):142&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19861415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24172895</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">37161583</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2040-3372</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>21</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nanoscale</Title>
          <ISOAbbreviation>Nanoscale</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Erythrocyte membrane-camouflaged DNA-functionalized upconversion nanoparticles for tumor-targeted chemotherapy and immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>9457</StartPage>
          <EndPage>9476</EndPage>
          <MedlinePgn>9457-9476</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1039/d3nr00542a</ELocationID>
        <Abstract>
          <AbstractText>A synergistic combination of treatment with immunogenic cell death (ICD) inducers and immunoadjuvants may be a practical way to boost the anticancer response and successfully induce an immune response. The use of HR@UCNPs/CpG-Apt/DOX, new biomimetic drug delivery nanoparticles generated to combat breast cancer, is reported here as a unique strategy to produce immunogenicity and boost cancer immunotherapy. HR@UCNPs/CpG-Apt/DOX (HR-UCAD) consists of two parts. The core is composed of an immunoadjuvant CpG (a toll-like receptor 9 agonist) fused with a dendritic cell-specific aptamer sequence (CpG-Apt) to decorate upconversion nanoparticles (UCNPs) with the successful intercalation of doxorubicin (DOX) into the consecutive base pairs of Apt-CpG to construct an immune nanodrug UCNPs@CpG-Apt/DOX. The targeting molecule hyaluronic acid (HA) was inserted into a red blood cell membrane (RBCm) to form the shell (HR). HR-UCAD possessed a strong capacity to specifically induce ICD. Following DOX-induced ICD of cancer cells, sufficient exposure to tumor antigens and UCNPs@CpG-Apt (UCA) activated the tumor-specific immune response and reversed the immunosuppressive tumor microenvironment. In addition, HR-UCAD has good biocompatibility and increases the active tumor-targeting effect. Furthermore, HR-UCAD exhibits excellent near-infrared upconversion luminescence emission at 804 nm under irradiation with a 980 nm laser, which has great potential in biomedical imaging. Thus, the RBCm-camouflaged drug delivery system is a promising targeted chemotherapy and immunotherapy nanocomplex that could be used for effective targeted breast cancer treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kou</LastName>
            <ForeName>Qinjie</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0009-0008-9272-4685</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yufen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yanrong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. 603196@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xisheng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Haiye</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Rong</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. 603196@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. 603196@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nie</LastName>
            <ForeName>Xinmin</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0003-3104-2505</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Engineering Technology Research Center of Optoelectronic Health Detection, Changsha, 410000, Hunan, China. niexinmin@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2023</Year>
          <Month>06</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nanoscale</MedlineTA>
        <NlmUniqueID>101525249</NlmUniqueID>
        <ISSNLinking>2040-3364</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004910" MajorTopicYN="N">Erythrocyte Membrane</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>4</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">37161583</ArticleId>
        <ArticleId IdType="doi">10.1039/d3nr00542a</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36482512</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1868-503X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomolecular concepts</Title>
          <ISOAbbreviation>Biomol Concepts</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Subcellular elements responsive to the biomechanical activity of triple-negative breast cancer-derived small extracellular vesicles.</ArticleTitle>
        <Pagination>
          <StartPage>322</StartPage>
          <EndPage>333</EndPage>
          <MedlinePgn>322-333</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1515/bmc-2022-0024</ELocationID>
        <Abstract>
          <AbstractText>Triple-negative breast cancer (TNBC) stands out for its aggressive, fast spread, and highly metastatic behavior and for being unresponsive to the classical hormonal therapy. It is considered a disease with a poor prognosis and limited treatment options. Among the mechanisms that contribute to TNBC spreading, attention has been recently paid to small extracellular vesicles (sEVs), nano-sized vesicles that by transferring bioactive molecules to recipient cells play a crucial role in the intercellular communication among cancer, healthy cells, and tumor microenvironment. In particular, TNBC-derived sEVs have been shown to alter proliferation, metastasis, drug resistance, and biomechanical properties of target cells. To shed light on the molecular mechanisms involved in sEVs mediation of cell biomechanics, we investigated the effects of sEVs on the main subcellular players, i.e., cell membrane, cytoskeleton, and nuclear chromatin organization. Our results unveiled that TNBC-derived sEVs are able to promote the formation and elongation of cellular protrusions, soften the cell body, and induce chromatin decondensation in recipient cells. In particular, our data suggest that chromatin decondensation is the main cause of the global cell softening. The present study added new details and unveiled a novel mechanism of activity of the TNBC-derived sEVs, providing information for the efficient translation of sEVs to cancer theranostics.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 the author(s), published by De Gruyter.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Senigagliesi</LastName>
            <ForeName>Beatrice</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bedolla</LastName>
            <ForeName>Diana E</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Area Science Park, Padriciano 99, Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Birarda</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zanetti</LastName>
            <ForeName>Michele</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Officina dei Materiali Consiglio Nazionale delle Ricerche, CNR-IOM, Trieste, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physics, University of Trieste, Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lazzarino</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Officina dei Materiali Consiglio Nazionale delle Ricerche, CNR-IOM, Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vaccari</LastName>
            <ForeName>Lisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parisse</LastName>
            <ForeName>Pietro</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Istituto Officina dei Materiali Consiglio Nazionale delle Ricerche, CNR-IOM, Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Casalis</LastName>
            <ForeName>Loredana</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Elettra-Sincrotrone Trieste S.C.p.A., Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Biomol Concepts</MedlineTA>
        <NlmUniqueID>101518829</NlmUniqueID>
        <ISSNLinking>1868-5021</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="Y">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">atomic force microscopy nanoindentation</Keyword>
        <Keyword MajorTopicYN="N">cellular protrusions</Keyword>
        <Keyword MajorTopicYN="N">chromatin condensation</Keyword>
        <Keyword MajorTopicYN="N">fourier transformed infrared spectroscopy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>1</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36482512</ArticleId>
        <ArticleId IdType="doi">10.1515/bmc-2022-0024</ArticleId>
        <ArticleId IdType="pii">bmc-2022-0024</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Nikoloff JM, Saucedo-Espinosa MA, Kling A, Dittrich PS. Identifying extracellular vesicle populations from single cells. Proc Natl Acad Sci U S A. Sep. 2021;118(38). 10.1073/pnas.2106630118.</Citation>
        </Reference>
        <Reference>
          <Citation>van Niel G, D&#x2019;Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213&#x2013;28. 10.1038/nrm.2017.125.</Citation>
        </Reference>
        <Reference>
          <Citation>Th&#xe9;ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). J Extracell Vesicles. 2018;7:15357501&#x2013;47.</Citation>
        </Reference>
        <Reference>
          <Citation>An T, Qin S, Xu Y, Tang Y, Huang Y, Situ B, et al. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell vesicles. 2015;4:27522. 10.3402/jev.v4.27522.</Citation>
        </Reference>
        <Reference>
          <Citation>Malm T, Loppi S, Kanninen KM. Exosomes in alzheimer&#x2019;s disease. Neurochem Int. Jul. 2016;97:193&#x2013;9. 10.1016/j.neuint.2016.04.011.</Citation>
        </Reference>
        <Reference>
          <Citation>Casta&#xf1;o C, Novials A, P&#xe1;rrizas M. Exosomes and diabetes. Diabetes Metab Res Rev. Mar. 2019;35(3):e3107. 10.1002/dmrr.3107.</Citation>
        </Reference>
        <Reference>
          <Citation>Abhange K, Makler A, Wen Y, Ramnauth N, Mao W, Asghar W, et al. Small extracellular vesicles in cancer. Bioact Mater. 2021;6(11):3705&#x2013;43. 10.1016/j.bioactmat.2021.03.015.</Citation>
        </Reference>
        <Reference>
          <Citation>Keller S, Ridinger J, Rupp A-K, Janssen JWG, Altevogt P. Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. Jun. 2011;9:86. 10.1186/1479-5876-9-86.</Citation>
        </Reference>
        <Reference>
          <Citation>Zebrowska A, Widlak P, Whiteside T, Pietrowska M. Signaling of tumor-derived sev impacts melanoma progression. Int J Mol Sci. Jul. 2020;21(14). 10.3390/ijms21145066.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang Y, Cai G, Li Q. Exosomes as actively targeted nanocarriers for cancer therapy. Int J Nanomed. 2020;15:4257&#x2013;73. 10.2147/IJN.S239548.</Citation>
        </Reference>
        <Reference>
          <Citation>He C, Zheng S, Luo Y, Wang B. Exosome theranostics: Biology and translational medicine. Theranostics. 2018;8(1):237&#x2013;55. 10.7150/thno.21945.</Citation>
        </Reference>
        <Reference>
          <Citation>Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer Targets Ther. 2019;11:151&#x2013;64. 10.2147/BCTT.S176070.</Citation>
        </Reference>
        <Reference>
          <Citation>Yeo W. Treatment horizons for triple-negative breast cancer. Hong Kong J Radiology. 2015;18(2):111&#x2013;8. 10.12809/hkjr1515321.</Citation>
        </Reference>
        <Reference>
          <Citation>Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611&#x2013;29. 10.1038/nrclinonc.2017.44.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin T, Ye L, Sanders A, Lane J, Jiang W. Cancer Invasion and Metastasis: Molecular and Cellular perspective. Austin (TS): Landes Bioscience. Vol. 9; 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>Lekka M. Discrimination between normal and cancerous cells using AFM. Bionanoscience. 2016;6(1):65&#x2013;80. 10.1007/s12668-016-0191-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Luo Q, Kuang D, Zhang B, Song G. Cell stiffness determined by atomic force microscopy and its correlation with cell motility. Biochim Biophys Acta&#x2009;&#x2013;&#x2009;General Subj. 2016;1860(9):1953&#x2013;60. 10.1016/j.bbagen.2016.06.010.</Citation>
        </Reference>
        <Reference>
          <Citation>Alibert C, Goud B, Manneville JB. Are cancer cells really softer than normal cells? Biol Cell. 2017;109(5):167&#x2013;89. 10.1111/boc.201600078.</Citation>
        </Reference>
        <Reference>
          <Citation>Green TM, Alpaugh ML, Barsky SH, Rappa G, Lorico A. Breast cancer-derived extracellular vesicles: Characterization and contribution to the metastatic phenotype. BioMed Res Int. 2015;2015. 10.1155/2015/634865.</Citation>
        </Reference>
        <Reference>
          <Citation>Goh CY, Wyse C, Ho M, O&#x2019;Beirne E, Howard J, Lindsay S, et al. Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses? Cancer Lett. 2020;473:90&#x2013;7. 10.1016/j.canlet.2019.12.046.</Citation>
        </Reference>
        <Reference>
          <Citation>Kannan A, Philley JV, Hertweck KL, Ndetan H, Singh KP, Sivakumar S, et al. Cancer testis antigen promotes triple negative breast cancer metastasis and is traceable in the circulating extracellular vesicles. Sci Rep. Aug. 2019;9(1):11632. 10.1038/s41598-019-48064-w.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Rel. Feb. 2020;318:1&#x2013;15. 10.1016/j.jconrel.2019.12.005.</Citation>
        </Reference>
        <Reference>
          <Citation>Na-Er A, Xu Y-Y, Liu Y-H, Gan Y-J. Upregulation of serum exosomal SUMO1P3 predicts unfavorable prognosis in triple negative breast cancer. Eur Rev Med Pharmacol Sci. Jan. 2021;25(1):154&#x2013;60. 10.26355/eurrev_202101_24379.</Citation>
        </Reference>
        <Reference>
          <Citation>Senigagliesi B, Samperi G, Cefarin N, Gneo L, Petrosino S, Apollonio M, et al. Triple negative breast cancer-derived small extracellular vesicles as modulator of biomechanics in target cells. Nanomedicine. Jul. 2022;44:102582. 10.1016/j.nano.2022.102582.</Citation>
        </Reference>
        <Reference>
          <Citation>L&#xfc;chtefeld I, Bartolozzi A, Mej&#xed;a Morales J, Dobre O, Basso M, Zambelli T, et al. Elasticity spectra as a tool to investigate actin cortex mechanics. J Nanobiotechnology. 2020;18(1):147. 10.1186/s12951-020-00706-2.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim S-O, Kim J, Okajima T, Cho N-J. Mechanical properties of paraformaldehyde-treated individual cells investigated by atomic force microscopy and scanning ion conductance microscopy. Nano Converg. 2017;4(1):5. 10.1186/s40580-017-0099-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Grimm KB, Oberleithner H, Fels J. Fixed endothelial cells exhibit physiologically relevant nanomechanics of the cortical actin web. Nanotechnology. May 2014;25(21):215101. 10.1088/0957-4484/25/21/215101.</Citation>
        </Reference>
        <Reference>
          <Citation>Zucchiatti P, Mitri E, Kenig S, Bill&#xe8; F, Kourousias G, Bedolla DE, et al. Contribution of Ribonucleic Acid (RNA) to the fourier transform infrared (FTIR) Spectrum of eukaryotic cells. Anal Chem. 2016;88(24):12090&#x2013;8. 10.1021/acs.analchem.6b02744.</Citation>
        </Reference>
        <Reference>
          <Citation>Toplak M, Read ST, Sandt C, Borondics F. Quasar: easy machine learning for biospectroscopy. Cells. Sep. 2021;10(9). 10.3390/cells10092300.</Citation>
        </Reference>
        <Reference>
          <Citation>Toplak M, Birarda G, Read S, Sandt C, Rosendahl SM, Vaccari L, et al. Infrared orange: connecting hyperspectral data with machine learning. Synchrotron Radiat N. Jul. 2017;30(4):40&#x2013;5. 10.1080/08940886.2017.1338424.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang N. Mechanical interactions among cytoskeletal filaments. Hypertens. Jul. 1998;32(1):162&#x2013;5. 10.1161/01.hyp.32.1.162.</Citation>
        </Reference>
        <Reference>
          <Citation>Ujihara Y, Nakamura M, Miyazaki H, Wada S. Proposed spring network cell model based on a minimum energy concept. Ann Biomed Eng. Apr. 2010;38(4):1530&#x2013;8. 10.1007/s10439-010-9930-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Calzado-Mart&#xed;n A, Encinar M, Tamayo J, Calleja M, San Paulo A. Effect of actin organization on the stiffness of living breast cancer cells revealed by peak-force modulation atomic force microscopy. ACS Nano. 2016;10(3):3365&#x2013;74. 10.1021/acsnano.5b07162.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim N-G, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through hippo signaling-pathway components. Proc Natl Acad Sci U S A. Jul. 2011;108(29):11930&#x2013;5. 10.1073/pnas.1103345108.</Citation>
        </Reference>
        <Reference>
          <Citation>Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. Jun. 2009;28(1&#x2013;2):15&#x2013;33. 10.1007/s10555-008-9169-0.</Citation>
        </Reference>
        <Reference>
          <Citation>Senigagliesi B, Penzo C, Severino LU, Maraspini R, Petrosino S, Morales-Navarrete H, et al. The high mobility group A1 (HMGA1) chromatin architectural factor modulates nuclear stiffness in breast cancer cells. Int J Mol Sci. 2019;20(11). 10.3390/ijms20112733.</Citation>
        </Reference>
        <Reference>
          <Citation>Berdyyeva TK, Woodworth CD, Sokolov I. Human epithelial cells increase their rigidity with ageing in vitro: Direct measurements. Phys Med Biol. Jan. 2005;50(1):81&#x2013;92. 10.1088/0031-9155/50/1/007.</Citation>
        </Reference>
        <Reference>
          <Citation>Sokolov I, Iyer S, Woodworth CD. Recovery of elasticity of aged human epithelial cells in vitro. Nanomedicine. Mar. 2006;2(1):31&#x2013;6. 10.1016/j.nano.2005.12.002.</Citation>
        </Reference>
        <Reference>
          <Citation>Vahabikashi A, Park CY, Perkumas K, Zhang Z, Deurloo EK, Wu H, et al. Probe sensitivity to cortical versus intracellular cytoskeletal network stiffness. Biophys J. Feb. 2019;116(3):518&#x2013;29. 10.1016/j.bpj.2018.12.021.</Citation>
        </Reference>
        <Reference>
          <Citation>Qi Y, Andolfi L, Frattini F, Mayer F, Lazzarino M, Hu J. Membrane stiffening by STOML3 facilitates mechanosensation in sensory neurons. Nat Commun. Oct. 2015;6:8512. 10.1038/ncomms9512.</Citation>
        </Reference>
        <Reference>
          <Citation>Perissinotto F, Stani C, De Cecco E, Vaccari L, Rondelli V, Posocco P, et al. Iron-mediated interaction of alpha synuclein with lipid raft model membranes. Nanoscale. Apr. 2020;12(14):7631&#x2013;40. 10.1039/d0nr00287a.</Citation>
        </Reference>
        <Reference>
          <Citation>Mih&#xe1;ly J, De&#xe1;k R, Szigy&#xe1;rt&#xf3; IC, B&#xf3;ta A, Beke-Somfai T, Varga Z. Characterization of extracellular vesicles by IR spectroscopy: Fast and simple classification based on amide and C[sbnd]H stretching vibrations. Biochim Biophys Acta&#x2009;&#x2013;&#x2009;Biomembr. 2017;1859(3):459&#x2013;66. 10.1016/j.bbamem.2016.12.005.</Citation>
        </Reference>
        <Reference>
          <Citation>St&#x119;pie&#x144; E&#x141;, Kami&#x144;ska A, Surman M, Karbowska D, Wr&#xf3;bel A, Przyby&#x142;o M. Fourier-Transform InfraRed (FT-IR) spectroscopy to show alterations in molecular composition of EV subpopulations from melanoma cell lines in different malignancy. Biochem Biophys Rep. Mar. 2021;25:100888. 10.1016/j.bbrep.2020.100888.</Citation>
        </Reference>
        <Reference>
          <Citation>Szentirmai V, Wacha A, N&#xe9;meth C, Kitka D, R&#xe1;cz A, H&#xe9;berger K, et al. Reagent-free total protein quantification of intact extracellular vesicles by attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy. Anal Bioanal Chem. Jul. 2020;412(19):4619&#x2013;28. 10.1007/s00216-020-02711-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Perissinotto F, Senigagliesi B, Vaccari L, Pachetti M, D&#x2019;Amico F, Amenitsch H, et al. Chapter six&#x2009;&#x2013;&#x2009;multi-technique analysis of extracellular vesicles: not only size matters. In Bongiovanni A, Pocsfalvi G, Manno M, VBT-A in B, Kralj-Igli&#x10d; LS-A, editors. Advances in biomembranes and lipid self-assembly. New York: Academic Press; Vol. 32, 2020, p. 157&#x2013;77.</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar S, Srinivasan A, Nikolajeff F. Role of infrared spectroscopy and imaging in cancer diagnosis. Curr Med Chem. 2017;25(9):1055&#x2013;72. 10.2174/0929867324666170523121314.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang JS, Shi JS, Xu YZ, Duan XY, Zhang L, Wang J, et al. FT-IR spectroscopic analysis of normal and cancerous tissues of esophagus. World J Gastroenterol. 2003;9(9):1897&#x2013;9. 10.3748/wjg.v9.i9.1897.</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar S, Shabi TS, Goormaghtigh E. A FTIR imaging characterization of fibroblasts stimulated by various breast cancer cell lines. PLoS One. 2014;9(11). 10.1371/journal.pone.0111137.</Citation>
        </Reference>
        <Reference>
          <Citation>Khamis ZI, Sahab ZJ, Sang Q-XA. Active roles of tumor stroma in breast cancer metastasis. Int J Breast Cancer. 2012;2012:574025. 10.1155/2012/574025.</Citation>
        </Reference>
        <Reference>
          <Citation>Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. Apr. 2002;62(7):1966&#x2013;70.</Citation>
        </Reference>
        <Reference>
          <Citation>Chiotaki R, Polioudaki H, Theodoropoulos PA. Differential nuclear shape dynamics of invasive andnon-invasive breast cancer cells are associated with actin cytoskeleton organization and stability. Biochem Cell Biol. 2014;92(4):287&#x2013;95. 10.1139/bcb-2013-0120.</Citation>
        </Reference>
        <Reference>
          <Citation>Fischer T, Hayn A, Mierke CT. Effect of nuclear stiffness on cell mechanics and migration of human breast cancer cells. Front Cell Dev Biol. 2020;8. 10.3389/fcell.2020.00393.</Citation>
        </Reference>
        <Reference>
          <Citation>Morrish RB, Hermes M, Metz J, Stone N, Pagliara S, Chahwan R, et al. Single cell imaging of nuclear architecture changes. Front Cell Dev Biol. 2019;7:141. 10.3389/fcell.2019.00141.</Citation>
        </Reference>
        <Reference>
          <Citation>da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. Jan. 2020;145:102855. 10.1016/j.critrevonc.2019.102855.</Citation>
        </Reference>
        <Reference>
          <Citation>Ozawa PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, de Souza Fonseca Ribeiro EM, Cavalli LR. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat. 2018;172(3):713&#x2013;23. 10.1007/s10549-018-4925-5.</Citation>
        </Reference>
        <Reference>
          <Citation>Chhabra ES, Higgs HN. The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol. Oct. 2007;9(10):1110&#x2013;21. 10.1038/ncb1007-1110.</Citation>
        </Reference>
        <Reference>
          <Citation>Shibue T, Brooks MW, Inan MF, Reinhardt F, Weinberg RA. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discovery. Aug. 2012;2(8):706&#x2013;21. 10.1158/2159-8290.CD-11-0239.</Citation>
        </Reference>
        <Reference>
          <Citation>Shibue T, Brooks MW, Weinberg RA. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell. Oct. 2013;24(4):481&#x2013;98. 10.1016/j.ccr.2013.08.012.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacquemet G, Paatero I, Carisey AF, Padzik A, Orange JS, Hamidi H, et al. FiloQuant reveals increased filopodia density during breast cancer progression. J Cell Biol. Oct. 2017;216(10):3387&#x2013;3403. 10.1083/jcb.201704045.</Citation>
        </Reference>
        <Reference>
          <Citation>Heusermann W, Hean J, Trojer D, Steib E, von Bueren S, Graff-Meyer A, et al. Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. J Cell Biol. 2016;213(2):173&#x2013;84. 10.1083/jcb.201506084.</Citation>
        </Reference>
        <Reference>
          <Citation>Dutta D, Palmer X-L, Ortega-Rodas J, Balraj V, Dastider IG, Chandra S. Biomechanical and biophysical properties of breast cancer cells under varying glycemic regimens. Breast Cancer. 2020;14:1178223420972362. 10.1177/1178223420972362.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu J, Zhou Y, Obayemi JD, Du J, Soboyejo WO. An investigation of the viscoelastic properties and the actin cytoskeletal structure of triple negative breast cancer cells. J Mech Behav Biomed Mater. Oct. 2018;86:1&#x2013;13. 10.1016/j.jmbbm.2018.05.038.</Citation>
        </Reference>
        <Reference>
          <Citation>Shim S, Kim MG, Jo K, Kang YS, Lee B, Yang S, et al. Dynamic characterization of human breast cancer cells using a piezoresistive microcantilever. J Biomech Eng. Oct. 2010;132(10):104501. 10.1115/1.4002180.</Citation>
        </Reference>
        <Reference>
          <Citation>Tabatabaei M, Tafazzoli-Shadpour M, Khani MM. Correlation of the cell mechanical behavior and quantified cytoskeletal parameters in normal and cancerous breast cell lines. Biorheology. 2019:56(4):207&#x2013;19. 10.3233/BIR-190214.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35165418</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4679</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature cell biology</Title>
          <ISOAbbreviation>Nat Cell Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance.</ArticleTitle>
        <Pagination>
          <StartPage>168</StartPage>
          <EndPage>180</EndPage>
          <MedlinePgn>168-180</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41556-022-00843-w</ELocationID>
        <Abstract>
          <AbstractText>Metastatic breast cancer cells disseminate to organs with a soft microenvironment. Whether and how the mechanical properties of the local tissue influence their response to treatment remains unclear. Here we found that a soft extracellular matrix empowers redox homeostasis. Cells cultured on a soft extracellular matrix display increased peri-mitochondrial F-actin, promoted by Spire1C and Arp2/3 nucleation factors, and increased DRP1- and MIEF1/2-dependent mitochondrial fission. Changes in mitochondrial dynamics lead to increased production of mitochondrial reactive oxygen species and activate the NRF2 antioxidant transcriptional response, including increased cystine uptake and glutathione metabolism. This retrograde response endows cells with resistance to oxidative stress and reactive oxygen species-dependent chemotherapy drugs. This is relevant in a mouse model of metastatic breast cancer cells dormant in the lung soft tissue, where inhibition of DRP1 and NRF2 restored cisplatin sensitivity and prevented disseminated cancer-cell awakening. We propose that targeting this mitochondrial dynamics- and redox-based mechanotransduction pathway could open avenues to prevent metastatic relapse.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Romani</LastName>
            <ForeName>Patrizia</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-1149-4304</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nirchio</LastName>
            <ForeName>Nunzia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arboit</LastName>
            <ForeName>Mattia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology (DiBio), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barbieri</LastName>
            <ForeName>Vito</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tosi</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michielin</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Child Health, NIHR Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shibuya</LastName>
            <ForeName>Soichi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-4274-1312</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Child Health, NIHR Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benoist</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-0116-2629</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Child Health, NIHR Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Danchen</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-3901-5907</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Queen's University, Kingston, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hindmarch</LastName>
            <ForeName>Charles Colin Thomas</ForeName>
            <Initials>CCT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Queen's University, Kingston, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giomo</LastName>
            <ForeName>Monica</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Industrial Engineering (DII), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Venetian Institute of Molecular Medicine (VIMM), Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Urciuolo</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fondazione Istituto di Ricerca Pediatrica (IRP), Città della Speranza, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giamogante</LastName>
            <ForeName>Flavia</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences (DSB), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roveri</LastName>
            <ForeName>Antonella</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3252-0559</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chakravarty</LastName>
            <ForeName>Probir</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinformatics Platform, The Francis Crick Institute, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montagner</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3080-2138</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calì</LastName>
            <ForeName>Tito</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-8901-1659</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences (DSB), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elvassore</LastName>
            <ForeName>Nicola</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-7029-6287</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Child Health, NIHR Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Industrial Engineering (DII), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Venetian Institute of Molecular Medicine (VIMM), Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Archer</LastName>
            <ForeName>Stephen L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Queen's University, Kingston, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Coppi</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-1659-0207</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Child Health, NIHR Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosato</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-5263-8386</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martello</LastName>
            <ForeName>Graziano</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-5520-085X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biology (DiBio), University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dupont</LastName>
            <ForeName>Sirio</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-6869-1966</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine (DMM), University of Padua, Padua, Italy. sirio.dupont@unipd.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>figshare</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>10.6084/m9.figshare.7338764</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL071115</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RC1 HL099462</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Cell Biol</MedlineTA>
        <NlmUniqueID>100890575</NlmUniqueID>
        <ISSNLinking>1465-7392</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051376">Actin-Related Protein 2-3 Complex</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000199">Actins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C561316">MIEF1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C585230">MIEF2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010445">Peptide Elongation Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000592292">SPIRE1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.5</RegistryNumber>
          <NameOfSubstance UI="C110768">DNM1L protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.5</RegistryNumber>
          <NameOfSubstance UI="D034281">Dynamins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Cell Biol. 2022 Feb;24(2):133-134</RefSource>
          <PMID Version="1">35165419</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051376" MajorTopicYN="N">Actin-Related Protein 2-3 Complex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021982" MajorTopicYN="N">Cell-Matrix Junctions</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005109" MajorTopicYN="N">Extracellular Matrix</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040542" MajorTopicYN="N">Mechanotransduction, Cellular</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063154" MajorTopicYN="N">Mitochondrial Dynamics</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010445" MajorTopicYN="N">Peptide Elongation Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35165418</ArticleId>
        <ArticleId IdType="doi">10.1038/s41556-022-00843-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41556-022-00843-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Min, E. &amp; Schwartz, M. A. Translocating transcription factors in fluid shear stress-mediated vascular remodeling and disease. Exp. Cell. Res. 376, 92&#x2013;97 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30633880</ArticleId>
            <ArticleId IdType="pmc">8211025</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2019.01.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petridou, N. I., Spir&#xf3;, Z. &amp; Heisenberg, C.-P. Multiscale force sensing in development. Nat. Cell Biol. 19, 581&#x2013;588 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28561050</ArticleId>
            <ArticleId IdType="doi">10.1038/ncb3524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschumperlin, D. J., Ligresti, G., Hilscher, M. B. &amp; Shah, V. H. Mechanosensing and fibrosis. J. Clin. Invest. 128, 74&#x2013;84 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29293092</ArticleId>
            <ArticleId IdType="pmc">5749510</ArticleId>
            <ArticleId IdType="doi">10.1172/JCI93561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vining, K. H. &amp; Mooney, D. J. Mechanical forces direct stem cell behaviour in development and regeneration. Nat. Rev. Mol. Cell Biol. 18, 728&#x2013;742 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29115301</ArticleId>
            <ArticleId IdType="pmc">5803560</ArticleId>
            <ArticleId IdType="doi">10.1038/nrm.2017.108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphrey, J. D., Dufresne, E. R. &amp; Schwartz, M. A. Mechanotransduction and extracellular matrix homeostasis. Nat. Rev. Mol. Cell Biol. 15, 802&#x2013;812 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25355505</ArticleId>
            <ArticleId IdType="pmc">4513363</ArticleId>
            <ArticleId IdType="doi">10.1038/nrm3896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iskratsch, T., Wolfenson, H. &amp; Sheetz, M. P. Appreciating force and shape&#x2014;the rise of mechanotransduction in cell biology. Nat. Rev. Mol. Cell Biol. 15, 825&#x2013;833 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25355507</ArticleId>
            <ArticleId IdType="doi">10.1038/nrm3903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammadi, H. &amp; Sahai, E. Mechanisms and impact of altered tumour mechanics. Nat. Cell Biol. 20, 766&#x2013;774 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29950570</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-018-0131-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gensbittel, V. et al. Mechanical adaptability of tumor cells in metastasis. Dev. Cell 56, 164&#x2013;179 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33238151</ArticleId>
            <ArticleId IdType="doi">10.1016/j.devcel.2020.10.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montagner, M. &amp; Dupont, S. Mechanical Forces as Determinants of Disseminated Metastatic Cell Fate. Cells 9, 250 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Romani, P., Valcarcel-Jimenez, L., Frezza, C. &amp; Dupont, S. Crosstalk between mechanotransduction and metabolism. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/s41580-020-00306-w (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Romani, P. et al. Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP. Nat. Cell Biol. 21, 338&#x2013;347 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30718857</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-018-0270-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutscher, M. et al. Real-time imaging of the intracellular glutathione redox potential. Nat. Methods 5, 553&#x2013;559 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18469822</ArticleId>
            <ArticleId IdType="doi">10.1038/nmeth.1212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao, R. et al. Genetically encoded fluorescent sensors reveal dynamic regulation of NADPH metabolism. Nat. Methods 14, 720&#x2013;728 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28581494</ArticleId>
            <ArticleId IdType="pmc">5555402</ArticleId>
            <ArticleId IdType="doi">10.1038/nmeth.4306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawk, M. A. et al. RIPK1-mediated induction of mitophagy compromises the viability of extracellular-matrix-detached cells. Nat. Cell Biol. 20, 272&#x2013;284 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29459781</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-018-0034-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang, L. et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255&#x2013;258 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27049945</ArticleId>
            <ArticleId IdType="pmc">4860952</ArticleId>
            <ArticleId IdType="doi">10.1038/nature17393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schafer, Z. T. et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109&#x2013;113 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19693011</ArticleId>
            <ArticleId IdType="pmc">2931797</ArticleId>
            <ArticleId IdType="doi">10.1038/nature08268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki, H. et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277, 44765&#x2013;44771 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12235164</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M208704200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo de la Vega, M., Chapman, E. &amp; Zhang, D. D. NRF2 and the hallmarks of cancer. Cancer Cell 34, 21&#x2013;43 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29731393</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.03.022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sies, H. &amp; Jones, D. P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 21, 363&#x2013;383 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32231263</ArticleId>
            <ArticleId IdType="doi">10.1038/s41580-020-0230-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agyeman, A. S. et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res. Treat. 132, 175&#x2013;187 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21597922</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-011-1536-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes, J. D. &amp; Dinkova-Kostova, A. T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39, 199&#x2013;218 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24647116</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tibs.2014.02.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panieri, E., Telkoparan-Akillilar, P., Suzen, S. &amp; Saso, L. The NRF2/KEAP1 axis in the regulation of tumor metabolism: mechanisms and therapeutic perspectives. Biomolecules 10, 791 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 23, 1362&#x2013;1368 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28967920</ArticleId>
            <ArticleId IdType="pmc">5677540</ArticleId>
            <ArticleId IdType="doi">10.1038/nm.4407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Barrueco, R. et al. Inhibition of the autocrine IL-6&#x2013;JAK2&#x2013;STAT3&#x2013;calprotectin axis as targeted therapy for HR[&#x2212;]/HER2[+] breast cancers. Genes Dev. 29, 1631&#x2013;1648 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26227964</ArticleId>
            <ArticleId IdType="pmc">4536311</ArticleId>
            <ArticleId IdType="doi">10.1101/gad.262642.115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vera-Ramirez, L., Vodnala, S. K., Nini, R., Hunter, K. W. &amp; Green, J. E. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat. Commun. 9, 1944 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29789598</ArticleId>
            <ArticleId IdType="pmc">5964069</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-018-04070-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medina, S. H. et al. Identification of a mechanogenetic link between substrate stiffness and chemotherapeutic response in breast cancer. Biomaterials 202, 1&#x2013;11 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30818087</ArticleId>
            <ArticleId IdType="pmc">6474249</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2019.02.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Havas, K. M. et al. Metabolic shifts in residual breast cancer drive tumor recurrence. J. Clin. Invest. 127, 2091&#x2013;2105 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28504653</ArticleId>
            <ArticleId IdType="pmc">5451224</ArticleId>
            <ArticleId IdType="doi">10.1172/JCI89914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing, H. et al. Early evaluation of relative changes in tumor stiffness by shear wave elastography predicts the response to neoadjuvant chemotherapy in patients with breast cancer. J. Ultrasound Med. 35, 1619&#x2013;1627 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27302898</ArticleId>
            <ArticleId IdType="doi">10.7863/ultra.15.08052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu, C.-K. et al. Caveolin-1 controls hyperresponsiveness to mechanical stimuli and fibrogenesis-associated RUNX2 activation in keloid fibroblasts. J. Invest. Dermatol. 138, 208&#x2013;218 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28899682</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jid.2017.05.041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang, C. &amp; Ogawa, R. Fibroproliferative disorders and their mechanobiology. Connect. Tissue Res. 53, 187&#x2013;196 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22329637</ArticleId>
            <ArticleId IdType="doi">10.3109/03008207.2011.642035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179&#x2013;183 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654799</ArticleId>
            <ArticleId IdType="doi">10.1038/nature10137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn, S.-G. &amp; Thiele, D. J. Redox regulation of mammalian heat shock factor 1 is essential for Hsp gene activation and protection from stress. Genes Dev. 17, 516&#x2013;528 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12600944</ArticleId>
            <ArticleId IdType="pmc">195992</ArticleId>
            <ArticleId IdType="doi">10.1101/gad.1044503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendillo, M. L. et al. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 150, 549&#x2013;562 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22863008</ArticleId>
            <ArticleId IdType="pmc">3438889</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tharp, K. M. et al. Adhesion-mediated mechanosignaling forces mitohormesis. Cell Metab. 33, 1322&#x2013;1341 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34019840</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cmet.2021.04.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo, M. et al. Heat stress activates YAP/TAZ to induce the heat shock transcriptome. Nat. Cell Biol. 22, 1447&#x2013;1459 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33199845</ArticleId>
            <ArticleId IdType="pmc">7757600</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-020-00602-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandel, N. S. Evolution of mitochondria as signaling organelles. Cell Metab. 22, 204&#x2013;206 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26073494</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cmet.2015.05.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shadel, G. S. &amp; Horvath, T. L. Mitochondrial ROS signaling in organismal homeostasis. Cell 163, 560&#x2013;569 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26496603</ArticleId>
            <ArticleId IdType="pmc">4634671</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2015.10.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yun, J. &amp; Finkel, T. Mitohormesis. Cell Metab. 19, 757&#x2013;766 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24561260</ArticleId>
            <ArticleId IdType="pmc">4016106</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cmet.2014.01.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon, S. J. &amp; Stockwell, B. R. The hallmarks of ferroptosis. Ann. Rev. Cancer Biol. 3, 35&#x2013;54 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-cancerbio-030518-055844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini, F. &amp; Maiorino, M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic. Biol. Med. 152, 175&#x2013;185 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32165281</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.02.027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertero, T. et al. Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy. Cell Metab. 29, 124&#x2013;140 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30293773</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cmet.2018.09.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty, M. et al. Mechanical stiffness controls dendritic cell metabolism and function. Cell Rep. 34, 108609 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33440149</ArticleId>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.108609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan, A. U. H. et al. Mitochondrial complex I activity signals antioxidant response through ERK5. Sci. Rep. 8, 7420 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29743487</ArticleId>
            <ArticleId IdType="pmc">5943249</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-018-23884-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santacatterina, F. et al. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. Oncotarget 7, 490&#x2013;508 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">4808013</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.6357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu, D. et al. Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury. FASEB J. 34, 1447&#x2013;1464 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31914641</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.201901467R</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giacomello, M., Pyakurel, A., Glytsou, C. &amp; Scorrano, L. The cell biology of mitochondrial membrane dynamics. Nat. Rev. Mol. Cell Biol. 21, 204&#x2013;224 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32071438</ArticleId>
            <ArticleId IdType="doi">10.1038/s41580-020-0210-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraus, F., Roy, K., Pucadyil, T. J. &amp; Ryan, M. T. Function and regulation of the divisome for mitochondrial fission. Nature 590, 57&#x2013;66 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33536648</ArticleId>
            <ArticleId IdType="doi">10.1038/s41586-021-03214-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cieri, D. et al. SPLICS: a split green fluorescent protein-based contact site sensor for narrow and wide heterotypic organelle juxtaposition. Cell Death Differ. 25, 1131&#x2013;1145 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29229997</ArticleId>
            <ArticleId IdType="doi">10.1038/s41418-017-0033-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallese, F. et al. An expanded palette of improved SPLICS reporters detects multiple organelle contacts in vitro and in vivo. Nat. Commun. 11, 6069 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33247103</ArticleId>
            <ArticleId IdType="pmc">7699637</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-020-19892-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bordt, E. A. et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev. Cell 40, 583&#x2013;594 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28350990</ArticleId>
            <ArticleId IdType="pmc">5398851</ArticleId>
            <ArticleId IdType="doi">10.1016/j.devcel.2017.02.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassidy-Stone, A. et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell 14, 193&#x2013;204 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18267088</ArticleId>
            <ArticleId IdType="pmc">2267902</ArticleId>
            <ArticleId IdType="doi">10.1016/j.devcel.2007.11.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins, K., Dasgupta, A., Chen, K.-H., Mewburn, J. &amp; Archer, S. L. The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: implications for human disease. Clin. Sci. 130, 1861&#x2013;1874 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/CS20160030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasgupta, A. et al. An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: diagnostic and therapeutic implications. FASEB J. 34, 5106&#x2013;5127 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32068312</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.201903117R</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koirala, S. et al. Interchangeable adaptors regulate mitochondrial dynamin assembly for membrane scission. Proc. Natl Acad. Sci. USA 110, E1342&#x2013;E1351 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23530241</ArticleId>
            <ArticleId IdType="pmc">3625255</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1300855110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osellame, L. D. et al. Cooperative and independent roles of the Drp1 adaptors Mff, MiD49 and MiD51 in mitochondrial fission. J. Cell Sci. 129, 2170&#x2013;2181 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27076521</ArticleId>
            <ArticleId IdType="pmc">6919635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lomakin, A. J. et al. Competition for actin between two distinct F-actin networks defines a bistable switch for cell polarization. Nat. Cell Biol. 17, 1435&#x2013;1445 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26414403</ArticleId>
            <ArticleId IdType="pmc">4628555</ArticleId>
            <ArticleId IdType="doi">10.1038/ncb3246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pocaterra, A. et al. Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development. Commun. Biol. 4, 1&#x2013;13 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42003-021-02286-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez, C. &amp; Kovar, D. R. Internetwork competition for monomers governs actin cytoskeleton organization. Nat. Rev. Mol. Cell Biol. 17, 799&#x2013;810 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27625321</ArticleId>
            <ArticleId IdType="pmc">5125073</ArticleId>
            <ArticleId IdType="doi">10.1038/nrm.2016.106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang, Q., Zhang, X.-F., Pollard, T. D. &amp; Forscher, P. Arp2/3 complex-dependent actin networks constrain myosin II function in driving retrograde actin flow. J. Cell Biol. 197, 939&#x2013;956 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22711700</ArticleId>
            <ArticleId IdType="pmc">3384413</ArticleId>
            <ArticleId IdType="doi">10.1083/jcb.201111052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlier, M.-F. &amp; Shekhar, S. Global treadmilling coordinates actin turnover and controls the size of actin networks. Nat. Rev. Mol. Cell Biol. 18, 389&#x2013;401 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28248322</ArticleId>
            <ArticleId IdType="doi">10.1038/nrm.2016.172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korobova, F., Ramabhadran, V. &amp; Higgs, H. N. An actin-dependent step in mitochondrial fission mediated by the ER-associated formin INF2. Science 339, 464&#x2013;467 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23349293</ArticleId>
            <ArticleId IdType="doi">10.1126/science.1228360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, S. et al. Transient assembly of F-actin on the outer mitochondrial membrane contributes to mitochondrial fission. J. Cell Biol. 208, 109&#x2013;123 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25547155</ArticleId>
            <ArticleId IdType="pmc">4284235</ArticleId>
            <ArticleId IdType="doi">10.1083/jcb.201404050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manor, U. et al. A mitochondria-anchored isoform of the actin-nucleating spire protein regulates mitochondrial division. eLife 4, e08828 (2015).</Citation>
        </Reference>
        <Reference>
          <Citation>Posern, G., Sotiropoulos, A. &amp; Treisman, R. Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. Mol. Biol. Cell 13, 4167&#x2013;4178 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12475943</ArticleId>
            <ArticleId IdType="pmc">138624</ArticleId>
            <ArticleId IdType="doi">10.1091/mbc.02-05-0068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helle, S. C. J. et al. Mechanical force induces mitochondrial fission. eLife 6, e30292 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29119945</ArticleId>
            <ArticleId IdType="pmc">5679753</ArticleId>
            <ArticleId IdType="doi">10.7554/eLife.30292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleele, T. et al. Distinct fission signatures predict mitochondrial degradation or biogenesis. Nature 593, 435&#x2013;439 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33953403</ArticleId>
            <ArticleId IdType="doi">10.1038/s41586-021-03510-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore, A. S. et al. Actin cables and comet tails organize mitochondrial networks in mitosis. Nature 591, 659&#x2013;664 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33658713</ArticleId>
            <ArticleId IdType="pmc">7990722</ArticleId>
            <ArticleId IdType="doi">10.1038/s41586-021-03309-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkan, D. &amp; Chambers, A. F. &#x3b2;1-Integrin: a potential therapeutic target in the battle against cancer recurrence. Clin. Cancer Res. 17, 7219&#x2013;7223 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21900388</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-0642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montagner, M. &amp; Sahai, E. In vitro models of breast cancer metastatic dormancy. Front. Cell Dev. Biol. 8, 37 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32195244</ArticleId>
            <ArticleId IdType="pmc">7062644</ArticleId>
            <ArticleId IdType="doi">10.3389/fcell.2020.00037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein, C. A. Cancer progression and the invisible phase of metastatic colonization. Nat. Rev. Cancer 20, 681&#x2013;694 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33024261</ArticleId>
            <ArticleId IdType="doi">10.1038/s41568-020-00300-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkan, D. et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241&#x2013;6250 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18676848</ArticleId>
            <ArticleId IdType="pmc">2561279</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkan, D. et al. Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. Cancer Res. 70, 5706&#x2013;5716 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20570886</ArticleId>
            <ArticleId IdType="pmc">3436125</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-2356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsafadi, H. N. et al. Applications and approaches for three-dimensional precision-cut lung slices. Disease modeling and drug discovery. Am. J. Respir. Cell Mol. Biol. 62, 681&#x2013;691 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31991090</ArticleId>
            <ArticleId IdType="pmc">7401444</ArticleId>
            <ArticleId IdType="doi">10.1165/rcmb.2019-0276TR</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giobbe, G. G. et al. Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid culture. Nat. Commun. 10, 5658 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31827102</ArticleId>
            <ArticleId IdType="pmc">6906306</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-019-13605-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maghsoudlou, P. et al. Preservation of micro-architecture and angiogenic potential in a pulmonary acellular matrix obtained using intermittent intra-tracheal flow of detergent enzymatic treatment. Biomaterials 34, 6638&#x2013;6648 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23727263</ArticleId>
            <ArticleId IdType="pmc">3988964</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2013.05.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, F. et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J. Cell Biol. 190, 693&#x2013;706 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20733059</ArticleId>
            <ArticleId IdType="pmc">2928007</ArticleId>
            <ArticleId IdType="doi">10.1083/jcb.201004082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girton, T. S., Oegema, T. R. &amp; Tranquillo, R. T. Exploiting glycation to stiffen and strengthen tissue equivalents for tissue engineering. J. Biomed. Mater. Res. 46, 87&#x2013;92 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10357139</ArticleId>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4636(199907)46:1&lt;87::AID-JBM10&gt;3.0.CO;2-K</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy, R., Boskey, A. &amp; Bonassar, L. J. Processing of type I collagen gels using non-enzymatic glycation. J. Biomed. Mater. Res. A 93, 843&#x2013;851 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19658163</ArticleId>
            <ArticleId IdType="pmc">2935617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goddard, E. T., Bozic, I., Riddell, S. R. &amp; Ghajar, C. M. Dormant tumour cells, their niches and the influence of immunity. Nat. Cell Biol. 20, 1240&#x2013;1249 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30361702</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-018-0214-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehman, J. et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 26, 2175&#x2013;2186 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22321727</ArticleId>
            <ArticleId IdType="pmc">3336787</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.11-196543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi, N. et al. 3D culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and ferroptosis. Mol. Cell https://doi.org/10.1016/j.molcel.2020.10.010 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, K., Wang, Y., Deng, X., Guo, L. &amp; Wu, C. Extracellular matrix stiffness regulates mitochondrial dynamics through PINCH-1- and kindlin-2-mediated signalling. Curr. Res. Cell Biol. 2, 100008 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.crcbio.2021.100008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang, H. et al. Materials stiffness-dependent redox metabolic reprogramming of mesenchymal stem cells for secretome-based therapeutic angiogenesis. Adv. Healthcare Mater. 8, 1900929 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adhm.201900929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khacho, M. et al. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. Cell Stem Cell 19, 232&#x2013;247 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27237737</ArticleId>
            <ArticleId IdType="doi">10.1016/j.stem.2016.04.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatch, A. L., Ji, W.-K., Merrill, R. A., Strack, S. &amp; Higgs, H. N. Actin filaments as dynamic reservoirs for Drp1 recruitment. Mol. Biol. Cell 27, 3109&#x2013;3121 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27559132</ArticleId>
            <ArticleId IdType="pmc">5063618</ArticleId>
            <ArticleId IdType="doi">10.1091/mbc.e16-03-0193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer, C. S. et al. MiD49 and MiD51, new components of the mitochondrial fission machinery. EMBO Rep. 12, 565&#x2013;573 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21508961</ArticleId>
            <ArticleId IdType="pmc">3128275</ArticleId>
            <ArticleId IdType="doi">10.1038/embor.2011.54</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore, A. S., Wong, Y. C., Simpson, C. L. &amp; Holzbaur, E. L. F. Dynamic actin cycling through mitochondrial subpopulations locally regulates the fission-fusion balance within mitochondrial networks. Nat. Commun. 7, 12886 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27686185</ArticleId>
            <ArticleId IdType="pmc">5056443</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms12886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, X. &amp; Hajn&#xf3;czky, G. Altered fusion dynamics underlie unique morphological changes in mitochondria during hypoxia&#x2013;reoxygenation stress. Cell Death Differ. 18, 1561&#x2013;1572 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21372848</ArticleId>
            <ArticleId IdType="pmc">3172112</ArticleId>
            <ArticleId IdType="doi">10.1038/cdd.2011.13</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazono, Y. et al. Uncoupled mitochondria quickly shorten along their long axis to form indented spheroids, instead of rings, in a fission-independent manner. Sci. Rep. 8, 350 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29321618</ArticleId>
            <ArticleId IdType="pmc">5762872</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-017-18582-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maguire, S. L. et al. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. J. Pathol. 240, 315&#x2013;328 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27512948</ArticleId>
            <ArticleId IdType="pmc">5082563</ArticleId>
            <ArticleId IdType="doi">10.1002/path.4778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pocaterra, A. et al. F-actin dynamics regulates mammalian organ growth and cell fate maintenance. J. Hepatol. 71, 130&#x2013;142 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30878582</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2019.02.022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ignesti, M. et al. A polydnavirus-encoded ANK protein has a negative impact on steroidogenesis and development. Insect Biochem. Mol. Biol. 95, 26&#x2013;32 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29559251</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ibmb.2018.03.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romani, P. et al. Dynamin controls extracellular level of Awd/Nme1 metastasis suppressor protein. Naunyn Schmiedebergs Arch. Pharmacol. 389, 1171&#x2013;1182 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27449069</ArticleId>
            <ArticleId IdType="doi">10.1007/s00210-016-1268-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romani, P., Duchi, S., Gargiulo, G. &amp; Cavaliere, V. Evidence for a novel function of Awd in maintenance of genomic stability. Sci. Rep. 7, 16820 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29203880</ArticleId>
            <ArticleId IdType="pmc">5714947</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-017-17217-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen, K.-H. et al. Epigenetic dysregulation of the dynamin-related protein 1 binding partners MiD49 and MiD51 increases mitotic mitochondrial fission and promotes pulmonary arterial hypertension: mechanistic and therapeutic implications. Circulation 138, 287&#x2013;304 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29431643</ArticleId>
            <ArticleId IdType="pmc">6050130</ArticleId>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.031258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enzo, E. et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34, 1349&#x2013;1370 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25796446</ArticleId>
            <ArticleId IdType="pmc">4491996</ArticleId>
            <ArticleId IdType="doi">10.15252/embj.201490379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagen, C. K. et al. High contrast microstructural visualization of natural acellular matrices by means of phase-based x-ray tomography. Sci. Rep. 5, 18156 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26657471</ArticleId>
            <ArticleId IdType="pmc">4677348</ArticleId>
            <ArticleId IdType="doi">10.1038/srep18156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urciuolo, A. et al. Intravital three-dimensional bioprinting. Nat. Biomed. Eng. 4, 901&#x2013;915 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32572195</ArticleId>
            <ArticleId IdType="doi">10.1038/s41551-020-0568-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albrengues, J. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361, eaao4227 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Montagner, M. et al. Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. Nat. Cell Biol. 22, 289&#x2013;296 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32094692</ArticleId>
            <ArticleId IdType="pmc">7610690</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-020-0474-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibue, T., Brooks, M. W. &amp; Weinberg, R. A. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell 24, 481&#x2013;498 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24035453</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.08.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aston, W. J. et al. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer 17, 684 (2017).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33493685</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>541</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Matrix hardness regulates the cancer cell malignant progression through cytoskeletal network.</ArticleTitle>
        <Pagination>
          <StartPage>95</StartPage>
          <EndPage>101</EndPage>
          <MedlinePgn>95-101</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2021.01.014</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(21)00049-8</ELocationID>
        <Abstract>
          <AbstractText>The tumor microenvironment is a complex microenvironment that combines the biochemical and biophysical factors. When the cells are exposed to the microenvironment, the direct biophysical factor is the matrix hardness. As an auxiliary indicator of clinical disease diagnosis, it is still not clear how the matrix hardness induces cell malignant changes and the regulation mechanisms. In this study, we identified that hard matrix significantly promoted cancer cell migratory behaviors. Cell shape was closely associated with cancer cell malignancy, the high malignant cells were associated with high ratios of length/width and low circularity. F-actin networks were also linked with extracellular matrix, it was not regularly distributed when cells were in non-malignant tumor phases or under F-actin inhibition. F-actin might play the key role that transmitted the signal from extracellular matrix to the intracellular organelles. Further study confirmed that active YAP was translocated to nucleus on hard matrix. Cells on hard matrix with cytochalasin D reversed the cancer cell malignancy, meanwhile F-actin re-distributed to the membrane and YAP nucleus translocations were hindered. This work confirmed that F-actin and YAP were upstream-downstream cascade for the cellular and nucleus outside-in signal transductions. The above results demonstrated that hard matrix promoted breast cancer cell malignant behaviors through F-actin network and YAP activation. These results not only described the signal transductions from extracellular to intracellular that was initiated by the biophysical tumor microenvironment, but provided clinical intervention ideas for cancer treatments.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Yonggang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, PR China; School of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jialing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Imageology, North Sichuan Medical College, Nanchong, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Peiru</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Dongmei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Aifa</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, PR China. Electronic address: tangaifa2018@email.szu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tao</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, PR China; Department of Pathology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, PR China. Electronic address: taojia@nsmc.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000199">Actins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>22144-77-0</RegistryNumber>
          <NameOfSubstance UI="D015638">Cytochalasin D</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="Y">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048430" MajorTopicYN="Y">Cell Shape</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015638" MajorTopicYN="N">Cytochalasin D</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005109" MajorTopicYN="N">Extracellular Matrix</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006244" MajorTopicYN="Y">Hardness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">F-actin</Keyword>
        <Keyword MajorTopicYN="N">Matrix hardness</Keyword>
        <Keyword MajorTopicYN="N">Nucleus</Keyword>
        <Keyword MajorTopicYN="N">Shape</Keyword>
        <Keyword MajorTopicYN="N">Signal transduction</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest We declare that there have no conflict of interest to state.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33493685</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2021.01.014</ArticleId>
        <ArticleId IdType="pii">S0006-291X(21)00049-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33233417</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>22</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Early Transcriptomic Response to OxLDL in Human Retinal Pigment Epithelial Cells.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">8818</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21228818</ELocationID>
        <Abstract>
          <AbstractText>In the sub-retinal pigment epithelium (sub-RPE) space of the aging macula, deposits of oxidized phospholipids, oxidized derivatives of cholesterol and associated oxidized low-density lipoproteins (OxLDL) are considered contributors to the onset and development of age-related macular degeneration (AMD). We investigated the gene expression response of a human-derived RPE cell line exposed for short periods of time to non-cytotoxic levels of OxLDL or LDL. In our cell model, treatment with OxLDL, but not LDL, generated an early gene expression response which affected more than 400 genes. Gene pathway analysis unveiled gene networks involved in the regulation of various cellular functions, including acute response to oxidative stress via up-regulation of antioxidative gene transcripts controlled by nuclear factor erythroid-2 related factor 2 (NRF2), and up-regulation of aryl hydrocarbon receptor-controlled detoxifying gene transcripts. In contrast, circadian rhythm-controlling genes and genes involved in lipid metabolism were strongly down-regulated. Treatment with low-density lipoprotein (LDL) did not induce the regulation of these pathways. These findings show that RPE cells are able to selectively respond to the oxidized forms of LDL via the up-regulation of gene pathways involved in molecular mechanisms that minimize cellular oxidative damage, and the down-regulation of the expression of genes that regulate the intracellular levels of lipids and lipid derivatives. The effect on genes that control the cellular circadian rhythm suggests that OxLDL might also disrupt the circadian clock-dependent phagocytic activity of the RPE. The data reveal a complex cellular response to a highly heterogeneous oxidative stress-causing agent such as OxLDL commonly present in drusen formations.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Koirala</LastName>
            <ForeName>Diwa</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-7950-0259</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences; The University of Tennessee Health Science Center, Memphis, TN 38163, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beranova-Giorgianni</LastName>
            <ForeName>Sarka</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences; The University of Tennessee Health Science Center, Memphis, TN 38163, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giorgianni</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences; The University of Tennessee Health Science Center, Memphis, TN 38163, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>NA</GrantID>
            <Agency>Retina Research Foundation</Agency>
          </Grant>
          <Grant>
            <GrantID>M2016068</GrantID>
            <Agency>BrightFocus Foundation</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018336">Receptors, Aryl Hydrocarbon</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C099252">oxidized low density lipoprotein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>97C5T2UQ7J</RegistryNumber>
          <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008266" MajorTopicYN="N">Macula Lutea</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018336" MajorTopicYN="N">Receptors, Aryl Hydrocarbon</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">drusen</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">oxidized LDL</Keyword>
        <Keyword MajorTopicYN="N">retinal pigment epithelium</Keyword>
        <Keyword MajorTopicYN="N">transcriptome</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33233417</ArticleId>
        <ArticleId IdType="pmc">PMC7700619</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms21228818</ArticleId>
        <ArticleId IdType="pii">ijms21228818</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Friedman D.S., O&#x2019;Colmain B.J., Mu&#xf1;oz B., Tomany S.C., Mccarty C., De Jong P.T.V.M., Nemesure B., Mitchell P., Kempen J. Prevalence of Age-Related Macular Degeneration in the United States. Arch. Ophthalmol. 2004;122:564&#x2013;572. doi: 10.1001/archopht.122.4.564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.122.4.564</ArticleId>
            <ArticleId IdType="pubmed">15078675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowak J.Z. Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharmacol. Rep. 2006;58:353&#x2013;363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16845209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Zamil W.M., Yassin S.A. Recent developments in age-related macular degeneration: A review. Clin. Interv. Aging. 2017;12:1313&#x2013;1330. doi: 10.2147/CIA.S143508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CIA.S143508</ArticleId>
            <ArticleId IdType="pmc">PMC5573066</ArticleId>
            <ArticleId IdType="pubmed">28860733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang K.-H., Do Y.-J., Son D., Son E., Choi J.-S., Kim E. AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration. Cell Death Dis. 2018;8:e2526. doi: 10.1038/cddis.2016.437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.437</ArticleId>
            <ArticleId IdType="pmc">PMC5386356</ArticleId>
            <ArticleId IdType="pubmed">28055012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeAngelis M.M., Owen L.A., Morrison M.A., Morgan D.J., Li M., Shakoor A., Vitale A., Iyengar S., Stambolian D., Kim I.K., et al. Genetics of age-related macular degeneration (AMD) Hum. Mol. Genet. 2017;26:R246. doi: 10.1093/hmg/ddx343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddx343</ArticleId>
            <ArticleId IdType="pmc">PMC6262235</ArticleId>
            <ArticleId IdType="pubmed">28977452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez I.R., Larr&#xe1;yoz I.M. Cholesterol oxidation in the retina: Implications of 7KCh formation in chronic inflammation and age-related macular degeneration. J. Lipid Res. 2010;51:2847&#x2013;2862. doi: 10.1194/jlr.R004820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1194/jlr.R004820</ArticleId>
            <ArticleId IdType="pmc">PMC2936760</ArticleId>
            <ArticleId IdType="pubmed">20567027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Handa J.T., Cano M., Wang L., Datta S., Liu T. Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration. Biochim. et Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:430&#x2013;440. doi: 10.1016/j.bbalip.2016.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbalip.2016.07.013</ArticleId>
            <ArticleId IdType="pmc">PMC5280582</ArticleId>
            <ArticleId IdType="pubmed">27480216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratnayaka J.A., Serpell L.C., Lotery A.J. Dementia of the eye: The role of amyloid beta in retinal degeneration. Eye. 2015;29:1013&#x2013;1026. doi: 10.1038/eye.2015.100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2015.100</ArticleId>
            <ArticleId IdType="pmc">PMC4541342</ArticleId>
            <ArticleId IdType="pubmed">26088679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levitan I., Volkov S., Subbaiah P.V. Oxidized LDL: Diversity, Patterns of Recognition, and Pathophysiology. Antioxidants Redox Signal. 2010;13:39&#x2013;75. doi: 10.1089/ars.2009.2733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2009.2733</ArticleId>
            <ArticleId IdType="pmc">PMC2877120</ArticleId>
            <ArticleId IdType="pubmed">19888833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binder C.J., Papac-Milicevic C.J.B.N., Witztum J.L. Innate sensing of oxidation-specific epitopes in health and disease. Nat. Rev. Immunol. 2016;16:485&#x2013;497. doi: 10.1038/nri.2016.63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2016.63</ArticleId>
            <ArticleId IdType="pmc">PMC7097710</ArticleId>
            <ArticleId IdType="pubmed">27346802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weigel A.L., Handa J.T., Hjelmeland L.M. Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free. Radic. Biol. Med. 2002;33:1419&#x2013;1432. doi: 10.1016/S0891-5849(02)01082-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0891-5849(02)01082-1</ArticleId>
            <ArticleId IdType="pubmed">12419474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cano M., Wang L., Wan J., Barnett B.P., Ebrahimi K., Qian J., Handa J.T. Oxidative stress induces mitochondrial dysfunction and a protective unfolded protein response in RPE cells. Free. Radic. Biol. Med. 2014;69:1&#x2013;14. doi: 10.1016/j.freeradbiomed.2014.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC3960355</ArticleId>
            <ArticleId IdType="pubmed">24434119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada Y., Tian J., Yang Y., Cutler R.G., Wu T., Telljohann R.S., Mattson M.P., Handa J.T. Oxidized low density lipoproteins induce a pathologic response by retinal pigmented epithelial cells. J. Neurochem. 2008;105:1187&#x2013;1197. doi: 10.1111/j.1471-4159.2008.05211.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2008.05211.x</ArticleId>
            <ArticleId IdType="pubmed">18182060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnanaguru G., Choi A.R., Amarnani D., D&#x2019;Amore P.A. Oxidized Lipoprotein Uptake Through the CD36 Receptor Activates the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells. Investig. Ophthalmol. Vis. Sci. 2016;57:4704&#x2013;4712. doi: 10.1167/iovs.15-18663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.15-18663</ArticleId>
            <ArticleId IdType="pmc">PMC5024668</ArticleId>
            <ArticleId IdType="pubmed">27607416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordiyenko N., Campos M., Lee J.W., Fariss R.N., Sztein J., Rodriguez I.R. RPE Cells Internalize Low-Density Lipoprotein (LDL) and Oxidized LDL (oxLDL) in Large Quantities In Vitro and In Vivo. Investig. Ophthalmol. Vis. Sci. 2004;45:2822&#x2013;2829. doi: 10.1167/iovs.04-0074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.04-0074</ArticleId>
            <ArticleId IdType="pubmed">15277509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuda O., Pietka T.A., Demianova Z., Kudova E., Cvacka J., Kopecky J., Abumrad N.A. Sulfo-N-succinimidyl Oleate (SSO) Inhibits Fatty Acid Uptake and Signaling for Intracellular Calcium via Binding CD36 Lysine 164 SSO ALSO INHIBITS OXIDIZED LOW DENSITY LIPOPROTEIN UPTAKE BY MACROPHAGES. J. Biol. Chem. 2013;288:15547&#x2013;15555. doi: 10.1074/jbc.M113.473298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.473298</ArticleId>
            <ArticleId IdType="pmc">PMC3668716</ArticleId>
            <ArticleId IdType="pubmed">23603908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weismann D., Hartvigsen K., Lauer N., Bennett K.L., Scholl H.P.N., Issa P.C., Cano M., Brandst&#xe4;tter H., Tsimikas S., Skerka C., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nat. Cell Biol. 2011;478:76&#x2013;81. doi: 10.1038/nature10449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10449</ArticleId>
            <ArticleId IdType="pmc">PMC4826616</ArticleId>
            <ArticleId IdType="pubmed">21979047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tonelli C., Chio I.I.C., Tuveson D.A. Transcriptional Regulation by Nrf2. Antioxidants Redox Signal. 2018;29:1727&#x2013;1745. doi: 10.1089/ars.2017.7342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2017.7342</ArticleId>
            <ArticleId IdType="pmc">PMC6208165</ArticleId>
            <ArticleId IdType="pubmed">28899199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kr&#xf6;nke G., Bochkov V.N., Huber J., Gruber F., Bl&#xfc;ml S., F&#xfc;rnkranz A., Kadl A., Binder B.R., Leitinger N. Oxidized Phospholipids Induce Expression of Human Heme Oxygenase-1 Involving Activation of cAMP-responsive Element-binding Protein. J. Biol. Chem. 2003;278:51006&#x2013;51014. doi: 10.1074/jbc.M304103200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M304103200</ArticleId>
            <ArticleId IdType="pubmed">14523007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maines M.D. THE HEME OXYGENASE SYSTEM:A Regulator of Second Messenger Gases. Annu. Rev. Pharmacol. Toxicol. 1997;37:517&#x2013;554. doi: 10.1146/annurev.pharmtox.37.1.517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pharmtox.37.1.517</ArticleId>
            <ArticleId IdType="pubmed">9131263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L.J., Lee T.S., Lee F.Y., Pai R.C., Chau L.Y. Expression of heme oxygenase-1 in atherosclerotic lesions. Am. J. Pathol. 1998;152:711&#x2013;720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1858397</ArticleId>
            <ArticleId IdType="pubmed">9502413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis D., Moore A.R., Willoughby D.A. Heme oxygenase isoform expression in cellular and antibody-mediated models of acute inflammation in the rat. J. Pathol. 2000;190:627&#x2013;634. doi: 10.1002/(SICI)1096-9896(200004)190:5&lt;627::AID-PATH556&gt;3.0.CO;2-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-9896(200004)190:5&lt;627::AID-PATH556&gt;3.0.CO;2-2</ArticleId>
            <ArticleId IdType="pubmed">10727990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauer M., Bauer I. Heme Oxygenase-1: Redox Regulation and Role in the Hepatic Response to Oxidative Stress. Antioxidants Redox Signal. 2002;4:749&#x2013;758. doi: 10.1089/152308602760598891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/152308602760598891</ArticleId>
            <ArticleId IdType="pubmed">12470502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bucolo C., Drago F., Maisto R., Romano G.L., D&#x2019;Agata V., Maugeri G., Giunta S. Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2-mediated activation of the Nrf2/HO-1 pathway. J. Cell. Physiol. 2019;234:17295&#x2013;17304. doi: 10.1002/jcp.28347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.28347</ArticleId>
            <ArticleId IdType="pubmed">30770549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee T.-S., Chau L.-Y. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat. Med. 2002;8:240&#x2013;246. doi: 10.1038/nm0302-240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0302-240</ArticleId>
            <ArticleId IdType="pubmed">11875494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittal&#xe0; V., Fidilio A., Lazzara F., Platania C.B.M., Salerno L., Foresti R., Drago F., Bucolo C. Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative Stress on Retinal Pigmented Epithelial Cells. Oxidative Med. Cell. Longev. 2017;2017:1&#x2013;11. doi: 10.1155/2017/1420892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/1420892</ArticleId>
            <ArticleId IdType="pmc">PMC5660806</ArticleId>
            <ArticleId IdType="pubmed">29158871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Synowiec E., Szaflik J., Chmielewska M., Wozniak K., Sklodowska A., Waszczyk M., Dorecka M., Blasiak J., Szaflik J.P. An association between polymorphism of the heme oxygenase-1 and -2 genes and age-related macular degeneration. Mol. Biol. Rep. 2012;39:2081&#x2013;2087. doi: 10.1007/s11033-011-0955-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11033-011-0955-3</ArticleId>
            <ArticleId IdType="pmc">PMC3271228</ArticleId>
            <ArticleId IdType="pubmed">21647550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finnemann S.C., Chang Y. Visual Transduction and Non-Visual Light Perception. Springer; New York, NY, USA: 2008. Photoreceptor&#x2014;RPE Interactions; pp. 67&#x2013;86.</Citation>
        </Reference>
        <Reference>
          <Citation>Lavail M.M. Rod outer segment disk shedding in rat retina: Relationship to cyclic lighting. Science. 1976;194:1071&#x2013;1074. doi: 10.1126/science.982063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.982063</ArticleId>
            <ArticleId IdType="pubmed">982063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young R.W., Bok D. Participation of the retinal pigment epithelium in the rod outer segment renewal process. J. Cell Biol. 1969;42:392&#x2013;403. doi: 10.1083/jcb.42.2.392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.42.2.392</ArticleId>
            <ArticleId IdType="pmc">PMC2107669</ArticleId>
            <ArticleId IdType="pubmed">5792328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guido M.E., Pico E.G., Cont&#xed;n M.A., Valdez D., Nieto P.S., Verra D.M., Acosta-Rodriguez V.A., De Zaval&#xed;a N., Rosenstein R.E. Inner retinal circadian clocks and non-visual photoreceptors: Novel players in the circadian system. Prog. Neurobiol. 2010;92:484&#x2013;504. doi: 10.1016/j.pneurobio.2010.08.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pneurobio.2010.08.005</ArticleId>
            <ArticleId IdType="pubmed">20736045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoni F., Safa H., Finnemann S.C. Understanding photoreceptor outer segment phagocytosis: Use and utility of RPE cells in culture. Exp. Eye Res. 2014;126:51&#x2013;60. doi: 10.1016/j.exer.2014.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2014.01.010</ArticleId>
            <ArticleId IdType="pmc">PMC4145030</ArticleId>
            <ArticleId IdType="pubmed">24780752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karan G., Lillo C., Yang Z., Cameron D.J., Locke K.G., Zhao Y., Thirumalaichary S., Li C., Birch D.G., Vollmer-Snarr H.R., et al. Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor degeneration in mutant ELOVL4 transgenic mice: A model for macular degeneration. Proc. Natl. Acad. Sci. USA. 2005;102:4164&#x2013;4169. doi: 10.1073/pnas.0407698102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0407698102</ArticleId>
            <ArticleId IdType="pmc">PMC554798</ArticleId>
            <ArticleId IdType="pubmed">15749821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorey C.K., Wu G., Ebenstein D., Garsd A., Weiter J.J. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Investig. Ophthalmol. Vis. Sci. 1989;30:1691&#x2013;1699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2759786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villegas-Perez M.P. [Light exposure, lipofuscin and age-related macular degeneration] Arch. de la Soc. Esp. de Oftalmol. 2005;80:565&#x2013;568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16245192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fanjul-Moles M.L., L&#xf3;pez-Riquelme G.O. Relationship between Oxidative Stress, Circadian Rhythms, and AMD. Oxidative Med. Cell. Longev. 2016;2016:1&#x2013;18. doi: 10.1155/2016/7420637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/7420637</ArticleId>
            <ArticleId IdType="pmc">PMC4738726</ArticleId>
            <ArticleId IdType="pubmed">26885250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trammell R.A., Verhulst S., Toth L. Effects of Sleep Fragmentation on Sleep and Markers of Inflammation in Mice. Comp. Med. 2014;64:13&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3929215</ArticleId>
            <ArticleId IdType="pubmed">24512957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leproult R., Holmb&#xe4;ck U., Van Cauter E. Circadian Misalignment Augments Markers of Insulin Resistance and Inflammation, Independently of Sleep Loss. Diabetes. 2014;63:1860&#x2013;1869. doi: 10.2337/db13-1546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db13-1546</ArticleId>
            <ArticleId IdType="pmc">PMC4030107</ArticleId>
            <ArticleId IdType="pubmed">24458353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maury E., Hong H., Bass J. Circadian disruption in the pathogenesis of metabolic syndrome. Diabetes Metab. 2014;40:338&#x2013;346. doi: 10.1016/j.diabet.2013.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabet.2013.12.005</ArticleId>
            <ArticleId IdType="pubmed">24433933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q., Bozack S.N., Yan Y., Boulton M.E., Grant M.B., Busik J.V. Regulation of Retinal Inflammation by Rhythmic Expression of MiR-146a in Diabetic Retina. Investig. Ophthalmol. Vis. Sci. 2014;55:3986&#x2013;3994. doi: 10.1167/iovs.13-13076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.13-13076</ArticleId>
            <ArticleId IdType="pmc">PMC4073658</ArticleId>
            <ArticleId IdType="pubmed">24867582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smit-McBride Z., Moisseiev E., Modjtahedi S.P., Telander D.G., Hjelmeland L.M., Morse L.S. Comparison of In Vivo Gene Expression Profiling of RPE/Choroid following Intravitreal Injection of Dexamethasone and Triamcinolone Acetonide. J. Ophthalmol. 2016;2016:1&#x2013;13. doi: 10.1155/2016/9856736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/9856736</ArticleId>
            <ArticleId IdType="pmc">PMC4939337</ArticleId>
            <ArticleId IdType="pubmed">27429799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honma S., Kawamoto T., Takagi Y., Fujimoto K., Sato F., Noshiro M., Kato Y., Honma K.-I. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nat. Cell Biol. 2002;419:841&#x2013;844. doi: 10.1038/nature01123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01123</ArticleId>
            <ArticleId IdType="pubmed">12397359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin L., Wu N., Curtin J.C., Qatanani M., Szwergold N.R., Reid R.A., Waitt G.M., Parks D.J., Pearce K.H., Wisely G.B., et al. Rev-erb, a Heme Sensor That Coordinates Metabolic and Circadian Pathways. Science. 2007;318:1786&#x2013;1789. doi: 10.1126/science.1150179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1150179</ArticleId>
            <ArticleId IdType="pubmed">18006707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillaumond F., Grechez-Cassiau A., Subramaniam M., Brangolo S., Peteri-Brunback B., Staels B., Fievet C., Spelsberg T.C., Delaunay F., Teboul M. Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver. Mol. Cell. Biol. 2010;30:3059&#x2013;3070. doi: 10.1128/MCB.01141-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01141-09</ArticleId>
            <ArticleId IdType="pmc">PMC2876690</ArticleId>
            <ArticleId IdType="pubmed">20385766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sp&#xf6;rl F., Korge S., J&#xfc;rchott K., Wunderskirchner M., Schellenberg K., Heins S., Specht A., Stoll C., Klemz R., Maier B., et al. Kruppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes. Proc. Natl. Acad. Sci. USA. 2012;109:10903&#x2013;10908. doi: 10.1073/pnas.1118641109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1118641109</ArticleId>
            <ArticleId IdType="pmc">PMC3390879</ArticleId>
            <ArticleId IdType="pubmed">22711835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duguay D., Cermakian N. The crosstalk between physiology and circadian clock proteins. Chronobiol. Int. 2009;26:1479&#x2013;1513. doi: 10.3109/07420520903497575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07420520903497575</ArticleId>
            <ArticleId IdType="pubmed">20030537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward S.M., Fernando S.J., Hou T.Y., Duffield G.E. The Transcriptional Repressor ID2 Can Interact with the Canonical Clock Components CLOCK and BMAL1 and Mediate Inhibitory Effects onmPer1Expression. J. Biol. Chem. 2010;285:38987&#x2013;39000. doi: 10.1074/jbc.M110.175182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.175182</ArticleId>
            <ArticleId IdType="pmc">PMC2998095</ArticleId>
            <ArticleId IdType="pubmed">20861012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko G.Y. Circadian regulation in the retina: From molecules to network. Eur. J. Neurosci. 2020;51:194&#x2013;216. doi: 10.1111/ejn.14185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.14185</ArticleId>
            <ArticleId IdType="pmc">PMC6441387</ArticleId>
            <ArticleId IdType="pubmed">30270466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko C.H., Takahashi J.S. Molecular components of the mammalian circadian clock. Hum. Mol. Genet. 2006;15:R271&#x2013;R277. doi: 10.1093/hmg/ddl207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddl207</ArticleId>
            <ArticleId IdType="pubmed">16987893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowrey P.L., Takahashi J.S. Genetics of Circadian Rhythms in Mammalian Model Organisms. Genet. Circadian Rhythm. 2011;74:175&#x2013;230. doi: 10.1016/b978-0-12-387690-4.00006-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/b978-0-12-387690-4.00006-4</ArticleId>
            <ArticleId IdType="pmc">PMC3709251</ArticleId>
            <ArticleId IdType="pubmed">21924978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaeger C., Tischkau S.A. Role of Aryl Hydrocarbon Receptor in Circadian Clock Disruption and Metabolic Dysfunction. Environ. Health Insights. 2016;10:EHI.S38343&#x2013;41. doi: 10.4137/EHI.S38343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/EHI.S38343</ArticleId>
            <ArticleId IdType="pmc">PMC4990151</ArticleId>
            <ArticleId IdType="pubmed">27559298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dikic I. Proteasomal and Autophagic Degradation Systems. Annu. Rev. Biochem. 2017;86:193&#x2013;224. doi: 10.1146/annurev-biochem-061516-044908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-061516-044908</ArticleId>
            <ArticleId IdType="pubmed">28460188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain A., Lamark T., Sj&#xf8;ttem E., Larsen K.B., Awuh J.A., &#xd8;vervatn A., McMahon M., Hayes J.D., Johansen T. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 2010;285:22576&#x2013;22591. doi: 10.1074/jbc.M110.118976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.118976</ArticleId>
            <ArticleId IdType="pmc">PMC2903417</ArticleId>
            <ArticleId IdType="pubmed">20452972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viiri J., Hyttinen J.M., Ryhanen T., Rilla K., Paimela T., Kuusisto E., Siitonen A., Urtti A., Salminen A., Kaarniranta K. p62/sequestosome 1 as a regulator of proteasome inhibitor-induced autophagy in human retinal pigment epithelial cells. Mol. Vis. 2010;16:1399&#x2013;1414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2913138</ArticleId>
            <ArticleId IdType="pubmed">20680098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S., Ha S.D., Coleman M., Meshkibaf S., Kim S.O. p62/SQSTM1 enhances NOD2-mediated signaling and cytokine production through stabilizing NOD2 oligomerization. PLoS ONE. 2013;8:e57138. doi: 10.1371/journal.pone.0057138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0057138</ArticleId>
            <ArticleId IdType="pmc">PMC3577775</ArticleId>
            <ArticleId IdType="pubmed">23437331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neale B.M., Fagerness J., Reynolds R., Sobrin L., Parker M., Raychaudhuri S., Tan P.L., Oh E.C., Merriam J.E., Souied E., et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC) Proc. Natl. Acad. Sci. USA. 2010;107:7395&#x2013;7400. doi: 10.1073/pnas.0912019107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0912019107</ArticleId>
            <ArticleId IdType="pmc">PMC2867697</ArticleId>
            <ArticleId IdType="pubmed">20385826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds R., Rosner B., Seddon J.M. Serum Lipid Biomarkers and Hepatic Lipase Gene Associations with Age-Related Macular Degeneration. Ophthalmology. 2010;117:1989&#x2013;1995. doi: 10.1016/j.ophtha.2010.07.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2010.07.009</ArticleId>
            <ArticleId IdType="pmc">PMC3081670</ArticleId>
            <ArticleId IdType="pubmed">20888482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fritsche L.G., Chen W., Schu M., Yaspan B.L., Yu Y., Thorleifsson G., Zack D.J., Arakawa S., Cipriani V., Ripke S., et al. Seven new loci associated with age-related macular degeneration. Nat. Genet. 2013;45:433&#x2013;439. doi: 10.1038/ng.2578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2578</ArticleId>
            <ArticleId IdType="pmc">PMC3739472</ArticleId>
            <ArticleId IdType="pubmed">23455636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein R., Myers C.E., Buitendijk G.H., Rochtchina E., Gao X., de Jong P.T., Sivakumaran T.A., Burlutsky G., McKean-Cowdin R., Hofman A., et al. Lipids, lipid genes, and incident age-related macular degeneration: The three continent age-related macular degeneration consortium. Am. J. Ophthalmol. 2014;158:513&#x2013;524. doi: 10.1016/j.ajo.2014.05.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2014.05.027</ArticleId>
            <ArticleId IdType="pmc">PMC4138281</ArticleId>
            <ArticleId IdType="pubmed">24879949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Ma K.L., Ruan X.Z., Liu B.C. Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Int. J. Biol. Sci. 2016;12:569&#x2013;579. doi: 10.7150/ijbs.14027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.14027</ArticleId>
            <ArticleId IdType="pmc">PMC4807419</ArticleId>
            <ArticleId IdType="pubmed">27019638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janowski B.A. The hypocholesterolemic agent LY295427 up-regulates INSIG-1, identifying the INSIG-1 protein as a mediator of cholesterol homeostasis through SREBP. Proc. Natl. Acad. Sci. USA. 2002;99:12675&#x2013;12680. doi: 10.1073/pnas.202471599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.202471599</ArticleId>
            <ArticleId IdType="pmc">PMC130519</ArticleId>
            <ArticleId IdType="pubmed">12242342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19131956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szklarczyk D., Gable A.L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N.T., Morris J.H., Bork P., et al. STRING v11: Protein&#x2013;protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607&#x2013;D613. doi: 10.1093/nar/gky1131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kr&#xe4;mer A., Green J., Pollard J., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523&#x2013;530. doi: 10.1093/bioinformatics/btt703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btt703</ArticleId>
            <ArticleId IdType="pmc">PMC3928520</ArticleId>
            <ArticleId IdType="pubmed">24336805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverstein R.L., Li W., Park Y.M., Rahaman S.O. Mechanisms of Cell Signaling by the Scavenger Receptor CD36: Implications in Atherosclerosis and Thrombosis. Trans. Am. Clin. Clim. Assoc. 2010;121:206&#x2013;220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917163</ArticleId>
            <ArticleId IdType="pubmed">20697562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan G., Jiang S., Yu L., Liu S. Oxidized low density lipoprotein (oxLDL) promotes mitochondrial dysfunction and induces apoptosis in retinal pigmented epithelium cells. Int. J. Clin. Exp. Pathol. 2017;10:1619&#x2013;1626.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32761300</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-4919</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>475</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular and cellular biochemistry</Title>
          <ISOAbbreviation>Mol Cell Biochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.</ArticleTitle>
        <Pagination>
          <StartPage>79</StartPage>
          <EndPage>91</EndPage>
          <MedlinePgn>79-91</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11010-020-03861-0</ELocationID>
        <Abstract>
          <AbstractText>Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. However, the immune tolerance limits the effect of chemotherapeutic drugs. Therefore, the mechanism of cisplatin in promoting PD-L1 expression by YAP1 was investigated in the present study, and we found that cisplatin increased the expression level of YAP1 in the mouse liver with H22 cells. Meanwhile, cisplatin improved the expression level of PD-L1, IL-1β and CCL2 in the tumor microenvironment. Further, cisplatin also enhanced the expression level of YAP1 in shYAP1 HepG2215 cells. The expression of PD-L1 was decreased by Verteporfin, YAP1 inhibitor, during the treatment of DEN/TCPOBOP-induced liver cancer in C57BL/6 mice. These results suggested that cisplatin could deteriorate the immunosuppressive microenvironment through increasing PD-L1, CCL2, IL-1β by upregulated YAP1 expression. Therefore, the study suggested that YAP1 blockade destroyed the immunosuppressive microenvironment of cancer to improve the effect of chemotherapy in HCC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shenghao</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-7008-8824</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hebei Key Laboratory of Integrative Medicine On Liver Kidney Patterns, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Jingmin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhiqin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Liyuan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Yinglin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Wenhan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Qingzhuo</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Xinli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, No.3 Xingyuan Road, Shijiazhuang, 050200, Hebei, China. sxlsunshine@sina.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hebei Key Laboratory of Integrative Medicine On Liver Kidney Patterns, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China. sxlsunshine@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>(81873112)</GrantID>
            <Agency>the National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>(H2017423011)</GrantID>
            <Agency>the Project of Natural Fund of Hebei province</Agency>
          </Grant>
          <Grant>
            <GrantID>(A201902015)</GrantID>
            <Agency>Talent Project Training Funding Project of Hebei Province</Agency>
          </Grant>
          <Grant>
            <GrantID>(SLRC2019043)</GrantID>
            <Agency>Hundred Outstanding Innovative Talents Support Program of Universities in Hebei Province</Agency>
          </Grant>
          <Grant>
            <GrantID>(A201904)</GrantID>
            <Agency>the Research Fund from Hebei Key Laboratory of Integrative Medicine on Liver&#x2011;kidney patterns</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Mol Cell Biochem</MedlineTA>
        <NlmUniqueID>0364456</NlmUniqueID>
        <ISSNLinking>0300-8177</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0X9PA28K43</RegistryNumber>
          <NameOfSubstance UI="D000077362">Verteporfin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008114" MajorTopicYN="N">Liver Neoplasms, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077362" MajorTopicYN="N">Verteporfin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cisplatin</Keyword>
        <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Immunosuppressive microenvironment</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">YAP1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32761300</ArticleId>
        <ArticleId IdType="doi">10.1007/s11010-020-03861-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s11010-020-03861-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32748749</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1873-5576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current cancer drug targets</Title>
          <ISOAbbreviation>Curr Cancer Drug Targets</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.</ArticleTitle>
        <Pagination>
          <StartPage>868</StartPage>
          <EndPage>874</EndPage>
          <MedlinePgn>868-874</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/1568009620999200730184514</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Obesity is a significant risk factor for the development of types of cancer. Programmed death 1 and its ligand programmed death-ligand 1 (PD-L1) play a crucial role in tumor immune escape. Although, the role of PD-L1 in obesity-associated hepatocellular carcinoma (HCC) remains unknown. We previously showed that the natural flavonoid pentamethylquercetin (PMQ) possesses anti-obesity properties.</AbstractText>
          <AbstractText Label="OBJECTIVE">This study was designed to investigate the effects of PMQ on the development of HCC in obese mice and whether PMQ regulates PD-L1 and expression in HCC.</AbstractText>
          <AbstractText Label="METHODS">Monosodium glutamate-induced obese mice were inoculated with H22 tumor cells. Tumor volumes and weights were measured. In vitro, 3T3-L1 preadipocytes were differentiated and lipid accumulation was measured by oil-red staining, and IFN-&#x3b3; level was detected by Elisa. Hepatoma HepG2 cells were treated with conditional media from 3T3-L1 adipocytes (adi-CM). Western blotting was applied to detect PD-L1 protein levels in tumor tissue and HepG2 cells.</AbstractText>
          <AbstractText Label="RESULTS">Compared with control mice, H22 tumors grew faster and exhibited higher PD-L1 protein levels in obese mice. PMQ inhibited H22 tumor growth and reduced PD-L1 expression in tumor tissues. PD-L1 protein level was elevated in adi-CM-treated HepG2 cells. IFN-&#x3b3; was detectable in adi-CM and exogenous IFN-&#x3b3; induced PD-L1 expression in HepG2 cells. PMQ affected the differentiation of 3T3-L1 preadipocytes, decreased the level of IFN-&#x3b3; secreted by adipocytes and downregulated adi-CM-induced PD-L1 expression in HepG2 cells.</AbstractText>
          <AbstractText Label="CONCLUSION">PMQ could inhibit HCC progression in obese mice at least in part through down-regulating adipocytes-induced PD-L1 expression via IFN-&#x3b3; signaling.</AbstractText>
          <CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zhi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Wen-Qi</ForeName>
            <Initials>WQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Tian-Qi</ForeName>
            <Initials>TQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Wen-Chao</ForeName>
            <Initials>WC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Xin-Yu</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Hubei, China</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Curr Cancer Drug Targets</MedlineTA>
        <NlmUniqueID>101094211</NlmUniqueID>
        <ISSNLinking>1568-0096</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498919">Cd274 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000611649">IFNG protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9IKM0I5T1E</RegistryNumber>
          <NameOfSubstance UI="D011794">Quercetin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D041721" MajorTopicYN="N">3T3-L1 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017667" MajorTopicYN="N">Adipocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008820" MajorTopicYN="N">Mice, Obese</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011794" MajorTopicYN="Y">Quercetin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">H22</Keyword>
        <Keyword MajorTopicYN="N">HepG2</Keyword>
        <Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">Pentamethylquercetin</Keyword>
        <Keyword MajorTopicYN="N">adipocytes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32748749</ArticleId>
        <ArticleId IdType="doi">10.2174/1568009620999200730184514</ArticleId>
        <ArticleId IdType="pii">CCDT-EPUB-108740</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32726482</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7006</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>111</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer science</Title>
          <ISOAbbreviation>Cancer Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>3503</StartPage>
          <EndPage>3515</EndPage>
          <MedlinePgn>3503-3515</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.14588</ELocationID>
        <Abstract>
          <AbstractText>Hepatocellular carcinoma (HCC) represents the majority of liver cancer and is the fourth most common cause of cancer-related death. Although advances in molecular targeted therapy have shown promise, none of these agents has yet demonstrated significant clinical benefit. Bromo- and extraterminal domain (BET) protein inhibitors have been considered potential therapeutic drugs for HCC but the biological activity remains unclear. This study found that BET protein inhibition did not effectively suppress the progression of HCC, using a transgenic HCC mouse model. Mechanistically, the BET protein inhibitor JQ1 upregulated the expression of programmed cell death-ligand 1 (PD-L1) on the plasma membrane in vivo and in vitro. Moreover, JQ1 enhanced the expression of Rab8A, which upregulated the expression of PD-L1 on the plasma membrane. This study also showed that JQ1 combined with anti-PD-L1 Ab effectively suppressed HCC progression, and this benefit was obtained by enhancing the activation and cytotoxic capabilities of CD8 T cells. These results revealed the crucial role and regulation of BET protein inhibition on the expression of PD-L1 in HCC. Thus, combining BET protein inhibition with immune checkpoint blockade offers an efficient therapeutic approach for HCC.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miao</LastName>
            <ForeName>Xiaolong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Xiawei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Synthetic Biology and Biotechnology Laboratory, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Deqiang</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Pengwei</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, and Department of Cardiology of Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Dandan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, and Department of Cardiology of Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xinyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, and Department of Cardiology of Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Xianfeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Hongguang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Weilin</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0001-9432-2649</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Qiming</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, and Department of Cardiology of Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Weihua</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-3221-4316</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81470527</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81870306</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2015XZZX004-21</GrantID>
            <Agency>Fundamental Research Funds for the Central Universities</Agency>
          </Grant>
          <Grant>
            <GrantID>LR13H020001</GrantID>
            <Agency>Zhejiang Provincial 151 Talent Project, and Zhejiang Provincial Outstanding Youth Foundation</Agency>
          </Grant>
          <Grant>
            <GrantID>81522006</GrantID>
            <Agency>National Science Foundation for Outstanding Young Scholars of China</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cancer Sci</MedlineTA>
        <NlmUniqueID>101168776</NlmUniqueID>
        <ISSNLinking>1347-9032</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000624329">bromodomain and extra-terminal domain protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BET protein</Keyword>
        <Keyword MajorTopicYN="N">JQ1</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32726482</ArticleId>
        <ArticleId IdType="pmc">PMC7540980</ArticleId>
        <ArticleId IdType="doi">10.1111/cas.14588</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Llovet JM, Zucman&#x2010;Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27158749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Global Burden of Disease Cancer C , Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability&#x2010;adjusted life&#x2010;years for 32 cancer Groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524&#x2010;548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6103527</ArticleId>
            <ArticleId IdType="pubmed">27918777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378&#x2010;390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18650514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599&#x2010;616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30061739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 3 trial. Lancet. 2017;389(10064):56&#x2010;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27932229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first&#x2010;line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non&#x2010;inferiority trial. Lancet. 2018;391(10126):1163&#x2010;1173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29433850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abou&#x2010;Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54&#x2010;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7523244</ArticleId>
            <ArticleId IdType="pubmed">29972759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alghamdi S, Khan I, Beeravolu N, et al. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Stem Cell Res Ther. 2016;7:22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4736146</ArticleId>
            <ArticleId IdType="pubmed">26830473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilan O, Rioja I, Knezevic K, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368(6489):387&#x2010;394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32193360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Tong Y, Zhang X, Pan M, Chen S. Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. Drug Des Devel Ther. 2015;9:5851&#x2010;5862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4634829</ArticleId>
            <ArticleId IdType="pubmed">26586936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YH, Sui XM, Sui YN, et al. BRD4 induces cell migration and invasion in HCC cells through MMP&#x2010;2 and MMP&#x2010;9 activation mediated by the Sonic hedgehog signaling pathway. Oncol Lett. 2015;10(4):2227&#x2010;2232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4579919</ArticleId>
            <ArticleId IdType="pubmed">26622824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Dong Z, Cai J, et al. BRD4 promotes tumor growth and epithelial&#x2010;mesenchymal transition in hepatocellular carcinoma. Int J Immunopathol Pharmacol. 2015;28(1):36&#x2010;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25816404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li GQ, Guo WZ, Zhang Y, et al. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget. 2016;7(3):2462&#x2010;2474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4823048</ArticleId>
            <ArticleId IdType="pubmed">26575167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Elements of cancer immunity and the cancer&#x2010;immune set point. Nature. 2017;541(7637):321&#x2010;330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28102259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Xu J, Liu M, et al. Adoptive CD8(+) T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23&#x2010;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31356845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450&#x2010;461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD&#x2010;L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6729004</ArticleId>
            <ArticleId IdType="pubmed">31488176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD&#x2010;1&#x2010;mediated inhibition. Science. 2017;355(6332):1428&#x2010;1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6286077</ArticleId>
            <ArticleId IdType="pubmed">28280247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El&#x2010;Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open&#x2010;label, non&#x2010;comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492&#x2010;2502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7539326</ArticleId>
            <ArticleId IdType="pubmed">28434648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE&#x2010;224): a non&#x2010;randomised, open&#x2010;label phase 2 trial. Lancet Oncol. 2018;19(7):940&#x2010;952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29875066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6827249</ArticleId>
            <ArticleId IdType="pubmed">31684985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen L, Xin B, Wu P, et al. An efficient combination immunotherapy for primary liver cancer by harmonized activation of innate and adaptive immunity in mice. Hepatology. 2019;69(6):2518&#x2010;2532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6541536</ArticleId>
            <ArticleId IdType="pubmed">30693544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD&#x2010;L1 expression in cancer. Mol Cell. 2019;76(3):359&#x2010;370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6981282</ArticleId>
            <ArticleId IdType="pubmed">31668929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Marlin MC. Rab family of GTPases. Methods Mol Biol. 2015;1298:1&#x2010;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5903570</ArticleId>
            <ArticleId IdType="pubmed">25800828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diekmann Y, Seixas E, Gouw M, Tavares&#x2010;Cadete F, Seabra MC, Pereira&#x2010;Leal JB. Thousands of rab GTPases for the cell biologist. PLoS Comput Biol. 2011;7(10):e1002217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3192815</ArticleId>
            <ArticleId IdType="pubmed">22022256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langemeyer L, Frohlich F, Ungermann C. Rab GTPase function in endosome and lysosome biogenesis. Trends Cell Biol. 2018;28(11):957&#x2010;970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30025982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy JM, Raut NGR, Seifert JL, Hynds DL. Regulation of small GTPase prenylation in the nervous system. Mol Neurobiol. 2020;57(5):2220&#x2010;2231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31989383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syn NL, Teng MWL, Mok TSK, Soo RA. De&#x2010;novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18(12):e731&#x2010;e741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29208439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wellenstein MD, de Visser KE. Cancer&#x2010;cell&#x2010;intrinsic mechanisms shaping the tumor immune landscape. Immunity. 2018;48(3):399&#x2010;416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29562192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350&#x2010;1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7391259</ArticleId>
            <ArticleId IdType="pubmed">29567705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6734524</ArticleId>
            <ArticleId IdType="pubmed">31500650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin Y, Sun M, Zhan X, et al. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC. J Exp Clin Cancer Res. 2019;38(1):83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377788</ArticleId>
            <ArticleId IdType="pubmed">30770740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Han X. Anti&#x2010;PD&#x2010;1/PD&#x2010;L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384&#x2010;3391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4588282</ArticleId>
            <ArticleId IdType="pubmed">26325035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiteside TL, Demaria S, Rodriguez&#x2010;Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res. 2016;22(8):1845&#x2010;1855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4943317</ArticleId>
            <ArticleId IdType="pubmed">27084738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peranen J. Rab8 GTPase as a regulator of cell shape. Cytoskeleton (Hoboken). 2011;68(10):527&#x2010;539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21850707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bond LM, Peden AA, Kendrick&#x2010;Jones J, Sellers JR, Buss F. Myosin VI and its binding partner optineurin are involved in secretory vesicle fusion at the plasma membrane. Mol Biol Cell. 2011;22(1):54&#x2010;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3016977</ArticleId>
            <ArticleId IdType="pubmed">21148290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu H, Bengsch F, Svoronos N, et al. BET bromodomain inhibition promotes anti&#x2010;tumor immunity by suppressing PD&#x2010;L1 expression. Cell Rep. 2016;16(11):2829&#x2010;2837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5177024</ArticleId>
            <ArticleId IdType="pubmed">27626654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melaiu O, Mina M, Chierici M, et al. PD&#x2010;L1 is a therapeutic target of the bromodomain inhibitor JQ1 and combined with HLA class I, a promising prognostic biomarker in neuroblastoma. Clin Cancer Res. 2017;23(15):4462&#x2010;4472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28270499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hogg SJ, Vervoort SJ, Deswal S, et al. BET&#x2010;bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD&#x2010;L1. Cell Rep. 2017;18(9):2162&#x2010;2174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5340981</ArticleId>
            <ArticleId IdType="pubmed">28249162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adeegbe DO, Liu S, Hattersley MM, et al. BET bromodomain inhibition cooperates with PD&#x2010;1 blockade to facilitate antitumor response in Kras&#x2010;Mutant non&#x2010;small cell lung cancer. Cancer Immunol Res. 2018;6(10):1234&#x2010;1245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6170698</ArticleId>
            <ArticleId IdType="pubmed">30087114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang CY, Wang Y, Luo GY, et al. Relationship between PD&#x2010;L1 expression and CD8+ T&#x2010;cell immune responses in hepatocellular carcinoma. J Immunother. 2017;40(9):323&#x2010;333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29028787</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32041983</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Feb</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity.</ArticleTitle>
        <Pagination>
          <StartPage>2287</StartPage>
          <MedlinePgn>2287</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2287</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-58871-1</ELocationID>
        <Abstract>
          <AbstractText>Nandrolone is a testosterone analogue with anabolic properties commonly abused worldwide, recently utilized also as therapeutic agent in chronic diseases, cancer included. Here we investigated the impact of nandrolone on the metabolic phenotype in HepG2 cell line. The results attained show that pharmacological dosage of nandrolone, slowing cell growth, repressed mitochondrial respiration, inhibited the respiratory chain complexes I and III and enhanced mitochondrial reactive oxygen species (ROS) production. Intriguingly, nandrolone caused a significant increase of stemness-markers in both 2D and 3D cultures, which resulted to be CxIII-ROS dependent. Notably, nandrolone negatively affected differentiation both in healthy hematopoietic and mesenchymal stem cells. Finally, nandrolone administration in mice confirmed the up-regulation of stemness-markers in liver, spleen and kidney. Our observations show, for the first time, that chronic administration of nandrolone, favoring maintenance of stem cells in different tissues would represent a precondition that, in addition to multiple hits, might enhance risk of carcinogenesis raising warnings about its abuse and therapeutic utilization.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Agriesti</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-8911-7691</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tataranni</LastName>
            <ForeName>Tiziana</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pacelli</LastName>
            <ForeName>Consiglia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto c/o OO.RR., 71100, Foggia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scrima</LastName>
            <ForeName>Rosella</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto c/o OO.RR., 71100, Foggia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laurenzana</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruggieri</LastName>
            <ForeName>Vitalba</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cela</LastName>
            <ForeName>Olga</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto c/o OO.RR., 71100, Foggia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazzoccoli</LastName>
            <ForeName>Carmela</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salerno</LastName>
            <ForeName>Monica</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania - A.O.U. "Policlinico - V. Emanuele", via S. Sofia, 87 - Sector 10, Building B - 95123, Catania, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sessa</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto c/o OO.RR., 71100, Foggia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sani</LastName>
            <ForeName>Gabriele</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Roma, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pomara</LastName>
            <ForeName>Cristoforo</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania - A.O.U. "Policlinico - V. Emanuele", via S. Sofia, 87 - Sector 10, Building B - 95123, Catania, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Capitanio</LastName>
            <ForeName>Nazzareno</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto c/o OO.RR., 71100, Foggia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piccoli</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-9739-4680</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy. claudia.piccoli@unifg.it.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto c/o OO.RR., 71100, Foggia, Italy. claudia.piccoli@unifg.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045930">Anabolic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045222">Electron Transport Chain Complex Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6PG9VR430D</RegistryNumber>
          <NameOfSubstance UI="D009277">Nandrolone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045930" MajorTopicYN="N">Anabolic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019069" MajorTopicYN="N">Cell Respiration</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045222" MajorTopicYN="N">Electron Transport Chain Complex Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009277" MajorTopicYN="N">Nandrolone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014410" MajorTopicYN="N">Tumor Stem Cell Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32041983</ArticleId>
        <ArticleId IdType="pmc">PMC7010785</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-020-58871-1</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-020-58871-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 2001;86:5108&#x2013;5117. doi: 10.1210/jcem.86.11.7983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.86.11.7983</ArticleId>
            <ArticleId IdType="pubmed">11701661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pomara C, et al. Effects of Nandrolone Stimulation on Testosterone Biosynthesis in Leydig Cells. J. Cell. Physiol. 2016;231:1385&#x2013;1391. doi: 10.1002/jcp.25272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.25272</ArticleId>
            <ArticleId IdType="pmc">PMC5064776</ArticleId>
            <ArticleId IdType="pubmed">26626779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347&#x2013;351. doi: 10.1038/nature14406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14406</ArticleId>
            <ArticleId IdType="pmc">PMC4506215</ArticleId>
            <ArticleId IdType="pubmed">26030522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cops EJ, et al. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J. Steroid Biochem. Mol. Biol. 2008;110:236&#x2013;243. doi: 10.1016/j.jsbmb.2007.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsbmb.2007.10.014</ArticleId>
            <ArticleId IdType="pubmed">18515094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood RI. Reinforcing aspects of androgens. Physiol. Behav. 2004;83:279&#x2013;289. doi: 10.1016/j.physbeh.2004.08.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.physbeh.2004.08.012</ArticleId>
            <ArticleId IdType="pubmed">15488545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barceloux DG, Palmer RB. Anabolic-androgenic steroids. Dis.&#x2013;Mon. DM. 2013;59:226&#x2013;248. doi: 10.1016/j.disamonth.2013.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.disamonth.2013.03.010</ArticleId>
            <ArticleId IdType="pubmed">23719201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannitrapani L, et al. Sex hormones and risk of liver tumor. Ann. N. Y. Acad. Sci. 2006;1089:228&#x2013;236. doi: 10.1196/annals.1386.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1386.044</ArticleId>
            <ArticleId IdType="pubmed">17261770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwingel PA, et al. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int. Off. J. Int. Assoc. Study Liver. 2011;31:348&#x2013;353. doi: 10.1111/j.1478-3231.2010.02346.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1478-3231.2010.02346.x</ArticleId>
            <ArticleId IdType="pubmed">21040407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socas L, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br. J. Sports Med. 2005;39:e27. doi: 10.1136/bjsm.2004.013599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjsm.2004.013599</ArticleId>
            <ArticleId IdType="pmc">PMC1725213</ArticleId>
            <ArticleId IdType="pubmed">15849280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solbach P, et al. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterol. 2015;15:60. doi: 10.1186/s12876-015-0288-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12876-015-0288-0</ArticleId>
            <ArticleId IdType="pmc">PMC4461943</ArticleId>
            <ArticleId IdType="pubmed">25986067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solimini R, et al. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. Eur. Rev. Med. Pharmacol. Sci. 2017;21:7&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28379599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh S-H, Chen P-J. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78(Suppl 1):172&#x2013;179. doi: 10.1159/000315247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000315247</ArticleId>
            <ArticleId IdType="pubmed">20616601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma W-L, Lai H-C, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr. Relat. Cancer. 2014;21:R165&#x2013;182. doi: 10.1530/ERC-13-0283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-13-0283</ArticleId>
            <ArticleId IdType="pmc">PMC4165608</ArticleId>
            <ArticleId IdType="pubmed">24424503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma W-L, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135:947&#x2013;955. doi: 10.1053/j.gastro.2008.05.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2008.05.046</ArticleId>
            <ArticleId IdType="pmc">PMC2753209</ArticleId>
            <ArticleId IdType="pubmed">18639551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanda T, Jiang X, Yokosuka O. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World J. Gastroenterol. 2014;20:9229&#x2013;9236. doi: 10.3748/wjg.v20.i26.8535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i26.8535</ArticleId>
            <ArticleId IdType="pmc">PMC4110552</ArticleId>
            <ArticleId IdType="pubmed">25071315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, et al. Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. Exp. Cell Res. 2014;323:326&#x2013;336. doi: 10.1016/j.yexcr.2014.02.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2014.02.017</ArticleId>
            <ArticleId IdType="pubmed">24583399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C-K, Luo J, Lee SO, Chang C. Concise review: androgen receptor differential roles in stem/progenitor cells including prostate, embryonic, stromal, and hematopoietic lineages. Stem Cells Dayt. Ohio. 2014;32:2299&#x2013;2308. doi: 10.1002/stem.1722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1722</ArticleId>
            <ArticleId IdType="pubmed">24740898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer. 2008;8:755&#x2013;768. doi: 10.1038/nrc2499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2499</ArticleId>
            <ArticleId IdType="pubmed">18784658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717&#x2013;728. doi: 10.1016/j.stem.2012.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2012.05.007</ArticleId>
            <ArticleId IdType="pubmed">22704512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flores-T&#xe9;llez TN, Villa-Trevi&#xf1;o S, Pi&#xf1;a-V&#xe1;zquez C. Road to stemness in hepatocellular carcinoma. World J. Gastroenterol. 2017;23:6750&#x2013;6776. doi: 10.3748/wjg.v23.i37.6750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i37.6750</ArticleId>
            <ArticleId IdType="pmc">PMC5645611</ArticleId>
            <ArticleId IdType="pubmed">29085221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, et al. Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma. Oncotarget. 2016;7:36814&#x2013;36828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5095041</ArticleId>
            <ArticleId IdType="pubmed">27167111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia, D., Park, J. H., Jung, K. H., Levine, H. &amp; Kaipparettu, B. A. Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States. Cells7 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5870353</ArticleId>
            <ArticleId IdType="pubmed">29534029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varum S, et al. Enhancement of human embryonic stem cell pluripotency through inhibition of the mitochondrial respiratory chain. Stem Cell Res. 2009;3:142&#x2013;156. doi: 10.1016/j.scr.2009.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.scr.2009.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC2837416</ArticleId>
            <ArticleId IdType="pubmed">19716358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C-T, Hsu S-H, Wei Y-H. Mitochondrial bioenergetic function and metabolic plasticity in stem cell differentiation and cellular reprogramming. Biochim. Biophys. Acta. 2012;1820:571&#x2013;576. doi: 10.1016/j.bbagen.2011.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2011.09.013</ArticleId>
            <ArticleId IdType="pubmed">21983491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pereira SL, et al. Inhibition of mitochondrial complex III blocks neuronal differentiation and maintains embryonic stem cell pluripotency. PloS One. 2013;8:e82095. doi: 10.1371/journal.pone.0082095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0082095</ArticleId>
            <ArticleId IdType="pmc">PMC3847032</ArticleId>
            <ArticleId IdType="pubmed">24312632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells Dayt. Ohio. 2011;29:486&#x2013;495. doi: 10.1002/stem.590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.590</ArticleId>
            <ArticleId IdType="pmc">PMC4374603</ArticleId>
            <ArticleId IdType="pubmed">21425411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spitkovsky D, et al. Activity of complex III of the mitochondrial electron transport chain is essential for early heart muscle cell differentiation. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004;18:1300&#x2013;1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15180963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem. J. 2009;417:1&#x2013;13. doi: 10.1042/BJ20081386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20081386</ArticleId>
            <ArticleId IdType="pmc">PMC2605959</ArticleId>
            <ArticleId IdType="pubmed">19061483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamun, M. A., Mannoor, K., Cao, J., Qadri, F. &amp; Song, X. SOX2 in Cancer Stemness: Tumor Malignancy and Therapeutic Potentials. J. Mol. Cell Biol., 10.1093/jmcb/mjy080 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7109607</ArticleId>
            <ArticleId IdType="pubmed">30517668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salerno M, et al. Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: a literature review. Oncotarget. 2018;9:19415&#x2013;19426. doi: 10.18632/oncotarget.24767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.24767</ArticleId>
            <ArticleId IdType="pmc">PMC5922407</ArticleId>
            <ArticleId IdType="pubmed">29721213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther. 2001;23:1355&#x2013;1390. doi: 10.1016/S0149-2918(01)80114-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0149-2918(01)80114-4</ArticleId>
            <ArticleId IdType="pubmed">11589254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kicman AT. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008;154:502&#x2013;521. doi: 10.1038/bjp.2008.165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjp.2008.165</ArticleId>
            <ArticleId IdType="pmc">PMC2439524</ArticleId>
            <ArticleId IdType="pubmed">18500378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira EN, et al. Nandrolone decanoate is able to modulate proliferation and adhesion of myoblasts. Endocr. Regul. 2014;48:152&#x2013;158. doi: 10.4149/endo_2014_03_152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4149/endo_2014_03_152</ArticleId>
            <ArticleId IdType="pubmed">25110214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wijnhoven HJH, Ennen L, Rodenburg RJT, Dekhuijzen PNR. Mitochondrial function in diaphragm of emphysematous hamsters after treatment with nandrolone. Int. J. Chron. Obstruct. Pulmon. Dis. 2006;1:83&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2706598</ArticleId>
            <ArticleId IdType="pubmed">18046906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleier L, Dr&#xf6;se S. Superoxide generation by complex III: from mechanistic rationales to functional consequences. Biochim. Biophys. Acta. 2013;1827:1320&#x2013;1331. doi: 10.1016/j.bbabio.2012.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbabio.2012.12.002</ArticleId>
            <ArticleId IdType="pubmed">23269318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robb EL, et al. Control of mitochondrial superoxide production by reverse electron transport at complex I. J. Biol. Chem. 2018;293:9869&#x2013;9879. doi: 10.1074/jbc.RA118.003647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.003647</ArticleId>
            <ArticleId IdType="pmc">PMC6016480</ArticleId>
            <ArticleId IdType="pubmed">29743240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S. Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front. Oncol. 2018;8:203. doi: 10.3389/fonc.2018.00203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2018.00203</ArticleId>
            <ArticleId IdType="pmc">PMC5996058</ArticleId>
            <ArticleId IdType="pubmed">29922594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshmukh A, Deshpande K, Arfuso F, Newsholme P, Dharmarajan A. Cancer stem cell metabolism: a potential target for cancer therapy. Mol. Cancer. 2016;15:69. doi: 10.1186/s12943-016-0555-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-016-0555-x</ArticleId>
            <ArticleId IdType="pmc">PMC5101698</ArticleId>
            <ArticleId IdType="pubmed">27825361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morandi A, Taddei ML, Chiarugi P, Giannoni E. Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. Front. Oncol. 2017;7:40. doi: 10.3389/fonc.2017.00040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2017.00040</ArticleId>
            <ArticleId IdType="pmc">PMC5348536</ArticleId>
            <ArticleId IdType="pubmed">28352611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan AS, Baty JW, Berridge MV. The role of mitochondrial electron transport in tumorigenesis and metastasis. Biochim. Biophys. Acta. 2014;1840:1454&#x2013;1463. doi: 10.1016/j.bbagen.2013.10.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2013.10.016</ArticleId>
            <ArticleId IdType="pubmed">24141138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gammage PA, Frezza C. Mitochondrial DNA: the overlooked oncogenome? BMC Biol. 2019;17:53. doi: 10.1186/s12915-019-0668-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12915-019-0668-y</ArticleId>
            <ArticleId IdType="pmc">PMC6615100</ArticleId>
            <ArticleId IdType="pubmed">31286943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontaine E. Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences. Front. Endocrinol. 2018;9:753. doi: 10.3389/fendo.2018.00753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2018.00753</ArticleId>
            <ArticleId IdType="pmc">PMC6304344</ArticleId>
            <ArticleId IdType="pubmed">30619086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I. Metformin as an Anticancer Agent. Trends Pharmacol. Sci. 2018;39:867&#x2013;878. doi: 10.1016/j.tips.2018.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2018.07.006</ArticleId>
            <ArticleId IdType="pmc">PMC6153060</ArticleId>
            <ArticleId IdType="pubmed">30150001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prager BC, Xie Q, Bao S, Rich JN. Cancer Stem Cells: The Architects of the Tumor Ecosystem. Cell Stem Cell. 2019;24:41&#x2013;53. doi: 10.1016/j.stem.2018.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2018.12.009</ArticleId>
            <ArticleId IdType="pmc">PMC6350931</ArticleId>
            <ArticleId IdType="pubmed">30609398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta PB, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146:633&#x2013;644. doi: 10.1016/j.cell.2011.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.07.026</ArticleId>
            <ArticleId IdType="pubmed">21854987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br&#xe4;nnvall K, Bogdanovic N, Korhonen L, Lindholm D. 19-Nortestosterone influences neural stem cell proliferation and neurogenesis in the rat brain. Eur. J. Neurosci. 2005;21:871&#x2013;878. doi: 10.1111/j.1460-9568.2005.03942.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2005.03942.x</ArticleId>
            <ArticleId IdType="pubmed">15787693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, X.-H., De Gasperi, R., Bauman, W. A. &amp; Cardozo, C. P. Nandrolone-induced nuclear accumulation of MyoD protein is mediated by Numb, a Notch inhibitor, in C2C12 myoblasts. Physiol. Rep. 6, (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5789652</ArticleId>
            <ArticleId IdType="pubmed">29333723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allouh MZ, Rosser BWC. Nandrolone decanoate increases satellite cell numbers in the chicken pectoralis muscle. Histol. Histopathol. 2010;25:133&#x2013;140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20017100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saitoh T, et al. Comparison of erythropoietic response to androgen in young and old senescence accelerated mice. Mech. Ageing Dev. 1999;109:125&#x2013;139. doi: 10.1016/S0047-6374(99)00032-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0047-6374(99)00032-9</ArticleId>
            <ArticleId IdType="pubmed">10515662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamamoto T, et al. Effects of androgen on transient endogenous spleen colonies and other hemopoietic stem cells in mice. Exp. Hematol. 1985;13:616&#x2013;622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4029290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Zhang M. Effects of androgen and progestin on the proliferation and differentiation of osteoblasts. Exp. Ther. Med. 2018;16:4722&#x2013;4728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6257455</ArticleId>
            <ArticleId IdType="pubmed">30542427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sirianni R, et al. Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation. Mol. Cell. Endocrinol. 2012;363:100&#x2013;110. doi: 10.1016/j.mce.2012.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2012.08.002</ArticleId>
            <ArticleId IdType="pubmed">22906881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chimento A, et al. Nandrolone and stanozolol induce Leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system. J. Cell. Physiol. 2012;227:2079&#x2013;2088. doi: 10.1002/jcp.22936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.22936</ArticleId>
            <ArticleId IdType="pubmed">21769864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccoli C, et al. To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma. Br. J. Pharmacol. 2013;169:1652&#x2013;1671. doi: 10.1111/bph.12253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.12253</ArticleId>
            <ArticleId IdType="pmc">PMC3753828</ArticleId>
            <ArticleId IdType="pubmed">23714011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr. Biol. CB. 2014;24:R453&#x2013;462. doi: 10.1016/j.cub.2014.03.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2014.03.034</ArticleId>
            <ArticleId IdType="pmc">PMC4055301</ArticleId>
            <ArticleId IdType="pubmed">24845678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sart S, Song L, Li Y. Controlling Redox Status for Stem Cell Survival, Expansion, and Differentiation. Oxid. Med. Cell. Longev. 2015;2015:105135. doi: 10.1155/2015/105135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/105135</ArticleId>
            <ArticleId IdType="pmc">PMC4530287</ArticleId>
            <ArticleId IdType="pubmed">26273419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding S, et al. Redox Regulation in Cancer Stem Cells. Oxid. Med. Cell. Longev. 2015;2015:750798. doi: 10.1155/2015/750798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/750798</ArticleId>
            <ArticleId IdType="pmc">PMC4529979</ArticleId>
            <ArticleId IdType="pubmed">26273424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogasawara MA, Zhang H. Redox regulation and its emerging roles in stem cells and stem-like cancer cells. Antioxid. Redox Signal. 2009;11:1107&#x2013;1122. doi: 10.1089/ars.2008.2308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2008.2308</ArticleId>
            <ArticleId IdType="pubmed">18999985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liou G-Y, Storz P. Reactive oxygen species in cancer. Free Radic. Res. 2010;44:479&#x2013;496. doi: 10.3109/10715761003667554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10715761003667554</ArticleId>
            <ArticleId IdType="pmc">PMC3880197</ArticleId>
            <ArticleId IdType="pubmed">20370557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Mu D, Feng K. Hierarchical potential differentiation of liver cancer stem cells. Adv. Clin. Exp. Med. Off. Organ Wroclaw Med. Univ. 2017;26:1137&#x2013;1141. doi: 10.17219/acem/66343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17219/acem/66343</ArticleId>
            <ArticleId IdType="pubmed">29211363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra L, et al. Liver stem cells and hepatocellular carcinoma. Hepatol. Baltim. Md. 2009;49:318&#x2013;329. doi: 10.1002/hep.22704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.22704</ArticleId>
            <ArticleId IdType="pmc">PMC2726720</ArticleId>
            <ArticleId IdType="pubmed">19111019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics. 2006;117:e577&#x2013;589. doi: 10.1542/peds.2005-1429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2005-1429</ArticleId>
            <ArticleId IdType="pubmed">16510635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adolescents and anabolic steroids: a subject review. American Academy of Pediatrics. Committee on Sports Medicine and Fitness. Pediatrics99, 904&#x2013;908 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9190555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalaby AM, Bahey NG. Reversal of the hepatic damage induced by the supraphysiological dose of nandrolone decanoate after its withdrawal in the adult male rat. Tissue Cell. 2018;53:44&#x2013;52. doi: 10.1016/j.tice.2018.05.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tice.2018.05.013</ArticleId>
            <ArticleId IdType="pubmed">30060826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomasetti C, Vogelstein B. Cancer risk: role of environment&#x2014;response. Science. 2015;347:729&#x2013;731. doi: 10.1126/science.aaa6592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaa6592</ArticleId>
            <ArticleId IdType="pubmed">25678653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tataranni Tiziana, Agriesti Francesca, Pacelli Consiglia, Ruggieri Vitalba, Laurenzana Ilaria, Mazzoccoli Carmela, Della Sala Gerardo, Panebianco Concetta, Pazienza Valerio, Capitanio Nazzareno, Piccoli Claudia. Dichloroacetate Affects Mitochondrial Function and Stemness-Associated Properties in Pancreatic Cancer Cell Lines. Cells. 2019;8(5):478. doi: 10.3390/cells8050478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8050478</ArticleId>
            <ArticleId IdType="pmc">PMC6562462</ArticleId>
            <ArticleId IdType="pubmed">31109089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Benedetto A, Carbone C, Mori G. Dental pulp stem cells isolation and osteogenic differentiation: a good promise for tissue engineering. Methods Mol. Biol. Clifton NJ. 2014;1210:117&#x2013;130. doi: 10.1007/978-1-4939-1435-7_9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-1435-7_9</ArticleId>
            <ArticleId IdType="pubmed">25173164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riezzo I, et al. Chronic nandrolone administration promotes oxidative stress, induction of pro-inflammatory cytokine and TNF-&#x3b1; mediated apoptosis in the kidneys of CD1 treated mice. Toxicol. Appl. Pharmacol. 2014;280:97&#x2013;106. doi: 10.1016/j.taap.2014.06.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2014.06.031</ArticleId>
            <ArticleId IdType="pubmed">25065671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tataranni T, et al. Rewiring carbohydrate catabolism differentially affects survival of pancreatic cancer cell lines with diverse metabolic profiles. Oncotarget. 2017;8:41265&#x2013;41281. doi: 10.18632/oncotarget.17172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.17172</ArticleId>
            <ArticleId IdType="pmc">PMC5522241</ArticleId>
            <ArticleId IdType="pubmed">28476035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scrima R, et al. Para-hydroxyphenylpyruvate inhibits the pro-inflammatory stimulation of macrophage preventing LPS-mediated nitro-oxidative unbalance and immunometabolic shift. PloS One. 2017;12:e0188683. doi: 10.1371/journal.pone.0188683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0188683</ArticleId>
            <ArticleId IdType="pmc">PMC5703549</ArticleId>
            <ArticleId IdType="pubmed">29176872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cela O, et al. Bupivacaine uncouples the mitochondrial oxidative phosphorylation, inhibits respiratory chain complexes I and III and enhances ROS production: results of a study on cell cultures. Mitochondrion. 2010;10:487&#x2013;496. doi: 10.1016/j.mito.2010.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mito.2010.05.005</ArticleId>
            <ArticleId IdType="pubmed">20546950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quarato G, et al. Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression. Biochem. Pharmacol. 2014;89:545&#x2013;556. doi: 10.1016/j.bcp.2014.03.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2014.03.018</ArticleId>
            <ArticleId IdType="pubmed">24726442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tataranni T, et al. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells. Stem Cell Res. Ther. 2019;10:171. doi: 10.1186/s13287-019-1293-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13287-019-1293-y</ArticleId>
            <ArticleId IdType="pmc">PMC6567456</ArticleId>
            <ArticleId IdType="pubmed">31196186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tataranni T, et al. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. Br. J. Haematol. 2015;170:236&#x2013;246. doi: 10.1111/bjh.13381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.13381</ArticleId>
            <ArticleId IdType="pubmed">25825160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoccoli C, et al. N-acetylaspartate (NAA) induces neuronal differentiation of SH-SY5Y neuroblastoma cell line and sensitizes it to chemotherapeutic agents. Oncotarget. 2016;7:26235&#x2013;26246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5041977</ArticleId>
            <ArticleId IdType="pubmed">27036033</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31682397</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1948-7193</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Dec</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS chemical neuroscience</Title>
          <ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Liproxstatin-1 Attenuates Morphine Tolerance through Inhibiting Spinal Ferroptosis-like Cell Death.</ArticleTitle>
        <Pagination>
          <StartPage>4824</StartPage>
          <EndPage>4833</EndPage>
          <MedlinePgn>4824-4833</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.9b00539</ELocationID>
        <Abstract>
          <AbstractText>Morphine tolerance is a classic, challenging clinical issue. However, the mechanism underlying this phenomenon remains poorly understood. Recently, studies have shown that ferroptosis correlates with drug resistance. Therefore, this study investigated whether spinal cord ferroptosis contributes to morphine tolerance. C57BL/6 mice were continuously subcutaneously injected with morphine, with or without the ferroptosis inhibitor liproxstatin-1. We found that chronic morphine exposure led to morphine antinociception tolerance, accompanied by loss of spinal cord neurons, increase in the levels of iron, malondialdehyde, and reactive oxygen species, and decreases in the levels of superoxide dismutase. Additionally, inflammatory response and mitochondrial shrinkage, processes that are involved in ferroptosis, were observed. Simultaneously, we found that 10 mg/kg of liproxstatin-1 could alleviate iron overload by balancing transferrin receptor protein 1/ferroportin expression and attenuate morphine tolerance by increasing glutathione peroxidase 4 levels, while reducing the levels of malondialdehyde and reactive oxygen species. It also downregulated the expression of extracellularly regulated protein kinases that had been induced by chronic morphine exposure. Our results indicate that spinal cord ferroptosis contributes to morphine tolerance, while liproxstatin-1 attenuates the development of morphine tolerance. These findings suggest that ferroptosis may be a potential therapeutic target for morphine tolerance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xuhui</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-9791-2051</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology, Union Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Tongtong</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Miaomiao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chuanhan</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Wenlong</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-9263-294X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-1004-654X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , 430030 Hubei Province , China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Chem Neurosci</MedlineTA>
        <NlmUniqueID>101525337</NlmUniqueID>
        <ISSNLinking>1948-7193</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C480029">Tfrc protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595890">liproxstatin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C409881">metal transporting protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4Y8F71G49Q</RegistryNumber>
          <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>76I7G6D29C</RegistryNumber>
          <NameOfSubstance UI="D009020">Morphine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C000611332">glutathione peroxidase 4, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.99.-</RegistryNumber>
          <NameOfSubstance UI="C077623">Ptgs2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.99.1</RegistryNumber>
          <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004361" MajorTopicYN="N">Drug Tolerance</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006930" MajorTopicYN="N">Hyperalgesia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019190" MajorTopicYN="N">Iron Overload</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008315" MajorTopicYN="N">Malondialdehyde</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009020" MajorTopicYN="N">Morphine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059225" MajorTopicYN="N">Nociception</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">morphine tolerance</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">spinal cord</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31682397</ArticleId>
        <ArticleId IdType="doi">10.1021/acschemneuro.9b00539</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30741049</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-2394</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of liposome research</Title>
          <ISOAbbreviation>J Liposome Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Biotin anchored nanostructured lipid carriers for targeted delivery of doxorubicin in management of mammary gland carcinoma through regulation of apoptotic modulator.</ArticleTitle>
        <Pagination>
          <StartPage>21</StartPage>
          <EndPage>36</EndPage>
          <MedlinePgn>21-36</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/08982104.2019.1579839</ELocationID>
        <Abstract>
          <AbstractText>Mammary gland tumour has the highest incidence rate and mortality in women, worldwide. The present study envisaged a molecularly targeted nanostructured lipid carrier (NLCs) for doxorubicin (Dox) delivery capable of inducing cellular apoptosis in mammary gland tumour. NLCs were prepared utilizing Perilla frutescens oil (54-69% ω3-fatty acid) as liquid lipid to enhance entrapment of Dox through molecular ion pairing. Biotin decorated NLCs (b-Dox-NLCs) were evaluated in vitro and in vivo. The b-Dox-NLCs showed particle size of 105.2 ± 3.5 nm, zeta potential -35 ± 2 mV, entrapment 99.15 ± 1.71%, drug content 19.67 ± 2.6 mg.g[-1], biotin content 5.85 ± 0.64 µg.g[-1] and drug release 98.67 ± 2.43% (facilitated by acidic microenvironment) respectively. MTT assay and Flow cytometric analysis revealed higher anti-proliferative capability of b-Dox-NLCs to force apoptosis in MCF-7 cell line vis-à-vis marketed Dox, evidenced by reactive oxygen species level and mitochondrial membrane potential mediated apoptosis. Enhanced antitumor targeting, therapeutic safety and efficacy was exhibited by b-Dox-NLCs, as investigated through tumour volume, animal survival, weight variation, cardiotoxicity and biodistribution studies in 7,12-Dimethylbenz[a]anthracene induced mammary gland tumour. Immunoblotting assay demonstrated b-Dox-NLCs downregulated anti-apoptotic proteins, i.e. bcl-2, MMP-9 while upregulated pro-apoptotic proteins, i.e. caspase-9, p16 and BAX. The experimental results suggest that biotinylated ω3-fatty acid augmented NLCs loaded with Dox are capable of inducing programmed cell death in mammary tumour and can be utilized as safe and effective delivery system with enhanced potential for mammary gland carcinoma therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tripathi</LastName>
            <ForeName>Chandra B</ForeName>
            <Initials>CB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parashar</LastName>
            <ForeName>Poonam</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arya</LastName>
            <ForeName>Malti</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Mahendra</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanoujia</LastName>
            <ForeName>Jovita</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaithwas</LastName>
            <ForeName>Gaurav</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saraf</LastName>
            <ForeName>Shubhini A</ForeName>
            <Initials>SA</Initials>
            <Identifier Source="ORCID">0000-0002-4180-0931</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Biosciences &amp; Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>03</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Liposome Res</MedlineTA>
        <NlmUniqueID>9001952</NlmUniqueID>
        <ISSNLinking>0898-2104</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6SO6U10H04</RegistryNumber>
          <NameOfSubstance UI="D001710">Biotin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EH46A1TLD7</RegistryNumber>
          <NameOfSubstance UI="C034020">anthracene</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000873" MajorTopicYN="N">Anthracenes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001710" MajorTopicYN="N">Biotin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">MCF-7 Cell lines</Keyword>
        <Keyword MajorTopicYN="N">flow cytometry</Keyword>
        <Keyword MajorTopicYN="N">immunoblotting</Keyword>
        <Keyword MajorTopicYN="N">nanostructured lipid carriers</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30741049</ArticleId>
        <ArticleId IdType="doi">10.1080/08982104.2019.1579839</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29473753</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-6992</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nano letters</Title>
          <ISOAbbreviation>Nano Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>1908</StartPage>
          <EndPage>1915</EndPage>
          <MedlinePgn>1908-1915</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.nanolett.7b05263</ELocationID>
        <Abstract>
          <AbstractText>Various delivery vectors have been integrated within biologically derived membrane systems to extend their residential time and reduce their reticuloendothelial system (RES) clearance during systemic circulation. However, rational design is still needed to further improve the in situ penetration efficiency of chemo-drug-loaded membrane delivery-system formulations and their release profiles at the tumor site. Here, a macrophage-membrane-coated nanoparticle is developed for tumor-targeted chemotherapy delivery with a controlled release profile in response to tumor microenvironment stimuli. Upon fulfilling its mission of tumor homing and RES evasion, the macrophage-membrane coating can be shed via morphological changes driven by extracellular microenvironment stimuli. The nanoparticles discharged from the outer membrane coating show penetration efficiency enhanced by their size advantage and surface modifications. After internalization by the tumor cells, the loaded drug is quickly released from the nanoparticles in response to the endosome pH. The designed macrophage-membrane-coated nanoparticle (cskc-PPiP/PTX@Ma) exhibits an enhanced therapeutic effect inherited from both membrane-derived tumor homing and step-by-step controlled drug release. Thus, the combination of a biomimetic cell membrane and a cascade-responsive polymeric nanoparticle embodies an effective drug delivery system tailored to the tumor microenvironment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Kaimin</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-9442-8312</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qinjun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Lisha</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yujie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yifei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xinli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yongzhuo</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-7067-8915</Identifier>
            <AffiliationInfo>
              <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 501 Haike Road , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Jianjun</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-2561-9291</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-4833-9121</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 201203 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA207584</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nano Lett</MedlineTA>
        <NlmUniqueID>101088070</NlmUniqueID>
        <ISSNLinking>1530-6984</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040761" MajorTopicYN="N">Biomimetic Materials</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">biomimetic delivery system</Keyword>
        <Keyword MajorTopicYN="N">breast-cancer targeting</Keyword>
        <Keyword MajorTopicYN="N">cascade-responsiveness</Keyword>
        <Keyword MajorTopicYN="N">macrophage-membrane coating</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29473753</ArticleId>
        <ArticleId IdType="mid">NIHMS1619177</ArticleId>
        <ArticleId IdType="pmc">PMC7470025</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.nanolett.7b05263</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cai K; Wang AZ; Yin L; Cheng JJ Control. Release 2017, 263, 211&#x2013;222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28062299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan SM; Brayden DJ Curr. Opin. Pharmacol 2014, 18, 120&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T; Choi H; Zhou R; Chen IW PLoS One 2014, 9, e103576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4121285</ArticleId>
            <ArticleId IdType="pubmed">25090653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magana IB; Yendluri RB; Adhikari P; Goodrich GP; Schwartz JA; Sherer EA; O&#x2019;Neal DP Ther. Deliv 2015, 6, 777&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26228771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knop K; Hoogenboom R; Fischer D; Schubert US Angew. Chem. Int. Ed. Engl 2010, 49, 6288&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20648499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang S; Cao Z Adv. Mater 2010, 22, 920&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20217815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CM; Zhang L; Aryal S; Cheung C; Fang RH; Zhang L Proc. Natl. Acad. Sci. U. S. A 2011, 108, 10980&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131364</ArticleId>
            <ArticleId IdType="pubmed">21690347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luk BT; Zhang L J. Control. Release 2015, 220, 600&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4688192</ArticleId>
            <ArticleId IdType="pubmed">26210440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CM; Fang RH; Copp J; Luk BT; Zhang L Nat. Nanotechnol 2013, 8, 336&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3648601</ArticleId>
            <ArticleId IdType="pubmed">23584215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao W; Hu CM; Fang RH; Luk BT; Su J; Zhang L Adv. Mater 2013, 25, 3549&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4138311</ArticleId>
            <ArticleId IdType="pubmed">23712782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao L; He Z; Meng QF; Zhou Z; Bu LL; Guo SS; Liu W; Zhao XZ J. Biomed. Mater. Res. A 2017, 105, 521&#x2013;530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27718539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xuan M; Shao J; Dai L; He Q; Li J Adv. Healthc. Mater 2015, 4, 1645&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25960053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek SK; Makkouk AR; Krasieva T; Sun CH; Madsen SJ; Hirschberg H J. Neurooncol 2011, 104, 439&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3161184</ArticleId>
            <ArticleId IdType="pubmed">21221712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madsen SJ; Christie C; Hong SJ; Trinidad A; Peng Q; Uzal FA; Hirschberg H Lasers Med. Sci 2015, 30, 1357&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4730872</ArticleId>
            <ArticleId IdType="pubmed">25794592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long KB; Beatty GL Oncoimmunology 2013, 2, e26860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3902119</ArticleId>
            <ArticleId IdType="pubmed">24498559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagemann T; Balkwill F; Lawrence T Cancer Cell 2007, 12, 300&#x2013;1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2592547</ArticleId>
            <ArticleId IdType="pubmed">17936555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyvonen Z; Hamalainen V; Ruponen M; Lucas B; Rejman J; Vercauteren D; Demeester J; De Smedt S; Braeckmans K J. Control. Release 2012, 162, 167&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22709591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ur RZ; Hoekstra D; Zuhorn IS ACS Nano 2013, 7, 3767&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23597090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuberg P; Kichler A Adv. Genet 2014, 88, 263&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25409609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao K; Zhang Y; Ding N; Huang S; Wu J; Li J; Yang C; Leng Q; Ye L; Lou J; Zhu L; Jiang C Adv. Healthc. Mater 2015, 4, 291&#x2013;300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25124929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y; Li J; Shao K; Huang R; Ye L; Lou J; Jiang C Biomaterials 2010, 31, 5246&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20382424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng N; Song Z; Liu Y; Zhang R; Zhang R; Yao C; Uckun FM; Yin L; Cheng J J. Control. Release 2015, 205, 231&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25683619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoneda T; Hiasa M; Nagata Y; Okui T; White F Biochim. Biophys. Acta 2015, 1848, 2677&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5356024</ArticleId>
            <ArticleId IdType="pubmed">25687976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peppicelli S; Bianchini F; Calorini L Cancer Metastasis Rev 2014, 33, 823&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24984804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson DG; Lynn DM; Langer R Angew. Chem. Int. Ed. Engl 2003, 42, 3153&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12866105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson DG; Akinc A; Hossain N; Langer R Mol. Ther 2005, 11, 426&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15727939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian X; Aruva MR; Qin W; Zhu W; Duffy KT; Sauter ER; Thakur ML; Wickstrom E J Nucl. Med 2004, 45, 2070&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15585484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian X; Chakrabarti A; Amirkhanov NV; Aruva MR; Zhang K; Mathew B; Cardi C; Qin W; Sauter ER; Thakur ML; Wickstrom E Ann N. Y. Acad. Sci 2005, 1059, 106&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16382049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV Clin. Cancer Res 2011, 17, 2314&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3073089</ArticleId>
            <ArticleId IdType="pubmed">21177763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun BF; Kobayashi H; Le N; Yoo TM; Drumm D; Paik CH; McAfee JG; Carrasquillo JA Cancer Res 1997, 57, 2754&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9205087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liebmann JE; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB Br. J. Cancer 1993, 68, 1104&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1968657</ArticleId>
            <ArticleId IdType="pubmed">7903152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liebmann J; Cook JA; Mitchell JB Lancet 1993, 342, 1428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7901713</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29431006</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-8534</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Stem cells and development</Title>
          <ISOAbbreviation>Stem Cells Dev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cell Density-Dependent Cytological Stage Profile and Its Application for a Screen of Cytostatic Agents Active Toward Leukemic Stem Cells.</ArticleTitle>
        <Pagination>
          <StartPage>488</StartPage>
          <EndPage>513</EndPage>
          <MedlinePgn>488-513</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1089/scd.2017.0245</ELocationID>
        <Abstract>
          <AbstractText>Proliferation and expansion of leukemia is driven by leukemic stem cells (LSCs). Multidrug resistance (MDR) of LSCs is one of the main reasons of failure and relapses in acute myeloid leukemia (AML) treatment. In this study, we show that maintaining HL-60 at low cell culture density or applying a 240-day treatment with anthrapyridazone (BS-121) increased the percentage of primitive cells, which include LSCs determining the overall stage profile. This change manifested in morphology, expression of both cell surface markers and redox-state proteins, as well as mitochondrial potential. Moreover, four sublines were generated, each with unique and characteristic stage profile and cytostatic sensitivity. Cell density-induced culture alterations (affecting stage profiles) were exploited in a screen of anthrapyridazones. Among the compound tested, C-123 was the most potent against primitive cell stages while generating relatively low amounts of reactive oxygen species (ROS). Furthermore, it had low toxicity in vivo and weakly affected blood morphology of healthy mice. The cell density-dependent stage profiles could be utilized in preliminary drug screens for activity against LSCs or in construction of patient-specific platforms to find drugs effective in case of AML relapse (drug extrapolation). The correlation between ROS generation in differentiated cells and toxic effect observed in HL-60 has a potential application in myelotoxicity predictions. The discovered properties of C-123 indicate its potential application in AML treatment, specifically in conditioned myeloablation preceding allogeneic transplantation and/or ex vivo treatment preceding autologous transplantation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lica</LastName>
            <ForeName>Jan J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grabe</LastName>
            <ForeName>Grzegorz J</ForeName>
            <Initials>GJ</Initials>
            <AffiliationInfo>
              <Affiliation>2 Department of Medicine, Imperial College London , London, United Kingdom .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heldt</LastName>
            <ForeName>Mateusz</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Misiak</LastName>
            <ForeName>Majus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bloch</LastName>
            <ForeName>Patrycja</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serocki</LastName>
            <ForeName>Marcin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>3 Department of Biology and Pharmaceutical Botany, Medical University of Gdansk , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Switalska</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>4 Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy , Polish Academy of Sciences, Wroclaw, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wietrzyk</LastName>
            <ForeName>Joanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>4 Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy , Polish Academy of Sciences, Wroclaw, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baginski</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hellmann</LastName>
            <ForeName>Andrzej</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>5 Department of Hematology and Transplantology, Medical University of Gdansk , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borowski</LastName>
            <ForeName>Edward</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>6 BLIRT S.A. (BioLab Innovative Research Technologies) , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skladanowski</LastName>
            <ForeName>Andrzej</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>1 Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology , Gdansk, Poland .</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>03</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Stem Cells Dev</MedlineTA>
        <NlmUniqueID>101197107</NlmUniqueID>
        <ISSNLinking>1547-3287</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054697">Cytostatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054697" MajorTopicYN="N">Cytostatic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018922" MajorTopicYN="N">HL-60 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007951" MajorTopicYN="N">Leukemia, Myeloid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">HL-60</Keyword>
        <Keyword MajorTopicYN="N">anthrapyridazones</Keyword>
        <Keyword MajorTopicYN="N">cell culture density-dependent cytological stage profile</Keyword>
        <Keyword MajorTopicYN="N">drug screening platform</Keyword>
        <Keyword MajorTopicYN="N">leukemic stem</Keyword>
        <Keyword MajorTopicYN="N">progenitor and precursor cells</Keyword>
        <Keyword MajorTopicYN="N">transporter-mediated multidrug resistance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29431006</ArticleId>
        <ArticleId IdType="doi">10.1089/scd.2017.0245</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">29066898</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1178-2013</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2017</Year>
            </PubDate>
          </JournalIssue>
          <Title>International journal of nanomedicine</Title>
          <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dual functions of silver nanoparticles in F9 teratocarcinoma stem cells, a suitable model for evaluating cytotoxicity- and differentiation-mediated cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>7529</StartPage>
          <EndPage>7549</EndPage>
          <MedlinePgn>7529-7549</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S145147</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Silver nanoparticles (AgNPs) exhibit strong antibacterial and anticancer activity owing to their large surface-to-volume ratios and crystallographic surface structure. Owing to their various applications, understanding the mechanisms of action, biological interactions, potential toxicity, and beneficial effects of AgNPs is important. Here, we investigated the toxicity and differentiation-inducing effects of AgNPs in teratocarcinoma stem cells.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">AgNPs were synthesized and characterized using various analytical techniques such as UV-visible spectroscopy, X-ray diffraction, energy-dispersive X-ray spectroscopy, and transmission electron microscopy. The cellular responses of AgNPs were analyzed by a series of cellular and biochemical assays. Gene and protein expressions were analyzed by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The AgNPs showed typical crystalline structures and spherical shapes (average size =20 nm). High concentration of AgNPs induced cytotoxicity in a dose-dependent manner by increasing lactate dehydrogenase leakage and reactive oxygen species. Furthermore, AgNPs caused mitochondrial dysfunction, DNA fragmentation, increased expression of apoptotic genes, and decreased expression of antiapoptotic genes. Lower concentrations of AgNPs induced neuronal differentiation by increasing the expression of differentiation markers and decreasing the expression of stem cell markers. Cisplatin reduced the viability of F9 cells that underwent AgNPs-induced differentiation.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results showed that AgNPs caused differentially regulated cytotoxicity and induced neuronal differentiation of F9 cells in a concentration-dependent manner. Therefore, AgNPs can be used for differentiation therapy, along with chemotherapeutic agents, for improving cancer treatment by targeting specific chemotherapy-resistant cells within a tumor. Furthermore, understanding the molecular mechanisms of apoptosis and differentiation in stem cells could also help in developing new strategies for cancer stem cell (CSC) therapies. The findings of this study could significantly contribute to the nanomedicine because this study is the first of its kind, and our results will lead to new strategies for cancer and CSC therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Jae Woong</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gurunathan</LastName>
            <ForeName>Sangiliyandi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Yun-Jung</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Jin-Hoi</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Int J Nanomedicine</MedlineTA>
        <NlmUniqueID>101263847</NlmUniqueID>
        <ISSNLinking>1176-9114</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3M4G523W1G</RegistryNumber>
          <NameOfSubstance UI="D012834">Silver</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054278" MajorTopicYN="N">Embryonal Carcinoma Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005109" MajorTopicYN="N">Extracellular Matrix</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012834" MajorTopicYN="N">Silver</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">cell viability</Keyword>
        <Keyword MajorTopicYN="N">cytotoxicity</Keyword>
        <Keyword MajorTopicYN="N">differentiation</Keyword>
        <Keyword MajorTopicYN="N">silver nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">teratocarcinoma stem cells</Keyword>
      </KeywordList>
      <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29066898</ArticleId>
        <ArticleId IdType="pmc">PMC5644540</ArticleId>
        <ArticleId IdType="doi">10.2147/IJN.S145147</ArticleId>
        <ArticleId IdType="pii">ijn-12-7529</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett. 2008;176(1):1&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge L, Li Q, Wang M, Ouyang J, Li X, Xing MM. Nanosilver particles in medical applications: synthesis, performance, and toxicity. Int J Nanomedicine. 2014;9:2399&#x2013;2407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4037247</ArticleId>
            <ArticleId IdType="pubmed">24876773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurunathan S, Kalishwaralal K, Vaidyanathan R, et al. Biosynthesis, purification and characterization of silver nanoparticles using Escherichia coli. Colloids Surf B Biointerfaces. 2009;74(1):328&#x2013;335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19716685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XF, Gurunathan S. Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy. Int J Nanomedicine. 2016;11:3655&#x2013;3675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4977082</ArticleId>
            <ArticleId IdType="pubmed">27536105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin SH, Ye MK, Kim HS, Kang HS. The effects of nanosilver on the proliferation and cytokine expression by peripheral blood mononuclear cells. Int Immunopharmacol. 2007;7(13):1813&#x2013;1818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17996693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S, Lee YK, Jung M, et al. Cellular toxicity of various inhalable metal nanoparticles on human alveolar epithelial cells. Inhal Toxicol. 2007;19(Suppl 1):59&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17886052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han JW, Gurunathan S, Jeong JK, et al. Oxidative stress mediated cytotoxicity of biologically synthesized silver nanoparticles in human lung epithelial adenocarcinoma cell line. Nanoscale Res Lett. 2014;9(1):459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4167841</ArticleId>
            <ArticleId IdType="pubmed">25242904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soto K, Garza KM, Murr LE. Cytotoxic effects of aggregated nanomaterials. Acta Biomater. 2007;3(3):351&#x2013;358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17275430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro. 2005;19(7):975&#x2013;983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16125895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XF, Choi YJ, Han JW, et al. Differential nanoreprotoxicity of silver nanoparticles in male somatic cells and spermatogonial stem cells. Int J Nanomedicine. 2015;10:1335&#x2013;1357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4337509</ArticleId>
            <ArticleId IdType="pubmed">25733828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han JW, Jeong JK, Gurunathan S, et al. Male- and female-derived somatic and germ cell-specific toxicity of silver nanoparticles in mouse. Nanotoxicology. 2016;10(3):361&#x2013;373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26470004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain SM, Javorina AK, Schrand AM, Duhart HM, Ali SF, Schlager JJ. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci. 2006;92(2):456&#x2013;463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16714391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurunathan S, Han JW, Eppakayala V, Jeyaraj M, Kim JH. Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells. Biomed Res Int. 2013;2013:535796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3722883</ArticleId>
            <ArticleId IdType="pubmed">23936814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurunathan S, Han JW, Park JH, et al. Reduced graphene oxide-silver nanoparticle nanocomposite: a potential anticancer nanotherapy. Int J Nanomedicine. 2015;10:6257&#x2013;6276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4599719</ArticleId>
            <ArticleId IdType="pubmed">26491296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kone BC, Kaleta M, Gullans SR. Silver ion (Ag+)-induced increases in cell membrane K+ and Na+ permeability in the renal proximal tubule: reversal by thiol reagents. J Membr Biol. 1988;102(1):11&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2456393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson C, Hussain SM, Schrand AM, et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B. 2008;112(43):13608&#x2013;13619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18831567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greulich C, Diendorf J, Simon T, Eggeler G, Epple M, K&#xf6;ller M. Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells. Acta Biomater. 2011;7(1):347&#x2013;354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20709196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MV, Neigh AM, Vermeulen JP, et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials. 2011;32(36):9810&#x2013;9817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21944826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan M, Liu Q. Differentiation therapy: a promising strategy for cancer treatment. Chin J Cancer. 2016;35:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4704415</ArticleId>
            <ArticleId IdType="pubmed">26739838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami S, Tashiro F. Prospects of differentiation therapy for cancer stem cells. Adv Tech Biol Med. 2015;3:144.</Citation>
        </Reference>
        <Reference>
          <Citation>Qin H, Zhu C, An Z, et al. Silver nanoparticles promote osteogenic differentiation of human urine-derived stem cells at noncytotoxic concentrations. Int J Nanomedicine. 2014;9:2469&#x2013;2478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4038528</ArticleId>
            <ArticleId IdType="pubmed">24899804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Wang L, Bai R, Zhang T, Chen C. Silver nanoparticles impede phorbol myristate acetate-induced monocyte-macrophage differentiation and autophagy. Nanoscale. 2015;7(38):16100&#x2013;16109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26372376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Z, Yin W, Zara JN, et al. The use of BMP-2 coupled &#x2013; nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials. 2010;31(35):9293&#x2013;9300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3202602</ArticleId>
            <ArticleId IdType="pubmed">20864167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zheng Z, Zara JN, et al. The antimicrobial and osteoinductive properties of silver nanoparticle/poly(DL-lactic-co-glycolic acid)-coated stainless steel. Biomaterials. 2012;33(34):8745&#x2013;8756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22959466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, He W, Fang Z, Kienzle A, Feng Q. Influence of silver nanoparticles on osteogenic differentiation of human mesenchymal stem cells. J Biomed Nanotechnol. 2014;10(7):1277&#x2013;1285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24804548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dayem AA, Kim B, Gurunathan S, et al. Biologically synthesized silver nanoparticles induce neuronal differentiation of SH-SY5Y cells via modulation of reactive oxygen species, phosphatases, and kinase signaling pathways. Biotechnol J. 2014;9(7):934&#x2013;943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24827677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alon N, Miroshnikov Y, Perkas N, Nissan I, Gedanken A, Shefi O. Substrates coated with silver nanoparticles as a neuronal regenerative material. Int J Nanomedicine. 2014;9(Suppl 1):23&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4024974</ArticleId>
            <ArticleId IdType="pubmed">24872701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan TC, Veeramani S, Lin FF, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer. 2006;13(1):151&#x2013;167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16601285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valentini A, Biancolella M, Amati F, et al. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Drug Metab Dispos. 2007;35(6):968&#x2013;972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17371798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin GS. Cell signaling and cancer. Cancer Cell. 2003;4(3):167&#x2013;174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warren CM, Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal. 2006;18(7):923&#x2013;933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16460914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braydich-Stolle LK, Lucas B, Schrand A, et al. Silver nanoparticles disrupt GDNF/Fyn kinase signaling in spermatogonial stem cells. Toxicol Sci. 2010;116(2):577&#x2013;589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2905406</ArticleId>
            <ArticleId IdType="pubmed">20488942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comfort KK, Maurer EI, Braydich-Stolle LK, Hussain SM. Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells. ACS Nano. 2011;5(12):10000&#x2013;10008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22070748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comfort KK, Maurer EI, Hussain SM. Slow release of ions from internalized silver nanoparticles modifies the epidermal growth factor signaling response. Colloids Surf B Biointerfaces. 2014;123:136&#x2013;142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25260222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14(5):381&#x2013;395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11882383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wortzel I, Seger R. The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer. 2011;2(3):195&#x2013;209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3128630</ArticleId>
            <ArticleId IdType="pubmed">21779493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao P, Malbon CC. Differentiation of F9 teratocarcinoma stem cells to primitive endoderm is regulated by the Gialpha2/Gsalpha axis via phospholipase C and not adenylylcyclase. J Biol Chem. 1996;271(48):30692&#x2013;30698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8940046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sastry M, Mayya KS, Bandyopadhyay K. pH dependent changes in the optical properties of carboxylic acid derivatized silver colloidal particles. Colloids Surf A Physicochem Eng Asp. 1997;127(1&#x2013;3):221&#x2013;228.</Citation>
        </Reference>
        <Reference>
          <Citation>Sastry M, Patil V, Sainkar SR. Electrostatically controlled diffusion of carboxylic acid derivatized silver colloidal particles in thermally evaporated fatty amine films. J Phys Chem B. 1998;102(8):1404&#x2013;1410.</Citation>
        </Reference>
        <Reference>
          <Citation>Gurunathan S, Jeong JK, Han JW, Zhang XF, Park JH, Kim JH. Multidimensional effects of biologically synthesized silver nanoparticles in Helicobacter pylori, Helicobacter felis, and human lung (L132) and lung carcinoma A549 cells. Nanoscale Res Lett. 2015;10:35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4384991</ArticleId>
            <ArticleId IdType="pubmed">25852332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jyoti K, Baunthiyal M, Singh A. Characterization of silver nanoparticles synthesized using Urtica dioica Linn. leaves and their synergistic effects with antibiotics. J Radiat Res Appl Sci. 2016;9(3):217&#x2013;227.</Citation>
        </Reference>
        <Reference>
          <Citation>Kalimuthu K, Suresh Babu R, Venkataraman D, Bilal M, Gurunathan S. Biosynthesis of silver nanocrystals by Bacillus licheniformis. Colloids Surf B Biointerfaces. 2008;65(1):150&#x2013;153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18406112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain D, Kachhwaha S, Jain R, Srivastava G, Kothari SL. Novel microbial route to synthesize silver nanoparticles using spore crystal mixture of Bacillus thuringiensis. Indian J Exp Biol. 2010;48(11):1152&#x2013;1156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21117457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaviya S, Santhanalakshmi J, Viswanathan B, Muthumary J, Srinivasan K. Biosynthesis of silver nanoparticles using citrus sinensis peel extract and its antibacterial activity. Spectrochim Acta A Mol Biomol Spectrosc. 2011;79(3):594&#x2013;598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21536485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Govender R, Phulukdaree A, Gengan RM, Anand K, Chuturgoon AA. Silver nanoparticles of Albizia adianthifolia: the induction of apoptosis in human lung carcinoma cell line. J Nanobiotechnology. 2013;11:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606379</ArticleId>
            <ArticleId IdType="pubmed">23418790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castiglioni S, Cazzaniga A, Perrotta C, Maier JA. Silver nanoparticles-induced cytotoxicity requires ERK activation in human bladder carcinoma cells. Toxicol Lett. 2015;237(3):237&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26149761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22(3):377&#x2013;388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4326572</ArticleId>
            <ArticleId IdType="pubmed">25257172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Zhong Z, Xu Z, Chen L, Wang Y. 2&#x2032;,7&#x2032;-Dichlorodi hydrofluorescein as a fluorescent probe for reactive oxygen species measurement: forty years of application and controversy. Free Radic Res. 2010;44(6):587&#x2013;604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20370560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sriram MI, Kanth SB, Kalishwaralal K, Gurunathan S. Antitumor activity of silver nanoparticles in Dalton&#x2019;s lymphoma ascites tumor model. Int J Nanomedicine. 2010;5:753&#x2013;762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2962271</ArticleId>
            <ArticleId IdType="pubmed">21042421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park EJ, Yi J, Kim Y, Choi K, Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol In Vitro. 2010;24(3):872&#x2013;878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19969064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avalos A, Haza AI, Mateo D, Morales P. Cytotoxicity and ROS production of manufactured silver nanoparticles of different sizes in hepatoma and leukemia cells. J Appl Toxicol. 2014;34(4):413&#x2013;423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24243578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6(5):513&#x2013;519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10802706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki N, Koussevitzky S, Mittler R, Miller G. ROS and redox signalling in the response of plants to abiotic stress. Plant Cell Environ. 2012;35(2):259&#x2013;270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21486305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong JK, Gurunathan S, Kang MH, et al. Hypoxia-mediated autophagic flux inhibits silver nanoparticle-triggered apoptosis in human lung cancer cells. Sci Rep. 2016;6:21688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4751501</ArticleId>
            <ArticleId IdType="pubmed">26867977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsin YH, Chen CF, Huang S, Shih TS, Lai PS, Chueh PJ. The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol Lett. 2008;179(3):130&#x2013;139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18547751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Risom L, M&#xf8;ller P, Loft S. Oxidative stress-induced DNA damage by particulate air pollution. Mutat Res. 2005;592(1&#x2013;2):119&#x2013;137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16085126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson NL, Gardner AM, Diener KM, et al. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J Biol Chem. 1996;271(6):3229&#x2013;3237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8621725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foldbjerg R, Olesen P, Hougaard M, Dang DA, Hoffmann HJ, Autrup H. PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes. Toxicol Lett. 2009;190(2):156&#x2013;162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19607894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiny PJ, Mukherjee A, Chandrasekaran N. DNA damage and mitochondria-mediated apoptosis of A549 lung carcinoma cells induced by biosynthesised silver and platinum nanoparticles. RSC Adv. 2016;6(33):27775&#x2013;27787.</Citation>
        </Reference>
        <Reference>
          <Citation>Gurunathan S, Park JH, Han JW, Kim JH. Comparative assessment of the apoptotic potential of silver nanoparticles synthesized by Bacillus tequilensis and Calocybe indica in MDA-MB-231 human breast cancer cells: targeting p53 for anticancer therapy. Int J Nanomedicine. 2015;10:4203&#x2013;4222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4494182</ArticleId>
            <ArticleId IdType="pubmed">26170659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J&#xe4;nicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998;273(16):9357&#x2013;9360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9545256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopinath P, Gogoi SK, Sanpui P, Paul A, Chattopadhyay A, Ghosh SS. Signaling gene cascade in silver nanoparticle induced apoptosis. Colloids Surf B Biointerfaces. 2010;77(2):240&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20197232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dziedzic A, Kubina R, Bu&#x142;dak RJ, Skonieczna M, Cholewa K. Silver nanoparticles exhibit the dose-dependent anti-proliferative effect against human squamous carcinoma cells attenuated in the presence of berberine. Molecules. 2016;21(3):365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6274313</ArticleId>
            <ArticleId IdType="pubmed">26999092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samberg ME, Loboa EG, Oldenburg SJ, Monteiro-Riviere NA. Silver nanoparticles do not influence stem cell differentiation but cause minimal toxicity. Nanomedicine (Lond) 2012;7(8):1197&#x2013;1209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3474209</ArticleId>
            <ArticleId IdType="pubmed">22583572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauksch L, Hartmann S, Szalay G, Alt V, Lips KS. In vitro assessment of nanosilver-functionalized PMMA bone cement on primary human mesenchymal stem cells and osteoblasts. PLoS One. 2014;9(12):e114740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4259364</ArticleId>
            <ArticleId IdType="pubmed">25485700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang DM, Chung TH, Hung Y, et al. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells. Toxicol Appl Pharmacol. 2008;231(2):208&#x2013;215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18519141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung TH, Wu SH, Yao M, et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials. 2007;28(19):2959&#x2013;2966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17397919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins CA, Watt FM. Dynamic regulation of retinoic acid-binding proteins in developing, adult and neoplastic skin reveals roles for beta-catenin and Notch signalling. Dev Biol. 2008;324(1):55&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18805411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Gao Y, Yu M, et al. Retinoic acid induces embryonic stem cell differentiation by altering both encoding RNA and microRNA expression. PLoS One. 2015;10(7):e132566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4498831</ArticleId>
            <ArticleId IdType="pubmed">26162091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendling O, Ghyselinck NB, Chambon P, Mark M. Roles of retinoic acid receptors in early embryonic morphogenesis and hindbrain patterning. Development. 2001;128(11):2031&#x2013;2038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11493525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young RA. Control of the embryonic stem cell state. Cell. 2011;144(6):940&#x2013;954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3099475</ArticleId>
            <ArticleId IdType="pubmed">21414485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113(5):631&#x2013;642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12787504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole MF, Johnstone SE, Newman JJ, Kagey MH, Young RA. Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Gene Dev. 2008;22(6):746&#x2013;755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2275428</ArticleId>
            <ArticleId IdType="pubmed">18347094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122(6):947&#x2013;956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3006442</ArticleId>
            <ArticleId IdType="pubmed">16153702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loh YH, Wu Q, Chew JL, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38(4):431&#x2013;440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16518401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Rao S, Chu J, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature. 2006;444(7117):364&#x2013;368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17093407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okumura-Nakanishi S, Saito M, Niwa H, Ishikawa F. Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells. J Biol Chem. 2005;280(7):5307&#x2013;5317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15557334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 2007;13:823&#x2013;832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2768758</ArticleId>
            <ArticleId IdType="pubmed">17615543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae KM, Su Z, Frye C, et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol. 2010;183(5):2045&#x2013;2053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4451595</ArticleId>
            <ArticleId IdType="pubmed">20303530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65(8):3025&#x2013;3029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15833827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piestun D, Kochupurakkal BS, Jacob-Hirsch J, et al. Nanog transforms NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun. 2006;343(1):279&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16540082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003;113(5):643&#x2013;655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12787505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavial F, Acloque H, Bertocchini F, et al. The Oct4 homologue PouV and Nanog regulate pluripotency in chicken embryonic stem cells. Development. 2007;134(19):3549&#x2013;3563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17827181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi S, Kimura H, Tada M, Nakatsuji N, Tada T. Nanog expression in mouse germ cell development. Gene Expr Patterns. 2005;5(5):639&#x2013;646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15939376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagy A, Vintersten K. Murine embryonic stem cells. Methods Enzymol. 2006;418:3&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wamaitha SE, del Valle I, Cho LT, et al. Gata6 potently initiates reprograming of pluripotent and differentiated cells to extraembryonic endoderm stem cells. Gene Dev. 2015;29(12):1239&#x2013;1255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4495396</ArticleId>
            <ArticleId IdType="pubmed">26109048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood. 1997;89(10):3624&#x2013;3635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9160667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998;92(9):3189&#x2013;3202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9787155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003;423(6938):448&#x2013;452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12717451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Kipps TJ, Zhang S. Wnt5a signaling in normal and cancer stem cells. Stem Cells Int. 2017;2017:5295286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5405594</ArticleId>
            <ArticleId IdType="pubmed">28491097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science. 2002;296(5573):1644&#x2013;1646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12040179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H, Mak PY, Mu H, et al. Combined inhibition of &#x3b2;-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017 Apr 18; Epub.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5628102</ArticleId>
            <ArticleId IdType="pubmed">28321124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang DH, Yoon JY, Lee SH, et al. Wnt5a is required for endothelial differentiation of embryonic stem cells and vascularization via pathways involving both Wnt/beta-catenin and protein kinase Calpha. Circ Res. 2009;104(3):372&#x2013;379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19096028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nayak RC, Chang KH, Vaitinadin NS, Cancelas JA. Rho GTPases control specific cytoskeleton-dependent functions of hematopoietic stem cells. Immunol Rev. 2013;256(1):255&#x2013;268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3830525</ArticleId>
            <ArticleId IdType="pubmed">24117826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CW, Montelatici E, Crisan M, et al. Perivascular multi-lineage progenitor cells in human organs: regenerative units, cytokine sources or both? Cytokine Growth Factor Rev. 2009;20(5&#x2013;6):429&#x2013;434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19926515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miano JM, Long X, Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol. 2007;292(1):C70&#x2013;C81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16928770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu P, Davis RJ. c-Jun NH(2)-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal. Mol Cell Biol. 2010;30(6):1329&#x2013;1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2832508</ArticleId>
            <ArticleId IdType="pubmed">20065035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiwari VK, Stadler MB, Wirbelauer C, Paro R, Sch&#xfc;beler D, Beisel C. A chromatin-modifying function of JNK during stem cell differentiation. Nat Genet. 2011;44(1):94&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22179133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bin&#xe9;truy B, Heasley L, Bost F, Caron L, Aouadi M. Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases. Stem Cells. 2007;25(5):1090&#x2013;1095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17218395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki R, Ogata H, Kobayashi Y. Requirement of thrombopoietin-induced activation of ERK for megakaryocyte differentiation and of p38 for erythroid differentiation. Ann Hematol. 2001;80(5):284&#x2013;291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11446731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruijtenberg S, van den Heuvel S. Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle. 2016;15(2):196&#x2013;212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4825819</ArticleId>
            <ArticleId IdType="pubmed">26825227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 2006;18(12):2089&#x2013;2097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16815674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455&#x2013;7464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braydich-Stolle L, Kostereva N, Dym M, Hofmann MC. Role of Src family kinases and N-Myc in spermatogonial stem cell proliferation. Dev Biol. 2007;304(1):34&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2077853</ArticleId>
            <ArticleId IdType="pubmed">17222400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH. Antiangiogenic properties of silver nanoparticles. Biomaterials. 2009;30(31):6341&#x2013;6350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19698986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalishwaralal K, Banumathi E, Ram Kumar Pandian S, et al. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloids Surf B Biointerfaces. 2009;73(1):51&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19481908</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28564604</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2211-1247</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>May</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell reports</Title>
          <ISOAbbreviation>Cell Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.</ArticleTitle>
        <Pagination>
          <StartPage>1858</StartPage>
          <EndPage>1873</EndPage>
          <MedlinePgn>1858-1873</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.05.014</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)30639-3</ELocationID>
        <Abstract>
          <AbstractText>Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM). Our in silico and wet-bench analyses indicate that non-mutated IDH1 mRNA and protein are commonly overexpressed in primary GBMs. We show that genetic and pharmacologic inactivation of IDH1 decreases GBM cell growth, promotes a more differentiated tumor cell state, increases apoptosis in response to targeted therapies, and prolongs the survival of animal subjects bearing patient-derived xenografts (PDXs). On a molecular level, diminished IDH1 activity results in reduced α-ketoglutarate (αKG) and NADPH production, paralleled by deficient carbon flux from glucose or acetate into lipids, exhaustion of reduced glutathione, increased levels of reactive oxygen species (ROS), and enhanced histone methylation and differentiation marker expression. These findings suggest that IDH1 upregulation represents a common metabolic adaptation by GBMs to support macromolecular synthesis, aggressive growth, and therapy resistance.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Calvert</LastName>
            <ForeName>Andrea E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chalastanis</LastName>
            <ForeName>Alexandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yongfei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hurley</LastName>
            <ForeName>Lisa A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kouri</LastName>
            <ForeName>Fotini M</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bi</LastName>
            <ForeName>Yingtao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Health and Biomedical Informatics, Department of Preventive Medicine, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kachman</LastName>
            <ForeName>Maureen</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Michigan Regional Comprehensive Metabolomics Resource Core, University of Michigan, Ann Arbor, MI 48105, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>May</LastName>
            <ForeName>Jasmine L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bartom</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Genetics, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hua</LastName>
            <ForeName>Youjia</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mishra</LastName>
            <ForeName>Rama K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, IL 60208, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schiltz</LastName>
            <ForeName>Gary E</ForeName>
            <Initials>GE</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, IL 60208, USA; Department of Pharmacology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dubrovskyi</LastName>
            <ForeName>Oleksii</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazar</LastName>
            <ForeName>Andrew P</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peter</LastName>
            <ForeName>Marcus E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Hongwu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cold Spring Harbor Laboratories, Cold Spring Harbor, NY 11724, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>James</LastName>
            <ForeName>C David</ForeName>
            <Initials>CD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burant</LastName>
            <ForeName>Charles F</ForeName>
            <Initials>CF</Initials>
            <AffiliationInfo>
              <Affiliation>Michigan Regional Comprehensive Metabolomics Resource Core, University of Michigan, Ann Arbor, MI 48105, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chandel</LastName>
            <ForeName>Navdeep S</ForeName>
            <Initials>NS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60615, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davuluri</LastName>
            <ForeName>Ramana V</ForeName>
            <Initials>RV</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Health and Biomedical Informatics, Department of Preventive Medicine, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horbinski</LastName>
            <ForeName>Craig</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60615, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stegh</LastName>
            <ForeName>Alexander H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Ken and Ruth Davee Department of Neurology, The Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, International Institute for Nanotechnology, Northwestern University, Chicago, IL 60611, USA. Electronic address: a-stegh@northwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 CA009560</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 LM011297</GrantID>
            <Acronym>LM</Acronym>
            <Agency>NLM NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA199091</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA060553</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA045508</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U24 DK097153</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Rep</MedlineTA>
        <NlmUniqueID>101573691</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C478770">FOXO6 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006657">Histones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007656">Ketoglutaric Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>53-59-8</RegistryNumber>
          <NameOfSubstance UI="D009249">NADP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DA87705X9K</RegistryNumber>
          <NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.1.41</RegistryNumber>
          <NameOfSubstance UI="D007521">Isocitrate Dehydrogenase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069347" MajorTopicYN="N">Erlotinib Hydrochloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007521" MajorTopicYN="N">Isocitrate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007656" MajorTopicYN="N">Ketoglutaric Acids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009249" MajorTopicYN="N">NADP</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EGFR</Keyword>
        <Keyword MajorTopicYN="N">GBM</Keyword>
        <Keyword MajorTopicYN="N">NADPH</Keyword>
        <Keyword MajorTopicYN="N">differentiation</Keyword>
        <Keyword MajorTopicYN="N">lipids</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
        <Keyword MajorTopicYN="N">reactive oxygen species (ROS)</Keyword>
        <Keyword MajorTopicYN="N">targeted therapy</Keyword>
        <Keyword MajorTopicYN="N">wild-type IDH1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28564604</ArticleId>
        <ArticleId IdType="mid">NIHMS878754</ArticleId>
        <ArticleId IdType="pmc">PMC5564207</ArticleId>
        <ArticleId IdType="doi">10.1016/j.celrep.2017.05.014</ArticleId>
        <ArticleId IdType="pii">S2211-1247(17)30639-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bartesaghi S, Graziano V, Galavotti S, Henriquez NV, Betts J, Saxena J, Minieri VAD, Karlsson A, Martins LM, Capasso M, et al. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Proc. Natl. Acad. Sci. U. S. A. 2015;112:1059&#x2013;1064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4313844</ArticleId>
            <ArticleId IdType="pubmed">25583481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic regulation by p53 family members. Cell Metab. 2013;18:617&#x2013;633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824073</ArticleId>
            <ArticleId IdType="pubmed">23954639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bian Y, Yu Y, Wang S, Li L. Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer. Biochem. Biophys. Res. Commun. 2015;463:612&#x2013;617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26043686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleeker FE, Atai NA, Lamba S, Jonker A, Rijikeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, et al. The prognostic IDH1(R132H) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119:487&#x2013;494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2841753</ArticleId>
            <ArticleId IdType="pubmed">20127344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boros LG, Lee PW, Brandes JL, Cascante M, Muscarella P, Schirmer WJ, Melvin WS, Ellison EC. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med. Hypotheses. 1998;50:55&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9488183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boros LG, Torday JS, Paul Lee WN, Rehan VK. Oxygen-induced metabolic changes and transdifferentiation in immature fetal rat lung lipofibroblasts. Mol. Genet. Metab. 2002;77:230&#x2013;236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12409271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EE, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann. Neurol. 2011;69:455&#x2013;463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21446021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462&#x2013;477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3910500</ArticleId>
            <ArticleId IdType="pubmed">24120142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061&#x2013;1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2671642</ArticleId>
            <ArticleId IdType="pubmed">18772890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network. Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 2015;372:2481&#x2013;2498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4530011</ArticleId>
            <ArticleId IdType="pubmed">26061751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charitou P, Rodriguez-Colman M, Gerrits J, van Triest M, Groot Koerkamp M, Hornsveld M, Holstege F, Verhoeven-Duif NM, Burgering BM. FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression. EMBO Rep. 2015;16:456&#x2013;466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4388612</ArticleId>
            <ArticleId IdType="pubmed">25648147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc. Natl. Acad. Sci. U. S. A. 2014;111:14217&#x2013;14222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4191757</ArticleId>
            <ArticleId IdType="pubmed">25225364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu B, Wu T, Miao L, Mei Y, Wu M. MiR-181a regulates lipid metabolism via IDH1. Sci. Rep. 2015;5:8801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4350072</ArticleId>
            <ArticleId IdType="pubmed">25739786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 2014;9:1&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23937436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, et al. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2015;112:E4288&#x2013;4297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4534291</ArticleId>
            <ArticleId IdType="pubmed">26187928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalziel K. Isocitrate dehydrogenase and related oxidative decarboxylases. FEBS Lett. 1980;117:11&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6774891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U. S. A. 2007;104:19345&#x2013;19350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2148292</ArticleId>
            <ArticleId IdType="pubmed">18032601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008;18:54&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2476215</ArticleId>
            <ArticleId IdType="pubmed">18387799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res. 2012;72:5843&#x2013;5855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23019225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellinger I, Poss M, Bruggemann M, Gromes A, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Muller SC. Systematic expression analysis of mitochondria complex I identifies NDUFS1 as a biomarker in clear-cell renal-cell carcinoma. Clin. Genitourin Cancer. 2016 Epub ahead of print.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28063846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furnari FB, Cloughesy FF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signaling networks in glioblastoma. Nature Rev. Cancer. 2015;15:302&#x2013;310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4875778</ArticleId>
            <ArticleId IdType="pubmed">25855404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Shyy JY, Watson AD, Phelps M, Radu CG, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl. Acad. Sci. U.S.A. 2009a;106:12932&#x2013;12937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2714280</ArticleId>
            <ArticleId IdType="pubmed">19625624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal. 2009b;2:ra82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2978002</ArticleId>
            <ArticleId IdType="pubmed">20009104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuya D, Amzajerdi AN, Soto H, Zhu S, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011;1:442&#x2013;456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3207317</ArticleId>
            <ArticleId IdType="pubmed">22059152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausinger RP. FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes. Crit. Rev. Biochem. Mol. Biol. 2004;39:21&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15121720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfran-Duque A, Suarez Y, Stern DF. Neuregulin-activated ERBB4 induces SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake. Sci. Signal. 2015;8:ra111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4666504</ArticleId>
            <ArticleId IdType="pubmed">26535009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirst J. Mitochondrial complex I. Annu. Rev. Biochem. 2013;82:551&#x2013;575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23527692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoefs SJ, Skjeldal OH, Rodenburg RJ, Nedregaard B, van Kaauwen EP, Spiekerkotter U, von Kleist-Retzow JC, Smeitink JA, Nijtmans LG, van den Heuvel LP. Novel mutations in the NDUFS1 gene cause low residual activities in human complex I deficiencies. Mol. Genet. Metab. 2010;100:251&#x2013;256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20382551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta. Neuropathol. 2013;125:621&#x2013;636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3633675</ArticleId>
            <ArticleId IdType="pubmed">23512379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods. 2009;347:70&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19567251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF, Brenner D, Harris IS, Chio II, Afzal S, et al. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio. Cell Death Differ. 2015;22:1837&#x2013;1845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4648331</ArticleId>
            <ArticleId IdType="pubmed">25882048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, Terada LS, Adams ND, McCabe MT, Pietrak B, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 2016;532:255&#x2013;258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4860952</ArticleId>
            <ArticleId IdType="pubmed">27049945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jo SH, Lee SH, Chun HS, Lee SM, Koh HJ, Lee SE, Chun JS, Park JW, Huh TL. Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase. Biochem. Biophys. Res. Commun. 2002;292:542&#x2013;549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11906195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalyanaraman S, Copeland NG, Gilbert DG, Jenkins NA, Gautam N. Structure and chromosomal localization of mouse G protein subunit gamma 4 gene. Genomics. 1998;49:147&#x2013;151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9570961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SY, Lee SM, Tak JK, Choi KS, Kwon TK, Park JW. Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase. Mol. Cell Biochem. 2007;302:27&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17646934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, Park JW, Park DC, Song BJ, Veech RL, et al. Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J. Biol. Chem. 2004;279:39968&#x2013;39974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15254034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, et al. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 2015;29:732&#x2013;745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387715</ArticleId>
            <ArticleId IdType="pubmed">25838542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 2011;29:4482&#x2013;4490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3236649</ArticleId>
            <ArticleId IdType="pubmed">22025148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam EW, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional harmony. Nature Rev. Cancer. 2013;13:482&#x2013;495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23792361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med. 2002;32:1185&#x2013;1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12031902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Losman JA, Kaelin WG., Jr What a difference a hydroxyl makes: mutant IDH1, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836&#x2013;852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3650222</ArticleId>
            <ArticleId IdType="pubmed">23630074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011;27:441&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21985671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mailloux RJ, Beriault R, Lemire J, Singh R, Chenier DR, Hamel RD, Appanna VD. The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS One. 2007;2:e690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1930152</ArticleId>
            <ArticleId IdType="pubmed">17668068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER. Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene. 2005;24:4549&#x2013;4558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15824735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15:827&#x2013;837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372870</ArticleId>
            <ArticleId IdType="pubmed">22682223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, et al. Acetate is a bioenergetics substrate for human glioblastoma and brain metastases. Cell. 2014;159:1603&#x2013;1614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4374602</ArticleId>
            <ArticleId IdType="pubmed">25525878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Rev. Cancer. 2007;7:763&#x2013;777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17882277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481:380&#x2013;384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3710581</ArticleId>
            <ArticleId IdType="pubmed">22101433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monticone M, Taherian R, Stigliani S, Carra E, Monteghirfo S, Longo L, Daga A, Dono M, Zupo S, Giaretti W, et al. NAC, tiron and trolox impair survival of cell cultures containing glioblastoma tumorigenic initiating cells by inhibition of cell cycle progression. PLoS One. 2014;9:e90085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3938592</ArticleId>
            <ArticleId IdType="pubmed">24587218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam WS, Park KM, Park JW. RNA interference targeting cytosolic NADP(+)-dependent isocitrate dehydrogenase exerts anti-obesity effect in vitro and in vivo. Biochim. Biophys. Acta. 2012;1822:1181&#x2013;1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22542506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005;64:479&#x2013;489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15977639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat. Chem. Biol. 2015;11:878&#x2013;886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5155016</ArticleId>
            <ArticleId IdType="pubmed">26436839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pal I, Patil V, Mondal B, Shukla S, Hegde AS, Arivazhagan A, Santosh V, Somasundaram K. Epigenetically silenced GNG4 inhibits SDF1a/CXCR4 signaling in mesenchymal glioblastoma. Genes Cancer. 2016;7:136&#x2013;147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4918951</ArticleId>
            <ArticleId IdType="pubmed">27382437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807&#x2013;1812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2820389</ArticleId>
            <ArticleId IdType="pubmed">18772396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010;102:932&#x2013;941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2897878</ArticleId>
            <ArticleId IdType="pubmed">20513808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shechter I, Dai P, Huo L, Guan G. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J. Lipid Res. 2003;44:2169&#x2013;2180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12923220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su CY, Chang YC, Yang CJ, Huang MS, Hsiao M. The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex I. Sci. Rep. 2016;12:31357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4981865</ArticleId>
            <ArticleId IdType="pubmed">27516145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan ZW, Xie S, Hu SY, Liao T, Liu P, Peng KH, Yang XZ, He ZL, Tang HY, Cui Y, et al. Caudatin targets TNFAIP1/NF&#x3ba;B and cytochrome c/caspase signaling to suppress tumor progression in human uterine cancer. Int. J. Oncol. 2016;49:1638&#x2013;1650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27633631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, Vokes NI, Stephanopoulos G, Cantley LC, Metallo CM, et al. Metabolic pathway alterations that support proliferation. Cold Spring Harb. Symp. Quant. Biol. 2011;76:325&#x2013;334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22262476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, et al. Glioblastoma therapy can be augmented by targeting IDH1-mediated NADPH biosynthesis. Cancer Res. 2017;77:960&#x2013;970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5726266</ArticleId>
            <ArticleId IdType="pubmed">27923831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of a-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. U. S. A. 2011;108:19611&#x2013;19616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241793</ArticleId>
            <ArticleId IdType="pubmed">22106302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf FW, Marks RM, Sarma V, Byers MG, Katz RW, Shows TB, Dixit VM. Characterization of a novel tumor necrosis factor-alpha-induced endothelial primary response gene. J. Biol. Chem. 1992;267:1317&#x2013;1326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1370465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656&#x2013;670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3472002</ArticleId>
            <ArticleId IdType="pubmed">22541435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Guo Z, Hu R, He X, Jiao X, Zhu X. Interaction between microRNA-181a and TNFAIP1 regulates pancreatic cancer proliferation and migration. Tumour Biol. 2015;36:9693&#x2013;9701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26152285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455:1129&#x2013;1133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4051433</ArticleId>
            <ArticleId IdType="pubmed">18948956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou C, Li X, Zhang X, Liu X, Tan Z, Yang C, Zhang J. microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NF&#x3ba;B signaling in human gastric carcinoma cells. Int. J. Oncol. 2013;42:635&#x2013;642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23242208</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28543431</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>233</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular physiology</Title>
          <ISOAbbreviation>J Cell Physiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of substrate stiffness on cancer cell volume homeostasis.</ArticleTitle>
        <Pagination>
          <StartPage>1414</StartPage>
          <EndPage>1423</EndPage>
          <MedlinePgn>1414-1423</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcp.26026</ELocationID>
        <Abstract>
          <AbstractText>Existing studies on the mechanism of cell volume regulation are mainly relevant to ion channels and osmosis in extracellular fluid. Recently, accumulating evidence has shown that cellular mechanical microenvironment also influences the cell volume. Herein, we investigated the regulation of substrate stiffness on the cell volume homeostasis of MCF-7 cells and their following migration behaviors. We found that cell volume increases with increasing substrate stiffness, which could be affected by blocking the cell membrane anion permeability and dopamine receptor. In addition, the cell migration is significantly inhibited by decreasing the cell volume using tamoxifen and such inhibition effect on migration is enhanced by increasing substrate stiffness. The cell membrane anion permeability might be the linker between cellular mechanical microenvironment and cellular volume homeostasis regulation. This work revealed the regulation of substrate stiffness on cell volume homeostasis for the first time, which would provide a new perspective into the understanding of cancer metastasis and a promising anti-cancer therapy through regulation of cell volume homeostasis.</AbstractText>
          <CopyrightInformation>&#xa9; 2017 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chai</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Xijing Hospital, Forth Military Medical University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sha</LastName>
            <ForeName>Baoyong</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Science, Xi'an Medical University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Manyun</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, School of Science, Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhuang</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical Engineering, Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0003-4351-0222</Identifier>
            <AffiliationInfo>
              <Affiliation>The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, School of Science, Xi'an Jiaotong University, Xi'an, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>06</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Cell Physiol</MedlineTA>
        <NlmUniqueID>0050222</NlmUniqueID>
        <ISSNLinking>0021-9541</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000180">Acrylic Resins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027321">Anion Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C583260">DRD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020100">Hydrogels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007038">Hypotonic Solutions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C534628">SCH 23390</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9003-05-8</RegistryNumber>
          <NameOfSubstance UI="C016679">polyacrylamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-34-5</RegistryNumber>
          <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q1O6DSW23R</RegistryNumber>
          <NameOfSubstance UI="D017878">4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017878" MajorTopicYN="N">4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000180" MajorTopicYN="N">Acrylic Resins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027321" MajorTopicYN="N">Anion Transport Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002463" MajorTopicYN="N">Cell Membrane Permeability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048429" MajorTopicYN="Y">Cell Size</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020100" MajorTopicYN="N">Hydrogels</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007038" MajorTopicYN="N">Hypotonic Solutions</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064587" MajorTopicYN="Y">Osmoregulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MCF-7 cell</Keyword>
        <Keyword MajorTopicYN="N">cell migration</Keyword>
        <Keyword MajorTopicYN="N">cell volume</Keyword>
        <Keyword MajorTopicYN="N">cellular mechanical microenvironment</Keyword>
        <Keyword MajorTopicYN="N">substrate stiffness</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28543431</ArticleId>
        <ArticleId IdType="doi">10.1002/jcp.26026</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28088625</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>104</Volume>
            <PubDate>
              <Year>2017</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Free radical biology &amp; medicine</Title>
          <ISOAbbreviation>Free Radic Biol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Absence of DJ-1 causes age-related retinal abnormalities in association with increased oxidative stress.</ArticleTitle>
        <Pagination>
          <StartPage>226</StartPage>
          <EndPage>237</EndPage>
          <MedlinePgn>226-237</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.freeradbiomed.2017.01.018</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0891-5849(17)30027-8</ELocationID>
        <Abstract>
          <AbstractText>Oxidative stress alters physiological function in most biological tissues and can lead to cell death. In the retina, oxidative stress initiates a cascade of events leading to focal loss of RPE and photoreceptors, which is thought to be a major contributing factor to geographic atrophy. Despite these implications, the molecular regulation of RPE oxidative stress under normal and pathological conditions remains largely unknown. A better understanding of the mechanisms involved in regulating RPE and photoreceptors oxidative stress response is greatly needed. To this end we evaluated photoreceptor and RPE changes in mice deficient in DJ-1, a protein that is thought to be important in protecting cells from oxidative stress. Young (3 months) and aged (18 months) DJ-1 knockout (DJ-1 KO) and age-matched wild-type mice were examined. In both group of aged mice, scanning laser ophthalmoscopy (SLO) showed the presence of a few autofluorescent foci. The 18 month-old DJ-1 KO retinas were also characterized by a noticeable increase in RPE fluorescence to wild-type. Optical coherence tomography (OCT) imaging demonstrated that all retinal layers were present in the eyes of both DJ-1 KO groups. ERG comparisons showed that older DJ-1 KO mice had reduced sensitivity under dark- and light-adapted conditions compared to age-matched control. Histologically, the RPE contained prominent vacuoles in young DJ-1 KO group with the appearance of enlarged irregularly shaped RPE cells in the older group. These were also evident in OCT and in whole mount RPE/choroid preparations labeled with phalloidin. Photoreceptors in the older DJ-1 KO mice displayed decreased immunoreactivity to rhodopsin and localized reduction in cone markers compared to the wild-type control group. Lower levels of activated Nrf2 were evident in retina/RPE lysates in both young and old DJ-1 KO mouse groups compared to wild-type control levels. Conversely, higher levels of protein carbonyl derivatives and iNOS immunoreactivity were detected in retina/RPE lysates from both young and old DJ-1 KO mice. These results demonstrate that DJ-1 KO mice display progressive signs of retinal/RPE degeneration in association with higher levels of oxidative stress markers. Collectively this analysis indicates that DJ-1 plays an important role in protecting photoreceptors and RPE from oxidative damage during aging.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bonilha</LastName>
            <ForeName>Vera L</ForeName>
            <Initials>VL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH 44195, USA; Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: bonilhav@ccf.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bell</LastName>
            <ForeName>Brent A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rayborn</LastName>
            <ForeName>Mary E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Samuels</LastName>
            <ForeName>Ivy S</ForeName>
            <Initials>IS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Research Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>King</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hollyfield</LastName>
            <ForeName>Joe G</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH 44195, USA; Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Chengsong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Huaibin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>I01 BX002754</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 EY025585</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>01</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Free Radic Biol Med</MedlineTA>
        <NlmUniqueID>8709159</NlmUniqueID>
        <ISSNLinking>0891-5849</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9009-81-8</RegistryNumber>
          <NameOfSubstance UI="D012243">Rhodopsin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.2.-</RegistryNumber>
          <NameOfSubstance UI="C503466">PARK7 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.2.-</RegistryNumber>
          <NameOfSubstance UI="D000071617">Protein Deglycase DJ-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020419" MajorTopicYN="N">Photoreceptor Cells, Vertebrate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071617" MajorTopicYN="N">Protein Deglycase DJ-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012162" MajorTopicYN="N">Retinal Degeneration</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012243" MajorTopicYN="N">Rhodopsin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aging</Keyword>
        <Keyword MajorTopicYN="N">DJ-1 knockout</Keyword>
        <Keyword MajorTopicYN="N">Histology</Keyword>
        <Keyword MajorTopicYN="N">Immunohistology</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">Photoreceptors</Keyword>
        <Keyword MajorTopicYN="N">Physiology</Keyword>
        <Keyword MajorTopicYN="N">Retina</Keyword>
        <Keyword MajorTopicYN="N">Retinal degeneration</Keyword>
        <Keyword MajorTopicYN="N">Retinal pigment epithelium</Keyword>
        <Keyword MajorTopicYN="N">Vacuoles</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest. None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28088625</ArticleId>
        <ArticleId IdType="mid">NIHMS845483</ArticleId>
        <ArticleId IdType="pmc">PMC5328840</ArticleId>
        <ArticleId IdType="doi">10.1016/j.freeradbiomed.2017.01.018</ArticleId>
        <ArticleId IdType="pii">S0891-5849(17)30027-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bandopadhyay R, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson&#x2019;s disease. Brain. 2004;127(Pt 2):420&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14662519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem. 2006;281(16):10816&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1850953</ArticleId>
            <ArticleId IdType="pubmed">16517609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Z, et al. Disassembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson&#x2019;s disease patients. Mol Neurodegener. 2009;4:30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2722623</ArticleId>
            <ArticleId IdType="pubmed">19604362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lev N, et al. DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. J Mol Neurosci. 2009;38(2):94&#x2013;102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18712292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sajjad MU, et al. DJ-1 modulates aggregation and pathogenesis in models of Huntington&#x2019;s disease. Hum Mol Genet. 2014;23(3):755&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24070869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonifati V, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12446870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulleman JD, et al. Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson&#x2019;s disease. Biochemistry. 2007;46(19):5776&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17451229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abou-Sleiman PM, Healy DG, Wood NW. Causes of Parkinson&#x2019;s disease: genetics of DJ-1. Cell Tissue Res. 2004;318(1):185&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15503154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu X, et al. Age-related changes in the retinal pigment epithelium (RPE) PLoS One. 2012;7(6):e38673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372495</ArticleId>
            <ArticleId IdType="pubmed">22701690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shadrach KG, et al. DJ-1-dependent regulation of oxidative stress in the retinal pigment epithelium (RPE) PLoS One. 2013;8(7):e67983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3699467</ArticleId>
            <ArticleId IdType="pubmed">23844142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonilha VL, et al. Loss of DJ-1 elicits retinal abnormalities, visual dysfunction, and increased oxidative stress in mice. Exp Eye Res. 2015;139:22&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4573318</ArticleId>
            <ArticleId IdType="pubmed">26215528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandran JS, et al. Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis. 2008;29(3):505&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2271119</ArticleId>
            <ArticleId IdType="pubmed">18187333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattapallil MJ, et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci. 2012;53(6):2921&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3376073</ArticleId>
            <ArticleId IdType="pubmed">22447858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curcio CA, et al. Distribution and morphology of human cone photoreceptors stained with anti-blue opsin. J Comp Neurol. 1991;312(4):610&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1722224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell BA, et al. Baseline imaging reveals preexisting retinal abnormalities in mice. Adv Exp Med Biol. 2012;723:459&#x2013;69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22183365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuels IS, et al. Light-evoked responses of the retinal pigment epithelium: changes accompanying photoreceptor loss in the mouse. J Neurophysiol. 2010;104(1):391&#x2013;402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2904221</ArticleId>
            <ArticleId IdType="pubmed">20484527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Peachey NS, Marmorstein AD. Light-evoked responses of the mouse retinal pigment epithelium. J Neurophysiol. 2004;91(3):1134&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2897140</ArticleId>
            <ArticleId IdType="pubmed">14614107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clements CM, et al. DJ-1, a cancer- and Parkinson&#x2019;s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A. 2006;103(41):15091&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1586179</ArticleId>
            <ArticleId IdType="pubmed">17015834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malhotra D, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. 2008;178(6):592&#x2013;604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2542433</ArticleId>
            <ArticleId IdType="pubmed">18556627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan L, Johnson DA, Johnson JA. Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur J Neurosci. 2010;31(6):967&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3305788</ArticleId>
            <ArticleId IdType="pubmed">20377612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madian AG, Regnier FE. Proteomic identification of carbonylated proteins and their oxidation sites. J Proteome Res. 2010;9(8):3766&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3214645</ArticleId>
            <ArticleId IdType="pubmed">20521848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng L, et al. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56(2):337&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17259377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115(4):497&#x2013;503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9109759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherepanoff S, et al. Bruch&#x2019;s membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2010;94(7):918&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19965817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan YF, et al. DJ-1 upregulates anti-oxidant enzymes and attenuates hypoxia/re-oxygenation-induced oxidative stress by activation of the nuclear factor erythroid 2-like 2 signaling pathway. Mol Med Rep. 2015;12(3):4734&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26081287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Nottia M, et al. DJ-1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of PARK7. Clin Genet. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27460976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eltoweissy M, et al. Protein DJ-1 and its anti-oxidative stress function play an important role in renal cell mediated response to profibrotic agents. Mol Biosyst. 2016;12(6):1842&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27109140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsanejad M, et al. DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress. PLoS One. 2014;9(9):e106601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4161380</ArticleId>
            <ArticleId IdType="pubmed">25210784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leibowitz HM, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973&#x2013;1975. Surv Ophthalmol. 1980;24(Suppl):335&#x2013;610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7444756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein R, et al. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36(1):182&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7822146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355(14):1474&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17021323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58(3):353&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16845209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28(1):1&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715284</ArticleId>
            <ArticleId IdType="pubmed">19026761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaarniranta K, et al. Age-related macular degeneration (AMD): Alzheimer&#x2019;s disease in the eye? J Alzheimers Dis. 2011;24(4):615&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21297256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinnunen K, et al. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol. 2012;90(4):299&#x2013;309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22112056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pujol-Lereis LM, et al. Interrelation Between Oxidative Stress and Complement Activation in Models of Age-Related Macular Degeneration. Adv Exp Med Biol. 2016;854:87&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26427398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadziahmetovic M, et al. Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci. 2008;49(6):2728&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2569891</ArticleId>
            <ArticleId IdType="pubmed">18326691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imamura Y, et al. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci U S A. 2006;103(30):11282&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1544079</ArticleId>
            <ArticleId IdType="pubmed">16844785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao H, et al. Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration. Invest Ophthalmol Vis Sci. 2014;55(7):4613&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4112607</ArticleId>
            <ArticleId IdType="pubmed">24985474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujihara M, et al. A human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD. Exp Eye Res. 2009;88(6):1115&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2729121</ArticleId>
            <ArticleId IdType="pubmed">19450445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinton DR, et al. Optic-nerve degeneration in Alzheimer&#x2019;s disease. N Engl J Med. 1986;315(8):485&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3736630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho WL, et al. Investigating degeneration of the retina in young and aged tau P301L mice. Life Sci. 2015;124:16&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25592136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CS, et al. Treadmill Exercise Attenuates Retinal Oxidative Stress in Naturally-Aged Mice: An Immunohistochemical Study. Int J Mol Sci. 2015;16(9):21008&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4613238</ArticleId>
            <ArticleId IdType="pubmed">26404251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuel MA, et al. Age-related alterations in neurons of the mouse retina. J Neurosci. 2011;31(44):16033&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3238393</ArticleId>
            <ArticleId IdType="pubmed">22049445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Archibald NK, et al. The retina in Parkinson&#x2019;s disease. Brain. 2009;132(Pt 5):1128&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19336464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schraermeyer U, et al. Tyrosinase biosynthesis in adult mammalian retinal pigment epithelial cells. Exp Eye Res. 2006;83(2):315&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16579986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodis-Wollner I. The visual system in Parkinson&#x2019;s disease. Res Publ Assoc Res Nerv Ment Dis. 1990;67:297&#x2013;316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2106154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodis-Wollner I. Visual electrophysiology in Parkinson&#x2019;s disease: PERG, VEP and visual P300. Clin Electroencephalogr. 1997;28(3):143&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9241467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodis-Wollner I. Visualizing the next steps in Parkinson disease. Arch Neurol. 2002;59(8):1233&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12164717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodis-Wollner I. Foveal vision is impaired in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2013;19(1):1&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22998939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes J, David AS. Visual hallucinations in Parkinson&#x2019;s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1737396</ArticleId>
            <ArticleId IdType="pubmed">11385004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satue M, et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson&#x2019;s disease patients. Eye (Lond) 2013;27(4):507&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3626016</ArticleId>
            <ArticleId IdType="pubmed">23429414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Martin E, et al. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson&#x2019;s disease. Ophthalmology. 2012;119(10):2161&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22749083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hariri S, et al. Noninvasive imaging of the early effect of sodium iodate toxicity in a rat model of outer retina degeneration with spectral domain optical coherence tomography. J Biomed Opt. 2013;18(2):26017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23396538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunea A, Jeffery G. The ageing photoreceptor. Vis Neurosci. 2007;24(2):151&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17640405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curcio CA, et al. Aging of the human photoreceptor mosaic: evidence for selective vulnerability of rods in central retina. Invest Ophthalmol Vis Sci. 1993;34(12):3278&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8225863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gresh J, et al. Structure-function analysis of rods and cones in juvenile, adult, and aged C57bl/6 and Balb/c mice. Vis Neurosci. 2003;20(2):211&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12916741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams GA, Jacobs GH. Cone-based vision in the aging mouse. Vision Res. 2007;47(15):2037&#x2013;46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2049007</ArticleId>
            <ArticleId IdType="pubmed">17509638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunea A, Powner MB, Jeffery G. Death by color: differential cone loss in the aging mouse retina. Neurobiol Aging. 2014;35(11):2584&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24929970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perkins GA, Ellisman MH, Fox DA. Three-dimensional analysis of mouse rod and cone mitochondrial cristae architecture: bioenergetic and functional implications. Mol Vis. 2003;9:60&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12632036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canet-Aviles RM, et al. The Parkinson&#x2019;s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A. 2004;101(24):9103&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC428480</ArticleId>
            <ArticleId IdType="pubmed">15181200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Junn E, et al. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res. 2009;87(1):123&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752655</ArticleId>
            <ArticleId IdType="pubmed">18711745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ambati J, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 2003;9(11):1390&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14566334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu L, et al. The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet. 2007;16(20):2411&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17666404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Justilien V, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci. 2007;48(10):4407&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6549721</ArticleId>
            <ArticleId IdType="pubmed">17898259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marmorstein LY, et al. Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration. Hum Mol Genet. 2007;16(20):2423&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17664227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, et al. Age-related retinopathy in NRF2-deficient mice. PLoS One. 2011;6(4):e19456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084871</ArticleId>
            <ArticleId IdType="pubmed">21559389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perusek L, et al. Di-retinoid-pyridinium-ethanolamine (A2E) Accumulation and the Maintenance of the Visual Cycle Are Independent of Atg7-mediated Autophagy in the Retinal Pigmented Epithelium. J Biol Chem. 2015;290(48):29035&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4661415</ArticleId>
            <ArticleId IdType="pubmed">26468292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyzogubov VV, et al. The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously Develops Dry-Type Age-Related Macular Degeneration-Like Phenotype. Am J Pathol. 2016;186(8):2088&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4973660</ArticleId>
            <ArticleId IdType="pubmed">27295359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malek G, et al. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci U S A. 2005;102(33):11900&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1187976</ArticleId>
            <ArticleId IdType="pubmed">16079201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollyfield JG, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 2008;14(2):194&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2748836</ArticleId>
            <ArticleId IdType="pubmed">18223656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, et al. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE. Invest Ophthalmol Vis Sci. 2008;49(4):1671&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716058</ArticleId>
            <ArticleId IdType="pubmed">18385090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha KN, et al. Increased glutathione synthesis through an ARE-Nrf2-dependent pathway by zinc in the RPE: implication for protection against oxidative stress. Invest Ophthalmol Vis Sci. 2006;47(6):2709&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16723490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stadtman ER. Protein oxidation in aging and age-related diseases. Ann N Y Acad Sci. 2001;928:22&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11795513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baraibar MA, et al. Protein oxidative damage at the crossroads of cellular senescence, aging, and age-related diseases. Oxid Med Cell Longev. 2012;2012:919832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3483731</ArticleId>
            <ArticleId IdType="pubmed">23125894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baraibar MA, Ladouce R, Friguet B. Proteomic quantification and identification of carbonylated proteins upon oxidative stress and during cellular aging. J Proteomics. 2013;92:63&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23689083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiou GC. Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther. 2001;17(2):189&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11324986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res. 2007;26(3):205&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17337232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piehl L, et al. Nitric oxide increases in the rat retina after continuous illumination. Brain Res. 2007;1156:112&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17499222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmo A, et al. Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. Nitric Oxide. 2000;4(6):590&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11139367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du Y, et al. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem. 2002;80(5):771&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11948240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leal EC, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48(11):5257&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17962481</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27556694</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>38</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Sep</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase.</ArticleTitle>
        <Pagination>
          <StartPage>62144</StartPage>
          <EndPage>62158</EndPage>
          <MedlinePgn>62144-62158</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.11394</ELocationID>
        <Abstract>
          <AbstractText>Breast cancer is the most common type of cancer affecting women. Despite the good prognosis when detected early, significant challenges remain in the treatment of metastatic breast cancer. The recruitment of the vacuolar H+-ATPase (V-H+-ATPase) to the plasma membrane, where it mediates the acidification of the tumor microenvironment (TME), is a recognized feature involved in the acquisition of a metastatic phenotype in breast cancer. Therefore, inhibitors of this pump have emerged as promising anticancer drugs. Lactoferrin (Lf) is a natural pro-apoptotic iron-binding glycoprotein with strong anticancer activity whose mechanism of action is not fully understood. Here, we show that bovine Lf (bLf) preferentially induces apoptosis in the highly metastatic breast cancer cell lines Hs 578T and MDA-MB-231, which display a prominent localisation of V-H+-ATPase at the plasma membrane, but not in the lowly metastatic T-47D or in the non-tumorigenic MCF-10-2A cell lines. We also demonstrate that bLf decreases the extracellular acidification rate and causes intracellular acidification in metastatic breast cancer cells and, much like the well-known proton pump inhibitors concanamycin A and bafilomycin A1, inhibits V-H+-ATPase in sub-cellular fractions. These data further support that bLf targets V-H+-ATPase and explain the selectivity of bLf for cancer cells, especially for highly metastatic breast cancer cells. Altogether, our results pave the way for more rational in vivo studies aiming to explore this natural non-toxic compound for metastatic breast cancer therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pereira</LastName>
            <ForeName>Cátia S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre of Biological Engineering (CEB), Department of Biological Engineering, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guedes</LastName>
            <ForeName>Joana P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre of Biological Engineering (CEB), Department of Biological Engineering, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonçalves</LastName>
            <ForeName>Marília</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loureiro</LastName>
            <ForeName>Luís</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castro</LastName>
            <ForeName>Lisandra</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gerós</LastName>
            <ForeName>Hernâni</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodrigues</LastName>
            <ForeName>Lígia R</ForeName>
            <Initials>LR</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Biological Engineering (CEB), Department of Biological Engineering, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Côrte-Real</LastName>
            <ForeName>Manuela</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Braga, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80890-47-7</RegistryNumber>
          <NameOfSubstance UI="C036978">concanamycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>88899-55-2</RegistryNumber>
          <NameOfSubstance UI="C040929">bafilomycin A1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D007781">Lactoferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007781" MajorTopicYN="N">Lactoferrin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025262" MajorTopicYN="N">Vacuolar Proton-Translocating ATPases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">V-H+-ATPase</Keyword>
        <Keyword MajorTopicYN="N">V-H+-ATPase inhibitor</Keyword>
        <Keyword MajorTopicYN="N">breast cancer</Keyword>
        <Keyword MajorTopicYN="N">extracellular acidification rate</Keyword>
        <Keyword MajorTopicYN="N">lactoferrin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27556694</ArticleId>
        <ArticleId IdType="pmc">PMC5308717</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.11394</ArticleId>
        <ArticleId IdType="pii">11394</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jin X, Mu P. Targeting Breast Cancer Metastasis. Breast Cancer Basic Clin Res. 2015;9:23&#x2013;34. doi: 10.4137/BCBCR.S25460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/BCBCR.S25460</ArticleId>
            <ArticleId IdType="pmc">PMC4559199</ArticleId>
            <ArticleId IdType="pubmed">26380552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendes TFS, Kluskens LD, Rodrigues LR. Triple Negative Breast Cancer: Nanosolutions for a Big Challenge. Adv Sci. 2015;2:1&#x2013;14. doi: 10.1002/advs.201500053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/advs.201500053</ArticleId>
            <ArticleId IdType="pmc">PMC5115335</ArticleId>
            <ArticleId IdType="pubmed">27980912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng S, Cai M, Liu P, Wei L, Wang J, Qi J, Deng L. Atp6v1c1 may regulate filament actin arrangement in breast cancer cells. PLoS One. 2014;9:e84833. doi: 10.1371/journal.pone.0084833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0084833</ArticleId>
            <ArticleId IdType="pmc">PMC3893128</ArticleId>
            <ArticleId IdType="pubmed">24454753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capecci J, Forgac M. The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells. J Biol Chem. 2013;288:32731&#x2013;41. doi: 10.1074/jbc.M113.503771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.503771</ArticleId>
            <ArticleId IdType="pmc">PMC3820907</ArticleId>
            <ArticleId IdType="pubmed">24072707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, Jay D, Martinez-Zaguilan R, Forgac M. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem. 2009;284:16400&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2713521</ArticleId>
            <ArticleId IdType="pubmed">19366680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salyer SA, Olberding JR, Distler A a, Lederer ED, Clark BJ, Delamere NA, Khundmiri SJ. Vacuolar ATPase driven potassium transport in highly metastatic breast cancer cells. Biochim Biophys Acta. 2013;1832:1734&#x2013;43. doi: 10.1016/j.bbadis.2013.04.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2013.04.023</ArticleId>
            <ArticleId IdType="pubmed">23639630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sennoune SR, Bakunts K, Mart&#xed;nez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Mart&#xed;nez-Zaguil&#xe1;n R. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004;286:C1443&#x2013;52. doi: 10.1152/ajpcell.00407.2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00407.2003</ArticleId>
            <ArticleId IdType="pubmed">14761893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>P&#xe9;rez-Say&#xe1;ns M, Somoza-Mart&#xed;n JM, Barros-Angueira F, Rey JMG, Garc&#xed;a-Garc&#xed;a A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev. 2009;35:707&#x2013;13. doi: 10.1016/j.ctrv.2009.08.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2009.08.003</ArticleId>
            <ArticleId IdType="pubmed">19758758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, Garc&#xec;a AG, Harguindey S, Fais S. Proton channels and exchangers in cancer. Biochim Biophys Acta. 2015;1848:2715&#x2013;26. doi: 10.1016/j.bbamem.2014.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2014.10.015</ArticleId>
            <ArticleId IdType="pubmed">25449995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JINWOO, Hayakawa Y, Beutler JA, Mckee TC, Bowman BJ, Bowman EJ. Discovery of a Novel Antitumor Benzolactone Enamide Class That Selectively Inhibits Mammalian Vacuolar-Type (H+)-ATPases. J Pharmacol Exp Ther. 2001;297:114&#x2013;120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11259534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, et al. Antimetastatic Effect of a Small-Molecule Vacuolar H+-ATPase Inhibitor in in Vitro and in Vivo Preclinical Studies. J Pharmacol Exp Ther. 2008;324:15&#x2013;22. doi: 10.1124/jpet.107.128587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.107.128587</ArticleId>
            <ArticleId IdType="pubmed">17909082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, Efferth T, Trauner D, Vollmar AM. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem. 2013;288:1385&#x2013;96. doi: 10.1074/jbc.M112.412007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.412007</ArticleId>
            <ArticleId IdType="pmc">PMC3543021</ArticleId>
            <ArticleId IdType="pubmed">23168408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol. 2009;212:341&#x2013;6. doi: 10.1242/jeb.024067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jeb.024067</ArticleId>
            <ArticleId IdType="pubmed">19151208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonz&#xe1;lez-Ch&#xe1;vez SA, Ar&#xe9;valo-Gallegos S, Rasc&#xf3;n-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009;33:301.e1&#x2013;8. doi: 10.1016/j.ijantimicag.2008.07.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijantimicag.2008.07.020</ArticleId>
            <ArticleId IdType="pubmed">18842395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Li Q, Ou Y, Han Z, Li K, Wang P, Zhou S. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res. 2011;34:987&#x2013;95. doi: 10.1007/s12272-011-0616-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12272-011-0616-z</ArticleId>
            <ArticleId IdType="pubmed">21725820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Li Q, Ou Y, Li K, Han Z, Wang P, Zhou S. Recombination adenovirus-mediated human lactoferrin cDNA inhibits the growth of human MCF-7 breast cancer cells. J Pharm Pharmacol. 2012;64:457&#x2013;63. doi: 10.1111/j.2042-7158.2011.01410.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2042-7158.2011.01410.x</ArticleId>
            <ArticleId IdType="pubmed">22309278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu XX, Jiang HR, Li HB, Zhang TN, Zhou Q, Liu N. Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J Dairy Sci. 2010;93:2344&#x2013;50. doi: 10.3168/jds.2009-2926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3168/jds.2009-2926</ArticleId>
            <ArticleId IdType="pubmed">20494139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Lima CF, Rodrigues LR. In vitro evaluation of bovine lactoferrin potential as an anticancer agent. Int Dairy J. 2015;40:6&#x2013;15. doi: 10.1016/j.idairyj.2014.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.idairyj.2014.08.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H. Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis. 2004;25:1961&#x2013;6. doi: 10.1093/carcin/bgh205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgh205</ArticleId>
            <ArticleId IdType="pubmed">15192017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D, Sakashita S, Morishita Y, Kano J. Binding of Lactoferrin to IGBP1 Triggers Apoptosis in a Lung Adenocarcinoma Cell Line. Anticancer Res. 2011;534:529&#x2013;534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21378334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Won S, Pyo C, Yoo N, Kim J, Choi S. Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie. 2009;91:102&#x2013;108. doi: 10.1016/j.biochi.2008.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2008.05.004</ArticleId>
            <ArticleId IdType="pubmed">18534198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh S-M, Pyo C-W, Kim Y, Choi S-Y. Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. Oncogene. 2004;23:8282&#x2013;91. doi: 10.1038/sj.onc.1208021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1208021</ArticleId>
            <ArticleId IdType="pubmed">15378004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoedt E, Chaoui K, Huvent I, Mariller C, Monsarrat B, Burlet-schiltz O, Pierce A. SILAC-Based Proteomic Profiling of the Human MDA-MB- 231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms : The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin. PLoS One. 2014;9:e104563. doi: 10.1371/journal.pone.0104563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104563</ArticleId>
            <ArticleId IdType="pmc">PMC4130549</ArticleId>
            <ArticleId IdType="pubmed">25116916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibbons JA, Kanwar JR, Kanwar RK. Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer. 2015;15:425. doi: 10.1186/s12885-015-1441-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-015-1441-4</ArticleId>
            <ArticleId IdType="pmc">PMC4440599</ArticleId>
            <ArticleId IdType="pubmed">25998617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brock JH. Lactoferrin-50 years on. Biochem Cell Biol. 2012;90:245&#x2013;51. doi: 10.1139/o2012-018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/o2012-018</ArticleId>
            <ArticleId IdType="pubmed">22574842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duarte DC, Nicolau A, Teixeira JA, Rodrigues LR. The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci. 2011;94:66&#x2013;76. doi: 10.3168/jds.2010-3629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3168/jds.2010-3629</ArticleId>
            <ArticleId IdType="pubmed">21183018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozkan P, Mutharasan R. A rapid method for measuring intracellular pH using BCECF-AM. Biochim Biophys Acta - Gen Subj. 2002;1572:143&#x2013;148. doi: 10.1016/S0304-4165(02)00303-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-4165(02)00303-3</ArticleId>
            <ArticleId IdType="pubmed">12204343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai K, Shimayasg A, Hiratanill N, Ohkumaji S. Purification and Characterization of Lysosomal H+-ATPase. J Biol Chem. 1993;268:5649&#x2013;5660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8449928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakano M, Imamura H, Toei M, Tamakoshi M, Yoshida M, Yokoyama K. ATP hydrolysis and synthesis of a rotary motor V-ATPase from Thermus thermophilus. J Biol Chem. 2008;283:20789&#x2013;96. doi: 10.1074/jbc.M801276200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M801276200</ArticleId>
            <ArticleId IdType="pmc">PMC3258951</ArticleId>
            <ArticleId IdType="pubmed">18492667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda M, Suno-Ikeda C, Shimabukuro K, Yoshida M, Yokoyama K. Mechanism of inhibition of the V-type molecular motor by tributyltin chloride. Biophys J. 2009;96:1210&#x2013;7. doi: 10.1016/j.bpj.2008.10.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpj.2008.10.031</ArticleId>
            <ArticleId IdType="pmc">PMC2716569</ArticleId>
            <ArticleId IdType="pubmed">19186155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowman EJ, Graham LA, Stevens TH, Bowman BJ. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae. J Biol Chem. 2004;279:33131&#x2013;8. doi: 10.1074/jbc.M404638200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M404638200</ArticleId>
            <ArticleId IdType="pubmed">15180988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept : 100 years of progress. Nat Rev Cancer. 2008;8:473&#x2013;480. doi: 10.1038/nrc2394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2394</ArticleId>
            <ArticleId IdType="pubmed">18469827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008;113:72&#x2013;7. doi: 10.1002/cncr.23519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.23519</ArticleId>
            <ArticleId IdType="pubmed">18484647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes TG, Falchook GS, Varadhachary A. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. Invest New Drugs. 2010;28:156&#x2013;62. doi: 10.1007/s10637-009-9233-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-009-9233-9</ArticleId>
            <ArticleId IdType="pubmed">19238327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oguchi S, Walker WA, Sanderson IR. Iron saturation alters the effect of lactoferrin on the proliferation and differentiation of human enterocytes (Caco-2 Cells) Biol Neonate. 1995;67:330&#x2013;339. doi: 10.1159/000244182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000244182</ArticleId>
            <ArticleId IdType="pubmed">7662812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel V, Licon-Munoz Y, Trujillo K, Bisoffi M, Parra KJ. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int J Cancer. 2013;132:E1&#x2013;10. doi: 10.1002/ijc.27811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.27811</ArticleId>
            <ArticleId IdType="pmc">PMC3504192</ArticleId>
            <ArticleId IdType="pubmed">22945374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, M&#xfc;ller R, Wagner E, Vollmar AM. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther. 2014;13:926&#x2013;37. doi: 10.1158/1535-7163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163</ArticleId>
            <ArticleId IdType="pubmed">24482380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, Wagner E, M&#xfc;ller R, et al. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res. 2012;72:5976&#x2013;87. doi: 10.1158/0008-5472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472</ArticleId>
            <ArticleId IdType="pubmed">22986742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, Capaccioli S. Natural compounds for cancer treatment and prevention. Pharmacol Res. 2009;59:365&#x2013;78. doi: 10.1016/j.phrs.2009.01.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2009.01.017</ArticleId>
            <ArticleId IdType="pubmed">19429468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T, Iwatsuki K. Twenty-five years of research on bovine lactoferrin applications. Biochimie. 2009;91:52&#x2013;7. doi: 10.1016/j.biochi.2008.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2008.05.021</ArticleId>
            <ArticleId IdType="pubmed">18585434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Jiang R, Przepiorski A, Reddy S, Palmano KP, Krissansen GW. &#x201c;Iron-saturated&#x201d; bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice. BMC Cancer. 2012;12:591. doi: 10.1186/1471-2407-12-591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-12-591</ArticleId>
            <ArticleId IdType="pmc">PMC3539967</ArticleId>
            <ArticleId IdType="pubmed">23231648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13:472&#x2013;82. doi: 10.1016/j.ccr.2008.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.05.005</ArticleId>
            <ArticleId IdType="pubmed">18538731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowry OH, Rosebrough NJ, Farr L, Randall RJ. Protein Measurement with the Folin Phenol Reagent. J Biol Chem. 1951;193:265&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14907713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues J, Silva RD, Noronha H, Pedras A, Ger&#xf3;s H, C&#xf4;rte-Real M. Flow cytometry as a novel tool for structural and functional characterization of isolated yeast vacuoles. Microbiology. 2013;159:848&#x2013;56. doi: 10.1099/mic.0.062570-0. 59:848&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/mic.0.062570-0</ArticleId>
            <ArticleId IdType="pubmed">23449920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vera-Estrella R, Barkla BJ, Higgins J, Blumwald E. Plant Defense Response to Fungal Pathogens. Plant Physiol. 1994;104:209&#x2013;215. http://dx.doi.org/10.1104/pp.104.1.209</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1104/pp.104.1.209</ArticleId>
            <ArticleId IdType="pmc">PMC159179</ArticleId>
            <ArticleId IdType="pubmed">12232073</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27228477</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1543-8392</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jul</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular pharmaceutics</Title>
          <ISOAbbreviation>Mol Pharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip.</ArticleTitle>
        <Pagination>
          <StartPage>2214</StartPage>
          <EndPage>2223</EndPage>
          <MedlinePgn>2214-23</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.6b00131</ELocationID>
        <Abstract>
          <AbstractText>Heterogeneous response and resistance of cancer cells to chemotherapeutic drugs pose a significant challenge for successful cancer treatments. In this study, an integrated experimental and theoretical analysis of cellular drug transport was developed. The experimental platform, called tumor-microenvironment-on-chip (T-MOC), is a microfluidic platform where cancer cells were cultured within a three-dimensional extracellular matrix perfused with interstitial fluid. Three types of human breast cancer cell lines (MCF-7, MDA-MB-231, and SUM-159PT) were cultured on this T-MOC platform, and their drug response and resistance to doxorubicin were characterized by time-lapse quantitative fluorescence microscopy. To study the effects of nanoparticle-mediated drug delivery, the transport and action of doxorubicin encapsulated nanoparticles were also examined. Based on the experimental data obtained, a theoretical model was developed to quantify and ultimately predict the cellular transport processes of drugs cell-type specifically. The results demonstrate that the cellular drug transport can be cell-type-specifically quantified by rate constants representing the uptake and efflux of doxorubicin across the cellular membrane.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shin</LastName>
            <ForeName>Kyeonggon</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical Engineering, Purdue University , West Lafayette, Indiana 47907, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klosterhoff</LastName>
            <ForeName>Brett S</ForeName>
            <Initials>BS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical Engineering, Purdue University , West Lafayette, Indiana 47907, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Bumsoo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical Engineering, Purdue University , West Lafayette, Indiana 47907, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Weldon School of Biomedical Engineering, Birck Nanotechnology Center, and Purdue Center for Cancer Research, Purdue University , West Lafayette, Indiana 47907, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HHSN261201400021C</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR000006</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR001108</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>06</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Pharm</MedlineTA>
        <NlmUniqueID>101197791</NlmUniqueID>
        <ISSNLinking>1543-8384</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">breast cancer</Keyword>
        <Keyword MajorTopicYN="N">cellular pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="N">doxorubicin</Keyword>
        <Keyword MajorTopicYN="N">nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">tumor-microenvironment-on-chip</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27228477</ArticleId>
        <ArticleId IdType="mid">NIHMS815583</ArticleId>
        <ArticleId IdType="pmc">PMC5032827</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.molpharmaceut.6b00131</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O&#x2019;Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570&#x2013;575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3349233</ArticleId>
            <ArticleId IdType="pubmed">22460902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108(2):153&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11832206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottesman MM. How Cancer Cells Evade Chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1993;53(4):747&#x2013;754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8094031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clinical Cancer Research. 2008;14(5):1368&#x2013;1376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18316557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JQ, Russo J. ER&#x3b1;-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2009;1796(2):162&#x2013;175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2937358</ArticleId>
            <ArticleId IdType="pubmed">19527773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudis CA, Gianni L. Triple-Negative Breast Cancer: An Unmet Medical Need. The Oncologist. 2011;16(Supplement 1):1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21278435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern pathology. 2006;19(2):264&#x2013;271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16341146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation. 2011;121(7):2750&#x2013;2767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3127435</ArticleId>
            <ArticleId IdType="pubmed">21633166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polyak K. Heterogeneity in breast cancer. Journal of Clinical Investigation. 2011;121:3786&#x2013;3788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195489</ArticleId>
            <ArticleId IdType="pubmed">21965334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 1978;38:3758&#x2013;3763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">698935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heldin CH, Rubin K, Pietras K, &#xd6;stman A. High interstitial fluid pressure &#x2014; an obstacle in cancer therapy. Nature Reviews Cancer. 2004;4:806&#x2013;813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15510161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. Interstitial hypertension in human breast and colorectoral tumors. Cancer Research. 1992;52:6371&#x2013;6374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1423283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tredan O, Galmarini CM, Partel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441&#x2013;1454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17895480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK. Transport of Molecules in the Tumor Interstitium: A review. Cancer Research. 1987;47:3039&#x2013;3051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3555767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozcelikkale A, Ghosh S, Han B. Multifaceted transport characteristics of nanomedicine: Needs for characterization in dynamic environment. Molecular Pharmaceutics. 2013 dx.doi.org/10.1021/mp3005947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp3005947</ArticleId>
            <ArticleId IdType="pubmed">23517188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han B, Qu C, Park K, Konieczny SF, Korc M. Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Letters. 2016 (in press)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4902790</ArticleId>
            <ArticleId IdType="pubmed">26688098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wlodkowic D, Cooper JM. Tumors on chips: oncology meets microfluidics. Curr Opin Chem Biol. 2010;14:556&#x2013;567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20832352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang CP, Lu J, Seon H, Lee AP, Flanagan LA, Kim HY, Putnam AJ, Jeon NL. Engineering microscle cellular niches for three-dimensional multicellular co-cultures. Lab on a Chip. 2009;9:1740&#x2013;1748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3758562</ArticleId>
            <ArticleId IdType="pubmed">19495458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albanese A, Lam AK, Sykes EA, Rocheleau JV, Chan WCW. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nature Communications. 2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3947376</ArticleId>
            <ArticleId IdType="pubmed">24177351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak B, Ozcelikkale A, Shin CS, Park K, Han B. Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip. Journal of Controlled Release. 2014;194:157&#x2013;167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4252353</ArticleId>
            <ArticleId IdType="pubmed">25194778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin CS, Kwak B, Han B, Park K. Development of an in vitro 3D tumor model to study therapeutic efficacy of an anticaner drug. Molecular Pharmaceutics. 2013;10:2167&#x2013;2175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3880422</ArticleId>
            <ArticleId IdType="pubmed">23461341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teo KY, DeHoyos TO, Dutton JC, Grinnell F, Han B. Effects of freezing-induced cell-fluid-matrix interactions on the cells and extracellular matrix of engineered tissues. Biomaterials. 2011;32:5380&#x2013;5390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3119347</ArticleId>
            <ArticleId IdType="pubmed">21549425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sodek KL, Ringuette MJ, Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. International Journal of Cancer. 2009;124(9):2060&#x2013;2070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19132753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevenson MD, Sieminski AL, McLeod CM, Byfield FJ, Barocas VH, Gooch Keith J. Pericellular Conditions Regulate Extent of Cell-Mediated Compaction of Collagen Gels. Biophysical Journal. 2010;99(1):19&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2895394</ArticleId>
            <ArticleId IdType="pubmed">20655829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi KY, Jeon EJ, Yoon HY, Lee BS, Na JH, Min KH, Kim SY, Myung SJ, Lee S, Chen X, Kwon IC, Choi K, Jeong SY, Kim K, Park JH. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials. 2012;33(26):6186&#x2013;6193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3617484</ArticleId>
            <ArticleId IdType="pubmed">22687759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi KY, Saravankumar G, Park JH, Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer. Colloids Surf B. 2012;99:82&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3306773</ArticleId>
            <ArticleId IdType="pubmed">22079699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. British Journal of Cancer. 2004;91(10):1775&#x2013;1781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2410050</ArticleId>
            <ArticleId IdType="pubmed">15477860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eikenberry S. A tumor cord model for Doxorubicin delivery and dose optimization in solid tumors. Theoretical Biology and Medical Modelling. 2009;6(1):16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2736154</ArticleId>
            <ArticleId IdType="pubmed">19664243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Kareh AW, Secomb T. A Mathematical Model for Comparison of Bolus Injection, Continuous Infusion, and Liposomal Delivery of Doxorubicin to Tumor Cells. Neoplasia. 2000;2(4):325&#x2013;338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1550297</ArticleId>
            <ArticleId IdType="pubmed">11005567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Kareh AW, Secomb TW. Two-Mechanism Peak Concentration Model for Cellular Pharmacodynamics of Doxorubicin. Neoplasia. 2005;7(7):705&#x2013;713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1501422</ArticleId>
            <ArticleId IdType="pubmed">16026650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells. Journal of Pharmacology and Experimental Therapeutics. 2008;324(1):95&#x2013;102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17947497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E, Tammi M. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. International Journal of Cancer. 2013;132(3):531&#x2013;539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22753277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24&#x2212; phenotype relates to &#x2018;triple-negative&#x2019; state and unfavorable prognosis in breast cancer patients. Med Oncol. 2011;28:745&#x2013;752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20405247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honeth G, Bendahl PO, Ringn&#xe9;r M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C. The CD44+/CD23&#x2212; phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2481503</ArticleId>
            <ArticleId IdType="pubmed">18559090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH. CD44(+)/CD24(&#x2212;/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol. 2012;43:364&#x2013;373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21835433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010;31(1):106&#x2013;114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19783037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi KY, Yoon HY, Kim JH, Bae SM, Park RW, Kang YM, Kim IS, Kwon IC, Choi K, Jeong SY, Kim K, Park JH. Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy. ACS Nano. 2011;5(11):8591&#x2013;8599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21967065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. Journal of Controlled Release. 2012;164:108&#x2013;114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3833679</ArticleId>
            <ArticleId IdType="pubmed">22800574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19:670&#x2013;686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1462166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN. Anthracyclines in the treatment of cancer: An overview. Drugs. 1997;54(Suppl 4):1&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9361955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gamen S, Anel A, Perez-Galan P, Lasierra P, Johnson D, Pineiro A, Naval J. Doxorubicin treatment activates a Z-VAD-sensitivie caspace, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000;258:223&#x2013;235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10912804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65:157&#x2013;170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23278683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47:219&#x2013;231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2203071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fackler OT, Grosse R. Cell motility through plasam membrane blebbing. J Cell Biol. 2008;181:879&#x2013;884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2426937</ArticleId>
            <ArticleId IdType="pubmed">18541702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mashima T, Naito M, Tsuruo T. Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis. Oncogene. 1999;18:2423&#x2013;2430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10229193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalton WS. The tumor microenvironment: focus on myeloma. Cancer Treatment Reviews. 2003;29:11&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12738239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jean C, Gravelle P, Fournie JJ, Laurent G. Influence of stress on extracellular matrix and integrin biology. Oncogene. 2011;30:2697&#x2013;2706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21339741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiraga T, Ito S, Nakamura H. Cancer stem&#x2013;like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer research. 2013;73(13):4112&#x2013;4122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23633482</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26990160</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1552-5783</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>57</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Investigative ophthalmology &amp; visual science</Title>
          <ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Mitochondrial-Derived Peptide Humanin Protects RPE Cells From Oxidative Stress, Senescence, and Mitochondrial Dysfunction.</ArticleTitle>
        <Pagination>
          <StartPage>1238</StartPage>
          <EndPage>1253</EndPage>
          <MedlinePgn>1238-53</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.15-17053</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the expression of humanin (HN) in human retinal pigment epithelial (hRPE) cells and its effect on oxidative stress-induced cell death, mitochondrial bioenergetics, and senescence.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Humanin localization in RPE cells and polarized RPE monolayers was assessed by confocal microscopy. Human RPE cells were treated with 150 &#x3bc;M tert-Butyl hydroperoxide (tBH) in the absence/presence of HN (0.5-10 &#x3bc;g/mL) for 24 hours. Mitochondrial respiration was measured by XF96 analyzer. Retinal pigment epithelial cell death and caspase-3 activation, mitochondrial biogenesis and senescence were analyzed by TUNEL, immunoblot analysis, mitochondrial DNA copy number, SA-&#x3b2;-Gal staining, and p16INK4a expression and HN levels by ELISA. Oxidative stress-induced changes in transepithelial resistance were studied in RPE monolayers with and without HN cotreatment.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A prominent localization of HN was found in the cytoplasmic and mitochondrial compartments of hRPE. Humanin cotreatment inhibited tBH-induced reactive oxygen species formation and significantly restored mitochondrial bioenergetics in hRPE cells. Exogenous HN was taken up by RPE and colocalized with mitochondria. The oxidative stress-induced decrease in mitochondrial bioenergetics was prevented by HN cotreatment. Humanin treatment increased mitochondrial DNA copy number and upregulated mitochondrial transcription factor A, a key biogenesis regulator protein. Humanin protected RPE cells from oxidative stress-induced cell death by STAT3 phosphorylation and inhibiting caspase-3 activation. Humanin treatment inhibited oxidant-induced senescence. Polarized RPE demonstrated elevated cellular HN and increased resistance to cell death.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Humanin protected RPE cells against oxidative stress-induced cell death and restored mitochondrial function. Our data suggest a potential role for HN therapy in the prevention of retinal degeneration, including AMD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sreekumar</LastName>
            <ForeName>Parameswaran G</ForeName>
            <Initials>PG</Initials>
            <AffiliationInfo>
              <Affiliation>Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishikawa</LastName>
            <ForeName>Keijiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spee</LastName>
            <ForeName>Chris</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Southern California, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mehta</LastName>
            <ForeName>Hemal H</ForeName>
            <Initials>HH</Initials>
            <AffiliationInfo>
              <Affiliation>USC Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Junxiang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>USC Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yen</LastName>
            <ForeName>Kelvin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>USC Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Pinchas</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>USC Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kannan</LastName>
            <ForeName>Ram</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hinton</LastName>
            <ForeName>David R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Southern California, Los Angeles, California, United States 4Department of Pathology, University of Southern California, Los Angeles, California, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 ES020812</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 GM090311</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1R01AG034430</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>EY01545</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EY001545</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 EY003040</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>EY03040</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1R01ES020812</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1P01AG034906</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 AG034906</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1R01GM090311</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
        <NlmUniqueID>7703701</NlmUniqueID>
        <ISSNLinking>0146-0404</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C427211">humanin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63231-63-0</RegistryNumber>
          <NameOfSubstance UI="D012313">RNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016922" MajorTopicYN="N">Cellular Senescence</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018507" MajorTopicYN="Y">Gene Expression Regulation, Developmental</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26990160</ArticleId>
        <ArticleId IdType="pmc">PMC4811181</ArticleId>
        <ArticleId IdType="doi">10.1167/iovs.15-17053</ArticleId>
        <ArticleId IdType="pii">2505550</ArticleId>
        <ArticleId IdType="sici">iovs-57-02-68</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ambati J,, Ambati BK,, Yoo SH,, Ianchulev S,, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003; 48: 257&#x2013;293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12745003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jong PT. Age-related macular degeneration. N Engl J Med. 2006; 355: 1474&#x2013;1485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17021323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein R,, Klein BE,, Tomany SC,, Meuer SM,, Huang GH. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology. 2002; 109: 1767&#x2013;1779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12359593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding X,, Patel M,, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009; 28: 1&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715284</ArticleId>
            <ArticleId IdType="pubmed">19026761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsunaga H,, Handa JT,, Gelfman CM,, Hjelmeland LM. The mRNA phenotype of a human RPE cell line at replicative senescence. Mol Vis. 1999; 5: 39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10617776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu D,, Wu J,, Spee C,, Ryan SJ,, Hinton DR. BMP4 mediates oxidative stress-induced retinal pigment epithelial cell senescence and is overexpressed in age-related macular degeneration. J Biol Chem. 2009; 284: 9529&#x2013;9539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666605</ArticleId>
            <ArticleId IdType="pubmed">19158083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodier F,, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011; 192: 547&#x2013;556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3044123</ArticleId>
            <ArticleId IdType="pubmed">21321098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozlowski MR. RPE cell senescence: a key contributor to age-related macular degeneration. Med Hypotheses. 2012; 78: 505&#x2013;510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22296808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto Y,, Niikura T,, Tajima H,, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001; 98: 6336&#x2013;6341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC33469</ArticleId>
            <ArticleId IdType="pubmed">11371646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C,, Yen K,, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. 2013; 24: 222&#x2013;228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3641182</ArticleId>
            <ArticleId IdType="pubmed">23402768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yen K,, Lee C,, Mehta H,, Cohen P. The emerging role of the mitochondrial-derived peptide humanin in stress resistance. J Mol Endocrinol. 2013; 50: R11&#x2013;R19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3705736</ArticleId>
            <ArticleId IdType="pubmed">23239898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tajima H,, Niikura T,, Hashimoto Y,, et al. Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett. 2002; 324: 227&#x2013;231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12009529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodzioch M,, Lapicka-Bodzioch K,, Zapala B,, Kamysz W,, Kiec-Wilk B,, Dembinska-Kiec A. Evidence for potential functionality of nuclearly-encoded humanin isoforms. Genomics. 2009; 94: 247&#x2013;256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19477263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo B,, Zhai D,, Cabezas E,, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003; 423: 456&#x2013;461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12732850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paharkova V,, Alvarez G,, Nakamura H,, Cohen P,, Lee KW. Rat Humanin is encoded and translated in mitochondria and is localized to the mitochondrial compartment where it regulates ROS production. Mol Cell Endocrinol. 2015; 413: 96&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26116236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein LE,, Cui L,, Gong Z,, Su K,, Muzumdar R. A humanin analog decreases oxidative stress and preserves mitochondrial integrity in cardiac myoblasts. Biochem Biophys Res Commun. 2013; 440: 197&#x2013;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3853355</ArticleId>
            <ArticleId IdType="pubmed">23985350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kariya S,, Takahashi N,, Ooba N,, Kawahara M,, Nakayama H,, Ueno S. Humanin inhibits cell death of serum-deprived PC12h cells. Neuroreport. 2002; 13: 903&#x2013;907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11997711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachar AR,, Scheffer L,, Schroeder AS,, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res. 2010; 88: 360&#x2013;366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2952532</ArticleId>
            <ArticleId IdType="pubmed">20562421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park TY,, Kim SH,, Shin YC,, et al. Amelioration of neurodegenerative diseases by cell death-induced cytoplasmic delivery of humanin. J Control Release. 2013; 166: 307&#x2013;315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23298615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kin T,, Sugie K,, Hirano M,, Goto Y,, Nishino I,, Ueno S. Humanin expression in skeletal muscles of patients with chronic progressive external ophthalmoplegia. J Hum Genet. 2006; 51: 555&#x2013;558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16639504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D,, Li H,, Yuan H,, et al. Humanin delays apoptosis in K562 cells by downregulation of P38 MAP kinase. Apoptosis. 2005; 10: 963&#x2013;971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16151632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin YP,, Keni J,, Wan J,, et al. Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. Endocrinology. 2013; 154: 3739&#x2013;3744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3776863</ArticleId>
            <ArticleId IdType="pubmed">23836030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuoka M,, Hashimoto Y. Humanin and the receptors for humanin. Mol Neurobiol. 2010; 41: 22&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19997871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikonen M,, Liu B,, Hashimoto Y,, et al. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci U S A. 2003; 100: 13042&#x2013;13047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC240741</ArticleId>
            <ArticleId IdType="pubmed">14561895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto Y,, Kurita M,, Aiso S,, Nishimoto I,, Matsuoka M. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Mol Biol Cell. 2009; 20: 2864&#x2013;2873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2695794</ArticleId>
            <ArticleId IdType="pubmed">19386761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto Y,, Kurita M,, Matsuoka M. Identification of soluble WSX-1 not as a dominant-negative but as an alternative functional subunit of a receptor for an anti-Alzheimer's disease rescue factor Humanin. Biochem Biophys Res Commun. 2009; 389: 95&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19703422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba T,, Yamada M,, Hashimoto Y,, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci. 2005; 25: 10252&#x2013;10261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6725789</ArticleId>
            <ArticleId IdType="pubmed">16267233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto Y,, Suzuki H,, Aiso S,, Niikura T,, Nishimoto I,, Matsuoka M. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life Sci. 2005; 77: 3092&#x2013;3104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16005025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luciano F,, Zhai D,, Zhu X,, et al. Cytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL. J Biol Chem. 2005; 280: 15825&#x2013;15835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15661735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai D,, Luciano F,, Zhu X,, Guo B,, Satterthwait AC,, Reed JC. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J Biol Chem. 2005; 280: 15815&#x2013;15824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15661737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res. 2011; 30: 217&#x2013;238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21440663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sreekumar PG,, Kannan R,, Yaung J,, Spee CK,, Ryan SJ,, Hinton DR. Protection from oxidative stress by methionine sulfoxide reductases in RPE cells. Biochem Biophys Res Commun. 2005; 334: 245&#x2013;253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15993845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonoda S,, Spee C,, Barron E,, Ryan SJ,, Kannan R,, Hinton DR. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. Nat Protoc. 2009; 4: 662&#x2013;6673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2688697</ArticleId>
            <ArticleId IdType="pubmed">19373231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonoda S,, Sreekumar PG,, Kase S,, et al. Attainment of polarity promotes growth factor secretion by retinal pigment epithelial cells: relevance to age-related macular degeneration. Aging (Albany NY). 2009; 2: 28&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2837203</ArticleId>
            <ArticleId IdType="pubmed">20228934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sreekumar PG,, Kannan R,, Kitamura M,, et al. &#x3b1;B crystallin is apically secreted within exosomes by polarized human retinal pigment epithelium and provides neuroprotection to adjacent cells. PLoS One. 2010; 5: e12578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2951891</ArticleId>
            <ArticleId IdType="pubmed">20949024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dranka BP,, Hill BG,, Darley-Usmar VM. Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic Biol Med. 2010; 48: 905&#x2013;914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2860730</ArticleId>
            <ArticleId IdType="pubmed">20093177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell T,, Johnson MS,, Ouyang X,, et al. Dysfunctional mitochondrial bioenergetics and oxidative stress in Akita(+/Ins2)-derived &#x3b2;-cells. Am J Physiol Endocrinol Metab. 2013; 305: E585&#x2013;E99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3761167</ArticleId>
            <ArticleId IdType="pubmed">23820623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y,, Liu H,, Ikeda Y,, et al. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. Stem Cell Res. 2012; 9: 196&#x2013;207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3619384</ArticleId>
            <ArticleId IdType="pubmed">22885101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demidenko ZN,, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008; 7: 3355&#x2013;3361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18948731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu D,, Sreekumar PG,, Hinton DR,, Kannan R. Expression and regulation of enzymes in the ceramide metabolic pathway in human retinal pigment epithelial cells and their relevance to retinal degeneration. Vision Res. 2010; 50: 643&#x2013;651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840213</ArticleId>
            <ArticleId IdType="pubmed">19765607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell CT,, Kolesar JE,, Kaufman BA. Mitochondrial transcription factor A regulates mitochondrial transcription initiation DNA packaging, and genome copy number. Biochim Biophys Acta. 2012; 1819: 921&#x2013;929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22465614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CH,, Wu SB,, Hong CH,, et al. Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers. Am J Pathol. 2011; 178: 2066&#x2013;2076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3081159</ArticleId>
            <ArticleId IdType="pubmed">21514422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoang PT,, Park P,, Cobb LJ,, et al. The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. Metabolism. 2010; 59: 343&#x2013;349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2932671</ArticleId>
            <ArticleId IdType="pubmed">19800083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C,, Wan J,, Miyazaki B,, et al. IGF-I regulates the age-dependent signaling peptide humanin. Aging Cell. 2014; 13: 958&#x2013;961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4172517</ArticleId>
            <ArticleId IdType="pubmed">25040290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogt SD,, Curcio CA,, Wang L,, et al. Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy. Exp Eye Res. 2011; 93: 413&#x2013;423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3202648</ArticleId>
            <ArticleId IdType="pubmed">21684273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muzumdar RH,, Huffman DM,, Calvert JW,, et al. Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol. 2010; 30: 1940&#x2013;1948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2941397</ArticleId>
            <ArticleId IdType="pubmed">20651283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zacharias DG,, Kim SG,, Massat AE,, et al. Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans. PLoS One. 2012; 7: e31065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3273477</ArticleId>
            <ArticleId IdType="pubmed">22328926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia Y,, Lue YH,, Swerdloff R,, et al. The cytoprotective peptide humanin is induced and neutralizes Bax after pro-apoptotic stress in the rat testis. Andrology. 2013; 1: 651&#x2013;659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3696635</ArticleId>
            <ArticleId IdType="pubmed">23686888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eriksson E,, Wickstr&#xf6;m M,, Perup LS,, et al. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment. J Natl Cancer Inst. 2014; 106:djt459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24586107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin H,, Liu T,, Wang WX,, et al. Protective effects of [Gly14]-Humanin on beta-amyloid-induced PC12 cell death by preventing mitochondrial dysfunction. Neurochem Int. 2010; 56: 417&#x2013;423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19941922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kariya S,, Hirano M,, Furiya Y,, Ueno S. Effect of humanin on ATP production: therapeutic candidate for mitochondrial disorders. Ann. Neurol. 2004; 56 (S8): 65.</Citation>
        </Reference>
        <Reference>
          <Citation>Sreekumar PG,, Chothe P,, Sharma KK,, et al. Antiapoptotic properties of &#x3b1;-crystallin-derived peptide chaperones and characterization of their uptake transporters in human RPE cells. Invest Ophthalmol Vis Sci. 2013; 54: 2787&#x2013;2798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3632268</ArticleId>
            <ArticleId IdType="pubmed">23532520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W,, Sreekumar PG,, Valluripalli V,, et al. Protein polymer nanoparticles engineered as chaperones protect against apoptosis in human retinal pigment epithelial cells. J Control Release. 2014; 191: 4&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4222838</ArticleId>
            <ArticleId IdType="pubmed">24780268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg TK,, Chang JY. Oxidative stress causes ERK phosphorylation and cell death in cultured retinal pigment epithelium: prevention of cell death by AG126 and 15-deoxy-delta 12, 14-PGJ2. BMC Ophthalmol. 2003; 3: 5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC153521</ArticleId>
            <ArticleId IdType="pubmed">12659653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byun JY,, Kim MJ,, Eum DY,, et al. Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol. 2009; 76: 734&#x2013;744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19574249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ong SB,, Gustafsson AB. New roles for mitochondria in cell death in the reperfused myocardium. Cardiovasc Res. 2012; 94: 190&#x2013;196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331612</ArticleId>
            <ArticleId IdType="pubmed">22108916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubli DA,, Gustafsson &#xc5;B. Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res. 2012; 111: 1208&#x2013;1221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3538875</ArticleId>
            <ArticleId IdType="pubmed">23065344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda M,, Ide T,, Fujino T,, et al. Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. PLoS One. 2015; 10: e0119687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4379048</ArticleId>
            <ArticleId IdType="pubmed">25822152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J,, Wang Q,, Chen N,, et al. Mitochondrial transcription factor A regulated ionizing radiation-induced mitochondrial biogenesis in human lung adenocarcinoma A549 cells. J Radiat Res. 2013; 54: 998&#x2013;1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3823773</ArticleId>
            <ArticleId IdType="pubmed">23645454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qui&#xf1;ones-Lombra&#xf1;a A,, Blanco JG. Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM). Biochim Biophys Acta. 2015; 1852: 1420&#x2013;1427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4433801</ArticleId>
            <ArticleId IdType="pubmed">25869329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonawitz ND,, Clayton DA,, Shadel GS. Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Mol Cell. 2006; 24: 813&#x2013;825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17189185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kariya S,, Hirano M,, Furiya Y,, Ueno S. Effect of humanin on decreased ATP levels of human lymphocytes harboring A3243G mutant mitochondrial DNA. Neuropeptides. 2005; 39: 97&#x2013;101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15752543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D,, Hilfiker A,, Fuchs M,, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004; 95: 187&#x2013;195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15192020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naylor RM,, Baker DJ,, van Deursen JM. Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin Pharmacol Ther. 2013; 93: 105&#x2013;116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4051295</ArticleId>
            <ArticleId IdType="pubmed">23212104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsunaga H,, Handa JT,, Aotaki-Keen A,, Sherwood SW,, West MD,, Hjelmeland LM. Beta-galactosidase histochemistry and telomere loss in senescent retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999; 40: 197&#x2013;202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9888444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelton DN,, Chang E,, Whittier PS,, Choi D,, Funk WD. Microarray analysis of replicative senescence. Curr Biol. 1999; 9: 939&#x2013;945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10508581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muzumdar RH,, Huffman DM,, Atzmon G,, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009; 4: e6334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2709436</ArticleId>
            <ArticleId IdType="pubmed">19623253</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26707081</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>10</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-244X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular medicine</Title>
          <ISOAbbreviation>Int J Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt.</ArticleTitle>
        <Pagination>
          <StartPage>369</StartPage>
          <EndPage>377</EndPage>
          <MedlinePgn>369-77</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijmm.2015.2441</ELocationID>
        <Abstract>
          <AbstractText>The sensitization of breast cancer stem cells (BrCSCs) to the inhibitive effects of radiotherapy through adjuvant therapy which targets oncogenic pathways represents a prospective strategy for improving the effect of radiation in patients with triple-negative breast cancer (TNBC). Mammalian target of rapamycin (mTOR) activation is one of the most frequent events in human malignancies, and is critical for sustaining the self‑renewing ability of cancer stem cells (CSCs); inhibition by rapamycin is an effective and promising strategy in anticancer treatments. In the present study, we found that mTOR activity was closely related to the self-renewal ability of BrCSCs, and in triple negative MDA-MB-453 and MDA-MB‑468 cells, rapamycin repression of mTOR phosphorylation decreased the number of mammospheres and helped to sensitize the resistant CSCs to low-dose radiation therapy. By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin‑induced asymmetric division (AD) of stem cells in cases of radiation‑treated breast cancer. The synergic effects of rapamycin and low-dose radiation induced the AD of stem cells, which then resulted in a decrease in the number of mammospheres, and both were mediated by MnSOD. Governed by Akt, the consequent inhibition of ROS formation and oxidative stress preserved the AD mode of stem cells, which is critical for an improved radiotherapy response in clinical treatment, as the tumor group is thus easier to eliminate with radiation therapy. We posit that an in-depth understanding of the interaction of radiation with CSCs has enormous potential and will make radiation even better and more effective.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Yuanhui</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510700, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Xinpei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Infection and Organ Function Support Laboratory, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong 510010, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Xiaohong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510700, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Shanyang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510700, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Int J Mol Med</MedlineTA>
        <NlmUniqueID>9810955</NlmUniqueID>
        <ISSNLinking>1107-3756</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060049" MajorTopicYN="N">Asymmetric Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011827" MajorTopicYN="N">Radiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26707081</ArticleId>
        <ArticleId IdType="pmc">PMC4716789</ArticleId>
        <ArticleId IdType="doi">10.3892/ijmm.2015.2441</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kanavos P. The rising burden of cancer in the developing world. Ann Oncol Suppl. 8:viii15&#x2013;viii23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16801335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Qin S, Fan C, Xu C, Du N, Ren H. Let-7: A regulator of the ER&#x3b1; signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep. 2013;29:2079&#x2013;2087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23467929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2&#x2013;S8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3695538</ArticleId>
            <ArticleId IdType="pubmed">23819024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21:185&#x2013;191. doi: 10.1038/mt.2012.180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2012.180</ArticleId>
            <ArticleId IdType="pmc">PMC3538304</ArticleId>
            <ArticleId IdType="pubmed">23032975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Y, Hu J, Shen Z, Yao R, Liu S, Li Y, Cong H, Wang X, Qiu W, Yue L. MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J Cell Mol Med. 2015;19:760&#x2013;769. doi: 10.1111/jcmm.12432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12432</ArticleId>
            <ArticleId IdType="pmc">PMC4395190</ArticleId>
            <ArticleId IdType="pubmed">25639535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu FJ, Wang XB, Cao AG. Screening and functional analysis of a differential protein profile of human breast cancer. Oncol Lett. 2014;7:1851&#x2013;1856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049688</ArticleId>
            <ArticleId IdType="pubmed">24932247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, Gutkind JS. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell. 2012;11:401&#x2013;414. doi: 10.1016/j.stem.2012.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2012.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC3477550</ArticleId>
            <ArticleId IdType="pubmed">22958932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009;5:279&#x2013;289. doi: 10.1016/j.stem.2009.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2009.06.017</ArticleId>
            <ArticleId IdType="pmc">PMC2939833</ArticleId>
            <ArticleId IdType="pubmed">19733540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem. 2011;18:2715&#x2013;2726. doi: 10.2174/092986711796011201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/092986711796011201</ArticleId>
            <ArticleId IdType="pubmed">21649579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubara S, Ding Q, Miyazaki Y, Kuwahata T, Tsukasa K, Takao S. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep. 2013;3:3230. doi: 10.1038/srep03230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep03230</ArticleId>
            <ArticleId IdType="pmc">PMC3828572</ArticleId>
            <ArticleId IdType="pubmed">24231729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E, Ren H, Pestell RG. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene. 2014;33:4967&#x2013;4977. doi: 10.1038/onc.2013.492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2013.492</ArticleId>
            <ArticleId IdType="pubmed">24240682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart PC, Mao M, de Abreu ALP, Ansenberger-Fricano K, Ekoue DN, Ganini D, Kajdacsy-Balla A, Diamond AM, Minshall RD, Consolaro ME, et al. MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Nat Commun. 2015;6:6053. doi: 10.1038/ncomms7053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7053</ArticleId>
            <ArticleId IdType="pmc">PMC4319569</ArticleId>
            <ArticleId IdType="pubmed">25651975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhar SK, Tangpong J, Chaiswing L, Oberley TD, St Clair DK. Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stages. Cancer Res. 2011;71:6684&#x2013;6695. doi: 10.1158/0008-5472.CAN-11-1233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1233</ArticleId>
            <ArticleId IdType="pmc">PMC3206134</ArticleId>
            <ArticleId IdType="pubmed">22009531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA. 2013;110:972&#x2013;977. doi: 10.1073/pnas.1221055110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1221055110</ArticleId>
            <ArticleId IdType="pmc">PMC3549132</ArticleId>
            <ArticleId IdType="pubmed">23277563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupaimoole R, Han HD, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011;30:368&#x2013;370. doi: 10.5732/cjc.011.10186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5732/cjc.011.10186</ArticleId>
            <ArticleId IdType="pmc">PMC4013410</ArticleId>
            <ArticleId IdType="pubmed">21627858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756&#x2013;760. doi: 10.1038/nature05236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05236</ArticleId>
            <ArticleId IdType="pubmed">17051156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips TM, McBride WH, Pajonk F. The response of CD24&#x2212;/low/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777&#x2013;1785. doi: 10.1093/jnci/djj495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djj495</ArticleId>
            <ArticleId IdType="pubmed">17179479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA. 2007;104:618&#x2013;623. doi: 10.1073/pnas.0606599104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0606599104</ArticleId>
            <ArticleId IdType="pmc">PMC1766434</ArticleId>
            <ArticleId IdType="pubmed">17202265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zielske SP, Spalding AC, Wicha MS, Lawrence TS. Ablation of breast cancer stem cells with radiation. Transl Oncol. 2011;4:227&#x2013;233. doi: 10.1593/tlo.10247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/tlo.10247</ArticleId>
            <ArticleId IdType="pmc">PMC3140010</ArticleId>
            <ArticleId IdType="pubmed">21804918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780&#x2013;783. doi: 10.1038/nature07733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07733</ArticleId>
            <ArticleId IdType="pmc">PMC2778612</ArticleId>
            <ArticleId IdType="pubmed">19194462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey-Guha I, Wolfer A, Yeh ACG, G Albeck J, Darp R, Leon E, Wulfkuhle J, Petricoin EF, III, Wittner BS, Ramaswamy S. Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci USA. 2011;108:12845&#x2013;12850. doi: 10.1073/pnas.1109632108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1109632108</ArticleId>
            <ArticleId IdType="pmc">PMC3150943</ArticleId>
            <ArticleId IdType="pubmed">21757645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells. 2010;28:639&#x2013;648. doi: 10.1002/stem.318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.318</ArticleId>
            <ArticleId IdType="pmc">PMC2940232</ArticleId>
            <ArticleId IdType="pubmed">20135685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol. 2014;90:615&#x2013;621. doi: 10.3109/09553002.2014.892227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/09553002.2014.892227</ArticleId>
            <ArticleId IdType="pmc">PMC4341971</ArticleId>
            <ArticleId IdType="pubmed">24527669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delort L, Perrier S, Dubois V, Billard H, Mracek T, Bing C, Vasson MP, Caldefie-Ch&#xe9;zet F. Zinc-&#x3b1;2-glycoprotein: a proliferative factor for breast cancer? In vitro study and molecular mechanisms. Oncol Rep. 2013;29:2025&#x2013;2029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23446778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Tang SC, Xu C, Wang C, Qin S, Du N, Liu J, Zhang Y, Li X, Luo G, et al. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1. J Cell Mol Med. 2015;19:1357&#x2013;1365. doi: 10.1111/jcmm.12522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12522</ArticleId>
            <ArticleId IdType="pmc">PMC4459849</ArticleId>
            <ArticleId IdType="pubmed">25702703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveras-Ferraros C, Cuf&#xed; S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, Menendez JA. Micro(mi) RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGF&#x3b2;-induced oncomiR miRNA-181a. Cell Cycle. 2011;10:1144&#x2013;1151. doi: 10.4161/cc.10.7.15210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.10.7.15210</ArticleId>
            <ArticleId IdType="pubmed">21368581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G, Wei J. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer. 2014;13:137. doi: 10.1186/1476-4598-13-137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-13-137</ArticleId>
            <ArticleId IdType="pmc">PMC4057898</ArticleId>
            <ArticleId IdType="pubmed">24889938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henle SJ, Wang G, Liang E, Wu M, Poo MM, Henley JR. Asymmetric PI(3,4,5)P3 and Akt signaling mediates chemotaxis of axonal growth cones. J Neurosci. 2011;31:7016&#x2013;7027. doi: 10.1523/JNEUROSCI.0216-11.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0216-11.2011</ArticleId>
            <ArticleId IdType="pmc">PMC3133771</ArticleId>
            <ArticleId IdType="pubmed">21562263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung CY, Potikyan G, Firtel RA. Control of cell polarity and chemotaxis by Akt/PKB and PI3 kinase through the regulation of PAKa. Mol Cell. 2001;7:937&#x2013;947. doi: 10.1016/S1097-2765(01)00247-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(01)00247-7</ArticleId>
            <ArticleId IdType="pubmed">11389841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32:35&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3532890</ArticleId>
            <ArticleId IdType="pubmed">21778573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzayans R, Andrais B, Scott A, Wang YW, Murray D. Ionizing radiation-induced responses in human cells with differing TP53 status. Int J Mol Sci. 2013;14:22409&#x2013;22435. doi: 10.3390/ijms141122409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms141122409</ArticleId>
            <ArticleId IdType="pmc">PMC3856071</ArticleId>
            <ArticleId IdType="pubmed">24232458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cataldi A, Di Giacomo V, Rapino M, Zara S, Rana RA. Ionizing radiation induces apoptotic signal through protein kinase C&#x3b4; (delta) and survival signal through Akt and cyclic-nucleotide response element-binding protein (CREB) in Jurkat T cells. Biol Bull. 2009;217:202&#x2013;212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19875824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landsverk KS, Lyng H, Stokke T. The response of malignant B lymphocytes to ionizing radiation: cell cycle arrest, apoptosis and protection against the cytotoxic effects of the mitotic inhibitor nocodazole. Radiat Res. 2004;162:405&#x2013;415. doi: 10.1667/RR3235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1667/RR3235</ArticleId>
            <ArticleId IdType="pubmed">15447042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 2010;4:404&#x2013;419. doi: 10.1016/j.molonc.2010.06.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2010.06.005</ArticleId>
            <ArticleId IdType="pmc">PMC3023958</ArticleId>
            <ArticleId IdType="pubmed">20599450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109:2587&#x2013;2596. doi: 10.1038/bjc.2013.642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.642</ArticleId>
            <ArticleId IdType="pmc">PMC3833225</ArticleId>
            <ArticleId IdType="pubmed">24129237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardo Y, Filipovi&#x107; A, Molyneux G, Periyasamy M, Giamas G, Hu Y, Trivedi PS, Wang J, Yag&#xfc;e E, Michel L, Coombes RC. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. Proc Natl Acad Sci USA. 2012;109:16558&#x2013;16563. doi: 10.1073/pnas.1206268109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1206268109</ArticleId>
            <ArticleId IdType="pmc">PMC3478621</ArticleId>
            <ArticleId IdType="pubmed">23012411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Shi K, Guan L, Cao T, Jiang Q, Yang Y, Xu C. ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett. 2010;584:2291&#x2013;2297. doi: 10.1016/j.febslet.2010.03.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2010.03.040</ArticleId>
            <ArticleId IdType="pubmed">20353787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal. 2012;16:1215&#x2013;1228. doi: 10.1089/ars.2012.4529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2012.4529</ArticleId>
            <ArticleId IdType="pmc">PMC3324813</ArticleId>
            <ArticleId IdType="pubmed">22316005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol. 2014;15:243&#x2013;256. doi: 10.1038/nrm3772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3772</ArticleId>
            <ArticleId IdType="pmc">PMC4095859</ArticleId>
            <ArticleId IdType="pubmed">24651542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neum&#xfc;ller RA, Knoblich JA. Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer. Genes Dev. 2009;23:2675&#x2013;2699. doi: 10.1101/gad.1850809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1850809</ArticleId>
            <ArticleId IdType="pmc">PMC2788323</ArticleId>
            <ArticleId IdType="pubmed">19952104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey-Guha I, Alves CP, Yeh AC, Salony, Sole X, Darp R, Ramaswamy S. A mechanism for asymmetric cell division resulting in proliferative asynchronicity. Mol Cancer Res. 2015;13:223&#x2013;230. doi: 10.1158/1541-7786.MCR-14-0474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-14-0474</ArticleId>
            <ArticleId IdType="pmc">PMC4336804</ArticleId>
            <ArticleId IdType="pubmed">25582703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69&#x2013;90. doi: 10.3322/caac.20107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.20107</ArticleId>
            <ArticleId IdType="pubmed">21296855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 2012;30:833&#x2013;844. doi: 10.1002/stem.1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1058</ArticleId>
            <ArticleId IdType="pmc">PMC3413333</ArticleId>
            <ArticleId IdType="pubmed">22489015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Printz C. Radiation treatment generates therapy-resistant cancer stem cells from less aggressive breast cancer cells. Cancer. 2012;118:3225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22711575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu L, Shao L, Li M, Zheng J, Wang J, Feng W, Chang J, Wang Y, Hauer-Jensen M, Zhou D. BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks. Radiat Res. 2013;179:160&#x2013;170. doi: 10.1667/RR3034.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1667/RR3034.1</ArticleId>
            <ArticleId IdType="pmc">PMC3607209</ArticleId>
            <ArticleId IdType="pubmed">23259762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai CH, Chang CS, Liu HH, Tsai YS, Hsu FM, Yu YL, Lai CK, Gandee L, Pong RC, Hsu HW, et al. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. Oncotarget. 2014;5:5523&#x2013;5534. doi: 10.18632/oncotarget.2133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2133</ArticleId>
            <ArticleId IdType="pmc">PMC4170639</ArticleId>
            <ArticleId IdType="pubmed">25015118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu Q, He Y, Ji J, Yao Y, Shen W, Luo J, Zhu W, Cao H, Geng Y, Xu J, et al. Hypoxia-inducible factor 1&#x3b1; (HIF-1&#x3b1;) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1&#x3b1;/CXCR4 pathway in non-small cell lung carcinoma cells. Oncotarget. 2015;6:10893&#x2013;10907. doi: 10.18632/oncotarget.3535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3535</ArticleId>
            <ArticleId IdType="pmc">PMC4484427</ArticleId>
            <ArticleId IdType="pubmed">25843954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Jiang S, Liu J, Wang H, Zhang Y, Tang SC, Wang J, Du N, Xu C, Wang C, et al. MiR-208a stimulates the cocktail of SOX2 and &#x3b2;-catenin to inhibit the let-7 induction of self-renewal repression of breast cancer stem cells and formed miR208a/let-7 feedback loop via LIN28 and DICER1. Oncotarget. 2015;6:32944&#x2013;32954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4741741</ArticleId>
            <ArticleId IdType="pubmed">26460550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruceru ML, Neagu M, Demoulin J-B, Constantinescu SN. Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. J Cell Mol Med. 2013;17:1218&#x2013;1235. doi: 10.1111/jcmm.12122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12122</ArticleId>
            <ArticleId IdType="pmc">PMC4159024</ArticleId>
            <ArticleId IdType="pubmed">23998913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalucci N, Tozzi L, Bogani C, Martinelli S, Rotunno G, Villeval JL, Vannucchi AM. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med. 2013;17:1385&#x2013;1396. doi: 10.1111/jcmm.12162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12162</ArticleId>
            <ArticleId IdType="pmc">PMC4117551</ArticleId>
            <ArticleId IdType="pubmed">24237791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659:284&#x2013;292. doi: 10.1016/j.mrrev.2008.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mrrev.2008.06.001</ArticleId>
            <ArticleId IdType="pubmed">18598780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy CT, Wetzel K, et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci USA. 2013;110:E1026&#x2013;E1034. doi: 10.1073/pnas.1217072110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1217072110</ArticleId>
            <ArticleId IdType="pmc">PMC3600458</ArticleId>
            <ArticleId IdType="pubmed">23431153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, Shao L, Spitz DR. Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res. 2014;122:1&#x2013;67. doi: 10.1016/B978-0-12-420117-0.00001-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-420117-0.00001-3</ArticleId>
            <ArticleId IdType="pmc">PMC4207279</ArticleId>
            <ArticleId IdType="pubmed">24974178</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26472041</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1757-6512</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Oct</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Stem cell research &amp; therapy</Title>
          <ISOAbbreviation>Stem Cell Res Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism.</ArticleTitle>
        <Pagination>
          <StartPage>198</StartPage>
          <MedlinePgn>198</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">198</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13287-015-0174-2</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cancer stem cells (CSCs) possess characteristics associated with normal stem cells, specifically the abilities to renew themselves and to give rise to all cell types (differentiation). It is assumed that induction of differentiation in CSCs would reduce their ability to form tumors. What triggers CSC differentiation and the role of "differentiation" in tumorigenesis remain elusive.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Glioma stem cell (GSC) lines and subcutaneous as well as orthotopic xenografts established from fresh surgical specimens of glioblastoma multiforme were used.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Exposure of GSCs to serum activates mitochondrial respiration and causes an increase in mitochondrial reactive oxygen species (ROS) as well as oxidative stress responses, leading to the appearance of differentiation morphology and a deceased expression of CSC markers. Chemical perturbation of the mitochondrial electron transport chain causes ROS increase and further downregulation of stem cell markers, while antioxidant N-acetyl-cysteine reduces ROS and suppresses the differentiation of GSCs. Surprisingly, the serum-induced differentiated GSCs exhibit greater ability to form tumor in both orthotopic and subcutaneous xenograft models, which can be suppressed by N-acetyl-cysteine. Mitochondrial ROS from the serum-stimulated cells triggered the activation of nuclear factor-kappa-B (NF&#x3ba;B) pathway, which is a potential mechanism for the promotion of tumorigenesis.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests that ROS generated from active mitochondrial respiration in the presence of serum is critical in CSCs activation, which promotes tumor development in vivo.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Shuqiang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 E Dongfeng Road, Guangzhou, Guangdong, 510060, China. yuanshq@sysucc.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yunxin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 E Dongfeng Road, Guangzhou, Guangdong, 510060, China. luyx@sysucc.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 E Dongfeng Road, Guangzhou, Guangdong, 510060, China. yangjing@sysucc.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. gchen@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sangbae</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. sangbae.kim@uth.tmc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. lfeng@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogasawara</LastName>
            <ForeName>Marcia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. mogasawara@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hammoudi</LastName>
            <ForeName>Naima</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. amian84@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Weiqin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. wqlu@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. huz012@eng.ucsd.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jinyun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. jliu7@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Colman</LastName>
            <ForeName>Howard</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuro-Oncology, University of Utah, Salt Lake City, UT, USA. howard.colman@hsc.utah.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Ju-Seog</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. jlee@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiao-Nan</ForeName>
            <Initials>XN</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Neuro-oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA. xiaonan@bcm.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Rui-Hua</ForeName>
            <Initials>RH</Initials>
            <AffiliationInfo>
              <Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 E Dongfeng Road, Guangzhou, Guangdong, 510060, China. xurh@sysucc.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 E Dongfeng Road, Guangzhou, Guangdong, 510060, China. phuang@mdanderson.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. phuang@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 E Dongfeng Road, Guangzhou, Guangdong, 510060, China. wangfeng@sysucc.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA100428</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA172724</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA100428</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Stem Cell Res Ther</MedlineTA>
        <NlmUniqueID>101527581</NlmUniqueID>
        <ISSNLinking>1757-6512</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003470">Culture Media</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D065767" MajorTopicYN="N">Activation, Metabolic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003470" MajorTopicYN="N">Culture Media</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26472041</ArticleId>
        <ArticleId IdType="pmc">PMC4606508</ArticleId>
        <ArticleId IdType="doi">10.1186/s13287-015-0174-2</ArticleId>
        <ArticleId IdType="pii">10.1186/s13287-015-0174-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895&#x2013;902. doi: 10.1038/nrc1232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1232</ArticleId>
            <ArticleId IdType="pubmed">14737120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755&#x2013;68. doi: 10.1038/nrc2499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2499</ArticleId>
            <ArticleId IdType="pubmed">18784658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26:2839&#x2013;45. doi: 10.1200/JCO.2007.15.1829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.1829</ArticleId>
            <ArticleId IdType="pmc">PMC2739000</ArticleId>
            <ArticleId IdType="pubmed">18539962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011;2011:941876. doi: 10.1155/2011/941876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2011/941876</ArticleId>
            <ArticleId IdType="pmc">PMC2958340</ArticleId>
            <ArticleId IdType="pubmed">20981352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R&#x2019;s of radiobiology revisited. Stem Cells. 2010;28:639&#x2013;48. doi: 10.1002/stem.318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.318</ArticleId>
            <ArticleId IdType="pmc">PMC2940232</ArticleId>
            <ArticleId IdType="pubmed">20135685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780&#x2013;3. doi: 10.1038/nature07733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07733</ArticleId>
            <ArticleId IdType="pmc">PMC2778612</ArticleId>
            <ArticleId IdType="pubmed">19194462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji AR, Ku SY, Cho MS, Kim YY, Kim YJ, Oh SK, et al. Reactive oxygen species enhance differentiation of human embryonic stem cells into mesendodermal lineage. Exp Mol Med. 2010;42:175&#x2013;86. doi: 10.3858/emm.2010.42.3.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3858/emm.2010.42.3.018</ArticleId>
            <ArticleId IdType="pmc">PMC2845002</ArticleId>
            <ArticleId IdType="pubmed">20164681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71:634&#x2013;9. doi: 10.1158/0008-5472.CAN-10-3220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-3220</ArticleId>
            <ArticleId IdType="pubmed">21266356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391&#x2013;403. doi: 10.1016/j.ccr.2006.03.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2006.03.030</ArticleId>
            <ArticleId IdType="pubmed">16697959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69&#x2013;82. doi: 10.1016/j.ccr.2006.11.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2006.11.020</ArticleId>
            <ArticleId IdType="pubmed">17222791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem. 2009;108:1031&#x2013;8. doi: 10.1002/jcb.22350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.22350</ArticleId>
            <ArticleId IdType="pmc">PMC2909872</ArticleId>
            <ArticleId IdType="pubmed">19760641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255:1707&#x2013;10. doi: 10.1126/science.1553558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1553558</ArticleId>
            <ArticleId IdType="pubmed">1553558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pervaiz S, Taneja R, Ghaffari S. Oxidative stress regulation of stem and progenitor cells. Antioxid Redox Signal. 2009;11:2777&#x2013;89. doi: 10.1089/ars.2009.2804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2009.2804</ArticleId>
            <ArticleId IdType="pubmed">19650689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, Shao L, Spitz DR. Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res. 2014;122:1&#x2013;67. doi: 10.1016/B978-0-12-420117-0.00001-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-420117-0.00001-3</ArticleId>
            <ArticleId IdType="pmc">PMC4207279</ArticleId>
            <ArticleId IdType="pubmed">24974178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauer H, Wartenberg M. Reactive oxygen species as signaling molecules in cardiovascular differentiation of embryonic stem cells and tumor-induced angiogenesis. Antioxid Redox Signal. 2005;7:1423&#x2013;34. doi: 10.1089/ars.2005.7.1423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2005.7.1423</ArticleId>
            <ArticleId IdType="pubmed">16356105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith J, Ladi E, Mayer-Proschel M, Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci U S A. 2000;97:10032&#x2013;7. doi: 10.1073/pnas.170209797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.170209797</ArticleId>
            <ArticleId IdType="pmc">PMC27662</ArticleId>
            <ArticleId IdType="pubmed">10944195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsatmali M, Walcott EC, Crossin KL. Newborn neurons acquire high levels of reactive oxygen species and increased mitochondrial proteins upon differentiation from progenitors. Brain Res. 2005;1040:137&#x2013;50. doi: 10.1016/j.brainres.2005.01.087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2005.01.087</ArticleId>
            <ArticleId IdType="pubmed">15804435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431:997&#x2013;1002. doi: 10.1038/nature02989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature02989</ArticleId>
            <ArticleId IdType="pubmed">15496926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res. 2013;12:119&#x2013;31. doi: 10.1016/j.scr.2013.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.scr.2013.09.012</ArticleId>
            <ArticleId IdType="pubmed">24185179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, et al. Glycomic and transcriptomic response of gsc11 glioblastoma stem cells to stat3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res. 2010;9:2098&#x2013;108. doi: 10.1021/pr900793a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr900793a</ArticleId>
            <ArticleId IdType="pubmed">20199106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007;99:1410&#x2013;4. doi: 10.1093/jnci/djm102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djm102</ArticleId>
            <ArticleId IdType="pubmed">17848677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, et al. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008;26:1414&#x2013;24. doi: 10.1634/stemcells.2007-1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/stemcells.2007-1009</ArticleId>
            <ArticleId IdType="pubmed">18403755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, Keating MJ, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286:32843&#x2013;53. doi: 10.1074/jbc.M111.260935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.260935</ArticleId>
            <ArticleId IdType="pmc">PMC3173179</ArticleId>
            <ArticleId IdType="pubmed">21795717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells. 2013;31:23&#x2013;34. doi: 10.1002/stem.1273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.1273</ArticleId>
            <ArticleId IdType="pmc">PMC3538380</ArticleId>
            <ArticleId IdType="pubmed">23132831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaiano N, Fishell G. The role of notch in promoting glial and neural stem cell fates. Annu Rev Neurosci. 2002;25:471&#x2013;90. doi: 10.1146/annurev.neuro.25.030702.130823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.neuro.25.030702.130823</ArticleId>
            <ArticleId IdType="pubmed">12052917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Karin M. Is NF-kappaB the sensor of oxidative stress? FASEB J. 1999;13:1137&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10385605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239&#x2013;67. doi: 10.1146/annurev.pharmtox.44.101802.121851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pharmtox.44.101802.121851</ArticleId>
            <ArticleId IdType="pubmed">14744246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72:1493&#x2013;505. doi: 10.1016/j.bcp.2006.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2006.04.011</ArticleId>
            <ArticleId IdType="pubmed">16723122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res. 2010;16:3121&#x2013;9. doi: 10.1158/1078-0432.CCR-09-2933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-2933</ArticleId>
            <ArticleId IdType="pmc">PMC3182451</ArticleId>
            <ArticleId IdType="pubmed">20530700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66:4553&#x2013;7. doi: 10.1158/0008-5472.CAN-05-3986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3986</ArticleId>
            <ArticleId IdType="pubmed">16651403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuddihy SL, Winterbourn CC, Hampton MB. Assessment of redox changes to hydrogen peroxide-sensitive proteins during EGF signaling. Antioxid Redox Signal. 2011;15:167&#x2013;74. doi: 10.1089/ars.2010.3843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2010.3843</ArticleId>
            <ArticleId IdType="pubmed">21254838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forman HJ, Maiorino M, Ursini F. Signaling functions of reactive oxygen species. Biochemistry. 2010;49:835&#x2013;42. doi: 10.1021/bi9020378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi9020378</ArticleId>
            <ArticleId IdType="pmc">PMC4226395</ArticleId>
            <ArticleId IdType="pubmed">20050630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Garcia D, Wood CD, Castro-Obregon S, Covarrubias L. Reactive oxygen species: a radical role in development? Free Radic Biol Med. 2010;49:130&#x2013;43. doi: 10.1016/j.freeradbiomed.2010.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.03.020</ArticleId>
            <ArticleId IdType="pubmed">20353819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigarella CL, Liang R, Ghaffari S. Stem cells and the impact of ROS signaling. Development. 2014;141:4206&#x2013;18. doi: 10.1242/dev.107086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.107086</ArticleId>
            <ArticleId IdType="pmc">PMC4302918</ArticleId>
            <ArticleId IdType="pubmed">25371358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells. 2009;27:40&#x2013;8. doi: 10.1634/stemcells.2008-0493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/stemcells.2008-0493</ArticleId>
            <ArticleId IdType="pubmed">18948646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007;53:503&#x2013;17. doi: 10.1016/j.neuron.2007.01.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2007.01.009</ArticleId>
            <ArticleId IdType="pmc">PMC1810344</ArticleId>
            <ArticleId IdType="pubmed">17296553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, et al. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell. 2012;21:11&#x2013;24. doi: 10.1016/j.ccr.2011.11.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.11.025</ArticleId>
            <ArticleId IdType="pubmed">22264785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang C, Atkinson SP, Vilella F, Lloret M, Armstrong L, Mann DA, et al. Opposing putative roles for canonical and noncanonical NFkappaB signaling on the survival, proliferation, and differentiation potential of human embryonic stem cells. Stem Cells. 2010;28:1970&#x2013;80. doi: 10.1002/stem.528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.528</ArticleId>
            <ArticleId IdType="pubmed">20882529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010;70:2516&#x2013;27. doi: 10.1158/0008-5472.CAN-09-3950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3950</ArticleId>
            <ArticleId IdType="pubmed">20215516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, et al. Blockade of the NFkappaB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene. 2011;30:3537&#x2013;48. doi: 10.1038/onc.2011.74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2011.74</ArticleId>
            <ArticleId IdType="pubmed">21423202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, et al. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011;104:1564&#x2013;74. doi: 10.1038/bjc.2011.126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.126</ArticleId>
            <ArticleId IdType="pmc">PMC3101904</ArticleId>
            <ArticleId IdType="pubmed">21487404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog. 2006;45:355&#x2013;61. doi: 10.1002/mc.20217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.20217</ArticleId>
            <ArticleId IdType="pubmed">16673382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;21:103&#x2013;15. doi: 10.1038/cr.2010.178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2010.178</ArticleId>
            <ArticleId IdType="pmc">PMC3193400</ArticleId>
            <ArticleId IdType="pubmed">21187859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, et al. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem. 2003;278:36916&#x2013;23. doi: 10.1074/jbc.M301598200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M301598200</ArticleId>
            <ArticleId IdType="pubmed">12842894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, et al. NFKBIA deletion in glioblastomas. N Engl J Med. 2011;364:627&#x2013;37. doi: 10.1056/NEJMoa1006312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1006312</ArticleId>
            <ArticleId IdType="pmc">PMC3652611</ArticleId>
            <ArticleId IdType="pubmed">21175304</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26392743</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>06</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1090-0535</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <PubDate>
              <Year>2015</Year>
            </PubDate>
          </JournalIssue>
          <Title>Molecular vision</Title>
          <ISOAbbreviation>Mol Vis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Thinning of the RPE and choroid associated with T lymphocyte recruitment in aged and light-challenged mice.</ArticleTitle>
        <Pagination>
          <StartPage>1051</StartPage>
          <EndPage>1059</EndPage>
          <MedlinePgn>1051-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Thinning of the RPE and the underlying vascular layer, the choroid, is observed with age in many human eye disorders. The reasons for this thinning are ill-defined. Here, we highlight the possible role of T lymphocyte recruitment in choroidoretinal thinning in aged and light-challenged mice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In age and light challenge models, we measured chemokine concentrations using enzyme-linked immunosorbent assay and used flow cytometry to characterize lymphocyte populations. We quantified thinning in eye immunosections and RPE65 expression using quantitative PCR.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Age and light challenge led to increased levels of the lymphotactic protein CXCL10 alone (aging) or in conjunction with CXCL9 (light challenge). Increased numbers of CD3+ T lymphocytes, most of them CD8+ cytotoxic T lymphocytes, were also observed in the choroid and retina of old mice and following light challenge. Influx of T lymphocytes was associated with RPE and choroidal thinning and diminished expression of RPE65 mRNA, an essential enzyme of the visual cycle.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The observations from this study suggest that cytotoxic CD8(+) T lymphocytes might participate in choroidal and RPE degeneration and that modulation of T lymphocyte recruitment might be a novel strategy to reduce choroidoretinal dysfunctions observed with age and following photo-oxidative stress.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Camelo</LastName>
            <ForeName>Serge</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>AP-HP, Unité de Recherche Clinique Lariboisière Saint-Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calippe</LastName>
            <ForeName>Bertrand</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lavalette</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dominguez</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hur</LastName>
            <ForeName>Justine</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Devevre</LastName>
            <ForeName>Estelle</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Plateforme d'imagerie, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, UMR S 872, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guillonneau</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raoul</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France ; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sennlaub</LastName>
            <ForeName>Florian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM, U968, Paris, France ; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France ; CNRS, UMR_7210, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>09</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Vis</MedlineTA>
        <NlmUniqueID>9605351</NlmUniqueID>
        <ISSNLinking>1090-0535</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C114753">CXCL10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C080810">CXCL9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054370">Chemokine CXCL9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.1.64</RegistryNumber>
          <NameOfSubstance UI="C052758">retinoid isomerohydrolase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.-</RegistryNumber>
          <NameOfSubstance UI="D019745">cis-trans-Isomerases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054370" MajorTopicYN="N">Chemokine CXCL9</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002829" MajorTopicYN="N">Choroid</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055668" MajorTopicYN="N">Photochemical Processes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019745" MajorTopicYN="N">cis-trans-Isomerases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26392743</ArticleId>
        <ArticleId IdType="pmc">PMC4558476</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol. 2009;148:445&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19541286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida Y, Fujiwara T, Imamura Y, Lima LH, Kurosaka D, Spaide RF. Choroidal thickness and visual acuity in highly myopic eyes. Retina. 2012;32:1229&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22466466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayton LN, Guymer RH, Luu CD. Choroidal thickness profiles in retinitis pigmentosa. Clin Experiment Ophthalmol. 2013;41:396&#x2013;403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22957991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhoot DS, Huo S, Yuan A, Xu D, Srivistava S, Ehlers JP, Traboulsi E, Kaiser PK. Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography. Br J Ophthalmol. 2013;97:66&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23093617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manjunath V, Taha M, Fujimoto JG, Duker JS. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol. 2010;150:325&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2926223</ArticleId>
            <ArticleId IdType="pubmed">20591395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8188481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-Medrano J, Flores-Moreno I, Pena-Garcia P, Montero JA, Duker JS, Ruiz-Moreno JM. Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2014;55:3532&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24845638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:4982&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4829357</ArticleId>
            <ArticleId IdType="pubmed">19357355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011;118:840&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21211846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coscas F, Puche N, Coscas G, Srour M, Francais C, Glacet-Bernard A, Querques G, Souied EH. Comparison of macular choroidal thickness in adult onset foveomacular vitelliform dystrophy and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014;55:64&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24282233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fein JG, Branchini LA, Manjunath V, Regatieri CV, Fujimoto JG, Duker JS. Analysis of short-term change in subfoveal choroidal thickness in eyes with age-related macular degeneration using optical coherence tomography. Ophthalmic Surg Lasers Imaging Retina. 2014;45:32&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4069121</ArticleId>
            <ArticleId IdType="pubmed">24392909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adhi M, Lau M, Liang MC, Waheed NK, Duker JS. Analysis of the thickness and vascular layers of the choroid in eyes with geographic atrophy using spectral-domain optical coherence tomography. Retina. 2014;34:306&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23873163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn EH, Khanna A, Tucker BA, Abramoff MD, Stone EM, Mullins RF. Structural and biochemical analyses of choroidal thickness in human donor eyes. Invest Ophthalmol Vis Sci. 2014;55:1352&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3945900</ArticleId>
            <ArticleId IdType="pubmed">24519422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JY, Lee DH, Lee JY, Yoon YH. Correlation between subfoveal choroidal thickness and the severity or progression of nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013;54:7812&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24204054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindner M, Bezatis A, Czauderna J, Becker E, Brinkmann CK, Schmitz-Valckenberg S, Fimmers R, Holz FG, Fleckenstein M. Choroidal thickness in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56:875&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25587059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yiu G. Advances in choroidal imaging with EDI-OCT. Retina Today. 2014</Citation>
        </Reference>
        <Reference>
          <Citation>Jonas JB, Forster TM, Steinmetz P, Schlichtenbrede FC, Harder BC. Choroidal thickness in age-related macular degeneration. Retina. 2014;34:1149&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24220257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yiu G, Chiu SJ, Petrou PA, Stinnett S, Sarin N, Farsiu S, Chew EY, Wong WT, Toth CA. Relationship of central choroidal thickness with age-related macular degeneration status. Am J Ophthalmol. 2015;159:617&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25526948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, Goletz P, Ma JX, Crouch RK, Pfeifer K. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet. 1998;20:344&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9843205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf G. Function of the protein RPE65 in the visual cycle. Nutr Rev. 2005;63:97&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15825812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15987797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redmond TM. Focus on Molecules: RPE65, the visual cycle retinol isomerase. Exp Eye Res. 2009;88:846&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2692084</ArticleId>
            <ArticleId IdType="pubmed">18762184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivert L, Keldbye H, Gouras P. Age-related changes in the basement membrane of the retinal pigment epithelium of Rpe65 -/- and wild-type mice. Graefe's archive for clinical and experimental ophthalmology = Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2005;243:250&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15378383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houssier M, Raoul W, Lavalette S, Keller N, Guillonneau X, Baragatti B, Jonet L, Jeanny JC, Behar-Cohen F, Coceani F, Scherman D, Lachapelle P, Ong H, Chemtob S, Sennlaub F. CD36 deficiency leads to choroidal involution via COX2 down-regulation in rodents. PLoS Med. 2008;5:e39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2245984</ArticleId>
            <ArticleId IdType="pubmed">18288886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA. 2009;106:18751&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774033</ArticleId>
            <ArticleId IdType="pubmed">19841260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U. Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging. 2014;35:2562&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24925811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121:1079&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24433969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonilha VL. Age and disease-related structural changes in the retinal pigment epithelium. Clin Ophthalmol. 2008;2:413&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2693982</ArticleId>
            <ArticleId IdType="pubmed">19668732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuner B, Komm A, Wellmann J, Dietzel M, Pauleikhoff D, Walter J, Busch M, Hense HW. Smoking history and the incidence of age-related macular degeneration--results from the Muenster Aging and Retina Study (MARS) cohort and systematic review and meta-analysis of observational longitudinal studies. Addict Behav. 2009;34:938&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19539431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollyfield JG. Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest Ophthalmol Vis Sci. 2010;51:1275&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20185837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, Barnstable C, Pang CP, Hoh J. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17053108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15761121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKay GJ, Patterson CC, Chakravarthy U, Dasari S, Klaver CC, Vingerling JR, Ho L, de Jong PT, Fletcher AE, Young IS, Seland JH, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Hingorani AD, Sofat R, Dean M, Sawitzke J, Seddon JM, Peter I, Webster AR, Moore AT, Yates JR, Cipriani V, Fritsche LG, Weber BH, Keilhauer CN, Lotery AJ, Ennis S, Klein ML, Francis PJ, Stambolian D, Orlin A, Gorin MB, Weeks DE, Kuo CL, Swaroop A, Othman M, Kanda A, Chen W, Abecasis GR, Wright AF, Hayward C, Baird PN, Guymer RH, Attia J, Thakkinstian A, Silvestri G. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. Hum Mutat. 2011;32:1407&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3217135</ArticleId>
            <ArticleId IdType="pubmed">21882290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sennlaub F, Auvynet C, Calippe B, Lavalette S, Poupel L, Hu SJ, Dominguez E, Camelo S, Levy O, Guyon E, Saederup N, Charo IF, Rooijen NV, Nandrot E, Bourges JL, Behar-Cohen F, Sahel JA, Guillonneau X, Raoul W, Combadiere C. CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice. EMBO Mol Med. 2013;5:1775&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3840491</ArticleId>
            <ArticleId IdType="pubmed">24142887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussenblatt RB, Ferris F., 3rd Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol. 2007;144:618&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2744410</ArticleId>
            <ArticleId IdType="pubmed">17698021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitcup SM, Sodhi A, Atkinson JP, Holers VM, Sinha D, Rohrer B, Dick AD. The role of the immune response in age-related macular degeneration. Int J Inflamm. 2013;2013:348092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3676958</ArticleId>
            <ArticleId IdType="pubmed">23762772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Liu B, Lukas TJ, Neufeld AH. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS ONE. 2008;3:e2339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2394659</ArticleId>
            <ArticleId IdType="pubmed">18523633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collier RJ, Wang Y, Smith SS, Martin E, Ornberg R, Rhoades K, Romano C. Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Invest Ophthalmol Vis Sci. 2011;52:8108&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21467172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruz-Guilloty F, Saeed AM, Duffort S, Cano M, Ebrahimi KB, Ballmick A, Tan Y, Wang H, Laird JM, Salomon RG, Handa JT, Perez VL. T cells and macrophages responding to oxidative damage cooperate in pathogenesis of a mouse model of age-related macular degeneration. PLoS ONE. 2014;9:e88201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3929609</ArticleId>
            <ArticleId IdType="pubmed">24586307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penfold P, Killingsworth M, Sarks S. An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch's membrane. Aust J Ophthalmol. 1984;12:23&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6732655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefe's archive for clinical and experimental ophthalmology = Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1985;223:69&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2408968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11033038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuenca N, Fernandez-Sanchez L, Campello L, Maneu V, De la Villa P, Lax P, Pinilla I. Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog Retin Eye Res. 2014;43:17&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25038518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008;9:315&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18654858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Payne AJ, Kaja S, Naumchuk Y, Kunjukunju N, Koulen P. Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. Int J Mol Sci. 2014;15:1865&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3958826</ArticleId>
            <ArticleId IdType="pubmed">24473138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Organisciak DT, Vaughan DK. Retinal light damage: mechanisms and protection. Prog Retin Eye Res. 2010;29:113&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831109</ArticleId>
            <ArticleId IdType="pubmed">19951742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combadi&#xe8;re C, Feumi C, Raoul W, Keller N, Rodero M, Pezard A, Lavalette S, Houssier M, Jonet L, Picard E, Debre P, Sirinyan M, Deterre P, Ferroukhi T, Cohen SY, Chauvaud D, Jeanny JC, Chemtob S, Behar-Cohen F, Sennlaub F. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest. 2007;117:2920&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1994614</ArticleId>
            <ArticleId IdType="pubmed">17909628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolosova NG, Muraleva NA, Zhdankina AA, Stefanova NA, Fursova AZ, Blagosklonny MV. Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol. 2012;181:472&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22683466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camelo S. Potential sources and roles of adaptive immunity in Age-related Macular Degeneration: Shall we rename AMD into Autoimmune Macular Disease? Autoimmune Dis. 2014;2014:532487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4022009</ArticleId>
            <ArticleId IdType="pubmed">24876950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrington DA, Tran TN, Lew KL, Van Remmen H, Gregerson DS. Different death stimuli evoke apoptosis via multiple pathways in retinal pigment epithelial cells. Exp Eye Res. 2006;83:638&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16682026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregerson DS, Lew KL, McPherson SW, Heuss ND, Ferrington DA. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing. Invest Ophthalmol Vis Sci. 2006;47:5385&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17122128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezzat MK, Hann CR, Vuk-Pavlovic S, Pulido JS. Immune cells in the human choroid. Br J Ophthalmol. 2008;92:976&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18577650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendel A, Granville DJ. Granzyme B cleavage of fibronectin disrupts endothelial cell adhesion, migration and capillary tube formation. Matrix Biol. 2013;32:14&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23228447</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24736663</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2014</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype.</ArticleTitle>
        <Pagination>
          <StartPage>e94568</StartPage>
          <MedlinePgn>e94568</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e94568</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0094568</ELocationID>
        <Abstract>
          <AbstractText>The developmental and stress-regulated alternative TrkAIII splice variant of the NGF receptor TrkA is expressed by advanced stage human neuroblastomas (NBs), correlates with worse outcome in high TrkA expressing unfavourable tumours and exhibits oncogenic activity in NB models. In the present study, we report that constitutive TrkAIII expression in human SH-SY5Y NB cells inhibits Rotenone, Paraquat and LY83583-induced mitochondrial free radical reactive oxygen species (ROS)-mediated death by stimulating SOD2 expression, increasing mitochondrial SOD2 activity and attenuating mitochondrial free radical ROS production, in association with increased mitochondrial capacity to produce H2O2, within the context of a more tumour stem cell-like phenotype. This effect can be reversed by the specific TrkA tyrosine kinase inhibitor GW441756, by the multi-kinase TrkA inhibitors K252a, CEP-701 and Gö6976, which inhibit SOD2 expression, and by siRNA knockdown of SOD2 expression, which restores the sensitivity of TrkAIII expressing SH-SY5Y cells to Rotenone, Paraquat and LY83583-induced mitochondrial free radical ROS production and ROS-mediated death. The data implicate the novel TrkAIII/SOD2 axis in promoting NB resistance to mitochondrial free radical-mediated death and staminality, and suggest that the combined use of TrkAIII and/or SOD2 inhibitors together with agents that induce mitochondrial free radical ROS-mediated death could provide a therapeutic advantage that may also target the stem cell niche in high TrkA expressing unfavourable NB.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ruggeri</LastName>
            <ForeName>Pierdomenico</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farina</LastName>
            <ForeName>Antonietta R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Ianni</LastName>
            <ForeName>Natalia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy; Department of Medical-Surgical Science and Biotechnology, University of Rome "La Sapienza", Latina, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cappabianca</LastName>
            <ForeName>Lucia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ragone</LastName>
            <ForeName>Marzia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ianni</LastName>
            <ForeName>Giulia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gulino</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, University of Rome "La Sapienza", Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mackay</LastName>
            <ForeName>Andrew R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>04</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="C431683">superoxide dismutase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.127</RegistryNumber>
          <NameOfSubstance UI="C051038">Inositol 1,4,5-trisphosphate 3-kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015513" MajorTopicYN="N">Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020917" MajorTopicYN="N">Receptor, trkA</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24736663</ArticleId>
        <ArticleId IdType="pmc">PMC3988074</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0094568</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-47896</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tacconelli A, Farina AR, Cappabianca L, DeSantis G, Tessitore A, et al. (2004) TrkA Alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6: 347&#x2013;360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15488758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farina AR, Tacconelli A, Cappabianca L, Cea G, Chioda A, et al. (2009) The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells. Oncogene 28: 4075&#x2013;4094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19734938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farina AR, Tacconelli A, Cappabianca L, Cea G, Panella S, et al. (2009) The TrkAIII splice variant targets the centrosome and promotes genetic instability. Mol Cell Biol 29: 4812&#x2013;4830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2725721</ArticleId>
            <ArticleId IdType="pubmed">19564412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farina AR, Cappabianca L, Ruggeri P, Di Ianni N, Ragone M, et al. (2012) Alternative TrkA splicing and neuroblastoma. In: Neuroblastoma Present and Future (Ed. Hiroyuki Shimada, Intech, Croatia); 111&#x2013;136.</Citation>
        </Reference>
        <Reference>
          <Citation>Farina AR, Di Ianni N, Cappabianca L, Ruggeri P, Ragone M, et al. (2013) TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype. Biomed Res Int Available: http://dx.doi.org/10.1155/2013/740187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/740187</ArticleId>
            <ArticleId IdType="pmc">PMC3690223</ArticleId>
            <ArticleId IdType="pubmed">23841091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schramm A, Schowe B, Fielitz K, Heilman M, Martin M, et al. (2012) Exon-level expression analysis identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict neuroblastoma outcome. Br J Cancer 107: 1409&#x2013;1417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3494449</ArticleId>
            <ArticleId IdType="pubmed">23047593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson AM, Iyer R, Mangino JL, Minturn JE, Zhao H, et al. (2012) TrkAIII isoform expression upregulates stem cell markers and correlates with worse outcome in neuroblastomas (NBs). Proc Adv Neuroblastoma Res p.164 (POT055).</Citation>
        </Reference>
        <Reference>
          <Citation>Tacconelli A, Farina AR, Cappabianca L, Cea G, Panella S, et al. (2007) TrkAIII expression in the thymus. J Neuroimmunol 183: 151&#x2013;161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17241672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson FL, Porcionatto MA, Bhattacharyya A, Stiles CD, Segal RA (1999) TrkA glycosylation regulates receptor localisation and activity. J Neurobiol 39: 323&#x2013;336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10235685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, et al. (2000) TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol 20: 5908&#x2013;5916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86068</ArticleId>
            <ArticleId IdType="pubmed">10913174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, et al. (1993) Tissue-specific alternative splicing generates two isoforms of the TrkA receptor. J Biol Chem 268: 15150&#x2013;15157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8325889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavenius E, Gestblom C, Johansson I, N&#xe5;nberg E, P&#xe5;hlman S (1995) Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth &amp; Differ 6: 727&#x2013;736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7669728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucarelli E, Kaplan D, Thiele CJ (1997) Activation of Trk-A but not Trk-B signal transduction pathway inhibits growth of neuroblastoma cells. Eur J Cancer 33: 2068&#x2013;2070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9516854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedogni B, Pani G, Colavitti R, Riccio A, Borrello S, et al. (2003) Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival. J Biol Chem 278: 16510&#x2013;16519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12609977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassano S, Agnese S, D&#x2019;Amato V, Papale M, Garbi C, et al. (2010) Reactive oxygen species, Ki-Ras, and mitochondrial superoxide dismutase cooperate in nerve growth factor-induced differentiation of PC12 cells. J Biol Chem 285: 24141&#x2013;24153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2911279</ArticleId>
            <ArticleId IdType="pubmed">20495008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehrer JP (2000) The Harber-Weiss reaction and the mechanisms of toxicity. Toxicology 149: 43&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10963860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miriyala S, Holley AK, St Clair DK (2011) Mitochondrial superoxide dismutase-signals of distinction. Anticancer Agents Med Chem 11: 181&#x2013;190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3427752</ArticleId>
            <ArticleId IdType="pubmed">21355846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhar SK, St. Clair DK (2012) Manganese superoxide dismutase regulation and cancer. Free Radical Biol Med 52: 2209&#x2013;2222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22561706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, et al. (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11: 367&#x2013;381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7493016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, et al. (1996) Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93: 9782&#x2013;9787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC38506</ArticleId>
            <ArticleId IdType="pubmed">8790408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richter C, Park JW, Ames BN (1988) Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci U S A 85: 6465&#x2013;6467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC281993</ArticleId>
            <ArticleId IdType="pubmed">3413108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung BH, Wong KY, Lin MC, Wong CK, Mashima T, et al. (2008) Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2. Br J Cancer 99: 283&#x2013;293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2480972</ArticleId>
            <ArticleId IdType="pubmed">18594523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JH, Choi IY, Kil IS, Kim SY, Yang ES, et al. (2001) Protective role of superoxide dismutases against ionizing radiation in yeast. Biochim Biophys Acta 1526: 191&#x2013;198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11325541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takada Y, Hachiya M, Park SH, Osawa Y, Ozawa T, et al. (2002) Role of reactive oxygen species in cells overexpressing manganese superoxide dismutase: mechanism for induction of radioresistance. Mol Cancer Res 1: 137&#x2013;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12496360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delhalle S, Deregowski V, Benoit V, Merville MP, Bours V (2002) NF-&#x3ba;B-dependent MnSOD expression protects adenocarcinoma cells from TNF-&#x3b1;-induced apoptosis. Oncogene 21: 3917&#x2013;3924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12032830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epperly MW, Guo H, Bernarding M, Gretton J, Jefferson M, et al. (2003) Delayed intratracheal injection of manganese superoxide dismutase (MnSOD)-plasmid/liposomes provides suboptimal protection against irradiation induced pulmonary injury compared to treatment before irradiation. Gen Ther Mol Biol 7: 61&#x2013;68.</Citation>
        </Reference>
        <Reference>
          <Citation>Fisher CJ, Goswami PC (2008) Mitochondria-targeted antioxidant enzyme activity regulates radioresistance in human pancreatic cancer cells. Cancer Biol Ther 7: 1271&#x2013;1279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2581876</ArticleId>
            <ArticleId IdType="pubmed">18497575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohr A, Buneker C, Gough RP, Zwacka RM (2008) MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene 27: 763&#x2013;774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17653087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dayem AA, Choi HY, Kim JH, Cho SG (2010) Role of oxidative stress in stem, cancer and cancer stem cells. Cancers 2: 859&#x2013;884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3835109</ArticleId>
            <ArticleId IdType="pubmed">24281098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee A, Dasgupta S, Sidransky D (2011) Mitochondrial subversion in cancer. Cancer Prev Res 4: 638&#x2013;654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3298745</ArticleId>
            <ArticleId IdType="pubmed">21543342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosoki A, Yonekura S, Zhao Q, Wei Z, Takasaki I, et al. (2012) Mitochondria-targeted superoxide dismutase (SOD2) regulates radiation resistance and radiation stress response in HeLa cells. J Radiat Res 53: 58&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22302046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao L, Clair DK (2009) Regulation of superoxide dismutase genes: implications in disease. Free Rad Biol Med 47: 344&#x2013;356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2731574</ArticleId>
            <ArticleId IdType="pubmed">19477268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung JE, Kim GS, Narasimhan P, Song YS, Chan PH (2009) Regulation of Mn-superoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia. J Neurosci 29: 7003&#x2013;7014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2712132</ArticleId>
            <ArticleId IdType="pubmed">19474327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhuri L, Nicholson AM, Kalen AL, Goswami PC (2012) Preferential selection of MnSOD transcripts in proliferating normal and cancer cells. Oncogene 31: 1207&#x2013;1216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208126</ArticleId>
            <ArticleId IdType="pubmed">21804600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuart JJ, Egry LA, Wong GH, Kaspar RL (2000) The 3&#x2032; UTR of human MnSOD mRNA hybridizes to a small cytoplasmic RNA and inhibits gene expression. Biochem Biophys Res Commun 274: 641&#x2013;648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10924331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knirsch L, Clerch LB (2001) Tyrosine phosphorylation regulates manganese superoxide dismutase (mnSOD) RNA-binding protein activity and MnSOD protein expression. Biochemistry 40: 7890&#x2013;7895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11425317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacMillan-Crow LA, Crow JP, Thompson JA (1998) Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 37: 1613&#x2013;1622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9484232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holley AK, Dhar SK, Xu Y, St Clair DK (2012) Manganese superoxide dismutase: beyond life and death. Amino Acids 42: 139&#x2013;158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2975048</ArticleId>
            <ArticleId IdType="pubmed">20454814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberley LW, Beuttner GR (1979) Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141&#x2013;1149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">217531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson KK, Ranganathan AC, Mansouri J, Rodriguez AM, Providence KM, et al. (2003) Elevated SOD2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res 9: 424&#x2013;432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12538496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, et al. (2007) Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res 67: 10260&#x2013;10267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17974967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hempel N, Ye H, Abessi B, Mian B, Melendez JA (2009) Altered redox status accompanies progression to metastatic bladder cancer. Free Rad Biol Med 46: 42&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2630461</ArticleId>
            <ArticleId IdType="pubmed">18930813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cecere F, Iuliano A, Albano F, Zappelli C, Castellano I, et al. (2010) Diclofenac-induced apoptosis in neuroblastoma cell line SH-SY5Y: Possible involvement of the mitochondrial superoxide dismutase. J Biomed Biotechnol 2010: 801726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2896885</ArticleId>
            <ArticleId IdType="pubmed">20625417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, et al. (1998) Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 18: 687&#x2013;697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6792529</ArticleId>
            <ArticleId IdType="pubmed">9425011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhavan L, Ourednik V, Ourednik J (2006) Increased &#x201c;vigilance&#x201d; of antioxidant mechanisms in neural stem cells potentiates their capability to resist oxidative stress. Stem Cells 24: 2110&#x2013;2119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16728559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhavan L, Ourednik V, Ourednik J (2008) Neural stem/progenitor cells initiate the formation of cellular networks that provide neuroprotection by growth factor-modulated antioxidant expression. Stem Cells 26: 254&#x2013;265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17962704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santillo M, Mondola P, Ser&#xf9; R, Annella T, Cassano S, et al. (2001) Opposing functions of Ki- and Ha-Ras genes in the regulation of redox signals. Current Biol 11: 614&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11369207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirkland RA, Saavedra GM, Franklin JL (2007) Rapid activation of antioxidant defences by nerve growth factor suppresses reactive oxygen species during neuronal apoptosis: evidence for a role in cytochrome c redistribution. J Neurosci 27: 11315&#x2013;11326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6673026</ArticleId>
            <ArticleId IdType="pubmed">17942726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg MM, Sternberg DW, Parada LF, Chao MV (1992) K-252a inhibits nerve growth factor-induced Trk proto-oncogene tyrosine phosphorylation and kinase activity. J Biol Chem 267: 13&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1730579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behrens MM, Strasser U, Choi DW (1999) G&#xf6;6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase. J Neurochem 72: 919&#x2013;924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10037462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood ER, Kuyper L, Petrov KG, Hunter RN, Harris PA (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett 14: 953&#x2013;957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15013000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang YT, Choi G, Bae YS, Burdett M, Moon HS, et al. (2002) Purine-based inhibitors of insositol-1, 4,5trisphosphate-3-kinase. Chembiochem 3: 897&#x2013;901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12210991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD O98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo . J Biol Chem 270: 27498&#x2013;27494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7499206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu SF, Ye X, Malik AB (1999) Inhibition of NF-&#x3ba;B by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100: 1330&#x2013;1337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10491379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, et al. (2002) Bay 11&#x2013;7082 inhibits transcription factor NF-&#x3ba;B and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100: 1828&#x2013;1834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12176906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Ragheb K, Lawler G, Sturgis J, Ralwa B, et al. (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278: 8516&#x2013;8525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12496265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong C, Liu XH, Hao XD, Chang J, Sun X (2013) Synthesis and biological evaluation of novel neuroprotective agents for paraquat-induced apoptosis in human neuronal SH-SY5Y cells. Eur J Med Chem 62: 187&#x2013;198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23353752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasegawa T, Bando A, Tsuchiya K, Abe S, Okamoto M, et al. (2004) Enzymatic and nonenzymatic formation of reactive oxygen species from 6-anilino-5, 8-quinolinequinone. Biochim Biophys Acta 1670: 19&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14729138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, et al. (1997) CEP-751 inhibits Trk receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer 72: 673&#x2013;679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9259409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to ImageJ: 25 years of image analysis. Nat Methods 9: 671&#x2013;675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5554542</ArticleId>
            <ArticleId IdType="pubmed">22930834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sims RR, Anderson MF (2008) Isolation of mitochondria from rat brain using Percoll density gradient centrifugation. Nat Protocols 3: 1228&#x2013;1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18600228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starkov AA (2010) Measurement of mitochondrial ROS production. Methods Mol Biol 648: 245&#x2013;255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3057530</ArticleId>
            <ArticleId IdType="pubmed">20700717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribble D, Goldstein NB, Norris DA, Shellman YG (2005) A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 5: 12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1142306</ArticleId>
            <ArticleId IdType="pubmed">15885144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baskic D, Popovic S, Ristic P, Arsenijevic NN (2006) Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridine orange/ethidium bromide. Cell Biol Int 30: 924&#x2013;932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16895761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weydert CJ, Cullen JJ (2010) Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protocols 5: 51&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2830880</ArticleId>
            <ArticleId IdType="pubmed">20057381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, et al. (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4: e4235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2626279</ArticleId>
            <ArticleId IdType="pubmed">19156211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T, Hosoi F, Yamaguchi-Iwa Y, Nakamura H, Masutani H, et al. (2002) Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondrial-dependent apoptosis. EMBO J 21: 1695&#x2013;1703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC125951</ArticleId>
            <ArticleId IdType="pubmed">11927553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meco D, Riccardi A, Servidei T (2005) Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett 228: 211&#x2013;219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15950376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melone MA, Giuliano M, Squillaro T, Alessio N, Casale F, et al. (2009) Genes involved in regulation of stem cell properties: studies on their expression in a small cohort of neuroblastoma patients. Cancer Biol Ther 8: 1300&#x2013;1306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19458492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Obeidi FA, Lam KI (2000) Development of inhibitors for protein tyrosine kinases. Oncogene 19: 5690&#x2013;5701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11114749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiningham KK, Cardozo ZA, Cook C, Cole MP, Stewart JC, et al. (2008) All-trans-retinoic acid induces manganese superoxide dismutase in human neuroblastoma cells through NF-kappaB. Free Radical Biol Med 44: 1610&#x2013;1616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2399892</ArticleId>
            <ArticleId IdType="pubmed">18280257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drubin DG, Feinstein SC, Shooter EM, Kirschner MW (1985) Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J Cell Biol 101: 1799&#x2013;807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2113947</ArticleId>
            <ArticleId IdType="pubmed">2997236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuijpers M, Hoogenraad CC (2011) Centrosomes, microtubules and neuronal development. Mol Cell Neurosci 48: 349&#x2013;358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21722732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ML, Chiou SH, Wu CW (2013) Targeting cancer stem cells: emerging role of Nanog transcription factor. OncoTargets and Therapy 6: 1207&#x2013;1220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3772775</ArticleId>
            <ArticleId IdType="pubmed">24043946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertuzzi A, Bruni C, Fasano A, Gandolfi A, Papa F, et al. (2010) Response of tumor spheroids to radiation: modelling and parameter estimation. Bull Math Biol 72: 1069&#x2013;1091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19915922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, et al. (2002) Expression of the neurotrophin receptor TrkA down regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 62: 1802&#x2013;1808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11912158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, et al. (2003) Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278: 37832&#x2013;37839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12853461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Li M, Jang J, Na H, Song N, et al. (2008) 15-deoxy-d12, 14-prostaglandin J2 rescues PC12 cells from H202-induced apoptosis through Nrf2-mediated upregulation of heme oxygenase-1: Potential roles for Akt and ERK1/2. Biochem Pharmacol 76: 1577&#x2013;1589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18775681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cozzi R, Ricordy R, Aglitti T, Gatta V, Perticone P, et al. (1997) Ascorbic acid and beta-carotene as modulators of oxidative damage. Carcinogenesis 18: 223&#x2013;228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9054610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicotera TM, Notaro J, Notaro S, Schumer J, Sandberg AA (1989) Elevated superoxide dismutase in Bloom&#x2019;s syndrome: a genetic condition of oxidative stress. Cancer Res 49: 5239&#x2013;5243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2766291</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24185179</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>09</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1876-7753</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Stem cell research</Title>
          <ISOAbbreviation>Stem Cell Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.</ArticleTitle>
        <Pagination>
          <StartPage>119</StartPage>
          <EndPage>131</EndPage>
          <MedlinePgn>119-31</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.scr.2013.09.012</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1873-5061(13)00138-4</ELocationID>
        <Abstract>
          <AbstractText>Reactive oxygen species (ROS) are involved in various aspects of cancer cell biology, yet their role in cancer stem cells (CSCs) has been poorly understood. In particular, it still remains unclear whether and how ROS control the self-renewal/differentiation process and the tumor-initiating capacity of CSCs. Here we show that ROS-mediated activation of p38 MAPK plays a pivotal role in the control of differentiation and tumor-initiating capacity of glioma-initiating cells (GICs) derived from human glioblastomas. Mechanistically, ROS triggered p38-dependent Bmi1 protein degradation and FoxO3 activation in GICs, which were shown to be responsible for the loss of their self-renewal capacity and differentiation, respectively. Thus, the results suggest that Bmi1 and FoxO3 govern distinct phases of transition from undifferentiated to fully differentiated cells. Furthermore, we also demonstrate in this study that oxidative stress deprives GICs of their tumor-initiating capacity through the activation of the ROS-p38 axis. As such, this is the first study to the best of our knowledge to delineate how ROS control self-renewal/differentiation and the tumor-initiating capacity of stem-like cancer cells. This study also suggests that targeting of the ROS-p38 axis could be a novel approach in the development of therapeutic strategies against gliomas, represented by glioblastoma.</AbstractText>
          <CopyrightInformation>&#xa9; 2013.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Atsushi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan; Department of Neurosurgery, Yamagata University School of Medicine, Yamagata 990-9585, Japan. Electronic address: asato@med.id.yamagata-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Okada</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shibuya</LastName>
            <ForeName>Keita</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan; Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata 990-9585, Japan; Global COE Program for Medical Sciences, Japan Society for the Promotion of Science, Tokyo 102-8471, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watanabe</LastName>
            <ForeName>Eriko</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan; Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata 990-9585, Japan; Global COE Program for Medical Sciences, Japan Society for the Promotion of Science, Tokyo 102-8471, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seino</LastName>
            <ForeName>Shizuka</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan; Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata 990-9585, Japan; Global COE Program for Medical Sciences, Japan Society for the Promotion of Science, Tokyo 102-8471, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Narita</LastName>
            <ForeName>Yoshitaka</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shibui</LastName>
            <ForeName>Soichiro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kayama</LastName>
            <ForeName>Takamasa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Yamagata University School of Medicine, Yamagata 990-9585, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kitanaka</LastName>
            <ForeName>Chifumi</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan; Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata 990-9585, Japan; Global COE Program for Medical Sciences, Japan Society for the Promotion of Science, Tokyo 102-8471, Japan. Electronic address: ckitanak@med.id.yamagata-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Stem Cell Res</MedlineTA>
        <NlmUniqueID>101316957</NlmUniqueID>
        <ISSNLinking>1873-5061</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C499517">FOXO3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071316">Forkhead Box Protein O3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5072-26-4</RegistryNumber>
          <NameOfSubstance UI="D019328">Buthionine Sulfoximine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="C481581">MAPK7 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048054">Mitogen-Activated Protein Kinase 7</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OU13V1EYWQ</RegistryNumber>
          <NameOfSubstance UI="C093642">SB 203580</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WYQ7N0BPYC</RegistryNumber>
          <NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019328" MajorTopicYN="N">Buthionine Sulfoximine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071316" MajorTopicYN="N">Forkhead Box Protein O3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048054" MajorTopicYN="N">Mitogen-Activated Protein Kinase 7</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2&#x2032;,7&#x2032;-dichlorofluorescein diacetate</Keyword>
        <Keyword MajorTopicYN="N">BSO</Keyword>
        <Keyword MajorTopicYN="N">CSC</Keyword>
        <Keyword MajorTopicYN="N">DCF-DA</Keyword>
        <Keyword MajorTopicYN="N">GFAP</Keyword>
        <Keyword MajorTopicYN="N">GIC</Keyword>
        <Keyword MajorTopicYN="N">GSH</Keyword>
        <Keyword MajorTopicYN="N">N-acetylcysteine</Keyword>
        <Keyword MajorTopicYN="N">NAC</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">cancer stem cell</Keyword>
        <Keyword MajorTopicYN="N">glial fibrillary acidic protein</Keyword>
        <Keyword MajorTopicYN="N">glioma-initiating cell</Keyword>
        <Keyword MajorTopicYN="N">glutathione</Keyword>
        <Keyword MajorTopicYN="N">l-buthionine-sulfoximine</Keyword>
        <Keyword MajorTopicYN="N">reactive oxygen species</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24185179</ArticleId>
        <ArticleId IdType="doi">10.1016/j.scr.2013.09.012</ArticleId>
        <ArticleId IdType="pii">S1873-5061(13)00138-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22505651</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>09</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-7445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>72</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution.</ArticleTitle>
        <Pagination>
          <StartPage>2949</StartPage>
          <EndPage>2956</EndPage>
          <MedlinePgn>2949-56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-11-4096</ELocationID>
        <Abstract>
          <AbstractText>Observing drug responses in the tumor microenvironment in vivo can be technically challenging. As a result, cellular responses to molecularly targeted cancer drugs are often studied in cell culture, which does not accurately represent the behavior of cancer cells growing in vivo. Using high-resolution microscopy and fluorescently labeled genetic reporters for apoptosis, we developed an approach to visualize drug-induced cell death at single-cell resolution in vivo. Stable expression of the mitochondrial intermembrane protein IMS-RP was established in human breast and pancreatic cancer cells. Image analysis was then used to quantify release of IMS-RP into the cytoplasm upon apoptosis and irreversible mitochondrial permeabilization. Both breast and pancreatic cancer cells showed higher basal apoptotic rates in vivo than in culture. To study drug-induced apoptosis, we exposed tumor cells to navitoclax (ABT-263), an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, both in vitro and in vivo. Although the tumors responded to Bcl-2 inhibition in vivo, inducing apoptosis in around 20% of cancer cells, the observed response was much higher in cell culture. Together, our findings show an imaging technique that can be used to directly visualize cell death within the tumor microenvironment in response to drug treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Earley</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Systems Biology, Massachusetts General Hospital, Boston 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vinegoni</LastName>
            <ForeName>Claudio</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dunham</LastName>
            <ForeName>Joshua</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorbatov</LastName>
            <ForeName>Rostic</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feruglio</LastName>
            <ForeName>Paolo Fumene</ForeName>
            <Initials>PF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weissleder</LastName>
            <ForeName>Ralph</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA164448</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>2P50CA086355</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 CA086355</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32-CA79443</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>2R01EB006432</GrantID>
            <Acronym>EB</Acronym>
            <Agency>NIBIB NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>S10 RR026360</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1P01CA139980</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1R01CA164448</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EB006432</GrantID>
            <Acronym>EB</Acronym>
            <Agency>NIBIB NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA139980</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>147336-22-9</RegistryNumber>
          <NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XKJ5VVK2WD</RegistryNumber>
          <NameOfSubstance UI="C528561">navitoclax</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057054" MajorTopicYN="N">Molecular Imaging</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22505651</ArticleId>
        <ArticleId IdType="mid">NIHMS451928</ArticleId>
        <ArticleId IdType="pmc">PMC3603290</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-4096</ArticleId>
        <ArticleId IdType="pii">0008-5472.CAN-11-4096</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Orth JD, Kohler RH, Foijer F, Sorger PK, Weissleder R, Mitchison TJ. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res. 2011;71:4608&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3129392</ArticleId>
            <ArticleId IdType="pubmed">21712408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell. 2008;30:11&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2858979</ArticleId>
            <ArticleId IdType="pubmed">18406323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholls SB, Chu J, Abbruzzese G, Tremblay KD, Hardy JA. Mechanism of a genetically encoded dark-to-bright reporter for caspase activity. J Biol Chem. 2011;286:24977&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137071</ArticleId>
            <ArticleId IdType="pubmed">21558267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewer A, Batchelor E, Gaglia G, Lahav G. Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell. 2010;142:89&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3003696</ArticleId>
            <ArticleId IdType="pubmed">20598361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian F, Deguchi K, Yamashita T, et al. In vivo imaging of autophagy in a mouse stroke model. Autophagy. 2010;6:1107&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20930570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ntziachristos V, Schellenberger EA, Ripoll J, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A. 2004;101:12294&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC514472</ArticleId>
            <ArticleId IdType="pubmed">15304657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blankenberg FG, Vanderheyden JL, Strauss HW, Tait JF. Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis. Nat Protoc. 2006;1:108&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17406220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001;7:1241&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11689890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10929711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dabov K, Foi A, Katkovnik V, Egiazarian K. Image denoising by sparse 3-D transform-domain collaborative filtering. IEEE Trans Image Process. 2007;16:2080&#x2013;95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17688213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fumene Feruglio P, Vinegoni C, Gros J, Sbarbati A, Weissleder R. Block matching 3D random noise filtering for absorption optical projection tomography. Phys Med Biol. 2010;55:5401&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2934766</ArticleId>
            <ArticleId IdType="pubmed">20736500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis Y, Bernardo-Faura M, Richter D, et al. Multi-Parametric Analysis and Modeling of Relationships between Mitochondrial Morphology and Apoptosis. PLoS One. 2012;7:e28694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3260148</ArticleId>
            <ArticleId IdType="pubmed">22272225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature. 2009;459:428&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2858974</ArticleId>
            <ArticleId IdType="pubmed">19363473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18451170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15902208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park CM, Bruncko M, Adickes J, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008;51:6902&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18841882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008;14:3268&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18519752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittet MJ, Weissleder R. Intravital imaging. Cell. 2011;147:983&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824153</ArticleId>
            <ArticleId IdType="pubmed">22118457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiner T, Earley S, Turetsky A, Weissleder R. Bioorthogonal small-molecule ligands for PARP1 imaging in living cells. Chembiochem. 2010;11:2374&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3034378</ArticleId>
            <ArticleId IdType="pubmed">20967817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budin G, Yang KS, Reiner T, Weissleder R. Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification. Angew Chem Int Ed Engl. 2011;50:9378&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3187564</ArticleId>
            <ArticleId IdType="pubmed">21948435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iannacone M, Moseman EA, Tonti E, et al. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature. 2010;465:1079&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2892812</ArticleId>
            <ArticleId IdType="pubmed">20577213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henrickson SE, Mempel TR, Mazo IB, et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol. 2008;9:282&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698867</ArticleId>
            <ArticleId IdType="pubmed">18204450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celli S, Albert ML, Bousso P. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nat Med. 2011;17:744&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21572426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vakoc BJ, Lanning RM, Tyrrell JA, et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med. 2009;15:1219&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759417</ArticleId>
            <ArticleId IdType="pubmed">19749772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Entenberg D, Wyckoff J, Gligorijevic B, et al. Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging. Nat Protoc. 2011;6:1500&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4028841</ArticleId>
            <ArticleId IdType="pubmed">21959234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573&#x2013;87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4030706</ArticleId>
            <ArticleId IdType="pubmed">21779009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10:445&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19546857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alencar H, Mahmood U, Kawano Y, Hirata T, Weissleder R. Novel multiwavelength microscopic scanner for mouse imaging. Neoplasia. 2005;7:977&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1502018</ArticleId>
            <ArticleId IdType="pubmed">16331883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barretto RP, Ko TH, Jung JC, et al. Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy. Nat Med. 2011;17:223&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3833825</ArticleId>
            <ArticleId IdType="pubmed">21240263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filonov GS, Piatkevich KD, Ting LM, Zhang J, Kim K, Verkhusha VV. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol. 2011;29:757&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3152693</ArticleId>
            <ArticleId IdType="pubmed">21765402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaqaman K, King EM, Amaro AC, et al. Kinetochore alignment within the metaphase plate is regulated by centromere stiffness and microtubule depolymerases. J Cell Biol. 2010;188:665&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2835940</ArticleId>
            <ArticleId IdType="pubmed">20212316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoma CR, Matov A, Gutbrodt KL, et al. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. J Cell Biol. 2010;190:991&#x2013;1003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3101603</ArticleId>
            <ArticleId IdType="pubmed">20855504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaqaman K, Loerke D, Mettlen M, et al. Robust single-particle tracking in live-cell time-lapse sequences. Nat Methods. 2008;5:695&#x2013;702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2747604</ArticleId>
            <ArticleId IdType="pubmed">18641657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andresen V, Alexander S, Heupel WM, Hirschberg M, Hoffman RM, Friedl P. Infrared multiphoton microscopy: subcellular-resolved deep tissue imaging. Curr Opin Biotechnol. 2009;20:54&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19324541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehm M, Huber HJ, Hellwig CT, Anguissola S, Dussmann H, Prehn JH. Dynamics of outer mitochondrial membrane permeabilization during apoptosis. Cell Death Differ. 2009;16:613&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19136937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan JY, Cui ZQ, Wei HP, et al. Split mCherry as a new red bimolecular fluorescence complementation system for visualizing protein-protein interactions in living cells. Biochem Biophys Res Commun. 2008;367:47&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18158915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22113996</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>08</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1460-2083</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Mar</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human molecular genetics</Title>
          <ISOAbbreviation>Hum Mol Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model.</ArticleTitle>
        <Pagination>
          <StartPage>1230</StartPage>
          <EndPage>1247</EndPage>
          <MedlinePgn>1230-47</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddr554</ELocationID>
        <Abstract>
          <AbstractText>Friedreich's ataxia (FRDA) is the most common inherited human ataxia and results from a deficiency of the mitochondrial protein, frataxin (FXN), which is encoded in the nucleus. This deficiency is associated with an iron-sulfur (Fe-S) cluster enzyme deficit leading to progressive ataxia and a frequently fatal cardiomyopathy. There is no cure. To determine whether exogenous replacement of the missing FXN protein in mitochondria would repair the defect, we used the transactivator of transcription (TAT) protein transduction domain to deliver human FXN protein to mitochondria in both cultured patient cells and a severe mouse model of FRDA. A TAT-FXN fusion protein bound iron in vitro, transduced into mitochondria of FRDA deficient fibroblasts and reduced caspase-3 activation in response to an exogenous iron-oxidant stress. Injection of TAT-FXN protein into mice with a conditional loss of FXN increased their growth velocity and mean lifespan by 53% increased their mean heart rate and cardiac output, increased activity of aconitase and reversed abnormal mitochondrial proliferation and ultrastructure in heart. These results show that a cell-penetrant peptide is capable of delivering a functional mitochondrial protein in vivo to rescue a very severe disease phenotype, and present the possibility of TAT-FXN as a protein replacement therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vyas</LastName>
            <ForeName>Piyush M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Riley Heart Research Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tomamichel</LastName>
            <ForeName>Wendy J</ForeName>
            <Initials>WJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pride</LastName>
            <ForeName>P Melanie</ForeName>
            <Initials>PM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Babbey</LastName>
            <ForeName>Clifford M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qiujuan</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mercier</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>Elizabeth M</ForeName>
            <Initials>EM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Payne</LastName>
            <ForeName>R Mark</ForeName>
            <Initials>RM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01HL 085098A1</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21NS 052198A1</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2011</Year>
          <Month>11</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Hum Mol Genet</MedlineTA>
        <NlmUniqueID>9208958</NlmUniqueID>
        <ISSNLinking>0964-6906</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015696">Gene Products, tat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033862">Iron-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C098527">frataxin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.-</RegistryNumber>
          <NameOfSubstance UI="C045073">Cre recombinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.-</RegistryNumber>
          <NameOfSubstance UI="D019426">Integrases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.3</RegistryNumber>
          <NameOfSubstance UI="D000154">Aconitate Hydratase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000154" MajorTopicYN="N">Aconitate Hydratase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005621" MajorTopicYN="N">Friedreich Ataxia</DescriptorName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015696" MajorTopicYN="N">Gene Products, tat</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019426" MajorTopicYN="N">Integrases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033862" MajorTopicYN="N">Iron-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22113996</ArticleId>
        <ArticleId IdType="pmc">PMC3284115</ArticleId>
        <ArticleId IdType="doi">10.1093/hmg/ddr554</ArticleId>
        <ArticleId IdType="pii">ddr554</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Harding A.E. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104:589&#x2013;620. doi:10.1093/brain/104.3.589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/104.3.589</ArticleId>
            <ArticleId IdType="pubmed">7272714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malo S., Latour Y., Cote M., Geoffroy G., Lemieux B., Barbeau A. Electrocardiographic and vectocardiographic findings in Friedreich's ataxia. Can. J. Neurol. Sci. 1976;3:323&#x2013;328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1000416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsou A.Y., Paulsen E.K., Lagedrost S.J., Perlman S.L., Mathews K.D., Wilmot G.R., Ravina B., Koeppen A.H., Lynch D.R. Mortality in friedreich ataxia. J. Neurol. Sci. 2011;307:46&#x2013;49. doi:10.1016/j.jns.2011.05.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2011.05.023</ArticleId>
            <ArticleId IdType="pubmed">21652007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schols L., Amoiridis G., Przuntek H., Frank G., Epplen J.T., Epplen C. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain. 1997;120(Pt 12):2131&#x2013;2140. doi:10.1093/brain/120.12.2131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/120.12.2131</ArticleId>
            <ArticleId IdType="pubmed">9448568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filla A., De Michele G., Marconi R., Bucci L., Carillo C., Castellano A.E., Iorio L., Kniahynicki C., Rossi F., Campanella G. Prevalence of hereditary ataxias and spastic paraplegias in Molise, a region of Italy. J. Neurol. 1992;239:351&#x2013;353. doi:10.1007/BF00867594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00867594</ArticleId>
            <ArticleId IdType="pubmed">1512613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo G., Menozzi P., Ferlini A., Fadda S., Di Donato S., Uziel G., Lucci B., Capodaglio L., Filla A., Campanella G. Incidence of Friedreich ataxia in Italy estimated from consanguineous marriages. Am. J. Hum. Genet. 1983;35:523&#x2013;529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1685654</ArticleId>
            <ArticleId IdType="pubmed">6859045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skre H. Friedreich's ataxia in Western Norway. Clin. Genet. 1975;7:287&#x2013;298. doi:10.1111/j.1399-0004.1975.tb00331.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1399-0004.1975.tb00331.x</ArticleId>
            <ArticleId IdType="pubmed">1126051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epplen C., Epplen J.T., Frank G., Miterski B., Santos E.J., Schols L. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum. Genet. 1997;99:834&#x2013;836. doi:10.1007/s004390050458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004390050458</ArticleId>
            <ArticleId IdType="pubmed">9187683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandolfo M. Friedreich ataxia. Arch. Neurol. 2008;65:1296&#x2013;1303. doi:10.1001/archneur.65.10.1296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.65.10.1296</ArticleId>
            <ArticleId IdType="pubmed">18852343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel P.I., Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am. J. Hum. Genet. 2001;69:15&#x2013;24. doi:10.1086/321283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/321283</ArticleId>
            <ArticleId IdType="pmc">PMC1226030</ArticleId>
            <ArticleId IdType="pubmed">11391483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gacy A.M., Goellner G.M., Spiro C., Chen X., Gupta G., Bradbury E.M., Dyer R.B., Mikesell M.J., Yao J.Z., Johnson A.J., et al. GAA instability in Friedreich's Ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Mol. Cell. 1998;1:583&#x2013;593. doi:10.1016/S1097-2765(00)80058-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(00)80058-1</ArticleId>
            <ArticleId IdType="pubmed">9660942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakamoto N., Ohshima K., Montermini L., Pandolfo M., Wells R.D. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem. 2001;276:27171&#x2013;27177. doi:10.1074/jbc.M101879200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M101879200</ArticleId>
            <ArticleId IdType="pubmed">11340071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman D., Jenssen K., Burnett R., Soragni E., Perlman S.L., Gottesfeld J.M. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2006;2:551&#x2013;558. doi:10.1038/nchembio815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio815</ArticleId>
            <ArticleId IdType="pubmed">16921367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montermini L., Richter A., Morgan K., Justice C.M., Julien D., Castellotti B., Mercier J., Poirier J., Capozzoli F., Bouchard J.P., et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann. Neurol. 1997;41:675&#x2013;682. doi:10.1002/ana.410410518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410410518</ArticleId>
            <ArticleId IdType="pubmed">9153531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filla A., De Michele G., Cavalcanti F., Pianese L., Monticelli A., Campanella G., Cocozza S. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 1996;59:554&#x2013;560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1914893</ArticleId>
            <ArticleId IdType="pubmed">8751856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Lyver E.R., Knight S.A., Pain D., Lesuisse E., Dancis A. Mrs3p, Mrs4p, and frataxin provide iron for Fe&#x2013;S cluster synthesis in mitochondria. J. Biol. Chem. 2006;281:22493&#x2013;22502. doi:10.1074/jbc.M604246200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M604246200</ArticleId>
            <ArticleId IdType="pubmed">16769722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang M.L., Becker E.M., Whitnall M., Rahmanto Y.S., Ponka P., Richardson D.R. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl Acad. Sci. USA. 2009;106:16381&#x2013;16386. doi:10.1073/pnas.0906784106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0906784106</ArticleId>
            <ArticleId IdType="pmc">PMC2752539</ArticleId>
            <ArticleId IdType="pubmed">19805308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon T., Cowan J.A. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem. 2004;279:25943&#x2013;25946. doi:10.1074/jbc.C400107200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C400107200</ArticleId>
            <ArticleId IdType="pubmed">15123683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correia A.R., Wang T., Craig E.A., Gomes C.M. Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region. Biochem. J. 2010;426:197&#x2013;203. doi:10.1042/BJ20091612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20091612</ArticleId>
            <ArticleId IdType="pmc">PMC2819628</ArticleId>
            <ArticleId IdType="pubmed">20001966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai C.L., Barondeau D.P. Human frataxin is an allosteric switch that activates the Fe&#x2013;S cluster biosynthetic complex. Biochemistry. 2010;49:9132&#x2013;9139. doi:10.1021/bi1013062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi1013062</ArticleId>
            <ArticleId IdType="pubmed">20873749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stemmler T.L., Lesuisse E., Pain D., Dancis A. Frataxin and mitochondrial FeS cluster biogenesis. J. Biol. Chem. 2010;285:26737&#x2013;26743. doi:10.1074/jbc.R110.118679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.R110.118679</ArticleId>
            <ArticleId IdType="pmc">PMC2930671</ArticleId>
            <ArticleId IdType="pubmed">20522547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmucker S., Martelli A., Colin F., Page A., Wattenhofer-Donze M., Reutenauer L., Puccio H. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron&#x2013;sulfur assembly complex. PLoS One. 2011;6:e16199. doi:10.1371/journal.pone.0016199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0016199</ArticleId>
            <ArticleId IdType="pmc">PMC3027643</ArticleId>
            <ArticleId IdType="pubmed">21298097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotig A., de L.P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A., Rustin P. Aconitase and mitochondrial iron&#x2013;sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 1997;17:215&#x2013;217. doi:10.1038/ng1097-215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1097-215</ArticleId>
            <ArticleId IdType="pubmed">9326946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lodi R., Cooper J.M., Bradley J.L., Manners D., Styles P., Taylor D.J., Schapira A.H. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA. 1999;96:11492&#x2013;11495. doi:10.1073/pnas.96.20.11492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.96.20.11492</ArticleId>
            <ArticleId IdType="pmc">PMC18061</ArticleId>
            <ArticleId IdType="pubmed">10500204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lodi R., Rajagopalan B., Blamire A.M., Cooper J.M., Davies C.H., Bradley J.L., Styles P., Schapira A.H. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc. Res. 2001;52:111&#x2013;119. doi:10.1016/S0008-6363(01)00357-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0008-6363(01)00357-1</ArticleId>
            <ArticleId IdType="pubmed">11557239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gakh O., Cavadini P., Isaya G. Mitochondrial processing peptidases. Biochim. Biophys. Acta. 2002;1592:63&#x2013;77. doi:10.1016/S0167-4889(02)00265-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0167-4889(02)00265-3</ArticleId>
            <ArticleId IdType="pubmed">12191769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavadini P., Adamec J., Taroni F., Gakh O., Isaya G. Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates. J. Biol. Chem. 2000;275:41469&#x2013;41475. doi:10.1074/jbc.M006539200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M006539200</ArticleId>
            <ArticleId IdType="pubmed">11020385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condo I., Ventura N., Malisan F., Rufini A., Tomassini B., Testi R. In vivo maturation of human frataxin. Hum. Mol. Genet. 2007;16:1534&#x2013;1540. doi:10.1093/hmg/ddm102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddm102</ArticleId>
            <ArticleId IdType="pubmed">17468497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmucker S., Argentini M., Carelle-Calmels N., Martelli A., Puccio H. The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet. 2008;17:3521&#x2013;3531. doi:10.1093/hmg/ddn244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddn244</ArticleId>
            <ArticleId IdType="pubmed">18725397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson D.R. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert. Opin. Investig. Drugs. 2003;12:235&#x2013;245. doi:10.1517/13543784.12.2.235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.12.2.235</ArticleId>
            <ArticleId IdType="pubmed">12556217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jauslin M.L., Meier T., Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003;17:1972&#x2013;1974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12923074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., Blamire A.M., Manners D., Styles P., Schapira A.H., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 2005;62:621&#x2013;626. doi:10.1001/archneur.62.4.621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.62.4.621</ArticleId>
            <ArticleId IdType="pubmed">15824263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puccio H., Simon D., Cossee M., Criqui-Filipe P., Tiziano F., Melki J., Hindelang C., Matyas R., Rustin P., Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe&#x2013;S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001;27:181&#x2013;186. doi:10.1038/84818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/84818</ArticleId>
            <ArticleId IdType="pubmed">11175786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569&#x2013;1572. doi:10.1126/science.285.5433.1569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.285.5433.1569</ArticleId>
            <ArticleId IdType="pubmed">10477521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Gaizo-Moore V., MacKenzie J.A., Payne R.M. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 2003;80:170&#x2013;180. doi:10.1016/j.ymgme.2003.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymgme.2003.08.017</ArticleId>
            <ArticleId IdType="pubmed">14567966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X.Y., Dinh A., Cronin J., Li S.C., Reiser J. Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain. J. Neurochem. 2008;104:1055&#x2013;1064. doi:10.1111/j.1471-4159.2007.05030.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2007.05030.x</ArticleId>
            <ArticleId IdType="pubmed">17986221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen K.D., Nori A., Tijerina M., Kopeckova P., Kopecek J. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J. Control. Release. 2003;87:89&#x2013;105. doi:10.1016/S0168-3659(02)00352-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0168-3659(02)00352-8</ArticleId>
            <ArticleId IdType="pubmed">12618026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Gaizo V., Payne R.M. A novel TAT-Mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther. 2003;7:720&#x2013;730. doi:10.1016/S1525-0016(03)00130-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1525-0016(03)00130-8</ArticleId>
            <ArticleId IdType="pubmed">12788645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra A., Lai G.H., Schmidt N.W., Sun V.Z., Rodriguez A.R., Tong R., Tang L., Cheng J., Deming T.J., Kamei D.T., et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc. Natl. Acad. Sci. U.S.A. 2011;108:16883&#x2013;16888. doi:10.1073/pnas.1108795108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1108795108</ArticleId>
            <ArticleId IdType="pmc">PMC3193208</ArticleId>
            <ArticleId IdType="pubmed">21969533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapoport M., Salman L., Sabag O., Patel M.S., Lorberboum-Galski H. Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency. J. Mol. Med. 2011;89:161&#x2013;170. doi:10.1007/s00109-010-0693-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-010-0693-3</ArticleId>
            <ArticleId IdType="pubmed">21079907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toro A., Grunebaum E. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J. Clin. Invest. 2006;116:2717&#x2013;2726. doi:10.1172/JCI25052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI25052</ArticleId>
            <ArticleId IdType="pmc">PMC1560347</ArticleId>
            <ArticleId IdType="pubmed">16964310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pendergrass W., Wolf N., Poot M. Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry A. 2004;61:162&#x2013;169. doi:10.1002/cyto.a.20033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cyto.a.20033</ArticleId>
            <ArticleId IdType="pubmed">15382028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poot M., Zhang Y.Z., Kramer J.A., Wells K.S., Jones L.J., Hanzel D.K., Lugade A.G., Singer V.L., Haugland R.P. Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. J. Histochem. Cytochem. 1996;44:1363&#x2013;1372. doi:10.1177/44.12.8985128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/44.12.8985128</ArticleId>
            <ArticleId IdType="pubmed">8985128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adamec J., Gakh O., Spizek J., Kalousek F. Complementation between mitochondrial processing peptidase (MPP) subunits from different species. Arch. Biochem. Biophys. 1999;370:77&#x2013;85. doi:10.1006/abbi.1999.1397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/abbi.1999.1397</ArticleId>
            <ArticleId IdType="pubmed">10496979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu T.W., Eftime R., Sztul E., Strauss A.W. Synthetic transit peptides inhibit import and processing of mitochondrial precursor proteins. J. Biol. Chem. 1989;264:9552&#x2013;9558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2722850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sztul E.S., Chu T.W., Strauss A.W., Rosenberg L.E. Import of the malate dehydrogenase precursor by mitochondria. Cleavage within leader peptide by matrix protease leads to formation of intermediate-sized form. J. Biol. Chem. 1988;263:12085&#x2013;12091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3042789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isaya G., Kalousek F., Fenton W.A., Rosenberg L.E. Cleavage of precursors by the mitochondrial processing peptidase requires a compatible mature protein or an intermediate octapeptide. J. Cell. Biol. 1991;113:65&#x2013;76. doi:10.1083/jcb.113.1.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.113.1.65</ArticleId>
            <ArticleId IdType="pmc">PMC2288917</ArticleId>
            <ArticleId IdType="pubmed">1672532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu C., Cortopassi G. Frataxin knockdown causes loss of cytoplasmic iron&#x2013;sulfur cluster functions, redox alterations and induction of heme transcripts. Arch. Biochem. Biophys. 2007;457:111&#x2013;122. doi:10.1016/j.abb.2006.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.abb.2006.09.010</ArticleId>
            <ArticleId IdType="pmc">PMC1847786</ArticleId>
            <ArticleId IdType="pubmed">17098208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., Szweda L.I. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science. 2004;305:242&#x2013;245. doi:10.1126/science.1098991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1098991</ArticleId>
            <ArticleId IdType="pubmed">15247478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mordente A., Martorana G.E., Minotti G., Giardina B. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone) Chem. Res. Toxicol. 1998;11:54&#x2013;63. doi:10.1021/tx970136j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/tx970136j</ArticleId>
            <ArticleId IdType="pubmed">9477226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillner M., Moore G.S., Cederberg H., Gustafsson K. Hydroquinone (environmental Health Criteria, No 157) Geneva, Switzerland: World Health Organization; 1994.</Citation>
        </Reference>
        <Reference>
          <Citation>Pastore C., Franzese M., Sica F., Temussi P., Pastore A. Understanding the binding properties of an unusual metal-binding protein&#x2013;a study of bacterial frataxin. Febs J. 2007;274:4199&#x2013;4210. doi:10.1111/j.1742-4658.2007.05946.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-4658.2007.05946.x</ArticleId>
            <ArticleId IdType="pubmed">17651435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radisky D.C., Babcock M.C., Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J. Biol. Chem. 1999;274:4497&#x2013;4499. doi:10.1074/jbc.274.8.4497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.8.4497</ArticleId>
            <ArticleId IdType="pubmed">9988680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foury F., Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997;411:373&#x2013;377. doi:10.1016/S0014-5793(97)00734-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(97)00734-5</ArticleId>
            <ArticleId IdType="pubmed">9271239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong A., Yang J., Cavadini P., Gellera C., Lonnerdal B., Taroni F., Cortopassi G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 1999;8:425&#x2013;430. doi:10.1093/hmg/8.3.425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/8.3.425</ArticleId>
            <ArticleId IdType="pubmed">9949201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin F., Girotti A.W. Elevated ferritin production, iron containment, and oxidant resistance in hemin-treated leukemia cells. Arch. Biochem. Biophys. 1997;346:131&#x2013;141. doi:10.1006/abbi.1997.0300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/abbi.1997.0300</ArticleId>
            <ArticleId IdType="pubmed">9328293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oubidar M., Marie C., Mossiat C., Bralet J. Effects of increasing intracellular reactive iron level on cardiac function and oxidative injury in the isolated rat heart. J. Mol. Cell. Cardiol. 1996;28:1769&#x2013;1776. doi:10.1006/jmcc.1996.0166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/jmcc.1996.0166</ArticleId>
            <ArticleId IdType="pubmed">8877786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sogabe K., Roeser N.F., Venkatachalam M.A., Weinberg J.M. Differential cytoprotection by glycine against oxidant damage to proximal tubule cells. Kidney Int. 1996;50:845&#x2013;854. doi:10.1038/ki.1996.384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.1996.384</ArticleId>
            <ArticleId IdType="pubmed">8872959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balla G., Vercellotti G.M., Eaton J.W., Jacob H.S. Iron loading of endothelial cells augments oxidant damage. J. Lab. Clin. Med. 1990;116:546&#x2013;554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2120376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cossee M., Puccio H., Gansmuller A., Koutnikova H., Dierich A., LeMeur M., Fischbeck K., Dolle P., Koenig M. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 2000;9:1219&#x2013;1226. doi:10.1093/hmg/9.8.1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/9.8.1219</ArticleId>
            <ArticleId IdType="pubmed">10767347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cinato E., Mirotsou M., Sablitzky F. Cre-mediated transgene activation in the developing and adult mouse brain. Genesis. 2001;31:118&#x2013;125. doi:10.1002/gene.10014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gene.10014</ArticleId>
            <ArticleId IdType="pubmed">11747202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Sharaby A.A., Egerbacher M., Hammoda A.K., Bock P. Immunohistochemical demonstration of Leu-7 (HNK-1), Neurone-specific Enolase (NSE) and Protein-Gene Peptide (PGP) 9.5 in the developing camel (Camelus dromedarius) heart. Anat. Histol. Embryol. 2001;30:321&#x2013;325. doi:10.1046/j.1439-0264.2001.00343.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1439-0264.2001.00343.x</ArticleId>
            <ArticleId IdType="pubmed">11820399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semba R., Asano T., Kato K. Physiological expression of neural marker proteins in the heart of young rats. Brain Res. Dev. Brain Res. 1990;54:217&#x2013;220. doi:10.1016/0165-3806(90)90144-N.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165-3806(90)90144-N</ArticleId>
            <ArticleId IdType="pubmed">2118839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bland J.M., Altman D.G. The logrank test. Br. Med. J. 2004;328:1073. doi:10.1136/bmj.328.7447.1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.328.7447.1073</ArticleId>
            <ArticleId IdType="pmc">PMC403858</ArticleId>
            <ArticleId IdType="pubmed">15117797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel A.L., Engstrom J.L., Meier P.P., Kimura R.E. Accuracy of methods for calculating postnatal growth velocity for extremely low birth weight infants. Pediatrics. 2005;116:1466&#x2013;1473. doi:10.1542/peds.2004-1699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2004-1699</ArticleId>
            <ArticleId IdType="pubmed">16322172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stehling O., Elsasser H.P., Bruckel B., Muhlenhoff U., Lill R. Iron&#x2013;sulfur protein maturation in human cells: evidence for a function of frataxin. Hum. Mol. Genet. 2004;13:3007&#x2013;3015. doi:10.1093/hmg/ddh324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddh324</ArticleId>
            <ArticleId IdType="pubmed">15509595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitnall M., Rahmanto Y.S., Sutak R., Xu X., Becker E.M., Mikhael M.R., Ponka P., Richardson D.R. The MCK mouse heart model of Friedreich's ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc. Natl Acad. Sci. USA. 2008;105:9757&#x2013;9762. doi:10.1073/pnas.0804261105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0804261105</ArticleId>
            <ArticleId IdType="pmc">PMC2474513</ArticleId>
            <ArticleId IdType="pubmed">18621680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seznec H., Simon D., Bouton C., Reutenauer L., Hertzog A., Golik P., Procaccio V., Patel M., Drapier J.C., Koenig M., et al. Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet. 2005;14:463&#x2013;474. doi:10.1093/hmg/ddi042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddi042</ArticleId>
            <ArticleId IdType="pubmed">15615771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martelli A., Wattenhofer-Donze M., Schmucker S., Bouvet S., Reutenauer L., Puccio H. Frataxin is essential for extramitochondrial Fe&#x2013;S cluster proteins in mammalian tissues. Hum. Mol. Genet. 2007;16:2651&#x2013;2658. doi:10.1093/hmg/ddm163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddm163</ArticleId>
            <ArticleId IdType="pubmed">17597094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lill R., Muhlenhoff U. Maturation of iron&#x2013;sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases. Annu. Rev. Biochem. 2008;77:669&#x2013;700. doi:10.1146/annurev.biochem.76.052705.162653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.76.052705.162653</ArticleId>
            <ArticleId IdType="pubmed">18366324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noble R.J., Nutter D.O. The demonstration of alternating contractile state in pulsus alternans. J. Clin. Invest. 1970;49:1166&#x2013;1177. doi:10.1172/JCI106331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI106331</ArticleId>
            <ArticleId IdType="pmc">PMC322583</ArticleId>
            <ArticleId IdType="pubmed">5422019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho C.Y. Echocardiographic assessment of diastolic function. In: Solomon S.D., Bulwer B.E., editors. Essential Echocardiography: A Practical Handbook. New York: Humana Press; 2007. pp. 119&#x2013;131.</Citation>
        </Reference>
        <Reference>
          <Citation>Dutka D.P., Donnelly J.E., Palka P., Lange A., Nunez D.J., Nihoyannopoulos P. Echocardiographic characterization of cardiomyopathy in Friedreich's ataxia with tissue Doppler echocardiographically derived myocardial velocity gradients. Circulation. 2000;102:1276&#x2013;1282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10982543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laguens R.P., Gomez-Dumm C.L. Fine structure of myocardial mitochondria in rats after exercise for one-half to two hours. Circ. Res. 1967;21:271&#x2013;279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6054010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laguens R.P., Weinschelbaun R., Favaloro R. Ultrastructural and morphometric study of the human heart muscle cell in acute coronary insufficiency. Hum. Pathol. 1979;10:695&#x2013;705. doi:10.1016/S0046-8177(79)80113-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0046-8177(79)80113-6</ArticleId>
            <ArticleId IdType="pubmed">527966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu W., Soonpaa M.H., Chen H., Shen W., Payne R.M., Liechty E.A., Caldwell R.L., Shou W., Field L.J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation. 2009;119:99&#x2013;106. doi:10.1161/CIRCULATIONAHA.108.799700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.799700</ArticleId>
            <ArticleId IdType="pmc">PMC2630181</ArticleId>
            <ArticleId IdType="pubmed">19103993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morvan D., Komajda M., Doan L.D., Brice A., Isnard R., Seck A., Lechat P., Agid Y., Grosgogeat Y. Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. Eur. Heart. J. 1992;13:1393&#x2013;1398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1396814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mottram P.M., Delatycki M.B., Donelan L., Gelman J.S., Corben L., Peverill R.E. Early changes in left ventricular long-axis function in Friedreich ataxia: relation with the FXN gene mutation and cardiac structural change. J. Am. Soc. Echocardiogr. 2011;24:782&#x2013;789. doi:10.1016/j.echo.2011.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.echo.2011.04.004</ArticleId>
            <ArticleId IdType="pubmed">21570254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regner S.R., Lagedrost S.J., Plappert T., Paulsen E.K., Friedman L.S., Snyder M.L., Perlman S.L., Mathews K.D., Wilmot G.R., Schadt K.A., et al. Analysis of Echocardiograms in a Large Heterogeneous Cohort of Patients with Friedreich Ataxia. Am. J. Cardiol. 2011 [Epub ahead of print]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace D.C. Mitochondrial diseases in man and mouse. Science. 1999;283:1482&#x2013;1488. doi:10.1126/science.283.5407.1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.283.5407.1482</ArticleId>
            <ArticleId IdType="pubmed">10066162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neupert W., Herrmann J.M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 2007;76:723&#x2013;749. doi:10.1146/annurev.biochem.76.052705.163409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.76.052705.163409</ArticleId>
            <ArticleId IdType="pubmed">17263664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gobbi H., Barbosa A.J., Teixeira V.P., Almeida H.O. Immunocytochemical identification of neuroendocrine markers in human cardiac paraganglion-like structures. Histochemistry. 1991;95:337&#x2013;340. doi:10.1007/BF00266960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00266960</ArticleId>
            <ArticleId IdType="pubmed">1827088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce J.M., Edwards Y.H., Harris H. Human enolase isozymes: electrophoretic and biochemical evidence for three loci. Ann. Hum. Genet. 1976;39:263&#x2013;276. doi:10.1111/j.1469-1809.1976.tb00130.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-1809.1976.tb00130.x</ArticleId>
            <ArticleId IdType="pubmed">5939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skowasch D., Jabs A., Andrie R., Dinkelbach S., Luderitz B., Bauriedel G. Presence of bone-marrow- and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc. Res. 2003;60:684&#x2013;691. doi:10.1016/j.cardiores.2003.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cardiores.2003.09.001</ArticleId>
            <ArticleId IdType="pubmed">14659814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haimoto H., Takahashi Y., Koshikawa T., Nagura H., Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab. Invest. 1985;52:257&#x2013;263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3974199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forss-Petter S., Danielson P.E., Catsicas S., Battenberg E., Price J., Nerenberg M., Sutcliffe J.G. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron. 1990;5:187&#x2013;197. doi:10.1016/0896-6273(90)90308-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0896-6273(90)90308-3</ArticleId>
            <ArticleId IdType="pubmed">2116814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frugier T., Tiziano F.D., Cifuentes-Diaz C., Miniou P., Roblot N., Dierich A., Le M.M., Melki J. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 2000;9:849&#x2013;858. doi:10.1093/hmg/9.5.849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/9.5.849</ArticleId>
            <ArticleId IdType="pubmed">10749994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quercia N., Somers G.R., Halliday W., Kantor P.F., Banwell B., Yoon G. Friedreich ataxia presenting as sudden cardiac death in childhood: clinical, genetic and pathological correlation, with implications for genetic testing and counselling. Neuromuscul. Disord. 2010;20:340&#x2013;342. doi:10.1016/j.nmd.2010.02.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2010.02.019</ArticleId>
            <ArticleId IdType="pubmed">20338762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campuzano V., Montermini L., Lutz Y., Cova L., Hindelang C., Jiralerspong S., Trottier Y., Kish S.J., Faucheux B., Trouillas P., et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 1997;6:1771&#x2013;1780. doi:10.1093/hmg/6.11.1771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/6.11.1771</ArticleId>
            <ArticleId IdType="pubmed">9302253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye N., Liu S., Lin Y., Rao P. Protective effects of intraperitoneal injection of TAT-SOD against focal cerebral ischemia/reperfusion injury in rats. Life Sciences. 2011;89:868&#x2013;874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21983418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asoh S., Ohsawa I., Mori T., Katsura K., Hiraide T., Katayama Y., Kimura M., Ozaki D., Yamagata K., Ohta S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl Acad. Sci. USA. 2002;99:17107&#x2013;17112. doi:10.1073/pnas.262460299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.262460299</ArticleId>
            <ArticleId IdType="pmc">PMC139277</ArticleId>
            <ArticleId IdType="pubmed">12475933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao G., Pei W., Ge H., Liang Q., Luo Y., Sharp F.R., Lu A., Ran R., Graham S.H., Chen J. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 2002;22:5423&#x2013;5431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6758230</ArticleId>
            <ArticleId IdType="pubmed">12097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D.W., Eum W.S., Jang S.H., Kim S.Y., Choi H.S., Choi S.H., An J.J., Lee S.H., Lee K.S., Han K., et al. Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol. Cells. 2005;19:88&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15750345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan G., Chen L.S., Lonnerdal B., Gellera C., Taroni F.A., Cortopassi G.A. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet. 2001;10:2099&#x2013;2107. doi:10.1093/hmg/10.19.2099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/10.19.2099</ArticleId>
            <ArticleId IdType="pubmed">11590127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant P.M., Roderick S.L., Grant G.A., Banaszak L.J., Strauss A.W. Comparison of the precursor and mature forms of rat heart mitochondrial malate dehydrogenase. Biochemistry. 1987;26:128&#x2013;134. doi:10.1021/bi00375a019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi00375a019</ArticleId>
            <ArticleId IdType="pubmed">3828294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant P.M., Tellam J., May V.L., Strauss A.W. Isolation and nucleotide sequence of a cDNA clone encoding rat mitochondrial malate dehydrogenase. Nucleic Acids Res. 1986;14:6053&#x2013;6066. doi:10.1093/nar/14.15.6053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/14.15.6053</ArticleId>
            <ArticleId IdType="pmc">PMC311621</ArticleId>
            <ArticleId IdType="pubmed">3755817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K., Besse E.K., Ha D., Kovtunovych G., Rouault T.A. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet. 2008;17:2265&#x2013;2273. doi:10.1093/hmg/ddn127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddn127</ArticleId>
            <ArticleId IdType="pmc">PMC2465796</ArticleId>
            <ArticleId IdType="pubmed">18424449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima H., Nakajima H.O., Tsai S.C., Field L.J. Expression of mutant p193 and p53 permits cardiomyocyte cell cycle reentry after myocardial infarction in transgenic mice. Circ. Res. 2004;94:1606&#x2013;1614. doi:10.1161/01.RES.0000132279.99249.f4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000132279.99249.f4</ArticleId>
            <ArticleId IdType="pubmed">15142950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X.M., Agrotis A., Autelitano D.J., Percy E., Woodcock E.A., Jennings G.L., Dart A.M., Du X.J. Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. Endocrinology. 2003;144:4097&#x2013;4105. doi:10.1210/en.2002-0214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2002-0214</ArticleId>
            <ArticleId IdType="pubmed">12933684</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20000005</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0387-821X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>31</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Dec</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of UOEH</Title>
          <ISOAbbreviation>J UOEH</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Potent antioxidant and radical-scavenging activity of Chenpi--compensatory and cooperative actions of ascorbic acid and citric acid.</ArticleTitle>
        <Pagination>
          <StartPage>311</StartPage>
          <EndPage>324</EndPage>
          <MedlinePgn>311-24</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Dried peels of Satsuma mandarin (Citrus unshiu Marcov.) have been used as traditional Chinese and Japanese medicine, which are called 'Chenpi'. In our present study, cold and hot water extracts of Chenpi exhibited a strong inhibitory activity against linoleic acid peroxidation and 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical-scavenging activity compared with o-methanol extract. When these extracts were separated into ethanol-soluble(ES) and ethanol-precipitable fractions, the dominant antioxidant and radical-scavenging activities were detected in the ES fractions, which suggests that these antioxidant and radical-scavenging activities are responsible for water-soluble and low-molecular-weight substances. As possible active principles for antioxidant activities in the water extracts, the contents of ascorbic acid and citric acid in these extracts were measured, and the antioxidant and radical-scavenging activities of these substances were assayed at various concentrations. The experimental results indicate that the antioxidant activity against lipid peroxidation in the water extracts is dominantly associated with citric acid, and the DPPH radical-scavenging activity of the water extracts is majorly responsible for ascorbic acid, suggesting a compensatory action of ascorbic acid and citric acid in expression of the antioxidant and radical-scavenging activities of Chenpi.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Higashi-Okai</LastName>
            <ForeName>Kiyoka</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Food and Nutritional Environment, College of Human Life Environment, Kinjo Gakuin University, Moriyanma-Ku, Nagoya 463-8521, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishikawa</LastName>
            <ForeName>Akiko</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yasumoto</LastName>
            <ForeName>Sayuri</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Okai</LastName>
            <ForeName>Yasuji</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>J UOEH</MedlineTA>
        <NlmUniqueID>7909645</NlmUniqueID>
        <ISSNLinking>0387-821X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2968PHW8QP</RegistryNumber>
          <NameOfSubstance UI="D019343">Citric Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9KJL21T0QJ</RegistryNumber>
          <NameOfSubstance UI="D019787">Linoleic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PQ6CK8PD0R</RegistryNumber>
          <NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="Y">Antioxidants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019343" MajorTopicYN="N">Citric Acid</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002957" MajorTopicYN="N">Citrus</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016166" MajorTopicYN="Y">Free Radical Scavengers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019787" MajorTopicYN="N">Linoleic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20000005</ArticleId>
        <ArticleId IdType="doi">10.7888/juoeh.31.311</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19559717</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0027-5107</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>669</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Oct</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Mutation research</Title>
          <ISOAbbreviation>Mutat Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>DNA damage and repair in age-related macular degeneration.</ArticleTitle>
        <Pagination>
          <StartPage>169</StartPage>
          <EndPage>176</EndPage>
          <MedlinePgn>169-76</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mrfmmm.2009.06.008</ELocationID>
        <Abstract>
          <AbstractText>Age-related macular degeneration (AMD) is a retinal degenerative disease that is the main cause of vision loss in individuals over the age of 55 in the Western world. Clinically relevant AMD results from damage to the retinal pigment epithelial (RPE) cells thought to be mainly caused by oxidative stress. The stress also affects the DNA of RPE cells, which promotes genome instability in these cells. These effects may coincide with the decrease in the efficacy of DNA repair with age. Therefore individuals with DNA repair impaired more than average for a given age may be more susceptible to AMD if oxidative stress affects their RPE cells. This may be helpful in AMD risk assessment. In the present work we determined the level of basal (measured in the alkaline comet assay) endogenous and endogenous oxidative DNA damage, the susceptibility to exogenous mutagens and the efficacy of DNA repair in lymphocytes of 100 AMD patients and 110 age-matched individuals without visual disturbances. The cells taken from AMD patients displayed a higher extent of basal endogenous DNA damage without differences between patients of dry and wet forms of the disease. DNA double-strand breaks did not contribute to the observed DNA damage as checked by the neutral comet assay and pulsed field gel electrophoresis. The extent of oxidative modification to DNA bases was greater in AMD patients than in the controls, as probed by DNA repair enzymes NTH1 and Fpg. Lymphocytes from AMD patients displayed a higher sensitivity to hydrogen peroxide and UV radiation and repaired lesions induced by these factors less effectively than the cells from the control individuals. We postulate that the impaired efficacy of DNA repair may combine with enhanced sensitivity of RPE cells to blue and UV lights, contributing to the pathogenesis of AMD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Szaflik</LastName>
            <ForeName>Jacek P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Medical University of Warsaw and Samodzielny Publiczny Szpital Okulistyczny, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Janik-Papis</LastName>
            <ForeName>Katarzyna</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Synowiec</LastName>
            <ForeName>Ewelina</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ksiazek</LastName>
            <ForeName>Dominika</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zaras</LastName>
            <ForeName>Magdalena</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wozniak</LastName>
            <ForeName>Katarzyna</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szaflik</LastName>
            <ForeName>Jerzy</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blasiak</LastName>
            <ForeName>Janusz</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2009</Year>
          <Month>06</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Mutat Res</MedlineTA>
        <NlmUniqueID>0400763</NlmUniqueID>
        <ISSNLinking>0027-5107</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016877">Oxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020552" MajorTopicYN="N">Comet Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004249" MajorTopicYN="Y">DNA Damage</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004260" MajorTopicYN="Y">DNA Repair</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016877" MajorTopicYN="N">Oxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014466" MajorTopicYN="N">Ultraviolet Rays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2009</Year>
          <Month>3</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2009</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2009</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19559717</ArticleId>
        <ArticleId IdType="doi">10.1016/j.mrfmmm.2009.06.008</ArticleId>
        <ArticleId IdType="pii">S0027-5107(09)00210-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18987612</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0172-780X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>29</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuro endocrinology letters</Title>
          <ISOAbbreviation>Neuro Endocrinol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alternation of retinoic acid induced neural differentiation of P19 embryonal carcinoma cells by reduction of reactive oxygen species intracellular production.</ArticleTitle>
        <Pagination>
          <StartPage>770</StartPage>
          <EndPage>774</EndPage>
          <MedlinePgn>770-4</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Intracellularly generated reactive oxygen species (ROS) are thought to modulate redox sensitive signaling pathways and thus regulate cell physiology including proliferation and differentiation. However, the role of ROS in neuronal differentiation of embryonic pluripotent cells is unknown. For this reason, the modification of retinoic acid (RA) induced neuronal differentiation of mouse embryonal carcinoma cells P19 by selected ROS scavengers and flavoprotein inhibitor was evaluated.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Intracellular ROS was evaluated by flowcytometry. Cellular redox status was evaluated based on total levels of reduced thiol groups in cells. The activity of the RA responsive element (RARE) was evaluated by luciferase reporter assay. The RA-induced neuronal differentiation was determined based on changes in the expression of protein markers characteristic for undifferentiated (Oct-4) and neuron-like cell differentiated cells (N-cadherin and III-beta tubulin).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">RA increased the intracellular ROS production that was accompanied by a decrease in thiol groups in cells. The ROS scavengers and flavoprotein inhibitor reduced RA-induced ROS production, RA-induced activity of RARE, and it decreased the RA-induced expression of N-cadherin and III-beta tubulin.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data outline a role of ROS as important molecules in the transduction of an intracellular signal during the neuronal differentiation of ES cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Konopka</LastName>
            <ForeName>Roman</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kubala</LastName>
            <ForeName>Lukas</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lojek</LastName>
            <ForeName>Antonin</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pacherník</LastName>
            <ForeName>Jirí</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Sweden</Country>
        <MedlineTA>Neuro Endocrinol Lett</MedlineTA>
        <NlmUniqueID>8008373</NlmUniqueID>
        <ISSNLinking>0172-780X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000098">Acetophenones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009861">Onium Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013438">Sulfhydryl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014815">Vitamins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5688UTC01R</RegistryNumber>
          <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6HJ411TU98</RegistryNumber>
          <NameOfSubstance UI="C007517">diphenyleneiodonium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B6J7B9UDTR</RegistryNumber>
          <NameOfSubstance UI="C056165">acetovanillone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PQ6CK8PD0R</RegistryNumber>
          <NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WYQ7N0BPYC</RegistryNumber>
          <NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000098" MajorTopicYN="N">Acetophenones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054278" MajorTopicYN="N">Embryonal Carcinoma Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009861" MajorTopicYN="N">Onium Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013438" MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2008</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2008</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18987612</ArticleId>
        <ArticleId IdType="pii">NEL290508A15</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">12021212</PMID>
      <DateCompleted>
        <Year>2002</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2011</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0013-7227</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>143</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2002</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Endocrinology</Title>
          <ISOAbbreviation>Endocrinology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Insulin and leptin combine additively to reduce food intake and body weight in rats.</ArticleTitle>
        <Pagination>
          <StartPage>2449</StartPage>
          <EndPage>2452</EndPage>
          <MedlinePgn>2449-52</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Leptin and insulin are distinct adiposity signals that regulate food intake and body weight. Because recent evidence suggests that the central catabolic action of each is mediated by the hypothalamic melanocortin system, we tested the hypothesis that leptin and insulin interact within the brain, either additively or synergistically, to suppress food intake and reduce body weight. Using a within-subjects design, we co-administered leptin and insulin into the 3rd cerebral ventricle (i.c.v.) over a wide range of doses, and compared the combined effects to what occurred following the administration of each peptide alone. The data suggest that leptin and insulin interact sub-additively to regulate food intake and body weight over the first few hours. That is, the ability of combinations of leptin and insulin to reduce food intake and body weight was less than what would be predicted by the sum of their independent actions. Over 24 hours, however, the combined doses fit a strictly additive model. These data therefore imply a redundancy in the functional intracellular pathways or neuronal circuits that leptin and insulin utilize in the acute regulation of food intake and body weight, and they further imply that over time, the redundancy dissipates.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Air</LastName>
            <ForeName>Ellen L</ForeName>
            <Initials>EL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267-0555, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benoit</LastName>
            <ForeName>Stephen C</ForeName>
            <Initials>SC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clegg</LastName>
            <ForeName>Deborah J</ForeName>
            <Initials>DJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seeley</LastName>
            <ForeName>Randy J</ForeName>
            <Initials>RJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woods</LastName>
            <ForeName>Stephen C</ForeName>
            <Initials>SC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DK10032</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK17844</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK54080</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK54890</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Endocrinology</MedlineTA>
        <NlmUniqueID>0375040</NlmUniqueID>
        <ISSNLinking>0013-7227</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020738">Leptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-79-3</RegistryNumber>
          <NameOfSubstance UI="D009074">Melanocyte-Stimulating Hormones</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004435" MajorTopicYN="N">Eating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020738" MajorTopicYN="N">Leptin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009074" MajorTopicYN="N">Melanocyte-Stimulating Hormones</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2002</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2002</Year>
          <Month>6</Month>
          <Day>19</Day>
          <Hour>10</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2002</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12021212</ArticleId>
        <ArticleId IdType="doi">10.1210/endo.143.6.8948</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">9949201</PMID>
      <DateCompleted>
        <Year>1999</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0964-6906</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1999</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Human molecular genetics</Title>
          <ISOAbbreviation>Hum Mol Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis.</ArticleTitle>
        <Pagination>
          <StartPage>425</StartPage>
          <EndPage>430</EndPage>
          <MedlinePgn>425-30</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Expansions of an intronic GAA repeat reduce the expression of frataxin and cause Friedreich's ataxia (FRDA), an autosomal recessive neurodegenerative disease. Frataxin is a mitochondrial protein, and disruption of a frataxin homolog in yeast results in increased sensitivity to oxidant stress, increased mitochondrial iron and respiration deficiency. These previous data support the hypothesis that FRDA is a disease of mitochondrial oxidative stress, a hypothesis we have tested in cultured cells from FRDA patients. FRDA fibroblasts were hypersensitive to iron stress and significantly more sensitive to hydrogen peroxide than controls. The iron chelator deferoxamine rescued FRDA fibroblasts more than controls from oxidant-induced death, consistent with a role for iron in the differential kinetics of death; however, mean mitochondrial iron content in FRDA fibroblasts was increased by only 40%. Treatment of cells with the intracellular Ca2+chelator BAPTA-AM rescued both FRDA fibroblasts and controls from oxidant-induced death. Treatment with apoptosis inhibitors rescued FRDA but not control fibroblasts from oxidant stress, and staurosporine-induced caspase 3 activity was higher in FRDA fibroblasts, consistent with the possibility that an apoptotic step upstream of caspase 3 is activated in FRDA fibroblasts. These results demonstrate that FRDA fibroblasts are sensitive to oxidant stress, and may be a useful model in which to elucidate the FRDA mechanism and therapeutic strategies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, 1311 Haring Hall, University of California, Davis, CA 95616, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cavadini</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gellera</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lonnerdal</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taroni</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cortopassi</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>E.0514</GrantID>
            <Acronym>TI_</Acronym>
            <Agency>Telethon</Agency>
            <Country>Italy</Country>
          </Grant>
          <Grant>
            <GrantID>AG 11967</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Hum Mol Genet</MedlineTA>
        <NlmUniqueID>9208958</NlmUniqueID>
        <ISSNLinking>0964-6906</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002614">Chelating Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033862">Iron-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C098527">frataxin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>139890-68-9</RegistryNumber>
          <NameOfSubstance UI="C070379">1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>526U7A2651</RegistryNumber>
          <NameOfSubstance UI="D004533">Egtazic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8558G7RUTR</RegistryNumber>
          <NameOfSubstance UI="D019289">Pyruvic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J06Y7MXW4D</RegistryNumber>
          <NameOfSubstance UI="D003676">Deferoxamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WHI7HQ7H85</RegistryNumber>
          <NameOfSubstance UI="D014529">Uridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002614" MajorTopicYN="N">Chelating Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003676" MajorTopicYN="N">Deferoxamine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004533" MajorTopicYN="N">Egtazic Acid</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005621" MajorTopicYN="N">Friedreich Ataxia</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033862" MajorTopicYN="Y">Iron-Binding Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019289" MajorTopicYN="N">Pyruvic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014529" MajorTopicYN="N">Uridine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1999</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1999</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1999</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9949201</ArticleId>
        <ArticleId IdType="doi">10.1093/hmg/8.3.425</ArticleId>
        <ArticleId IdType="pii">ddc051</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">9645394</PMID>
      <DateCompleted>
        <Year>1998</Year>
        <Month>09</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1071-5762</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>28</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1998</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Free radical research</Title>
          <ISOAbbreviation>Free Radic Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nitric oxide production in human macrophagic cells phagocytizing opsonized zymosan: direct characterization by measurement of the luminol dependent chemiluminescence.</ArticleTitle>
        <Pagination>
          <StartPage>179</StartPage>
          <EndPage>191</EndPage>
          <MedlinePgn>179-91</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>When differentiated into mature macrophages by the combination of all-trans retinoic acid and 1,25-dihydroxyvitamin D3, the human promonocytic cell lines U937 and THP-1 expressed inducible nitric oxide synthase (iNOS) transcripts. During their differentiation, the cells acquired the capacity to produce not only superoxide anion (O2.-) but also nitric oxide (.NO) in response to IgG (or IgE)-opsonized zymosan. The inhibitors of the iNOS pathway, aminoguanidine and NG-monomethyl-L-arginine (L-NMMA), suppressed the production of .NO and enhanced the steady-state concentration of O2.- determined. Conversely, superoxide dismutase (SOD) scavenged the O2.- released and increased the .NO-derived nitrite concentration detected. These data suggested a possible interaction between O2.- and .NO. In differentiated U937 (or THP-1) cells, IgG or IgE-opsonized zymosan induced a strong time-dependent luminol-dependent chemiluminescence (LDCL), which was abrogated by SOD and partially inhibited by aminoguanidine or L-NMMA. Since the iNOS inhibitors did not directly scavenge O2.-, LDCL determination in the presence or absence of SOD and/or iNOS inhibitors demonstrated a concomitant production of O2.- and .NO. These radicals induced the formation of a .NO-derived product(s), probably peroxynitrite (ONOO-), which was required to elicit maximal LDCL. Finally, LDCL measurement provided a convenient tool to characterize iNOS triggering and demonstrated an interaction between NADPH oxidase and iNOS products in human macrophagic cells phagocytizing opsonized-zymosan. These findings show that in activated macrophages, iNOS activity can be involved in LDCL and support the debated hypothesis of iNOS participation to the microbicidal activity of human macrophages.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gross</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM U431, Université de Montpellier II, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dugas</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spiesser</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vouldoukis</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Damais</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kolb</LastName>
            <ForeName>J P</ForeName>
            <Initials>JP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dugas</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dornand</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Free Radic Res</MedlineTA>
        <NlmUniqueID>9423872</NlmUniqueID>
        <ISSNLinking>1029-2470</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009566">Nitrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009895">Opsonin Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>11062-77-4</RegistryNumber>
          <NameOfSubstance UI="D013481">Superoxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1AVZ07U9S7</RegistryNumber>
          <NameOfSubstance UI="D019820">Xanthine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>26404-66-0</RegistryNumber>
          <NameOfSubstance UI="C039642">peroxynitric acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27JT06E6GR</RegistryNumber>
          <NameOfSubstance UI="D019323">omega-N-Methylarginine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37341-29-0</RegistryNumber>
          <NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5688UTC01R</RegistryNumber>
          <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5EXP385Q4F</RegistryNumber>
          <NameOfSubstance UI="D008165">Luminol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9010-72-4</RegistryNumber>
          <NameOfSubstance UI="D015054">Zymosan</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="C496319">NOS2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.17.3.2</RegistryNumber>
          <NameOfSubstance UI="D014969">Xanthine Oxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FXC9231JVH</RegistryNumber>
          <NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SCQ4EZQ113</RegistryNumber>
          <NameOfSubstance UI="C004479">pimagedine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002117" MajorTopicYN="N">Calcitriol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002474" MajorTopicYN="N">Cell-Free System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007948" MajorTopicYN="N">Leukemia, Monocytic, Acute</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008165" MajorTopicYN="N">Luminol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016403" MajorTopicYN="N">Lymphoma, Large B-Cell, Diffuse</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009566" MajorTopicYN="N">Nitrates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019001" MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009895" MajorTopicYN="N">Opsonin Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010587" MajorTopicYN="Y">Phagocytosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013481" MajorTopicYN="N">Superoxides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019820" MajorTopicYN="N">Xanthine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014969" MajorTopicYN="N">Xanthine Oxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015054" MajorTopicYN="N">Zymosan</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019323" MajorTopicYN="N">omega-N-Methylarginine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1998</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1998</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1998</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9645394</ArticleId>
        <ArticleId IdType="doi">10.3109/10715769809065803</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">7749930</PMID>
      <DateCompleted>
        <Year>1995</Year>
        <Month>06</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1073-2322</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>1</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1994</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Shock (Augusta, Ga.)</Title>
          <ISOAbbreviation>Shock</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cytokines inhibit fatty acid oxidation in isolated rat hepatocytes: synergy among TNF, IL-6, and IL-1.</ArticleTitle>
        <Pagination>
          <StartPage>123</StartPage>
          <EndPage>129</EndPage>
          <MedlinePgn>123-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We have developed an in vitro rat hepatocyte model in which cytokines inhibit fatty acid oxidation. Cytokine administration resulted in decreased fatty acid oxidation, ketone body production and acetyl CoA/CoA ratios. The inhibitory effects of TNF on fatty acid oxidation were enhanced by either IL-1 or IL-6. TNF (20 U/ml) + IL-6 (30 ng/ml) produced maximal inhibition, whereas IL-1 enhanced inhibition at submaximal TNF concentrations. The key to our model is that substrate input into the tricarboxylic acid cycle in the form of either alanine or pyruvate was required for cytokine mediated inhibition of fatty acid oxidation. Alanine or pyruvate may serve as a source for increased production of malonyl CoA, a potent inhibitor of fatty acid oxidation. We hypothesize that cytokines cause an inappropriate switch from fatty acid oxidation to fatty acid synthesis which has serious consequences for energy levels in the liver and can lead to end organ failure.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nachiappan</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Pennsylvania Medical School, Philadelphia 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curtiss</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corkey</LastName>
            <ForeName>B E</ForeName>
            <Initials>BE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kilpatrick</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DK19525</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK35914</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01-NS-17752</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Shock</MedlineTA>
        <NlmUniqueID>9421564</NlmUniqueID>
        <ISSNLinking>1073-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007657">Ketone Bodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>524-14-1</RegistryNumber>
          <NameOfSubstance UI="D008316">Malonyl Coenzyme A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>72-89-9</RegistryNumber>
          <NameOfSubstance UI="D000105">Acetyl Coenzyme A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8558G7RUTR</RegistryNumber>
          <NameOfSubstance UI="D019289">Pyruvic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OF5P57N2ZX</RegistryNumber>
          <NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000105" MajorTopicYN="N">Acetyl Coenzyme A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002952" MajorTopicYN="N">Citric Acid Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007657" MajorTopicYN="N">Ketone Bodies</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008316" MajorTopicYN="N">Malonyl Coenzyme A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019289" MajorTopicYN="N">Pyruvic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1994</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1994</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1994</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">7749930</ArticleId>
        <ArticleId IdType="doi">10.1097/00024382-199402000-00007</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">2086453</PMID>
      <DateCompleted>
        <Year>1991</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0165-2478</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>26</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1990</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunology letters</Title>
          <ISOAbbreviation>Immunol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolism and beta-cell function of rat pancreatic islets exposed to human interleukin-1 beta in the presence of a high glucose concentration.</ArticleTitle>
        <Pagination>
          <StartPage>245</StartPage>
          <EndPage>251</EndPage>
          <MedlinePgn>245-51</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>It has been postulated that one of the factors causing immune-mediated pancreatic beta-cell destruction in insulin-dependent diabetes mellitus (IDDM) is interleukin-1 (IL-1). Rat pancreatic islets exposed to human recombinant IL-1 beta (rIL-1 beta) for 48 h in vitro exhibit a markedly reduced glucose-stimulated insulin secretion. Also, a deleterious effect of glucose on beta-cell function, especially under conditions of a reduced beta-cell mass, which may exist in the early phase of IDDM has been suggested. In this study the response of rat pancreatic islets in vitro to a combination of the cytokine and high glucose concentration have therefore been assessed. Thus, islets were cultured for 48 h at either 11.1 or 56 mM glucose with or without 25 U/ml rIL-1 beta. Exposure to the cytokine reduced the islet DNA content at both glucose concentrations by 20-25%. In short-term incubations in the absence of rIL-1 beta after the preceding culture with the cytokine, the glucose-stimulated insulin release was reduced by 70% in islets cultured at 11.1 mM glucose and by only 40% after culture at 56 mM glucose, when compared to the corresponding control islets. The utilization of D-[5-3H]glucose, i.e., the catabolism of glucose in the glycolytic pathway, was the same in all groups of islets. However, the D-[6-14C]glucose oxidation rate, i.e., the metabolism of glucose in the Krebs cycle, was reduced by about 65% in rIL-1 beta exposed islets kept at 11.1 mM glucose and 46% in islets cultured at 56 mM glucose.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sandler</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Cell Biology, Uppsala University, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bendtzen</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eizirik</LastName>
            <ForeName>D L</ForeName>
            <Initials>DL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strandell</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Welsh</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Welsh</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Immunol Lett</MedlineTA>
        <NlmUniqueID>7910006</NlmUniqueID>
        <ISSNLinking>0165-2478</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078790" MajorTopicYN="N">Insulin Secretion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007515" MajorTopicYN="N">Islets of Langerhans</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012636" MajorTopicYN="N">Secretory Rate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1990</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1990</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1990</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2086453</ArticleId>
        <ArticleId IdType="doi">10.1016/0165-2478(90)90154-i</ArticleId>
        <ArticleId IdType="pii">0165-2478(90)90154-I</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">6418158</PMID>
      <DateCompleted>
        <Year>1984</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0232-766X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>42</Volume>
            <Issue>7-8</Issue>
            <PubDate>
              <Year>1983</Year>
            </PubDate>
          </JournalIssue>
          <Title>Biomedica biochimica acta</Title>
          <ISOAbbreviation>Biomed Biochim Acta</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Haemoglobin potentiates the respiration-inhibitory action of lipoxygenases via its pseudolipohydroperoxidase activity.</ArticleTitle>
        <Pagination>
          <StartPage>789</StartPage>
          <EndPage>803</EndPage>
          <MedlinePgn>789-803</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The inhibition of the NADH oxidase and of the succinate-cytochrome c oxidoreductase activities of beef heart submitochondrial particles (ETP) induced by reticulocyte lipoxygenase is strongly potentiated by haemoglobin added simultaneously or subsequently to lipoxygenase. Half-maximal potentiation was observed with 0.9 microM haemoglobin. Haemoglobin augments also the lipoxygenase-induced loss of acid-labile sulphur in ETP not related to respiratory inhibition. Soybean lipoxygenase produces only weak respiratory inhibition even at high concentrations in the absence of haemoglobin; strong inhibition is obtained, however, in the presence of haemoglobin. Among other haem compounds tested only free haemin but not cytochrome c and catalase exhibit identical effects. The action of haem compounds on the system ETP plus lipoxygenase is accompanied by their destruction. The experimental evidence indicates that the effects of haemoglobin described here are due to its ability to decompose catalytically hydroperoxy lipids generated by lipoxygenase. This catalytic property (pseudolipohydroperoxidase activity) was demonstrated with 13L-hydroperoxylinoleic acid as substrate. The relations between the various catalytic actions of haemoglobin related to lipid peroxidation are discussed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schewe</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hiebsch</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ludwig</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rapoport</LastName>
            <ForeName>S M</ForeName>
            <Initials>SM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Biomed Biochim Acta</MedlineTA>
        <NlmUniqueID>8304435</NlmUniqueID>
        <ISSNLinking>0232-766X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008054">Lipid Peroxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.13.11.12</RegistryNumber>
          <NameOfSubstance UI="D008084">Lipoxygenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.-</RegistryNumber>
          <NameOfSubstance UI="C023107">NADH oxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.-</RegistryNumber>
          <NameOfSubstance UI="D009247">NADH, NADPH Oxidoreductases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008054" MajorTopicYN="N">Lipid Peroxides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008084" MajorTopicYN="N">Lipoxygenase</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008929" MajorTopicYN="N">Mitochondria, Heart</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009247" MajorTopicYN="N">NADH, NADPH Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012156" MajorTopicYN="N">Reticulocytes</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013025" MajorTopicYN="N">Soybeans</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1983</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1983</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1983</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">6418158</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4370669</PMID>
      <DateCompleted>
        <Year>1975</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0001-6772</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>92</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1974</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta physiologica Scandinavica</Title>
          <ISOAbbreviation>Acta Physiol Scand</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparison between effects of cyclic AMP, dibutyryl cyclic AMP and luteinizing hormone on ovarian glycolysis.</ArticleTitle>
        <Pagination>
          <StartPage>181</StartPage>
          <EndPage>194</EndPage>
          <MedlinePgn>181-94</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Herlitz</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamberger</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahrén</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Acta Physiol Scand</MedlineTA>
        <NlmUniqueID>0370362</NlmUniqueID>
        <ISSNLinking>0001-6772</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27432CM55Q</RegistryNumber>
          <NameOfSubstance UI="D012710">Serum Albumin, Bovine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27Y3KJK423</RegistryNumber>
          <NameOfSubstance UI="D000628">Aminophylline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4A6ZS6Q2CL</RegistryNumber>
          <NameOfSubstance UI="D011691">Puromycin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63X7MBT2LQ</RegistryNumber>
          <NameOfSubstance UI="D003994">Bucladesine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-67-9</RegistryNumber>
          <NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GMW67QNF9C</RegistryNumber>
          <NameOfSubstance UI="D007930">Leucine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PDC6A3C0OX</RegistryNumber>
          <NameOfSubstance UI="D005990">Glycerol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000628" MajorTopicYN="N">Aminophylline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003994" MajorTopicYN="N">Bucladesine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046508" MajorTopicYN="N">Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005990" MajorTopicYN="N">Glycerol</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007016" MajorTopicYN="N">Hypophysectomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010053" MajorTopicYN="N">Ovary</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011691" MajorTopicYN="N">Puromycin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012710" MajorTopicYN="N">Serum Albumin, Bovine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1974</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1974</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1974</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4370669</ArticleId>
        <ArticleId IdType="doi">10.1111/j.1748-1716.1974.tb05735.x</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4415542</PMID>
      <DateCompleted>
        <Year>1974</Year>
        <Month>12</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0023-6837</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>31</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1974</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Laboratory investigation; a journal of technical methods and pathology</Title>
          <ISOAbbreviation>Lab Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relationship of ionic, water, and cell volume changes in cellular injury of Ehrlich ascites tumor cells.</ArticleTitle>
        <Pagination>
          <StartPage>207</StartPage>
          <EndPage>215</EndPage>
          <MedlinePgn>207-15</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Laiho</LastName>
            <ForeName>K U</ForeName>
            <Initials>KU</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trump</LastName>
            <ForeName>B F</ForeName>
            <Initials>BF</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Lab Invest</MedlineTA>
        <NlmUniqueID>0376617</NlmUniqueID>
        <ISSNLinking>0023-6837</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001557">Benzenesulfonates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003911">Dextrans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007461">Iodoacetates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>642-15-9</RegistryNumber>
          <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NEZ333N27</RegistryNumber>
          <NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FXS1BY2PGL</RegistryNumber>
          <NameOfSubstance UI="D008628">Mercury</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I38ZP9992A</RegistryNumber>
          <NameOfSubstance UI="D008274">Magnesium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RWP5GA015D</RegistryNumber>
          <NameOfSubstance UI="D011188">Potassium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000968" MajorTopicYN="N">Antimycin A</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001557" MajorTopicYN="N">Benzenesulfonates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001826" MajorTopicYN="N">Body Fluids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002286" MajorTopicYN="N">Carcinoma, Ehrlich Tumor</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002463" MajorTopicYN="N">Cell Membrane Permeability</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002498" MajorTopicYN="N">Centrifugation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003911" MajorTopicYN="N">Dextrans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007424" MajorTopicYN="N">Intracellular Fluid</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007461" MajorTopicYN="N">Iodoacetates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008274" MajorTopicYN="N">Magnesium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008628" MajorTopicYN="N">Mercury</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009942" MajorTopicYN="N">Organometallic Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013054" MajorTopicYN="N">Spectrophotometry, Atomic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1974</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1974</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1974</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4415542</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4353667</PMID>
      <DateCompleted>
        <Year>1973</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-2952</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>22</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>1973</Year>
              <Month>Aug</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical pharmacology</Title>
          <ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of highly specific inhibitors of oxidative phosphorylation, dicyclohexylcarbodiimide, antimycin A and piercidin A, on cyclic AMP accumulation induced by noradrenaline and theophylline in rat adipose tissue.</ArticleTitle>
        <Pagination>
          <StartPage>1957</StartPage>
          <EndPage>1964</EndPage>
          <MedlinePgn>1957-64</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dorigo</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Visco</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiandini</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fassina</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem Pharmacol</MedlineTA>
        <NlmUniqueID>0101032</NlmUniqueID>
        <ISSNLinking>0006-2952</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000418">Albumins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002234">Carbodiimides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010759">Phosphorus Isotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>538-75-0</RegistryNumber>
          <NameOfSubstance UI="D004024">Dicyclohexylcarbodiimide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>642-15-9</RegistryNumber>
          <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>C137DTR5RG</RegistryNumber>
          <NameOfSubstance UI="D013806">Theophylline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W3ENH1CV</RegistryNumber>
          <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000968" MajorTopicYN="N">Antimycin A</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002234" MajorTopicYN="N">Carbodiimides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004024" MajorTopicYN="N">Dicyclohexylcarbodiimide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004822" MajorTopicYN="N">Epididymis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010759" MajorTopicYN="N">Phosphorus Isotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013806" MajorTopicYN="N">Theophylline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1973</Year>
          <Month>8</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1973</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1973</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4353667</ArticleId>
        <ArticleId IdType="doi">10.1016/0006-2952(73)90077-4</ArticleId>
        <ArticleId IdType="pii">0006-2952(73)90077-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5025697</PMID>
      <DateCompleted>
        <Year>1972</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0013-7227</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>91</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1972</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Endocrinology</Title>
          <ISOAbbreviation>Endocrinology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Studies concerning the inhibition of glucose metabolism in thymus lymphocytes by cortisol and epinephrine.</ArticleTitle>
        <Pagination>
          <StartPage>233</StartPage>
          <EndPage>239</EndPage>
          <MedlinePgn>233-9</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Boyett</LastName>
            <ForeName>J D</ForeName>
            <Initials>JD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hofert</LastName>
            <ForeName>J F</ForeName>
            <Initials>JF</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Endocrinology</MedlineTA>
        <NlmUniqueID>0375040</NlmUniqueID>
        <ISSNLinking>0013-7227</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002247">Carbon Isotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>142M471B3J</RegistryNumber>
          <NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-79-2</RegistryNumber>
          <NameOfSubstance UI="D006003">Glycogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WI4X0X7BPJ</RegistryNumber>
          <NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YKH834O4BH</RegistryNumber>
          <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000311" MajorTopicYN="N">Adrenal Glands</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000332" MajorTopicYN="N">Aerobiosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000693" MajorTopicYN="N">Anaerobiosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002245" MajorTopicYN="N">Carbon Dioxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002247" MajorTopicYN="N">Carbon Isotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013950" MajorTopicYN="N">Thymus Gland</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1972</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1972</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1972</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5025697</ArticleId>
        <ArticleId IdType="doi">10.1210/endo-91-1-233</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4400160</PMID>
      <DateCompleted>
        <Year>1972</Year>
        <Month>03</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0039-128X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1971</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Steroids</Title>
          <ISOAbbreviation>Steroids</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of adenosine-3',5'-monophosphate on steroidogenesis and glycolysis in the rat adrenal gland incubated in vitro.</ArticleTitle>
        <Pagination>
          <StartPage>453</StartPage>
          <EndPage>469</EndPage>
          <MedlinePgn>453-69</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tsang</LastName>
            <ForeName>C P</ForeName>
            <Initials>CP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Péron</LastName>
            <ForeName>F G</ForeName>
            <Initials>FG</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Steroids</MedlineTA>
        <NlmUniqueID>0404536</NlmUniqueID>
        <ISSNLinking>0039-128X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006601">Hexoses</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007461">Iodoacetates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010756">Phosphoric Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0U46U6E8UK</RegistryNumber>
          <NameOfSubstance UI="D009243">NAD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>367-47-5</RegistryNumber>
          <NameOfSubstance UI="D005985">Glyceraldehyde</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>53-59-8</RegistryNumber>
          <NameOfSubstance UI="D009249">NADP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N712M78A8G</RegistryNumber>
          <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W980KJ009P</RegistryNumber>
          <NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000311" MajorTopicYN="N">Adrenal Glands</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001151" MajorTopicYN="N">Arsenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003345" MajorTopicYN="N">Corticosterone</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005985" MajorTopicYN="N">Glyceraldehyde</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006601" MajorTopicYN="N">Hexoses</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007461" MajorTopicYN="N">Iodoacetates</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009249" MajorTopicYN="N">NADP</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010756" MajorTopicYN="N">Phosphoric Acids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1971</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1971</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1971</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4400160</ArticleId>
        <ArticleId IdType="doi">10.1016/s0039-128x(71)80149-6</ArticleId>
        <ArticleId IdType="pii">S0039-128X(71)80149-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5487859</PMID>
      <DateCompleted>
        <Year>1971</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0003-5637</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>15</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>1970</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Antibiotiki</Title>
          <ISOAbbreviation>Antibiotiki</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Effect of tetracycline on respiration and glycolysis of normal and neoplastic cells].</ArticleTitle>
        <Pagination>
          <StartPage>928</StartPage>
          <EndPage>930</EndPage>
          <MedlinePgn>928-30</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vdovichenko</LastName>
            <ForeName>V I</ForeName>
            <Initials>VI</Initials>
          </Author>
        </AuthorList>
        <Language>rus</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Vliianie tetratsiklina na dykhanie i glikoliz normal'nykh i opukholevykh kletok.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Russia (Federation)</Country>
        <MedlineTA>Antibiotiki</MedlineTA>
        <NlmUniqueID>0375020</NlmUniqueID>
        <ISSNLinking>0003-5637</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>F8VB5M810T</RegistryNumber>
          <NameOfSubstance UI="D013752">Tetracycline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002286" MajorTopicYN="N">Carcinoma, Ehrlich Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013752" MajorTopicYN="N">Tetracycline</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1970</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1970</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1970</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5487859</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4245638</PMID>
      <DateCompleted>
        <Year>1970</Year>
        <Month>06</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-9258</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>245</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>1970</Year>
              <Month>Mar</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bongkrekic acid. An inhibitor of the adenine nucleotide translocase of mitochondria.</ArticleTitle>
        <Pagination>
          <StartPage>1319</StartPage>
          <EndPage>1326</EndPage>
          <MedlinePgn>1319-26</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Henderson</LastName>
            <ForeName>P J</ForeName>
            <Initials>PJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lardy</LastName>
            <ForeName>H A</ForeName>
            <Initials>HA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000227">Adenine Nucleotides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000963">Antimetabolites</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002247">Carbon Isotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003902">Detergents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004140">Dinitrophenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006027">Glycosides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007656">Ketoglutaric Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009840">Oligomycins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014118">Toxins, Biological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014475">Uncoupling Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I38ZP9992A</RegistryNumber>
          <NameOfSubstance UI="D008274">Magnesium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N712M78A8G</RegistryNumber>
          <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000227" MajorTopicYN="N">Adenine Nucleotides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000963" MajorTopicYN="N">Antimetabolites</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001151" MajorTopicYN="N">Arsenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001693" MajorTopicYN="N">Biological Transport, Active</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002247" MajorTopicYN="N">Carbon Isotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004140" MajorTopicYN="N">Dinitrophenols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006027" MajorTopicYN="N">Glycosides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007656" MajorTopicYN="N">Ketoglutaric Acids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008274" MajorTopicYN="N">Magnesium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009840" MajorTopicYN="N">Oligomycins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011549" MajorTopicYN="N">Pseudomonas</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014118" MajorTopicYN="N">Toxins, Biological</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014475" MajorTopicYN="N">Uncoupling Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014732" MajorTopicYN="N">Vibration</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1970</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1970</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1970</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4245638</ArticleId>
        <ArticleId IdType="pii">S0021-9258(18)63238-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4244467</PMID>
      <DateCompleted>
        <Year>1970</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-2960</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1970</Year>
              <Month>Feb</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemistry</Title>
          <ISOAbbreviation>Biochemistry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of sodium and potassium ions on mitochondrial oxidative phosphorylation. Studies with arsenate.</ArticleTitle>
        <Pagination>
          <StartPage>684</StartPage>
          <EndPage>689</EndPage>
          <MedlinePgn>684-9</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sandoval</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gómez-Puyou</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuena</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chávez</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peña</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochemistry</MedlineTA>
        <NlmUniqueID>0370623</NlmUniqueID>
        <ISSNLinking>0006-2960</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000227">Adenine Nucleotides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004140">Dinitrophenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010710">Phosphates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010759">Phosphorus Isotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9G34HU7RV0</RegistryNumber>
          <NameOfSubstance UI="D004492">Edetic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NEZ333N27</RegistryNumber>
          <NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N712M78A8G</RegistryNumber>
          <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RWP5GA015D</RegistryNumber>
          <NameOfSubstance UI="D011188">Potassium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000227" MajorTopicYN="N">Adenine Nucleotides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001151" MajorTopicYN="N">Arsenic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004140" MajorTopicYN="N">Dinitrophenols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004492" MajorTopicYN="N">Edetic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008365" MajorTopicYN="N">Manometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010759" MajorTopicYN="N">Phosphorus Isotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1970</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1970</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1970</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4244467</ArticleId>
        <ArticleId IdType="doi">10.1021/bi00805a031</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5412065</PMID>
      <DateCompleted>
        <Year>1970</Year>
        <Month>03</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0021-9258</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>245</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1970</Year>
              <Month>Jan</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Spectroscopic evidence for the control of respiration prior to phosphorylation in hamster brown fat cells.</ArticleTitle>
        <Pagination>
          <StartPage>382</StartPage>
          <EndPage>389</EndPage>
          <MedlinePgn>382-9</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Prusiner</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003580">Cytochromes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004988">Ethers, Cyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005994">Glycerophosphates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009840">Oligomycins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010710">Phosphates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013386">Succinates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014475">Uncoupling Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W3ENH1CV</RegistryNumber>
          <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000064" MajorTopicYN="N">Acclimatization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002001" MajorTopicYN="N">Adipose Tissue, Brown</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003080" MajorTopicYN="N">Cold Temperature</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003580" MajorTopicYN="N">Cytochromes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004735" MajorTopicYN="N">Energy Transfer</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004988" MajorTopicYN="N">Ethers, Cyclic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005994" MajorTopicYN="N">Glycerophosphates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009840" MajorTopicYN="N">Oligomycins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013053" MajorTopicYN="N">Spectrophotometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013386" MajorTopicYN="N">Succinates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014475" MajorTopicYN="N">Uncoupling Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1970</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1970</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1970</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5412065</ArticleId>
        <ArticleId IdType="pii">S0021-9258(18)63403-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5462572</PMID>
      <DateCompleted>
        <Year>1970</Year>
        <Month>06</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0003-5637</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1970</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Antibiotiki</Title>
          <ISOAbbreviation>Antibiotiki</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Mechanism of inhibition of respiration of Ehrlich ascites tumor cells by tetracycline].</ArticleTitle>
        <Pagination>
          <StartPage>50</StartPage>
          <EndPage>52</EndPage>
          <MedlinePgn>50-2</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vdovichenko</LastName>
            <ForeName>V I</ForeName>
            <Initials>VI</Initials>
          </Author>
        </AuthorList>
        <Language>rus</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Mekhanizm tormozheniia tetratsiklinom dykhaniia astsitnykh klotok opukholi &#xe9;rlikh.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Russia (Federation)</Country>
        <MedlineTA>Antibiotiki</MedlineTA>
        <NlmUniqueID>0375020</NlmUniqueID>
        <ISSNLinking>0003-5637</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002951">Citrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005650">Fumarates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007656">Ketoglutaric Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008293">Malates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010071">Oxaloacetates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013386">Succinates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>F8VB5M810T</RegistryNumber>
          <NameOfSubstance UI="D013752">Tetracycline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002286" MajorTopicYN="N">Carcinoma, Ehrlich Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002951" MajorTopicYN="N">Citrates</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002952" MajorTopicYN="N">Citric Acid Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046508" MajorTopicYN="N">Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="Y">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005650" MajorTopicYN="N">Fumarates</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007656" MajorTopicYN="N">Ketoglutaric Acids</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008293" MajorTopicYN="N">Malates</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010071" MajorTopicYN="N">Oxaloacetates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013386" MajorTopicYN="N">Succinates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013752" MajorTopicYN="N">Tetracycline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1970</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1970</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1970</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5462572</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5403609</PMID>
      <DateCompleted>
        <Year>1971</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0003-9780</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>181</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1969</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Archives internationales de pharmacodynamie et de therapie</Title>
          <ISOAbbreviation>Arch Int Pharmacodyn Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Spasmolytic activity of some denzo-gamma-pyrone derivatives.</ArticleTitle>
        <Pagination>
          <StartPage>343</StartPage>
          <EndPage>352</EndPage>
          <MedlinePgn>343-52</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Contessa</LastName>
            <ForeName>A R</ForeName>
            <Initials>AR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrari</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santi</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>RDa Re</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valenti</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Belgium</Country>
        <MedlineTA>Arch Int Pharmacodyn Ther</MedlineTA>
        <NlmUniqueID>0405353</NlmUniqueID>
        <ISSNLinking>0003-9780</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004140">Dinitrophenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005971">Glutamates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010276">Parasympatholytics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013386">Succinates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>24GP945V5T</RegistryNumber>
          <NameOfSubstance UI="D001464">Barium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>660YQ98I10</RegistryNumber>
          <NameOfSubstance UI="D011189">Potassium Chloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>M4I0D6VV5M</RegistryNumber>
          <NameOfSubstance UI="D002122">Calcium Chloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N9YNS0M02X</RegistryNumber>
          <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001464" MajorTopicYN="N">Barium</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002122" MajorTopicYN="N">Calcium Chloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004140" MajorTopicYN="N">Dinitrophenols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004336" MajorTopicYN="N">Drug Antagonism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005971" MajorTopicYN="N">Glutamates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007082" MajorTopicYN="N">Ileum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010276" MajorTopicYN="N">Parasympatholytics</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011189" MajorTopicYN="N">Potassium Chloride</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013386" MajorTopicYN="N">Succinates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1969</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1969</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1969</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5403609</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5377600</PMID>
      <DateCompleted>
        <Year>1970</Year>
        <Month>09</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0002-1148</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>1969</Year>
              <Season>Sep-Oct</Season>
            </PubDate>
          </JournalIssue>
          <Title>Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression</Title>
          <ISOAbbreviation>Agressologie</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Variations of lactacidemia, pyruvicemia and glycemia under the effect of L-tyrosine combined or not with folic acid].</ArticleTitle>
        <Pagination>
          <StartPage>387</StartPage>
          <EndPage>390</EndPage>
          <MedlinePgn>387-90</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Laborit</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olympie</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>fre</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Variations de la lactacid&#xe9;mie, de la pyruvic&#xe9;mie et de la glyc&#xe9;mie sous l'action de la L-tyrosine combin&#xe9;e ou non &#xe0; l'acide folique.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Agressologie</MedlineTA>
        <NlmUniqueID>0121575</NlmUniqueID>
        <ISSNLinking>0002-1148</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>42HK56048U</RegistryNumber>
          <NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>935E97BOY8</RegistryNumber>
          <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1969</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1969</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1969</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5377600</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5795469</PMID>
      <DateCompleted>
        <Year>1969</Year>
        <Month>09</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-3002</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>180</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1969</Year>
              <Month>Jun</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta</Title>
          <ISOAbbreviation>Biochim Biophys Acta</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In vitro studies of beating heart cells in culture. XII. The utilization of ATP and phosphocreatine in oligomycin and 2-deoxyglucose inhibited cells.</ArticleTitle>
        <Pagination>
          <StartPage>264</StartPage>
          <EndPage>270</EndPage>
          <MedlinePgn>264-70</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Seraydarian</LastName>
            <ForeName>M W</ForeName>
            <Initials>MW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Savageau</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harary</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta</MedlineTA>
        <NlmUniqueID>0217513</NlmUniqueID>
        <ISSNLinking>0006-3002</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006601">Hexoses</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009840">Oligomycins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>020IUV4N33</RegistryNumber>
          <NameOfSubstance UI="D010725">Phosphocreatine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046508" MajorTopicYN="N">Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006601" MajorTopicYN="N">Hexoses</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009840" MajorTopicYN="N">Oligomycins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010725" MajorTopicYN="N">Phosphocreatine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1969</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1969</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1969</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5795469</ArticleId>
        <ArticleId IdType="doi">10.1016/0005-2728(69)90113-3</ArticleId>
        <ArticleId IdType="pii">0005-2728(69)90113-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5805287</PMID>
      <DateCompleted>
        <Year>1969</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-2960</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1969</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochemistry</Title>
          <ISOAbbreviation>Biochemistry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of ionophorous antibiotics on the light-induced internal and external hydrogen ion changes and phosphorylation in bacterial chromatophores.</ArticleTitle>
        <Pagination>
          <StartPage>1360</StartPage>
          <EndPage>1370</EndPage>
          <MedlinePgn>1360-70</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nishimura</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pressman</LastName>
            <ForeName>B C</ForeName>
            <Initials>BC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochemistry</MedlineTA>
        <NlmUniqueID>0370623</NlmUniqueID>
        <ISSNLinking>0006-2960</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003486">Cyanides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004988">Ethers, Cyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NEZ333N27</RegistryNumber>
          <NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RWP5GA015D</RegistryNumber>
          <NameOfSubstance UI="D011188">Potassium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020130" MajorTopicYN="N">Bacterial Chromatophores</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002844" MajorTopicYN="N">Chromatium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003486" MajorTopicYN="N">Cyanides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004988" MajorTopicYN="N">Ethers, Cyclic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="Y">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008027" MajorTopicYN="Y">Light</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012246" MajorTopicYN="N">Rhodospirillum</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1969</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1969</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1969</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5805287</ArticleId>
        <ArticleId IdType="doi">10.1021/bi00832a009</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5762968</PMID>
      <DateCompleted>
        <Year>1969</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0003-9861</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>129</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1969</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Archives of biochemistry and biophysics</Title>
          <ISOAbbreviation>Arch Biochem Biophys</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of insulin and sodium dodecyl sulfate on rat hepatic cell respiration.</ArticleTitle>
        <Pagination>
          <StartPage>273</StartPage>
          <EndPage>276</EndPage>
          <MedlinePgn>273-6</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tarnoff</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strausser</LastName>
            <ForeName>H R</ForeName>
            <Initials>HR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arch Biochem Biophys</MedlineTA>
        <NlmUniqueID>0372430</NlmUniqueID>
        <ISSNLinking>0003-9861</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003902">Detergents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006601">Hexoses</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013386">Succinates</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006601" MajorTopicYN="N">Hexoses</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008365" MajorTopicYN="N">Manometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013386" MajorTopicYN="N">Succinates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1969</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1969</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1969</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5762968</ArticleId>
        <ArticleId IdType="doi">10.1016/0003-9861(69)90175-1</ArticleId>
        <ArticleId IdType="pii">0003-9861(69)90175-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4312199</PMID>
      <DateCompleted>
        <Year>1970</Year>
        <Month>02</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-3002</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>189</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1969</Year>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta</Title>
          <ISOAbbreviation>Biochim Biophys Acta</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Studies on the mechanism of inhibitionof the mitochondrial electron transport by antimycin. II. Antimycin as an allosteric inhibitor.</ArticleTitle>
        <Pagination>
          <StartPage>317</StartPage>
          <EndPage>326</EndPage>
          <MedlinePgn>317-26</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bryla</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaniuga</LastName>
            <ForeName>Z</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slater</LastName>
            <ForeName>E C</ForeName>
            <Initials>EC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta</MedlineTA>
        <NlmUniqueID>0217513</NlmUniqueID>
        <ISSNLinking>0006-3002</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000438">Alcohols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003580">Cytochromes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003902">Detergents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013386">Succinates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013885">Thiosulfates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0U46U6E8UK</RegistryNumber>
          <NameOfSubstance UI="D009243">NAD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12001-79-5</RegistryNumber>
          <NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1339-63-5</RegistryNumber>
          <NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>642-15-9</RegistryNumber>
          <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.3.99.1</RegistryNumber>
          <NameOfSubstance UI="D013385">Succinate Dehydrogenase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000438" MajorTopicYN="N">Alcohols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000968" MajorTopicYN="N">Antimycin A</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001647" MajorTopicYN="N">Bile Acids and Salts</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002623" MajorTopicYN="N">Chemistry Techniques, Analytical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003580" MajorTopicYN="N">Cytochromes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003956" MajorTopicYN="N">Dialysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008931" MajorTopicYN="N">Mitochondria, Muscle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009285" MajorTopicYN="N">Naphthoquinones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013385" MajorTopicYN="N">Succinate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013386" MajorTopicYN="N">Succinates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013885" MajorTopicYN="N">Thiosulfates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1969</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1969</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1969</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4312199</ArticleId>
        <ArticleId IdType="doi">10.1016/0005-2728(69)90162-5</ArticleId>
        <ArticleId IdType="pii">0005-2728(69)90162-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5713589</PMID>
      <DateCompleted>
        <Year>1969</Year>
        <Month>07</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-8318</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>31</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>1968</Year>
              <Season>Nov-Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Farmakologiia i toksikologiia</Title>
          <ISOAbbreviation>Farmakol Toksikol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[On the toxic effect of excessive doses of vitamin A and its combination with tocopherol on oxidative phosphorylation in rat liver mitochondrias].</ArticleTitle>
        <Pagination>
          <StartPage>733</StartPage>
          <EndPage>735</EndPage>
          <MedlinePgn>733-5</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kriukova</LastName>
            <ForeName>L V</ForeName>
            <Initials>LV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pechenina</LastName>
            <ForeName>M I</ForeName>
            <Initials>MI</Initials>
          </Author>
        </AuthorList>
        <Language>rus</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>O toksicheskom de&#x12d;stvii izbytochnykh doz vitamina a i ego kombinatsii s tokoferolom na okislitel'noe fosorilirovanie v mitokhondriiakh pecheni krys.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Russia (Federation)</Country>
        <MedlineTA>Farmakol Toksikol</MedlineTA>
        <NlmUniqueID>16920420R</NlmUniqueID>
        <ISSNLinking>0014-8318</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>11103-57-4</RegistryNumber>
          <NameOfSubstance UI="D014801">Vitamin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1406-18-4</RegistryNumber>
          <NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27YLU75U4W</RegistryNumber>
          <NameOfSubstance UI="D010758">Phosphorus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010758" MajorTopicYN="N">Phosphorus</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014801" MajorTopicYN="N">Vitamin A</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1968</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1968</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1968</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5713589</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5681459</PMID>
      <DateCompleted>
        <Year>1968</Year>
        <Month>11</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-2960</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>7</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>1968</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochemistry</Title>
          <ISOAbbreviation>Biochemistry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of antibiotics on ion transport and photophosphorylation in Rhodospirillum rubrum chromatophores.</ArticleTitle>
        <Pagination>
          <StartPage>3499</StartPage>
          <EndPage>3507</EndPage>
          <MedlinePgn>3499-507</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thore</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keister</LastName>
            <ForeName>D L</ForeName>
            <Initials>DL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shavit</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>San Pietro</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochemistry</MedlineTA>
        <NlmUniqueID>0370623</NlmUniqueID>
        <ISSNLinking>0006-2960</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002712">Chlorides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1KSV9V4Y4I</RegistryNumber>
          <NameOfSubstance UI="D002586">Cesium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9FN79X2M3F</RegistryNumber>
          <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NEZ333N27</RegistryNumber>
          <NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MLT4718TJW</RegistryNumber>
          <NameOfSubstance UI="D012413">Rubidium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RWP5GA015D</RegistryNumber>
          <NameOfSubstance UI="D011188">Potassium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020130" MajorTopicYN="N">Bacterial Chromatophores</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001693" MajorTopicYN="N">Biological Transport, Active</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002586" MajorTopicYN="N">Cesium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002712" MajorTopicYN="N">Chlorides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008566" MajorTopicYN="N">Membranes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012246" MajorTopicYN="N">Rhodospirillum</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012413" MajorTopicYN="N">Rubidium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1968</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1968</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1968</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5681459</ArticleId>
        <ArticleId IdType="doi">10.1021/bi00850a026</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">5682849</PMID>
      <DateCompleted>
        <Year>1968</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-3002</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>162</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1968</Year>
              <Month>Aug</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta</Title>
          <ISOAbbreviation>Biochim Biophys Acta</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of deuterium oxide on respiratory-chain phosphorylation in sub-mitochondrial particles.</ArticleTitle>
        <Pagination>
          <StartPage>170</StartPage>
          <EndPage>174</EndPage>
          <MedlinePgn>170-4</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Muraoka</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slater</LastName>
            <ForeName>E C</ForeName>
            <Initials>EC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta</MedlineTA>
        <NlmUniqueID>0217513</NlmUniqueID>
        <ISSNLinking>0006-3002</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009840">Oligomycins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AR09D82C7G</RegistryNumber>
          <NameOfSubstance UI="D003903">Deuterium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003903" MajorTopicYN="N">Deuterium</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008931" MajorTopicYN="N">Mitochondria, Muscle</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009840" MajorTopicYN="N">Oligomycins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010087" MajorTopicYN="N">Oxides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014732" MajorTopicYN="N">Vibration</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1968</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1968</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1968</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">5682849</ArticleId>
        <ArticleId IdType="doi">10.1016/0005-2728(68)90099-6</ArticleId>
        <ArticleId IdType="pii">0005-2728(68)90099-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">4300601</PMID>
      <DateCompleted>
        <Year>1968</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-2956</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1968</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of biochemistry</Title>
          <ISOAbbreviation>Eur J Biochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of piericidin A on energy-linked processes in submitochondrial particles.</ArticleTitle>
        <Pagination>
          <StartPage>402</StartPage>
          <EndPage>408</EndPage>
          <MedlinePgn>402-8</MedlinePgn>
        </Pagination>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vallin</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Löw</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Biochem</MedlineTA>
        <NlmUniqueID>0107600</NlmUniqueID>
        <ISSNLinking>0014-2956</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002729">Chloromercuribenzoates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013438">Sulfhydryl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>03L9OT429T</RegistryNumber>
          <NameOfSubstance UI="D012402">Rotenone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0CPP32S55X</RegistryNumber>
          <NameOfSubstance UI="D004112">Dimercaprol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0U46U6E8UK</RegistryNumber>
          <NameOfSubstance UI="D009243">NAD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1339-63-5</RegistryNumber>
          <NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.3.99.1</RegistryNumber>
          <NameOfSubstance UI="D013385">Succinate Dehydrogenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.9.3.1</RegistryNumber>
          <NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GWH6IJ239E</RegistryNumber>
          <NameOfSubstance UI="D000654">Amobarbital</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000654" MajorTopicYN="N">Amobarbital</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002729" MajorTopicYN="N">Chloromercuribenzoates</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003864" MajorTopicYN="N">Depression, Chemical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004112" MajorTopicYN="N">Dimercaprol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007306" MajorTopicYN="N">Insecticides</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008931" MajorTopicYN="N">Mitochondria, Muscle</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013302" MajorTopicYN="Y">Streptomyces</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013385" MajorTopicYN="N">Succinate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013438" MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014732" MajorTopicYN="N">Vibration</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1968</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1968</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1968</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">4300601</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
